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ABSTRACT 
Jason Robert Slizgi: Hepatic Transporter Function in Liver Disease: Impact on Hepatobiliary 
Disposition and Pharmacokinetics 
(Under the direction of Kim L.R. Brouwer) 
 The objective of this doctoral dissertation research was to understand how hepatic 
transporter function in liver disease affects hepatobiliary disposition and pharmacokinetics of 
endogenous and exogenous compounds. In particular, this dissertation focused on two forms of 
liver disease: non-alcoholic steatohepatitis (NASH) and autosomal dominant polycystic kidney 
disease (ADPKD). A multi-experimental, translational approach including transporter over-
expressing membrane vesicles, sandwich-cultured human hepatocytes, isolated perfused rat 
livers, metabolomic profiling, imaging, and an in vivo study in humans was employed. Based on 
reported changes in in vitro expression of organic anion transporting polypeptide (OATP), 
multidrug resistance-associated protein (MRP) 2 and MRP3 in liver tissue from patients with 
NASH, we tested the hypothesis that the disposition of 
99m
Technetium-mebrofenin (MEB), an 
OATP, MRP2, and MRP3 probe, was altered in this patient population. Systemic and hepatic 
concentrations of MEB were increased in patients with NASH compared to age- and sex-
matched healthy volunteers, consistent with impaired uptake and biliary excretion, and enhanced 
basolateral efflux of MEB.  
Tolvaptan and two metabolites, DM-4103 and DM-4107, were shown to be inhibitors of 
the major human hepatic bile acid transporters Na
+
-taurocholate cotransporting polypeptide 
(NTCP), bile salt export pump (BSEP), and MRP2, MRP3, and MRP4, which may contribute to 
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tolvaptan-associated liver injury in patients with ADPKD. Although impaired bile acid transport 
by tolvaptan and/or its metabolites may negatively impact bile acid homeostasis, the fact that 
liver injury has been observed only in patients with ADPKD suggests that other mechanism(s) 
and/or patient susceptibility factors may contribute to drug-induced liver injury (DILI) in this 
patient population. Metabolomic profiling of bile acids in polycystic kidney (PCK) rats, a rodent 
model of human ADPKD, revealed significantly increased concentrations of total bile acids and 
bile acids associated with hepatotoxicity in the serum and liver when compared to wild-type rats. 
Total serum bile acids positively correlated with measures of liver impairment (i.e. liver weight, 
total liver bile acids, total liver bile acids associated with hepatotoxicity, and cystic volume) 
suggesting that serum bile acids may be useful biomarkers for liver impairment in ADPKD. 
Further mechanistic studies revealed, for the first time, decreased biliary excretion of 5(6)-
carboxy-2’,7’-dichlorofluorescein (CDF), a fluorescent Oatp, Mrp2, and Mrp3 probe, in PCK 
rats using the isolated perfused rat liver model. In total, these data suggest that drug- and disease-
specific factors may play a role in the potential for bile acid-mediated hepatotoxicity associated 
with tolvaptan use in patients with ADPKD.  
This research has resulted in novel contributions that provide important insight into the 
impact of liver disease on hepatic transporter function. This information will significantly 
enhance our ability to understand and predict altered hepatic transporter function, which will 
improve the safety and effectiveness of drugs.  
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CHAPTER 1. Introduction
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Effect of Liver Disease on Hepatic Transporter Expression and Function 
INTRODUCTION 
The liver is an important organ in the biotransformation, disposition, and elimination of 
endogenous (e.g. macromolecules, bile acids) and exogenous molecules (e.g. drugs). Drug 
metabolizing enzymes play a central role in hepatic drug elimination; however, efforts over the 
past decade have revealed that transport proteins are also important determinants of hepatic 
clearance. Hepatic transporters are transmembrane proteins anchored in polarized hepatocytes, 
the primary parenchymal cell type of the liver, that facilitate the transport of molecules to and 
from sinusoidal blood and hepatocytes (basolateral transporters) or from hepatocytes into the 
biliary canaliculus (canalicular transporters). These transporters are classified into two 
superfamilies: the solute carrier (SLC) protein family and the adenosine triphosphate (ATP)-
binding cassette (ABC) protein family. 
The expression and function of transporters are subject to complex regulatory 
mechanisms and are contributing factors to interindividual variability. Characterizing sources 
that contribute to individual variability in drug transporter expression/function, and thus hepatic 
clearance, will improve the efficient development of new and safer pharmacological 
interventions and improve our mechanistic understanding of disease genesis/progression. The 
identification of drug-drug interactions (DDIs) and more recently, genetic polymorphisms, which 
                                                          
1
 A portion of this chapter is in preparation as a review article; Dr. Nilay Thakker authored the review of 
hepatocellular carcinoma and primary biliary cholangitis in this chapter.  
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influence the expression and/or function of drug transporters, have been under extensive 
investigation over the years. However, DDIs and genetic polymorphisms represent only a portion 
of the total contribution to interindividual variability.  
 Liver disease may influence the expression and function of hepatic transporters. Chronic 
liver disease is a significant source of morbidity and mortality in both industrialized and 
developing nations. It is estimated that one million deaths worldwide were attributed to liver 
cirrhosis alone in 2010, while many more were due to liver cancer and hepatitis (Mokdad et al., 
2014). The etiologies of liver disease are diverse and can include chronic alcohol abuse, 
viral/bacterial infection, fatty liver disease, and drug-induced injury – all of which may have 
genetic components that can influence the development, manifestation, and severity of disease. 
The purpose of this article is to review the literature characterizing and quantifying the effects of 
liver disease on the expression and function of hepatic transporters in humans. First, a brief 
overview of hepatic transporters will be provided. Then, the effects of cholestasis, hepatitis C 
(HCV) infection, hepatocellular carcinoma (HCC), human immunodeficiency virus (HIV) 
infection, non-alcoholic steatohepatitis (NASH), and primary biliary cholangitis (PBC) on 
hepatic transporter expression and function will be provided. In addition to highlighting current 
knowledge regarding the effect of liver disease on hepatic transporters, this review will identify 
knowledge gaps in our understanding of the contribution of liver disease to the complexity of 
variable drug disposition and elimination. 
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Basolateral Uptake Transporters 
Sodium-Taurocholate Cotransporting Polypeptide (NTCP) 
The SLC10A1 gene encodes NTCP, a key transport protein involved in the enterohepatic 
recirculation of bile acids (Hagenbuch et al., 1994). NTCP is homogenously expressed 
throughout the liver acinus and specifically coordinates the sodium-dependent uptake of bile 
acids from the sinusoidal blood to hepatocytes by electrogenically co-transporting two sodium 
ions and one bile acid molecule (Hagenbuch et al., 1996; Weinman et al., 1997). NTCP 
transports a variety of bile acids but appears to have higher affinity for glycine- and taurine-
conjugated bile acids compared to their unconjugated counterparts, and a higher affinity for 
dihydroxy bile acids (e.g. chendodeoxycholate and deoxycholate conjugates) than trihydroxy bile 
acids (e.g. cholate conjugates). Although little emphasis is placed on NTCP-mediated 
interactions during drug development, NTCP has been shown to transport drugs. For example, 
drug-conjugated bile acids have been proposed as a potential strategy for drug delivery (Vallejo 
et al., 2007). Approximately 35% of total rosuvastatin uptake into hepatocytes was accounted for 
by NTCP (Ho et al., 2006); however, it is not clear if this contribution is relevant in the presence 
of systemic bile acids, which may selectively outcompete rosuvastatin in vivo. Interestingly, 
NTCP was shown to be a functional receptor for the hepatitis B virus and thus, may serve as a 
novel therapeutic target to inhibit the viral entry mechanism (Watashi et al., 2014; Yan et al., 
2012).  
Organic Anion Transporters (OATs)  
OATs, classified in the SLC22A superfamily, are a ubiquitously expressed group of 
organic anion transporters that have broad distribution in such tissues as kidney, liver, brain, 
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pancreas, salivary glands, and skeletal muscle (Bleasby et al., 2006). These transporters 
generally mediate the transport of negatively charged endogenous and exogenous molecules in a 
bidirectional manner in exchange for dicarboxylate ions (Burckhardt et al., 2001; Simonson et 
al., 1994; Van Aubel et al., 2000), although uncharged and even cationic molecules have been 
reported as substrates (Cropp et al., 2008; Sweet et al., 1999). OATs also transport endogenous 
substances including cGMP, bile acids, and hormone derivatives (Kobayashi et al., 2002; Sekin 
et al., 1997; Sun et al., 2001). Prostaglandins and glutamate are examples of endogenous 
substrates of OAT2, whereas examples of xenobiotics include methotrexate, valproic acid, and 
allopurinol (Enomoto et al., 2002; Sekin et al., 1997; Shin et al., 2007; Sun et al., 2001). OAT7 is 
another liver-specific OAT that appears to have similar and overlapping substrate specificity 
with other OATs (Sekin et al., 1997; Shin et al., 2007). Despite the expression and function of 
OATs in the liver, there is little evidence demonstrating the clinical relevance of these 
transporters in the context of DDIs and/or genetic polymorphisms, although pravastatin recently 
was identified as a novel OAT7 substrate (Emami Riedmaier et al., 2016; Giacomini et al., 
2010). 
Organic Anion-Transporting Polypeptides (OATPs) 
OATPs are a class of proteins that belong to the SCLO superfamily with 12-
transmembrane spanning domains that are localized on the basolateral membrane of many 
epithelial cells. OATPs are highly expressed in the liver (predominantly OATP1B1, OATP1B3, 
and OATP2B1) (Badée et al., 2015; Hagenbuchand et al., 2008; Mikkaichi et al., 2004; Satlin et 
al., 1997). OATPs transport a wide variety of amphipathic and anionic substances in a 
bidirectional manner through countertransport with either bicarbonate or reduced glutathione (Li 
et al., 1998; Li et al., 2000; Kalliokoski et al., 2009). OATP substrates include endogenous 
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compounds such as bile acids, bilirubin, thyroid hormones, and steroid conjugates. Several drug 
classes have been characterized, or even specifically designed, as substrates for OATPs including 
3-hydroxy-3methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors (i.e. statins), 
angiotensin II receptor antagonists, angiotensin converting enzyme inhibitors, and cardiac 
glycosides (FDA Guidance, 2012; Kalliokoski et al., 2009). The liver-specific OATP1B1, 
OATP1B3, and to a lesser extent, OATP2B1, are considered clinically relevant drug transporters 
by the Food and Drug Administration (FDA) and are routinely evaluated during drug 
development (FDA Guidance, 2012).  
Organic Cation Transporters (OCTs) 
The first OCT (i.e. OCT1) was isolated and cloned from rat kidney by Gründemann et al. 
in 1994 and was later shown to display a 12-transmembrane structure that mediates the 
bidirectional transport of various small molecules (~60-350 Da) in an electrogenic manner 
(Koepsell et al., 2003). Similar to other transporters of the SLC family, OCTs display broad 
tissue distribution in such organs as the kidney, liver, and intestine. Three OCT isoforms have 
been identified in humans. OCT1 exhibits greatest expression in the liver. OCTs generally 
mediate the transport of small hydrophilic compounds with at least one positive charged amine 
moiety, although uncharged or anionic substrates have been reported (Koepsell et al., 2003). 
Classic substrates include tetraethylammonium (TEA) and the parkinsonian neurotoxin 1-
methyl-4-phenylpyridinium (MPP
+
); clinically relevant drug substrates include famotidine, 
ranitidine, and more recently, metformin (Bourdet et al., 2005; Cai et al., 2016; Han et al., 2015).  
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Canalicular Efflux Transporters 
Breast Cancer Resistance Protein (BCRP) 
BCRP (ABCG2) was first cloned by Doyle et al. (2003) and although its name suggests 
otherwise, BCRP is expressed in a variety of tissues and cell types (e.g. intestine, brain, liver, 
cardiac muscle). BCRP is a half transporter hypothesized to function as a homodimer or 
potentially a tetramer (Litman et al., 2001; Xu et al., 2004). In the liver, BCRP is localized to the 
canalicular membrane with broad substrate specificity, which includes organic ions, sulfate 
conjugates, and both negatively and positively charged molecules. BCRP substrates have been 
characterized primarily in the context of oncology due to the resistance of certain cancer types 
against chemotherapeutic agents. Some examples include mitoxantrone, SN-38, topotecan, and 
doxorubicin (Kawabata et al., 2001; Maliepaard et al., 1999; Nakagawa et al., 1992). However, 
BCRP can transport sulfate and glucuronide bile acid conjugates and may play a compensatory 
role when the function of other transporters (e.g. MRP2) are impaired (Pauli-Magnus et al., 
2006; Zamek-Gliszczynski et al., 2006). 
Bile Salt Export Pump (BSEP) 
ABCB11 encodes BSEP, a member of the ABC transporter family, which is the primary 
hepatocellular transporter responsible for secretion of bile acids into the bile canaliculus. BSEP 
is predominantly expressed throughout the human liver acinus. Bile acid transport requires the 
hydrolysis of ATP, which drives the conformational change in the transmembrane domain of 
BSEP, hence translocating bile acids from hepatocytes to the canalicular space. In addition to 
bile acids, BSEP has been reported to transport pravastatin (Hirano et al., 2005). Monoanionic 
and conjugated bile acids represent the majority of BSEP substrates; unconjugated bile acids do 
not appear to be substrates as evidenced by in vitro and in vivo human data (Carlton  et al., 2003; 
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Gerloff et al., 1999). Differences in substrate specificity between species have been reported; for 
example, human BSEP is able to transport taurolithocholate-3-sulfate although this is not true for 
the rodent orthologue (Byrne et al., 2002). The affinity (i.e., Km) for bile acids is generally in the 
low micromolar range across species, but differences in rank-order and specificity have been 
noted. For example, human BSEP has a higher affinity for taurocholate than mouse BSEP 
(human Km: 4.25 μM compared to mouse Km: 15-30 μM) (Byrne et al., 2002). 
Multidrug and Toxin Extrusion Protein 1 (MATE1) 
MATE1 (SLC47A1) is an H
+
/organic cation transporter first identified in 2005 that 
mediates the electrogenic transport of organic cations independent of a sodium gradient (Otsuka 
et al., 2005). It is primarily expressed on the canalicular membrane of hepatocytes and the 
luminal membrane of the proximal tubules and is thought to play a physiological role in the 
excretion of toxic endogenous substances, although several drugs have been identified as 
substrates (e.g. metformin, cimetidine, and acyclovir) (Nies et al., 2011).  
Multidrug Resistance-Associated Protein 2 (MRP2) 
MRP2 is a member of the ABCC family and one of nine recognized MRPs. First 
identified in the canalicular membrane of hepatocytes, MRP2 has been characterized in the 
kidney, small intestine, gallbladder, and placenta (Kepplerand et al., 1996; Meyer zu 
Schwabedissen et al., 2005; Sandusky et al., 2002; Schaub et al., 1999). MRP2 is a major driving 
force for bile-acid independent bile flow through the secretion of reduced glutathione, although it 
transports divalent and glucuronide- and sulfate-conjugated bile acids into the bile canaliculus. 
MRP2 is responsible for the biliary transport of many anionic drug/metabolites including 
methotrexate, acetaminophen-glucuronide, and etoposide (Büchler et al., 1996; Fahrmayr et al., 
2012). The physiological role of MRP2 is demonstrated by the characteristic elimination of 
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bilirubin (specifically, the conjugated species) as evidenced by in vitro data and in patients with 
Dubin-Johnson Syndrome, who harbor polymorphisms in the ABCC2 gene (Jemnitz et al., 2010; 
Keppler et al., 2014). This is further supported by the naturally occurring Mrp2-deficient rats 
(i.e. Eisai hyperbilirubinemic and CY/TR
-
 mutant rat strains), which have been a valuable in vivo 
model for understanding the role of MRP2 in drug disposition (Büchler et al., 1996; Kepplerand 
et al., 1996; Oswald et al., 2006).  
Multidrug Resistance Protein 1 (MDR1) 
MDR1, commonly known as P-glycoprotein (P-gp), was one of the first ABC proteins 
identified due to its important role in drug resistance in chemotherapy. Like other ABC 
transporters, P-gp is comprised of two membrane-bound domains each consisting of six 
transmembrane helices (Looand et al., 1995). Expression has been quantified in many tissues 
such as the liver, brain, testis, gut, and colon (Cordon-Cardo et al., 2000). Although the 
physiological role of P-gp has been debated, it likely plays a general role in the protection from 
xenobiotics and disposition of endogenous substances, as evidenced by its ability to transport a 
variety of amphipathic drugs, natural products, and peptides. P-gp transports 
immunosuppressants, hormones, calcium channel blockers, and cardiac glycosides, but P-gp 
expression and function have been studied the most in the context of cancer chemotherapy. Apart 
from being expressed in major organs governing drug disposition (e.g. the liver, gut), P-gp is 
overexpressed in many cancer cell types, which limits the distribution/exposure of 
chemotherapeutics to the site of action (Amin  et al., 2013; Mechetner et al., 1998; Vredenburg et 
al., 2001).  
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Basolateral Efflux Transporters 
Multidrug Resistance-Associated Protein 1 (MRP1) 
 The clinical relevance of MRP1, encoded by the ABCC1 gene, was first recognized in the 
transport of hydrophobic and hydrophilic anticancer agents such as vincristine and etoposide 
(Keppler et al., 2011; Slot et al., 2011; Zhou et al., 2008). Under normal conditions, the 
expression of MRP1 in the liver is low (Deeley et al., 2006; Stride et al., 1997). In vitro studies 
have established that MRP1 can transport a variety of physiological organic anions including 
drugs and their conjugated metabolites. For example, MRP1 can transport endogenous 
substances such as 17 beta-estradiol glucuronide, glutathione, leukotriene C4, folic acid, and 
vitamin B12, which may indicate its physiological role in cellular defense and oxidative stress   
(Deeley et al., 2006; Stride et al., 1997). 
Multidrug Resistance-Associated Protein 3 (MRP3) 
 MRP3, encoded by the ABCC3 gene, actively transports organic ions using energy 
generated by the hydrolysis of ATP. MRP3 is localized on the basolateral membrane of 
hepatocytes but is expressed in other tissues such as the gut, kidney, and adrenal cortex (Scheffer 
et al., 2002). In the context of the liver, MRP3 is thought to play an adaptive role in response to 
hepatocellular stress as evidenced by the upregulation of MRP3 in cholestatic conditions (Chai et 
al., 2012; Donner et al., 2001). MRP3 transports bulky organic anions from the hepatocyte to the 
systemic circulation and preferentially mediates the transport of glucuronide and, to a lesser 
extent, sulfate conjugates (e.g. bilirubin glucuronide, bile acid conjugates) (Borst et al., 2002; 
Hirohashi et al., 2000). Although MRP3 has been studied in the context of bile acid transport, 
several drugs and/or metabolites have been identified as MRP3 substrates such as acetaminophen 
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glucuronide, methotrexate, and sorafenib (Canet et al., 2015; Tomonari et al., 2016; Xiong et al., 
2002; Zeng et al., 2001).  
Multidrug Resistance-Associated Protein 4 (MRP4) 
 In contrast to MRP3, MRP4 (ABCC4) transports a dynamic range of endogenous 
molecules such as folate, bile acids, uric acid, eicosanoids, steroid hormones, and cyclic 
nucleotides (Borst et al., 2002; Zelcer et al., 2003). Although first characterized as a transporter 
that confers resistance to cytotoxic agents, MRP4 has since shown broad substrate specificity to 
drugs from many classes including antibiotics, antivirals, and cardiovascular agents. MRP4 is 
generally expressed in tissues with a barrier function such as the liver, brain, and intestine. In the 
liver, MRP4 is localized on the basolateral membrane and translocates molecules from the 
hepatocyte back to the systemic circulation. Similar to MRP3, it is thought that the physiological 
role of MRP4 is to protect the liver from toxic accumulation of bile acids as evidenced by 
marked increases in MRP4 expression in cholestasis (Gradhand et al., 2008). This hypothesis is 
further supported in Mrp4-knockout mice that exhibited severe obstructive cholestasis in the 
absence of Mrp4 (Mennone et al., 2006). 
Liver Disease 
 The effects of liver disease on hepatic transporter expression and function in humans are 
described in the following section. 
Cholestasis 
 Cholestasis is the impairment of bile formation (hepatocellular) and/or flow (obstructive) 
that can arise from a number of intrinsic and extrinsic factors. In response to accumulating bile 
constituents, adaptive mechanisms induce hepatoprotective systems (e.g. bile acid transporter 
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expression) aimed at reducing intracellular accumulation of bile acids, which can be hepatotoxic 
due to their detergent-like properties. 
The functional role of transporters in cholestasis is highlighted in patients harboring 
mutations in the ABC11 (BSEP) gene known as progressive familial intrahepatic cholestasis 2 
(PFIC2). First described by Clayton et al. (1969), the PFIC-2 phenotype is illustrated by pruritus, 
jaundice, and clinical signs of cholestasis (discolored stools, dark urine), which often leads to 
fulminant liver failure and death early in life (Clayton et al., 1969; Jacquemin et al., 2012). 
Message and protein analysis of hepatic bile acid uptake transporters (e.g. NTCP, OATP1B1 and 
OATP1B3) were found to be downregulated compared to control samples, whereas 
OATP2B1was unaffected (Keitel et al., 2005). Interestingly, MRP4, but not MRP3 was strongly 
upregulated in PFIC-2 livers, consistent with an adaptive response to increased hepatocellular 
bile acid concentrations. Although it is not clear why the authors did not observe increased 
MRP3 as would be expected in cholestasis, it must be noted that the sample size was small (n=4 
PFIC-2 and n=3 control samples). MRP2 was localized to the canalicular membrane and 
appeared to be downregulated in PFIC-2; however, this result did not reach statistical 
significance (Keitel et al., 2005). 
Because the etiologies of cholestasis can be diverse, altered transporter function may be 
causal or an adaptive response to cholestasis, or both. For example, intrahepatic cholestasis of 
pregnancy (ICP) is an acute form of cholestasis that typically presents in the third trimester of 
pregnancy and is associated with premature delivery, respiratory distress, and intrauterine death 
(Rook et al., 2012). In vivo studies revealed that the transcriptional dynamics of BSEP were 
inversely correlated with serum 17β-estradiol (E2) levels, implicating E2 levels in the repression 
of BSEP, which may increase susceptibility to ICP (Chen et al., 2015; Song et al., 2014). In the 
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same study, repression of BSEP expression also was demonstrated in human primary 
hepatocytes (Song et al., 2014). The procholestatic effects of estrogens and progesterone may 
also alter Mrp2; E2 administration causes endocytic internalization, as well as decreased 
expression and function of Mrp2 in rodents (Mottino et al., 2002; Trauner et al., 1997). 
Downregulation of hepatic sinusoidal transporters (i.e. Oatp1a1, Oatp1a4, and Oatp1b2) are 
likely an adaptive response to increased bile acid concentrations and cholestasis (Geier et al., 
2003; Simon et al., 1996). Although ethical considerations may preclude the quantification of 
hepatic transporter expression in ICP, the expression of OATP1B3 in placenta was decreased in 
pregnant women diagnosed with ICP, consistent with altered transporter expression revealed in 
animal studies (Wang et al., 2012). Zollner et al. (2001) reported that NTCP mRNA correlated 
with serum bile acids in patients with inflammatory cholestasis. Similar observations were 
reported for OATP1B1 and BSEP, but MRP2 mRNA was unchanged (Zollner et al., 2001). 
Given the limited availability of human samples, the application of animal models has 
provided information about the mechanisms underlying transporter expression/function in 
cholestasis. For example, ligation of the common bile duct in rodents leading to cholestasis 
decreased Mrp2 protein levels without a corresponding change in mRNA expression, suggestive 
of an impaired posttranslational modification effect (Paulusma et al., 2000). Immunofluorescent 
staining revealed intracellular localization of Mrp2, which may indicate that the Mrp2 trafficking 
pathway(s) to the canalicular membrane are compromised resulting in the endocytic retention of 
Mrp2 and possible lysosomal degradation. Indeed, retrieval of MRP2 from the canalicular 
membrane into the cytoplasm of hepatocytes has been reported in patients with cholestasis 
(Kojima et al., 2008). Although the exact mechanism underlying this observation has yet to be 
fully elucidated, altered binding and subsequent improper anchoring in the canalicular membrane 
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via radixin and/or other actin filament interactions appears to play a role (Elferink  et al., 2015; 
He et al., 2012; Kojima et al., 2008). 
 Few studies have investigated the effect of cholestasis on the pharmacokinetics and 
hepatobiliary disposition of drugs. Bile duct ligation in rats significantly increased the systemic 
concentrations of morphine-3-glucuronide, the active metabolite of the analgesic morphine, due, 
in part to increased expression of hepatic Mrp3 (Hasegawa et al., 2009). Message and protein 
expression of MRP3 were significantly increased by ~3-fold in patients with obstructive 
cholestasis (Chai et al., 2012); hence, it is conceivable that increased systemic exposure of 
morphine glucuronide(s) could impact pharmacodynamic activity and/or toxicity in this patient 
population. In experimental intrahepatic cholestasis induced by 17α-ethynylestradiol in rats, the 
antidiabetic effect of metformin was reduced due to impaired hepatic uptake of Oct1 (Jin et al., 
2009). Although clinical data are needed, these observations suggest that metformin efficacy 
(e.g. in gestational diabetes) may be impaired in diabetic patients with estrogen-associated ICP. 
In the same rodent model, systemic concentrations of doxorubicin were increased by ~60%, 
which was partially attributed to a ~67% reduction in Mrp2-mediated biliary excretion (Choi et 
al., 2013). Lastly, the apparent half-life and systemic exposure of digoxin was decreased in a 
rodent model of cholestasis, presumably through impaired P-gp-mediated enterohepatic 
recirculation (Harrison et al., 1976). 
Hepatitis C Infection 
 Hepatitis C virus (HCV) is a prevalent form of viral hepatitis. The risk of developing 
cirrhosis, liver cancers, or both is increased in HCV-infected patients (Gower et al., 2014). HCV 
induces hepatoprotective response pathways in response to fibrosis and hepatocellular injury that 
can affect normal gene expression patterns (Kurzawski et al., 2012). The World Health 
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Organization estimates that more than 150 million individuals are chronically infected with HCV 
(Chu et al., 2008). Thus, understanding altered expression and/or function genes involved in 
absorption, distribution, metabolism, and excretion (ADME) is crucial to pharmacotherapeutic 
intervention in this population. 
 Due to inflammation associated with viral infection, prevailing evidence implicates the 
coordinate downregulation of ADME genes by nuclear transcription factors [e.g. PXR, CAR, 
aryl hydrocarbon receptor (AHR), RXR), although interaction(s) with the HCV virus and the 
transcriptional factor RXR have be reported (Clément et al., 2009; Congiu et al., 2009; Tsutsumi 
et al., 2002). Therefore, the pathophysiological role of HCV in altered ADME expression cannot 
be dismissed. Relative mRNA expression of OATP1B1 and OATP2B1 was reduced in the livers 
of patients with chronic HCV infection, although the mechanistic link between inflammatory 
cytokines and OATP downregulation is not clear (Hanada et al., 2012; Nakai et al., 2008). 
Downregulation of NTCP, OAT2, and OCT1 correlated with fibrosis state but another study 
observed no difference compared to control samples (Hanada et al., 2012; Nakai et al., 2008). In 
the presence of HCV-induced cirrhosis, expression of NTCP, OATP1B3, and OCT1 are 
decreased compared to control samples using proteomic analysis (Wang et al., 2016). 
 Hepatic basolateral efflux transporters MRP3 and MRP4 are elevated compared to the 
livers of non-infected controls using mRNA analysis.  These data are consistent with Ogasawara 
et al. (2010) who identified MRP4 mRNA as a potential marker for liver disease (Kurzawski et 
al., 2012; Ogasawara et al., 2010; Ros et al., 2003). Under normal physiological conditions, 
MRP3 and MRP4 protein are expressed at low levels but are significantly increased in 
cholestatic and inflammatory conditions, possibly due to the activation of AHR and/or Nrf2 
observed in end-stage liver disease (Donner et al., 2001; Klaassen  et al., 2010; Mennone et al., 
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2006; Ros et al., 2003; Zollner et al., 2007). In contrast, the canalicular transporters BCRP and 
BSEP appeared to be downregulated whereas MRP1 and P-gp were upregulated. Some 
observations report that MRP2 is unaffected, although Hanada et al. (2012) found a negative 
correlation between fibrosis stage and MRP2 mRNA expression (Hanada et al., 2012; Kurzawski 
et al., 2012; Ogasawara et al., 2010; Ros et al., 2003). The impact of altered mRNA expression 
on protein expression has yet to be quantified, although immunohistochemistry shows increased 
MRP1 and P-gp staining in HCV liver biopsies (Ros et al., 2003). In HCV-induced cirrhosis, 
protein expression of BSEP, MRP2, and P-gp are downregulated whereas BCRP and MATE1 
are unchanged (Wang et al., 2016). To date, the clinical relevance of these findings in HCV-
infected patients is unclear. The systemic clearance of nelfinavir, a P-gp substrate, was reduced 
in HIV/HCV-co-infected patients compared to HIV-infected patients without HCV (Regazzi et 
al., 2005). However, P-gp is expressed in other tissues (e.g. gut, blood brain barrier) and thus, 
must be considered as a contributing factor to altered pharmacokinetics in HCV-associated P-gp 
function. Hepatic uptake and excretion of 
99m
Tc-mebrofenin was decreased in HCV-infected 
patients, suggestive of altered OATP-, MRP2-, and MRP3mediated function (Kula et al., 2010). 
Hepatocellular carcinoma  
 Hepatocellular carcinoma (HCC) is a malignancy of the liver cells that often occurs in 
patients with hepatic diseases such as cirrhosis or chronic hepatitis associated with HCV. There 
is a substantial body of evidence indicating that the expression of hepatic uptake and efflux 
transporters is altered in HCC. NTCP and OATP1B1 are the key transporters responsible for the 
uptake of drugs linked to bile acids as carrier molecules (Briz  et al., 2002; Kramer  et al., 1992; 
Zollner et al., 2005). Studies have shown that the expression of NTCP and OATP1B1 is 
significantly reduced in patients with HCC (Zollner et al., 2005). This is consistent with previous 
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in vitro studies that demonstrated reduced bile acid uptake in hepatoma cell lines (Kullak-Ublick 
et al., 1996; Marchegiano et al., 1992; von Dippe et al., 1990). These studies highlight the risk of 
liver toxicity during bile salt coupled chemotherapy because of reduced expression of NTCP and 
OATP1B1 (Zollner et al., 2005). OATP1B1 and OATP1B3 have been studied extensively in 
different types of cancers including HCC (Thakkar et al., 2015; Vavricka et al., 2004). Although 
initially considered to be liver specific, subsequent studies have shown that OATP1B1 and 
OATP1B3 frequently are expressed in multiple types of cancer tissues (Abe et al., 2001; Hamada  
et al., 2008; Kounnis et al., 2011; Muto et al., 2007; Thakkar et al., 2013; Thakkar et al., 2015). 
After the initial study reporting the reduced expression of OATP1B1 protein in HCC cell lines, 
many other in vitro studies reported similar findings (Cui et al., 2003; Libra  et al., 2006; Monks 
et al., 2007; Vander Borght  et al., 2005; Zollner et al., 2005). However, one study reported no 
significant change in expression of OATP1B1 compared to normal liver (Muto et al., 2007). 
These apparent differences may arise due to different detection methods (Muto et al., 2007; 
Zollner et al., 2005). Similarly, OATP1B3 mRNA and protein are reduced in HCC (Libra  et al., 
2006; Muto et al., 2007; Tsuboyama et al., 2010). Although studies in other cancer types have 
implied a potential association between OATP1B3 expression and clinical outcomes, the 
functional role of OATP1B3 in HCC remains to be investigated (Lockhart et al., 2008; Muto et 
al., 2007). 
 Interestingly, mRNA and protein expression of some other OATPs (e.g. OATP2A1, 
OATP3A1, OATP4A1 and OATP5A1) are reported to be upregulated in primary and metastatic 
liver cancer suggesting the potential role of these OATPs in supplying nutrients and hormones to 
tumor cells (Buxhofer-Ausch et al., 2013; Wlcek et al., 2011). OCT1 is downregulated in HCC 
compared to nonmalignant tissues, apparently through epigenetic mechanisms (Schaeffeler et al., 
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2011). The downregulation of OCT1 expression is clinically associated with tumor progression 
and poor outcomes in patients with HCC (Heise  et al., 2012; Schaeffeler et al., 2011). 
 Several studies indicate that the expression of canalicular and basolateral efflux 
transporters are altered in HCC. Although Borel et al. (2012) reported BCRP mRNA was 
unchanged, other studies reported a significant elevation of BCRP mRNA and protein expression 
in HCC compared to normal liver tissues (Sukowati et al., 2012; Sun et al., 2010). Interestingly, 
BCRP expression increased following chemotherapy in hepatoblastoma patients, which 
highlights its potential role in drug resistance in HCC (Sukowati et al., 2012; Vander Borght et 
al., 2008). On the other hand, BSEP expression was reported to be reduced secondary to 
inflammation-induced decreases in farnesoid X receptor (FXR) (Chen et al., 2013). Although the 
role of BSEP in resistance to chemotherapy is unclear, many studies have shown that elevated 
serum bile acid concentrations in the liver contribute to HCC pathogenesis (Bernstein  et al., 
2009; Chen et al., 2013; Gadaleta et al., 2010; Jansen et al., 2007; Knisely et al., 2006; 
Strautnieks et al., 2008). In fact, children with BSEP deficiency demonstrated a higher risk of 
cholestasis and HCC (Knisely et al., 2006; Strautnieks et al., 2008). Collectively, these findings 
highlight the potential role of BSEP and altered bile acid homeostasis in HCC progression (Chen 
et al., 2013). 
 P-gp expression in HCC displays divergent results at the mRNA and protein levels in 
some in vitro and in vivo studies, which may be related to different detection methods as well as 
tumor heterogeneity (Borel et al., 2012; Ng et al., 2000; Ros et al., 2003; Takanishi et al., 2009; 
Teeter et al., 1993; Zollner et al., 2005). The protein expression of P-gp showed a trend towards 
a reduction in HCC compared to normal hepatocytes (Ng et al., 2000; Takanishi et al., 2009; 
Zollner et al., 2005). In regard to its function, P-gp expression was inversely correlated with 
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chemotherapeutic response in patients with inoperable HCC (Chou et al., 1997; Ng et al., 2000). 
MRP2 expression in HCC was unchanged compared to normal hepatocyte tissues (Namisaki  et 
al., 2014; Pfeifer et al., 2014; Zollner et al., 2005). MRP1, which is not expressed in normal 
hepatocytes, is overexpressed at both the mRNA and protein levels in HCC (Bonin et ak,m 2002; 
Sukowati et al., 2012; Zhao et al., 2010). One study showed that the MRP1 promoter (-1666GG) 
polymorphism was a predictor of poor survival in patients with HCC from Southeast China 
(Zhao et al., 2010). MRP3 and MRP4 mRNA levels were reported to be upregulated in HCC 
(Borel et al., 2012; Nies et al., 2001; Ros et al., 2003). Although several studies have noted the 
altered expression of drug transporters in HCC, further investigations are necessary to examine 
their clinical significance in HCC. 
Human Immunodeficiency Virus (HIV) Infection 
 Similar to viral hepatitis, HIV is associated with chronic inflammation as evidenced by 
the presence of elevated proinflammatory cytokines such as interleukin (IL)-6 and tumor 
necrosis factor (TNF)-α (Appay et al., 2008). For example, mRNA and protein expression of 
major sinusoidal uptake transporters (i.e. OATP1B1, OATP1B3, OATP2B1, OCT1, OCT2, and 
NTCP) were downregulated in human hepatocytes when incubated with TNF- α, which resulted 
in reduced functional activity (Vee et al., 2009). Message and protein levels of MRP2 were 
increased by IL-6 or IL-1β exposure in sandwich-cultured human hepatocytes whereas BSEP 
protein expression appeared to decrease (Diao et al., 2010). In another study, MRP2 and BCRP 
were reported to be downregulated following exposure of IL-6 or IL-1β in primary human 
hepatocytes; therefore, additional mechanistic studies are required to definitively conclude that 
canalicular transporters are upregulated or downregulated. (Vee et al., 2009).). Based on these 
data, it is conceivable that liver transporter expression and/or function may be impacted in HIV-
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infected patients because such signaling molecules can modulate transporters in vitro. It also 
must be noted that the administration of antiretroviral therapy is associated with a reduction in 
cytokine levels that may contribute to interindividual variability in hepatic transporter expression 
in HIV-infected patients (Brazille et al., 2003). 
 Despite the aforementioned data, the effect of HIV infection on the expression of 
transporters has not been evaluated systematically. In addition, coinfection (e.g. bacterial 
infection) could contribute to altered transporter regulation. For example, gene expression of 
hepatic Mrp2, Bcrp, and Oatps was downregulated in HIV-1 transgenic rats co-infected with 
endotoxin (Ghoneim et al., 2016). P-gp and MRP2 protein levels in the rectal-sigmoid colon 
were lower in antiretroviral-naïve patients compared to non-infected subjects; whether similar 
expression patterns occur in the liver remains to be evaluated (De Rosa et al., 2013; Kis et al., 
2016). Data quantifying hepatic transporter protein expression followed by subsequent functional 
studies are needed. Altered ADME processes in clearance organs (i.e. intestine, liver, and 
kidney) in combination with the potential for induction by co-medications (e.g. protease 
inhibitors) highlights the complexity of predicting transporter-mediated drug disposition in HIV-
infected patients (Dixit et al., 2007; Foisy et al., 2008). 
Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis  
 Non-alcoholic fatty liver disease (NAFLD) consists of liver pathology ranging from 
simple steatosis to non-alcoholic steatohepatitis (NASH), an advanced inflammatory state of 
liver disease. NAFLD has become the most common form of liver disease in Western and 
industrialized nations driven by the prevailing obesity epidemic; it is estimated that ~20-30% of 
the general population is affected, although some reports are as high as 50% (Ali et al., 2009; 
Bedogni et al., 2005; Lomonaco et al., 2013; Younossi et al., 2016). For reasons not fully known, 
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some patients with NAFLD develop NASH, which may lead to hepatocarcinoma, cirrhosis, 
and/or fulminant liver failure. Due to the increasing prevalence of NAFLD and NASH, 
considerable research has been dedicated to quantifying how NASH affects ADME 
enzymes/transporters.  These findings may have important implications in the treatment and 
disposition of drugs in this patient population. 
 Global gene expression analysis first implicated a coordinated down regulation of hepatic 
uptake transporters (e.g., OATPs) in patients with NASH (Lake et al., 2011). Further reports by 
Cherrington and colleagues revealed a significant increase in OATP1B1, but a decrease in 
OATP1B3, and no change in OATP2B1 in human liver biopsies using immunoblot techniques.  
Interestingly,  no differences were observed in these transporters based on mRNA analysis 
(Clarke et al., 2014b). These findings are in contrast to data obtained from a commonly used 
diet-induced rodent model of NASH; mRNA and protein analyses were in agreement that rodent 
orthologues of human OATPs were decreased (Clarke et al., 2014a; Clarke et al., 2014b). These 
results support increased systemic concentrations of simvastatin acid, an OATP/Oatp substrate, 
in the rodent model of NASH compared to wild-type rats (Clarke et al., 2014a). NTCP, the 
primary hepatic bile acid transporter, is decreased in patients with NASH compared to patients 
with simple steatosis based on real-time reverse transcription polymerase chain reaction and 
immunoblot techniques; these data are consistent with a recent publication reporting that serum 
bile acids are increased in patients with NASH (Aguilar-Olivos et al., 2015; Ferslew et al., 
2015b). Rat Ntcp and Oat2 also were shown to decrease in an experimental rodent model of 
NASH, presumably mediated through pro-inflammatory cytokines known to decrease hepatic 
transporter expression (Fisher  et al., 2009; Tanaka et al., 2012). Pharmacokinetic studies that 
quantify the functional impact of altered uptake transporter expression are limited in humans. 
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However, our group recently reported increased systemic concentrations of 
99m
Tc-mebrofenin, a 
hepatobiliary diagnostic agent and OATP/MRP2/MRP3 substrate, in patients with biopsy-
confirmed NASH (Slizgi et al., (in preparation)). 
 In what appears to be an adaptation to prevent further damage by toxicants, hepatic efflux 
transporters are increased in NASH. For example, MRP3-6 are induced in liver biopsies from 
NASH patients, similar to findings in a rodent model of NASH (Hardwick  et al., 2011; Lickteig  
et al., 2007; Tanaka et al., 2012). Similarly, Mrp1 mRNA is increased ~5-fold compared to 
control animals (Tanaka et al., 2012). Functional drug disposition studies corroborate these 
findings as evidenced by increased plasma acetaminophen glucuronide concentrations in diet-
induced NASH animals attributable to increased Mrp3 expression (Lickteig  et al., 2007). 
Administration of morphine and acetaminophen to patients with NASH resulted in increased 
systemic concentrations of the glucuronide conjugates, consistent with increased function of 
MRP3 in this patient population (Canet  et al., 2015; Ferslew et al., 2015a). Although MRP2 is 
increased, a growing body of evidence supports a functional decrease in MRP2 due to disruption 
of cellular trafficking and/or improper localization away from the canalicular membrane (Fisher 
et al., 2009). This is supported by reports of reduced biliary excretion of acetaminophen 
glucuronide and pemetrexed, consistent with impaired Mrp2 function (Dzierlenga  et al., 2016; 
Lickteig et al., 2007). These findings corroborate enhanced hepatic retention and a prolonged 
half-life of the liver contrast agent gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid 
(Gd-EOB-DTPA) in NASH-induced rats (Tsuda et al., 2011). In contrast to Hardwick et al. 
(2011), who reported an increase in total MRP2 in human liver biopsies, a recent study reported 
decreased MRP2 in NASH patients, which correlated inversely with progression of NAFLD 
(Okushin et al., 2015). Decreased Mrp2 mRNA and protein expression were reported in a diet-
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induced rodent model of hypercholesterolemia (Okushin et al., 2016). Apparent discrepancies 
may be due to differences in analytical method(s) or to the heterogeneous population of NASH 
patients and interindividual variability in MRP2 expression.  Regardless, functional studies in 
humans are needed to evaluate the impact of altered MRP2 expression and/or localization. 
Although pharmacokinetic studies are limited, our group recently reported increased hepatic 
exposure of 
99m
Tc-mebrofenin in patients with biopsy-confirmed NASH, which lends credence 
to the hypothesis that altered trafficking and localization of MRP2 result in a functional decrease 
in MRP2-mediated efflux (Slizgi et al., (in preparation)). BCRP mRNA and protein expression is 
increased in NASH liver biopsies, but this finding was not observed in rodent models of NASH 
(Canet et al., 2014; Hardwick et al., 2011). Finally, rodent P-gp and BSEP/Bsep expression 
appear to be increased in NASH but protein expression has not been quantified (Aguilar-Olivos 
et al., 2015; Canet et al., 2014; Okushin et al., 2015). 
Primary Biliary Cholangitis  
Primary biliary cholangitis (PBC) is a disease that causes bile duct inflammation and 
chronic damage over time. This leads to a buildup of bile acids and toxins that can cause 
cholestasis, fibrosis, and cirrhosis. Several studies have reported that the mRNA and protein 
expression of NTCP, OATP1B1, and OATP1B3 are downregulated in PBC as compared to 
normal liver (Kojima  et al., 2003; Takeyama et al., 2012; Takeyama et al., 2015; Zollner et al., 
2003). These findings suggest the potential adaptation by hepatocytes to limit the accumulation 
of toxic bile acids (Zollner et al., 2003). 
 Studies performed in in vitro systems and human liver confirmed that efflux transporter 
expression is maintained or had a trend towards increased expression in PBC as compared to 
normal liver (Kojima  et al., 2003; Takeyama et al., 2012; Zollner et al., 2003). Zollner et al. 
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(2003) reported that BSEP and MRP2 expression were unchanged whereas expression of P-gp 
and MRP3 was upregulated in PBC. Interestingly, it was reported that these alterations may be 
related to the adaptation of transporters and the expression patterns may change from the early to 
late stage PBC (Takeyama et al., 2009; Takeyama et al., 2012). In addition to the changes in 
expression, the localization of MRP2 was altered in PBC stage III (Kojima  et al., 2003). MRP1 
and organic solute transporter (OST) α/β are upregulated in patients with PBC, presumably in 
inflamed tissue (Boyer et al., 2006; Kula et al., 2010; Takeyama et al., 2009; Teeter et al., 1993). 
MRP1 expression has been reported in  macrophages, which may further supports the hypothesis 
that MRP1 is upregulated during inflammation (Jorajuria et al., 2004). Further studies are 
required to better understand the functional role of MRP1 and OST α/β in PBC. 
Summary and Perspective 
 Among the challenges in diagnosing and treating liver disease is understanding its impact 
on hepatic transporter function and the disposition of clinically-relevant drugs, which may be 
further influenced by genetic and other environmental factors. The field of drug transport 
continues to evolve as more transporter-specific substrates and inhibitors are identified. 
However, clinically relevant probes are lacking due, in part, to the multiplicity of drug 
transporters (i.e. overlapping substrate specificity between transporters), the dynamic interplay 
between uptake, efflux, and metabolism processes, and the inability to quantify tissue-specific 
drug concentrations. Advances in magnetic resonance imaging (MRI) and positron emission 
tomography (PET), coupled with development of MRI and PET probes that are substrates for 
specific transporters, will continue to facilitate the quantification of hepatic transporter function, 
particularly canalicular efflux transporters, which should improve our ability to assess transporter 
function in diseases afflicting the liver. Finally, the amalgamation of such functional data can be 
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applied to pharmacokinetic modeling and systems pharmacology approaches to better understand 
and predict drug disposition in patients with liver disease. This will improve our fundamental 
understanding of drug efficacy and safety in these patient populations.  
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Table 1.1 Altered Expression of Hepatic Transporters in Liver Disease 
Transporter  Liver Disease  
Alterations  
(mRNA) 
 
Alterations  
(protein) 
 Technique  Reference 
NTCP/Ntcp  
Cholestasis 
 
↓ (~2-fold, human); 
↓ (~3-fold, rodent) 
 
↓ (~3-fold, human); 
↓ (~3-fold, rodent) 
 
RT-qPCR; 
NB; WB 
 
Chai et al., 2012; 
Chen et al., 2008; 
Geier et al., 2003; 
Zollner et al., 
2001 
HCV 
↑ (human) or 
↔ (human);  
↔ (rodent) 
- RT-qPCR 
Hanada et al., 
2012; Kikuchi et 
al., 2010; Nakai et 
al., 2008  
HCC ↓ (~2-fold, human) ↓ (human) 
RT-qPCR; 
NB 
Kullak-Ublick  et 
al., 1996; Zollner 
et al., 2005 
HIV - - - - 
NASH 
↑ (~1.5-fold, human)  
or ↓ (~2-5-fold, human); 
↓ (~2-fold, rodent) 
↓ (~5-fold, human) 
ISH; RT-
qPCR WB 
Aguilar-Olivos  et 
al., 2015; Fisher 
et al., 2009; 
Okushin et al., 
2015; Tanaka et 
al., 2012 
PBC/cirrhosis ↓ (~1.5-3-fold, human) ↓ (~2-fold, human) 
RT-qPCR; 
WB; IF 
Kojima  et al., 
2003; Takeyama  
et al., 2012; 
Zollner et al., 
2003 
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Transporter  Liver Disease  
Alterations  
(mRNA) 
 
Alterations  
(protein) 
 Technique  Reference 
OATP1B1/ 
Oatp1b2 
 
Cholestasis 
 
↓ (~2-fold, human); 
↓ (~2-fold, rodent) 
 
↔ (rodent) 
 
NB; RT-
qPCR; WB 
 
Chen et al., 2008; 
Geier  et al., 
2003; Zollner et 
al., 2001  
HCV 
↓ (~1.5-fold human); 
↔ (rodent) 
- RT-qPCR 
Hanada  et al., 
2012; Kikuchi et 
al., 2010; Nakai et 
al., 2008 
     
HCC 
↓ (~2-3-fold, human)  
or ↔ (human)  
↓ (human) 
RT-qPCR; IF; 
IHC; WB 
Cui et al., 2003; 
Kullak-Ublick  et 
al., 1996; Libra et 
al., 2006; Monks 
et al., 2007; 
Vavricka et al., 
2004 
HIV - - - - 
NASH 
↔ (human); 
↑ (~10-fold, rodent) or  
↔ ( rodent) or  
↓ (~2-fold, rodent) 
↑ (~5-fold, human); 
↑ (~10-fold, rodent) or  
↔ ( rodent) 
ISH; RT-
qPCR; WB 
Bedogni  et al., 
2005; Canet et al., 
2014; Clarke  et 
al., 2014; Fisher  
et al., 2009  
PBC/cirrhosis 
↔ (human) or ↓ (~2-3-
fold, human) 
↔ (human) or ↓ (~2-
fold, human) 
RT-qPCR; IF; 
WB 
Kojima et al., 
2003; More et al., 
Takeyama  et al., 
2012; 2013; 
Zollner et al., 
2003 
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Transporter  Liver Disease  
Alterations  
(mRNA) 
 
Alterations  
(protein) 
 
Technique 
 
Reference 
OATP1B3 
 
Cholestasis 
 
↓ (~2-fold, human); 
↓ (~2-fold, rodent) 
↔ (rodent) 
NB; RT-
qPCR; WB 
Chen et al., 2008; 
Geier et al., 2003  
HCV - - - - 
HCC  ↓ (~5-50-fold, human) ↓ (human) 
NB; RT-
qPCR; WB; 
IHC; IF 
Libra et al., 2006; 
Tsuboyama et al., 
2010; Vavricka et 
al., 2004 
 
HIV 
 
- - - - 
NASH ↔ (human) ↓ (~10-fold, human) ISH; WB 
Clarke  et al., 
2014 
PBC/cirrhosis 
↔ (human) or ↓ (~2-
fold, human) 
↔ (human) or ↓ (~2-3-
fold, human) 
RT-qPCR; IF; 
WB 
Kojima  et al., 
2003; More et al., 
2013; Takeyama  
et al., 2012; 
Zollner et al., 
2003 
OATP2B1/ 
Oatp2b1 
 
Cholestasis 
 
- 
 
- - 
 
- 
HCV 
↓ (, human); 
↑ (~2-fold rodent) 
- RT-qPCR 
Hanada  et al., 
2012; Kikuchi et 
al., 2010 
HCC - - - - 
HIV ↔ (rodent) - RT-qPCR 
Ghoneim et al., 
2016 
NASH 
↔ (human); 
↔ (rodent) 
↔ (human); 
↓ (~2-fold, rodent) 
ISH; WB 
Canet  et al., 
2014; Clarke  et 
al., 2014 
PBC/cirrhosis ↑ (human) ↑ (human)  
RT-qPCR ; 
WB 
 More et al., 2013 
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Transporter  Liver Disease  
Alterations  
(mRNA) 
 
Alterations  
(protein) 
 Technique  Reference 
OAT2/Oat2  
Cholestasis 
 
- 
 
- 
 
- 
 
- 
HCV 
↓ (human); 
↔ (rodent) 
- RT-qPCR 
Hanada  et al., 
2012; Kikuchi et 
al., 2010 
HCC - - - - 
HIV - - - - 
NASH ↓ (~2-fold, rodent)  RT-qPCR Fisher et al., 2009 
PBC/cirrhosis - - - - 
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Transporter  Liver Disease  
Alterations  
(mRNA) 
 
Alterations  
(protein) 
 Technique  Reference 
OCT1/Oct1  
Cholestasis  ↓ (~3-fold rodent) 
 
↓ (~2-fold rodent) 
 
RT-qPCR; 
WB 
 
Trauner et al., 
1997 
HCV  
↔ (human) or  
↓ (human); 
↓ (~2-fold rodent) 
- RT-qPCR 
Hanada  et al., 
2012; Nakai et al., 
2008 Kikuchi et 
al., 2010;  
HCC  ↓ (~2-3-fold, human) ↓ (human) 
RT-qPCR; 
WB; IF 
Heise  et al., 
2012; Schaeffeler 
et al., 2011 
HIV  - - - - 
NASH  - - - - 
PBC/cirrhosis  - - - - 
MRP1/Mrp1  
Cholestasis 
 
- 
 
- 
 
- 
 
- 
HCV ↑ (10-fold human) ↑ (human) 
RT-qPCR; 
IHC 
Ros et al., 2003 
HCC ↑ (human) ↑ (human) 
RT-qPCR ; 
WB 
Bonin  et al., 
2002; Ros et al., 
2003; Zhao et al., 
2010 
HIV ↔ (rodent) - RT-qPCR 
Ghoneim et al., 
2016 
NASH 
↑ (~2-fold, human); 
↑ (~2-fold, rodent) 
↑ (~2-fold, human) 
ISH; RT-
qPCR; WB 
Canet et al., 2014; 
Hardwick  et al., 
2011; Tanaka et 
al., 2012 
PBC/cirrhosis ↑ (human) ↑ (human) 
RT-qPCR ; 
IHC 
More et al., 2013; 
Ros et al., 2003 
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Transporter  Liver Disease  
Alterations  
(mRNA) 
 
Alterations  
(protein) 
 Technique  Reference 
MRP3/Mrp3  
Cholestasis 
 
↑ (~3-fold, human) 
 
↑ (~3-fold, human) 
 
RT-qPCR ; 
IHC 
 
Chai et al., 2012 
HCV 
↑ (~10-fold, human); 
↔ (rodent) 
↑ (~2-20-fold, human) 
RT-qPCR ; 
WB 
Kikuchi et al., 
2010; Ogasawara 
et al., 2010; Ros  
et al., 2003; 
HCC 
↑ (~2-fold, human); 
↔ (human) 
- 
 
RT-qPCR 
Bonin  et al., 
2002; Borel  et 
al., 2012; Nies et 
al., 2001; Ros  et 
al., 2003 
HIV ↑ (~3-fold, rodent) - RT-qPCR 
Ghoneim et al., 
2016 
NASH 
↑ (~2-fold, human);  
↓ (~2-fold, rodent) or  
↑ (~5-fold, rodent) 
↑ (~2-fold, human);  
↓ (~2-fold, rodent) or  
↑ (~3-fold, rodent) 
ISH; WB 
Canet et al. 2014; 
Clarke  et al., 
2014; Hardwick 
et al., 2011 
PBC/cirrhosis 
↑ (~10-fold, human) or ↓ 
(human, diabetic 
cirrhosis); ↔ (human, 
alcohol cirrhosis)  
↑ (human) and ↑ (human, 
diabetic and alcohol 
cirrhosis) 
RT-qPCR ; 
IHC 
Kojima et al., 
2003; More et al., 
2013; Ros  et al., 
2003; Zollner et 
al., 2003 
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Transporter  Liver Disease  
Alterations  
(mRNA) 
 
Alterations  
(protein) 
 Technique  Reference 
MRP4/Mrp4  
Cholestasis 
 
↑ (~1.5-fold, human) 
 
 
 
RT-qPCR   
Chai et al., 2012; 
Chen et al., 2008 
HCV 
↑ (~2-fold, human);  
↑ (~2-fold, rodent) 
↑ (~3-fold, human) 
RT-qPCR; 
WB 
 
Kikuchi et al., 
2010; Kurzawski  
et al., 2012; 
Ogasawara et al., 
2010 
HCC ↑ (~ 2-fold, human) - RT-qPCR  Borel et al., 2012 
HIV ↔ (rodent) - RT-qPCR  
Ghoneim et al., 
2016 
NASH 
↑ (~3-fold, human);  
↑ (~3-40-fold, rodent) 
↑ (~3-fold, human);  
↑ (~3-fold, rodent) 
ISH; RT-
qPCR; WB 
 
Canet et al., 2014; 
Clarke et al., 
2012; Hardwick  
et al., 2011; 
Tanaka  et al., 
2012 
PBC/cirrhosis ↔ (human) or ↑ (human) ↑ (human) 
RT-qPCR; 
IHC; WB 
 
More et al., 2013; 
Takeyama et al., 
2012 
BCRP/Bcrp  
Cholestasis 
 
- 
 
- 
 
- 
 
- 
HCV 
↓ (~2-fold, human); 
↓ (~2-fold, rodent) 
- RT-qPCR 
Kikuchi et al., 
2010; Kurzawski 
et al., 2012 
HCC 
↑ (human);  
↔ (human) 
↑ (human) 
RT-qPCR ; 
IHC 
Borel et al., 2012; 
Sukowati et al., 
2012; Sun et al., 
2010 
HIV ↔ (rodent) - RT-qPCR 
Ghoneim et al., 
2016 
NASH 
↑ (~2-fold, human);  
↑ (~5-fold, rodent) 
↑ (~2-fold, human);  
↔ (rodent) 
RT-qPCR; 
WB 
Canet  et al., 
2014; Hardwick 
et al., 2011 
PBC/cirrhosis ↑ (~ 2-fold, human) ↑ (human) 
RT-qPCR ; 
WB; IHC 
Hardwick  et al., 
2014; More et al., 
2013 
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Transporter  Liver Disease  
Alterations  
(mRNA) 
 
Alterations  
(protein) 
 Technique  Reference 
BSEP/Bsep  
Cholestasis 
 
↔ (human) or   
↓ (~2-fold, human); 
↓ (~2-fold, rodent) 
 
↔ (human); 
↓ (~2-fold, rodent) 
 
RT-qPCR; 
WB; IHC 
 
Chai et al., 2012; 
Chen et al., 2008; 
Song  et al., 2007; 
Zollner et al., 
2001 
HCV 
↑ (~2-fold human) or  
↓ ( human); 
↔ (rodent) 
↔ (human) 
RT-qPCR ; 
IHC 
Hanada et al., 
2012; Kikuchi et 
al., 2010 
Ogasawara  et al., 
2010; Ros  et al., 
2003 
HCC ↓ (human) ↓ (human) 
RT-qPCR; 
WB 
Chen et al., 2013; 
Knisely et al., 
2006 
HIV - - - - 
NASH 
↑ (~5-fold, human) or  
↓ (~2-fold, human); 
↔ (rodent) 
- RT-qPCR 
Aguilar-Olivos  et 
al., 2015; 
Okushin et al., 
2015; Tanaka et 
al., 2012 
PBC/cirrhosis 
↔ (human) or   
↓ (human) 
↔ (human) or   
↓ (human) 
IHC; RT-
qPCR; WB 
Kojima et al., 
2003; Takeyama 
et al., 2012 
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Transporter  Liver Disease  
Alterations  
(mRNA) 
 
Alterations  
(protein) 
 Technique  Reference 
MRP2/Mrp2  
Cholestasis 
 
↔ (human) or  
↓ (~2-fold, human) 
 
↓ (human) 
 
RT-qPCR; 
IHC 
 
Chen et al., 2008; 
Chai  et al., 2012; 
Zollner et al., 
2001  
HCV 
↔ (human) or  
↓ (~2-fold human); 
↔ (rodent) 
↔ (human) 
RT-qPCR; 
IHC 
Hanada et al., 
2012; Kikuchi et 
al., 2010 
Kurzawski  et al., 
2012; Ogasawara 
et al., 2010; Ros  
et al., 2003 
HCC ↔ (human) ↔ (human) 
RT-qPCR; 
IHC 
Hanada et al., 
2012; Namisaki et 
al., 2014 
HIV ↑ (~2-fold, rodent) ↑ (~1.5-fold, rodent) qPCR; WB 
Ghoneim et al., 
2016 
NASH 
↔ (human) or  
↓ (~2-fold, human); 
↔ (rodent) or  
↑ (~2-fold, rodent) 
↑ (~3-fold, human); 
↑ (~2-fold, rodent) or  
↔ (rodent) 
ISH; RT-
qPCR; WB 
Canet et al., 2014; 
Clarke et al., 
2014; Fisher et 
al., 2009; 
Hardwick et al., 
2011; Okushin et 
al., 2015; Tanaka 
et al., 2012 
PBC/cirrhosis ↔ (human) ↔ (human) 
RT-qPCR; 
WB; IHC 
Kojima  et al., 
2003; More et al., 
2013; Takeyama  
et al., 2012; 
Zollner et al., 
2003 
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Transporter  Liver Disease  
Alterations  
(mRNA) 
 
Alterations  
(protein) 
 Technique  Reference 
P-gp  
Cholestasis 
 
- 
 
↔ (human) 
 
IHC 
 
Zollner et al., 
2001 
HCV 
↑ (~2-5-fold, human);  
↔ (rodent) 
↑ (~20-fold, human) 
RT-qPCR; 
IHC 
Kikuchi et al., 
2010; Kurzawski  
et al., 2012; 
Ogasawara  et al., 
2010; Ros  et al., 
2003 
HCC ↑ (~ 2-5-fold, human) ↑ (human) 
RT-qPCR; 
WB 
Borel  et al., 
2012; Ng  et al., 
200; Ros  et al., 
2003; Takanishi 
et al., 2009; 
Teeter et al., 
1993; Zollner et 
al., 2005 
HIV - ↑ (~1.5-fold, rodent) WB 
Ghoneim et al., 
2016 
NASH ↑ (~2-fold, rodent) ↑ (~2-fold, rodent) ISH;WB Canet et al., 2014 
PBC/cirrhosis ↑ (human) ↑ (5-fold, human) 
RT-qPCR; 
WB; IHC 
Ros  et al., 2003; 
Zollner et al., 
2003 
Abbreviations: no data available (-); hepatocellular carcinoma (HCC); hepatitis C virus (HCV); human immunodeficiency virus (HIV); 
immunofluorescence microscopy (IF); immunohistochemistry (IHC);  in situ hybridization (ISH); nonalcoholic steatohepatitis (NASH); northern 
blot (NB); primary biliary cholangitis (PBC); quantitative reverse transcription polymerase chain reaction (RT-qPCR); western blot (WB) 
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Table 1.2 Altered Transporter-Mediated Drug Disposition in Liver Disease 
Liver Disease  Drug  Drug Class  
Altered Drug 
Disposition 
 
Implicated 
Transport Protein 
 Reference 
Cholestasis 
 Diethylstilbestrol  
Estrogen-replacement 
therapy 
 
↓ systemic clearance 
and ↑ liver injury 
 ND (rodent)  Klaassen et al., 1973 
 Rifampin  Antibiotic  ↑ half-life  ND (human)  Spring 1968 
 Digoxin  Cardiac glycoside  ↓ half-life  
ND (impaired 
enterohepatic 
recirculation) 
 Harrison et al., 1976 
 Doxorubicin  Chemotherapeutic  
↑ systemic 
concentrations 
 Mrp2 (rodent)  Choi et al., 2013 
 Metformin  Antidiabetic  
↓ systemic clearance 
and hepatic uptake; 
↓ suppression of 
glucose production 
 Oct1 (rodent)  Jin et al., 2009 
 Metformin  Antidiabetic  
↓ systemic clearance 
and hepatic uptake; 
↓ suppression of 
glucose production 
 Oct1 (rodent)  Jin et al., 2009 
HCV 
 Nelfinavir  Antiretroviral  
↑ systemic 
concentrations 
 P-gp (human)  Regazzi et al., 2015 
 
99m
Tc-mebrofenin  
Hepatobiliary 
radiodiagnostic  
 
↓ hepatic uptake, 
 ↑ Tmax, ↓ hepatic 
excretion 
 
OATP, MRP2 
(human) 
 Hanada et al., 2012 
HCC  Gd-EOB-DTPA  
Hepatobiliary 
contrast agent 
 ↑ or ↓ signal intensity  
OATP1B1 (human) 
OATP1B3 (human) 
MRP2 (human) 
 
Enomoto et al., 
2002; Shin et al., 
2007 
HIV  -  -  -  -  - 
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Liver Disease  Drug  Drug Class  
Altered Drug 
Disposition 
 
Implicated 
Transport Protein 
 Reference 
NASH  
APAP/APAP-
glucuronide 
 Analgesic  
↑ systemic 
concentrations;  
↓ biliary excretion 
 
MRP3 (human); 
Mrp2/Mrp3 (rodent) 
 Ferslew et al., 2015a 
Morphine/morphine-
glucuronide 
 Analgesic  
↑ systemic 
concentrations 
 MRP3 (human)  Canet et al., 2015 
99m
Tc-mebrofenin  
Hepatobiliary 
diagnostic  
 
↑ systemic 
concentrations;  
↑ hepatic exposure 
 
OATP, MRP2, MRP3 
(human) 
 
Slizgi et al.,  
(in preparation) 
Gd-EOB-DTPA  
Hepatobiliary 
diagnostic  
 ↑ hepatic exposure  Mrp2 (rodent)  Tsuda et al., 2011 
Methotrexate  Chemotherapeutic  
↑ liver and ↑ GI 
toxicity 
 ND (rodent)  
Hardwick et al., 
2014 
Pemetrexed  Chemotherapeutic  
↑ systemic 
concentrations;  
↓ biliary excretion 
 Mrp2 (rodent)  
Dzierlenga et al., 
2016 
Simvastatin  Cholesterol-lowering  
↑ systemic 
concentrations 
 Oatp (rodent)  Clarke et al., 2014a 
PBC/cirrhosis  Gd-EOB-DTPA  
Hepatobiliary 
contrast agent 
 
↓ hepatic signal 
intensity 
 OATP (human)  
Takeyama et al., 
2015 
Abbreviations: data not available (-); hepatocellular carcinoma (HCC); hepatitis C virus (HCV); human immunodeficiency virus (HIV); 
immunohistochemistry (IHC); nonalcoholic steatohepatitis (NASH); primary biliary cholangitis (PBC) 
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Bile Acids and their Pathophysiological Role in Drug-Induced Liver Injury 
Bile acids are a family of cholesterol-derived acidic steroids that function as emulsifying 
agents in the digestion and absorption of triglycerides and other complex lipids. Despite their 
well-known role in digestion/absorption, bile acids also act as signaling molecules and have been 
implicated in the etiology and pathogenesis of disease (Chiang et al., 2013). Hence, there is 
significant interest in understanding the role of bile acids in the pathophysiology of disease. This 
section will briefly review bile acids and their role in drug-induced liver injury (DILI), a liver 
pathology that is a focus of this dissertation.  
Synthesis and Transport 
Bile acids are amphipathic molecules consisting of four linked hydrocarbon rings with 
two or three hydroxyl groups and a terminal carboxyl group. Bile acid species are defined by 
their differences in side chain structure, stereochemistry of the six-member ring, and the position 
and stereochemistry of various hydroxyl groups; an excellent review of bile acid structure is 
provided by Monte et al. (2009). In humans, primary bile acids (i.e. cholic acid and 
chenodeoxycholic acid) are synthesized by the hydroxylation of cholesterol by P450 cholesterol 
7alpha-hydroxylase (CYP7A1), a rate-limiting enzyme in bile acid synthesis, followed by 
hydroxylation by P450 sterol 12α-hydroxylase (CYP8B1) (Martin et al., 1993; Swell et al., 1981; 
Zhang et al., 2001). This synthetic pathway is known as the “classic” pathway and accounts for 
~90% of total bile acid production (Ferdinandusse et al., 2006). The “alternative” pathway 
accounts for remaining bile acid synthesis and is initiated by P450 oxysterol 7α-hydroxylase 
(CYP27A1) in extrahepatic tissues (e.g. vascular endothelium) followed by hydroxylation by 
CYP7A1 in the liver (Norlin et al., 2007; Wu et al., 1999). Finally, bile acids are conjugated with 
taurine or glycine catalyzed by bile acid CoA:amino acid N-acyltransferase (Falany et al., 1994; 
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Scherstén et al., 1967); bile acids also can be conjugated with glucuronide or sulfate moieties, 
although to a less extent than amine conjugates. In total, over 16 enzymes have been identified in 
the conversion of cholesterol to various bile acid species (Russell et al., 2009). 
Amidated bile acids are actively excreted from hepatocytes into the canalicular 
membrane by the bile salt export pump (BSEP) in an adenosine triphosphate (ATP)-dependent 
manner. Other canalicular transport proteins, such as the multidrug resistance-associated protein 
(MRP) 2 and the breast cancer resistance protein (BCRP), have been shown to transport 
glucuronide and sulfate-bile acid conjugates (Blazquez et al., 2007; Akita et al., 2001). 
Alternatively, bile acids can be transported into the systemic circulation by basolateral efflux 
transporters including organic solute transporter (OST)α and OSTβ, MRP3, and MRP4 (Trauner 
and Boyer et al., 2003). Following excretion into the bile canaliculus, bile acids are stored in the 
gallbladder prior to secretion into the duodenum through the sphincter of Oddi. Although less 
recognized, cholangiocytes, epithelial cells lining the bile duct, are also capable of transporting 
bile acids. For example, the organic anion-transporting polypeptide (OATP) 1A2 is located on 
the apical membrane of cholangiocytes (Lee et al., 2005). Various OATP1A2 substrates 
including bile acids (e.g. taurocholic acid), steroid conjugates, and xenobiotics have been 
identified (Franke et al., 2009). The sodium-dependent bile acid transporter (ASBT) is another 
apical transporter capable of translocating bile acids from the canalicular space into 
cholangiocytes (Alpini et al., 1997; Alpini et al., 2001). Basolateral transporter expression (i.e. 
OSTα/OSTβ, MRP2, and MRP3) has been reported in cholangiocytes and these transporters are 
thought to play a role in the cholehepatic shunt pathway under pathophysiological conditions 
(Pauli-Magnus et al., 2006). For example, ASBT is induced in response to chronic cholestasis, 
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which is hypothesized to enhance biliary lipid secretion and choleresis (Alpini et al., 2001; 
Alpini et al., 2005). 
Following gallbladder contraction by cholecystokinin and subsequent release into the 
intestinal tract, bile acids are efficiently reabsorbed in the terminal ileum by ASBT and 
OSTα/OSTβ (Balakrishnan et al., 2006; Ballatori et al., 2005; Dawson et al., 2005; Shneider et 
al., 1995; Wong et al., 1994). It is estimated that 95% of bile acids are reabsorbed by the 
intestine and returned to the portal vein for active hepatic uptake by Na
+
-taurocholate 
cotransporting polypeptide (NTCP) and OATPs (e.g. OATP1B1 and OATP1B3), thus 
completing the enterohepatic recirculation of bile acids. It must be noted that bile acids undergo 
extensive modification in the intestinal tract mediated by bacterial and host enzymatic processes. 
Bacterial enzymes deconjugate/dehydroxylate bile acids back to their primary bile acid form, 
which can facilitate passive diffusion across the plasma membrane of enterocytes, although 
intestinal transporters readily transport bile acids as well. For example, bacterial 7α-
dehydroxylase converts cholic acid to dehydroxycholic acid by the removal of hydrogen at the 
C7 position (Bokkenheuser et al., 1969). Hydrolysis and dehydroxylation reactions are mediated 
by a board spectrum of anaerobic bacterial and are not detailed here. An extensive review of 
intestinal bile acid metabolism is provided by Ridlon et al. (2006). Bile acids also can be 
metabolized by human cytochrome P450 enzymes; for example, CYP3A converts lithocholic 
acid to hyocholic acid and ursodeoxycholic acid (Bodin et al., 2005; Chang et al., 1993; Chen et 
al., 2014). 
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Bile Acids and Toxicity 
 Although bile acids have important physiological functions, they can be cytotoxic and 
induce and/or contribute to organ dysfunction. Obstructive cholestasis, for example, is a 
condition in which the flow of bile to the gallbladder is impaired, resulting in hepatocellular 
buildup of bile acids and subsequent hepatotoxicity. Supraphysiological concentrations of 
hydrophobic secondary bile acids, such as lithocholic acid, have been associated with the risk of 
colon cancer (Ajouz et al., 2014; Cook et al., 1940). The detergent effects of bile acids appear to 
be correlated with hydrophobicity. Attili et al. (1986) reported the rank order of toxicity from 
greatest to least: lithocholic acid > deoxycholic acid > chenodeoxycholic acid > cholic acid > 
ursodeoxycholic acid.  
Bile acid-induced oxidative stress is a primary mechanism underlying bile acid toxicity 
(Sokol et al., 1991; Togashi et al., 1990). Due to their detergent like effects, it is suggested that 
bile acids directly impair mitochondrial respiration. Indeed, bile acids have been shown to 
enhance mitochondrial membrane permeability to protons, disrupt the structural integrity of 
mitochondrial components, and decrease enzymatic activity involved in the electron transport 
chain (Krähenbühl et al., 1994; Rolo et al., 2000). The generation of intracellular reactive oxygen 
species appears to be an early event in mitochondria-associated toxicity in rodents and humans 
(Soko et al., 1995; Soko et al., 2005). Subsequent depletion of antioxidants (e.g. glutathione) and 
constituents of the electron transport chain (e.g. ubiquinone-9 and ubiquinone-10) induce the 
mitochondrial permeability transition (MPT) leading to the initiation of apoptotic and necrotic 
pathways (Krähenbühl et al., 1995; Lemasters et al. 1998; Yerushalmi et al., 2001). More recent 
studies demonstrate that hydrophobic bile acids also can induce endoplasmic reticulum stress.  
For example, glycochenodeoxycholic acid induced the release of Ca
2+
 in rat hepatocytes and 
 41 
 
subsequent activation of calpain and caspase-12, two signaling molecules involved in the 
initiation of apoptosis (Iizaka et al., 2007; Tsuchiya et al., 2006). 
Bile Acid-Mediated Hepatotoxicity and Drug Administration 
The administration of drugs can impair synthesis and excretory processes involved in bile 
acid homeostasis and increase hepatocellular concentrations of bile acids, which can lead to 
hepatotoxicity. Other mechanisms that induce and/or contribute to DILI are discussed in Chen et 
al. (2015). Insight into the specific mechanism(s) underlying altered bile acid homeostasis during 
drug therapy first implicated inhibition of canalicular bile acid transporters, and subsequent 
increase in hepatocellular bile acids, by drugs. For example, impaired biliary bile acid secretion 
in rodents was reported with drugs associated with DILI such as troglitazone, cyclosporine A, 
and bosentan (Bohme et al., 1993; Fattinger et al., 2001; Funk et al., 2001). Particular interest 
has focused on BSEP inhibition, the rate-limiting step in bile acid-dependent biliary clearance of 
bile acids. A systematic evaluation by Morgan et al. (2010) revealed an association with 
inhibition of BSEP by drugs and DILI; data from this study demonstrated that drugs with an 
inhibitory potency (IC50) greater than 25 μM correlated with liver injury in humans. Subsequent 
studies indicated that inhibition of compensatory bile acid transporters (e.g. MRP2-4) increase 
the correlation between bile acid transporter inhibition and DILI (Köck et al., 2014; Morgan et 
al., 2013). Hence, high-throughput in vitro screening tools are used routinely in drug 
development to assess the potential for liver liabilities in humans. Other mechanisms involved in 
altered bile acid homeostasis that were not explored in this dissertation (e.g. impaired bile 
canaliculus dynamics, inhibition of bile acid metabolism, modulation of nuclear hormone 
receptors, altered phospholipid flux) have been demonstrated and are reviewed elsewhere 
(Burbank et al., 2016; He et al., 2015; Rodrigues et al. 2014). 
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Bile Acids as Biomarkers of DILI 
Biochemical measures such as serum transaminases, alkaline phosphatase, gamma-
glutamyl transferase, and total bilirubin remain the gold standard for the diagnosis of many liver 
diseases and the adjudication of DILI (Ozer et al., 2008; Watkins et al., 2009; Wolf et al. 1999). 
However, these measurements have limitations (e.g. lack specificity and/or sensitivity) and are 
sometimes difficult for clinicians to interpret (Knight et al., 2005; Thapa et al. 2007). Serum bile 
acids have been proposed as biomarkers of hepatobiliary disease including primary biliary 
cirrhosis, nonalcoholic and alcoholic steatohepatitis, intrahepatic cholestasis of pregnancy, and 
hepatitis C infection (Ferslew et al., 2015; Heikkinen et al. 1983; Murphy et al., 1972; Shlomai et 
al., 2013; Trinchet et al., 1994). Furthermore, signature patterns in the bile acid pool have been 
investigated to differentiate liver disease (Bathena et al., 2015; Ferslew et al., 2015; Kamano et 
al., 1999). For example, the ratio of cholic acid to chenodeoxycholic acid was significantly 
different in patients with compensated liver cirrhosis compared to patients with decompensated 
liver cirrhosis (Adachi et al., 1988). To date, serum bile acids are used for the clinical diagnosis 
of intrahepatic cholestasis of pregnancy (Huang et al., 2007; Pusl et al., 2007). Otherwise, bile 
acids are not used routinely in clinical practice to diagnose other hepatobiliary diseases, perhaps 
due to lack of specificity, interindividual variability, or difficulty in implementing bile acid 
profiling in routine clinical practice, among others reasons (Heaton et al., 1979; Steiner et al., 
2011).  
Recent research suggests that using serum bile acids to identify or diagnose DILI is 
promising. Yamazaki et al. (2013) first identified altered bile acid homeostasis as an early 
hepatotoxic signal after the administration of several hepatotoxins (e.g. acetaminophen, 
bendazac, cyclosporine A, carbamazepine) in rats. Serum glycocholate, 
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glycochenodeoxycholate, taurocholate, and taurochenodeoxycholate concentrations were 
consistently elevated in response to hepatotoxic drugs (Yamazaki et al., 2013). Another study by 
Luo et al. (2014) reported that animals with histopathological signs of hepatocellular necrosis 
displayed increases in serum cholic acid, glycholic acid, and taurocholic acid, whereas animals 
with signs of bile duct hyperplasia displayed increases in only the amidated conjugates of 
glycholic acid, and taurocholic acid; these data suggest that signature bile acid profiles may be 
able to differentiate different forms of DILI. Indeed, serum conjugated bile acid concentrations 
were higher in patients diagnosed with DILI (any form) compared to healthy controls (Luo et al., 
2015); elevated bile acid concentrations also have been reported in cyclosporine A-associated 
liver injury (Beger et al., 2015). The Safer And Faster Evidence-based Translation (SAFE-T) 
Consortium is currently assessing the utility of serum bile acids, among others, as biomarkers of 
DILI, which may aid in the diagnosis and prognosis of DILI before irreversible and/or fatal 
injury occurs (Weiler et al., 2015). 
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Autosomal Dominant Polycystic Kidney Disease: Basic Biology and Protein Transporter 
Function 
Polycystic kidney disease (PKD) is a common cause of renal failure due to the 
development of fluid-filled cysts and subsequent displacement/destruction of renal nephrons. 
PKD is genetically transmitted in a dominant form (autosomal dominant polycystic kidney 
disease; ADPKD) or in a recessive form (autosomal recessive polycystic kidney disease; 
ARPKD).  ADPKD is slowly progressive whereas ARPKD is typically more severe. For 
example, newborns with ARPKD are often born with massively enlarged cysts, congenital 
hepatic fibrosis, and aberrant intrahepatic bile ducts (Zerres et al., 1998).  Nearly one-half of 
affected newborns die shortly after birth, although children who are not symptomatic until later 
in life have a better prognosis (Deget et al., 1995; Zerres et al., 1996). This dissertation focused 
on ADPKD; a review of ARPKD is provided by Kaplan et al. (1988) and more recently, Hartung 
et al. (2014). 
Genetics and Cell Biology 
 ADPKD arises from mutations in the PKD1 (~85% of cases) or PKD2 (~15% of cases) 
gene. Although the hepatorenal manifestations are similar between both mutations, symptomatic 
renal decline presents later in life and is associated with longer survival and less complications in 
patients with PKD2 mutations compared to patients with PKD1 mutations (Hateboer et al., 
1999).  PKD1 encodes polycystin-1, a large integral membrane protein expressed in the primary 
cilia of many tissues such as the kidney, heart, muscle, and liver (Geng et al., 1997; Ong et al., 
1999; Zhou et al., 2009). Although the function of polycystin-1 is not fully understood, it has 
been proposed that polycystin-1 acts as cell surface signaling receptor that regulates intracellular 
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Ca
2+
 homoeostasis through the interaction with polycystin-2 (Dalagiorgou et al., 2010). Further 
studies indicate polycystin-1 behaves like a G protein-coupled receptor involved in regulating 
cell cycle arrest, presumably by the indirect inhibition of cyclin-dependent kinases, activators of 
cellular proliferation (Bhunia et al., 2002; Delmas et al., 2002; Hanaoka et al., 2000). PKD2 
encodes polycystin-2, a Ca
2+
-permeable cation channel that either localizes to the cilium, where 
it can interact with polycystin-1, or in intracellular compartments where it can modulate the 
release of intracellular Ca
2+
 (González-Perrett et al., 2001; Nauli et al., 2003). 
Cystogenesis 
 The natural history of cystogenesis in ADPKD patients is variable and not well 
understood. Bae et al. (2013) reported that the number of identifiable kidney cysts can range 
from as low as 10 cysts to more than 200 cysts using magnetic resonance imaging. Although all 
cells within the kidney contain the same germline (i.e. inherited) mutation, only a small portion 
of these cells become cystic. To explain this apparent anomaly, Reeders (1992) proposed a two-
hit hypothesis suggesting that a second “hit” to the wild-type PKD1 (or PKD2) allele is a 
prerequisite for focal cyst initiation and development, similar to the multi-hit hypotheses 
underlying the initiation of cancer cells. Indeed, germline and somatic mutations have been 
identified in patients with ADPKD (Qian et al., 1996; Watnick et al., 2000). Although 
mechanistic studies in mouse models of ADPKD support the hypothesis that somatic conversion 
is conceivable, recent studies indicate that gene dosage effects may help explain large 
interindividual variability in disease severity (Rossetti et al., 2009; Wu et al., 1998; Vujic et al., 
2010). Gene dosage, or haploinsufficiency, refers to the concept that mutation(s) affect the 
expressivity of particular genes (i.e. the number of gene products cells can produce), which may 
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lead to interindividual variability in a clinical phenotype, such as seen in ADPKD. This concept 
is fully explored in Eccles and Staynder (2014). 
Fluid Transport in ADPKD 
 Altered planar cell polarity and cyclic adenosine monophosphate (cAMP)-mediated cell 
proliferation is central to the macroscopic development of cysts (Grantham et al., 1987; 
Grantham, 1996). Furthermore, the accumulation of fluid within cysts suggests that cystic 
endothelium display unique ion-driven absorptive properties that results in subsequent osmotic 
movement of water into the cyst lumen. Investigation into the transport properties of cysts 
sparked interest when cysts were observed to rapidly refill after aspiration, although an early 
study by Jacobsson et al. (1977) was first to demonstrate the accumulation of water in cysts after 
the administration of 
3
H-H20 (Bennett et al., 1987). 
 Current data suggest that ion transport into the cyst cavity is driven by two transporters: 
the cystic fibrosis transmembrane regulator (CFTR) and Na
+
K
+
-ATPase. CFTR is a Cl
-
 channel 
that facilitates the movement of Cl
-
 ions into cysts whereas Na
+
K
+
-ATPase is an antiporter that 
exchanges Na
+
 for K
+
, both of which are present at the apical surface of cystic epithelium 
(Nakanishi et al., 2001; Wilson et al., 1991). Interestingly, the severity of ADPKD was 
diminished in patients with coexisting cystic fibrosis, a genetic disease in which patients lack 
functional CFTR (Xu et al., 2006). Elevated concentrations of cAMP appear to drive secretory 
processes associated with cystogenesis, which may be secondary to altered Ca
2+
 homeostasis 
and/or upregulation of vasopressin receptor(s) due to disruption of polycystin-1 binding to 
heterotrimeric G proteins (Gattone et al., 2003; Parnell et al., 1998; Wang et al., 2010). Indeed, 
cAMP is consistently elevated in both animal models of PKD and in patients with ADPKD 
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(Devuyst et al., 2013; Nagao et al., 2006; Starremans et al., 2008; Yamaguchi et al., 1997). 
Therapeutic strategies targeting fluid accumulation (e.g. vasopressin receptor antagonists, 
somatostatin receptor agonists) have been evaluated or are currently under investigation, 
although the long term efficacy and safety of successfully blocking fluid accumulation in cysts is 
unknown at this time. 
Hepatic cysts 
The liver is the most commonly affected extrarenal organ in ADPKD. Hogan et al. (2015) 
reported that ~70% of men and ~80% of women (age 15-49 years old) have detectable liver cysts 
using magnetic resonance imaging. The observation that hepatic cyst burden (i.e. number of 
cysts and cystic volume) is increased in women compared to men is consistent among studies 
(Bae et al., 2006; Chauvea et al. 2000; Levine et al., 1985; Hogan et al. 2015). The underlying 
mechanism appears to be related to the stimulatory effects of hormones (e.g. estrogens) and 
subsequent epithelial hyperproliferation (Everson et al., 2005; Sherstha et al., 1997); hence, 
clinicians recommend avoiding hormonal therapy or hormone-containing oral contraceptive 
therapy when symptomatic liver cystic disease presents (Chapman et al., 2015; Sherstha et al., 
1997). 
 Hepatic cysts derive from the biliary epithelium and thus display phenotypic and 
functional characteristics similar to cholangiocytes (Perrone et al., 1995). Similar to cell types of 
the kidney, cholangiocytes express polycystin-1 and polycystin-2; altered Ca
2+
 homeostasis due 
to genetic mutation(s) increases adenylyl cyclase6 activity and cAMP levels (Masyk et al., 
2006). cAMP-mediated fluid transport appears to be driven by CFTR and subsequent generation 
of an osmotic gradient, which facilitates water entry into the lumen. Interestingly, aquaporins, 
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transmembrane proteins that mediate the passive movement of water across epithelial cells, are 
abnormally expressed in ADPKD (Banales et al., 2008; Li et al., 2016). Overexpression of 
aquaporin-1 correlated with the cyst size, which may indicate that aquaporin(s) contribute to 
fluid accumulation and cystogenesis (Li et al., 2016). 
The polycystic kidney disease rat, a model of human ADPKD 
 The polycystic kidney (PCK) rat was discovered by Katsuyama et al. (2000). Further 
characterization by Lager et al., (2001), among others, have demonstrated that the PCK rat 
displays a natural history of hepatorenal features most similar to human ADPKD. PCK rat 
kidneys are normal at birth but progressively develop focal renal cysts that diminish renal 
function over time (Lager et al., 2001; Mason et al., 2010). Abnormal serum biochemistries (e.g. 
serum creatinine, proteinuria, blood urea nitrogen) are consistent with that seen in patients with 
ADPKD (Mason et al., 2010; Woon et al., 2015). PCK rats also develop hepatic cysts, which up 
until their discovery, had not been demonstrated in other rat models. For example, the 
Han:SPRD rat and chin rat models do not display progressive hepatic cyst development and even 
exhibit skeletal abnormalities, inconsistent with human ADPKD. (Gretz et al., 1996; Nauta et al., 
1999; Ohno et al., 1989; Schäfer et al., 1994). Remodeling of the biliary epithelium and 
dilatation of the intrahepatic bile ducts contribute to the formation of isolated cysts that are 
disconnected from the biliary tree in PCK rats over time (Masyuk et al., 2004). Cholangiocyte 
cilia were also structurally abnormal and shorter compared to normal cholangiocytes, similar to 
reports in ADPKD (Alvaro et al., 2008; Masyuk et al., 2003; Masyuk et al., 2004). Hence, the 
similar hepatorenal phenotype observed in PCK rats has provided tremendous value towards 
understanding the pathogenesis of ADPKD and therapeutic interventions (Blazer-Yost et al., 
2010; Wang et al., 2004; Wang et al., 2010). It must be noted that genetic analysis revealed 
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polycystic kidney disease in PCK rats is due to mutation(s) in the polycystic kidney and hepatic 
disease 1 (Pkhd1) gene, the rat orthologue of human PKHD1, and thus is genetically orthologous 
to human ARPKD (Ward et al., 2002). Therefore, genetic differences underlying the etiology of 
disease in PCK rats and human ADPKD may limit the extrapolation of information generated in 
this rodent model to humans.  
Drug transporters in ADPKD 
 The effect of ADPKD on the expression and function of clinically relevant drug 
transporters, as those outlined in Chapter 1 of this dissertation, have not been investigated. 
Because ion transporter function, cellular proliferation, extracellular matrix remodeling, and 
neovascularization all play an important role in cyst growth, it is conceivable that drug 
transporters may be affected due to overlapping signaling processes that are altered in this 
disease state. For example, cAMP, the signaling molecule elevated in ADPKD, has been shown 
to influence the translocation of Mrp2 and Mrp3 in in vitro studies (Chandra et al., 2005; Park et 
al., 2014; Roelofsen et al., 1998). 
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Project Rationale and Specific Aims 
The objective of this dissertation research was to understand how hepatic transporter 
function in liver disease affects the hepatobiliary disposition and pharmacokinetics of 
endogenous and exogenous compounds. In order to describe and predict the effect of liver 
disease on hepatobiliary disposition and pharmacokinetics, the expression and function of 
hepatic transporters in disease states must be better understood. This dissertation focused on two 
pathophysiological states of liver impairment: non-alcoholic steatohepatitis (NASH) and 
autosomal dominant polycystic kidney disease (ADPKD). 
Non-alcoholic steatohepatitis (NASH) 
NASH is an advanced inflammatory form of non-alcoholic fatty liver disease defined by 
histological confirmation of hepatic steatosis, hepatocyte ballooning, and lobular inflammation 
(Chalasani et al., 2012). NASH is a significant health concern, which can progress to advanced 
fibrosis/cirrhosis, hepatocellular carcinoma, and liver failure. Dysregulation of transporter 
expression has been reported in rodent models of NASH and in patients with NASH, as reviewed 
in the introductory section of this dissertation (Canet et al., 2015; Clarke et al., 2014; Ferslew et 
al., 2015; Hardwick et al., 2011). Specifically, hepatic uptake transporters (e.g. organic anion-
transporting polypeptides (OATPs)) are down-regulated while excretory transporters are up-
regulated (e.g. multidrug resistance protein (MRP) 3) in NASH. There are conflicting reports of 
altered MRP2 expression patterns in NASH that warrant further investigation. For example, 
Hardwick et al. (2011) reported that MRP2 protein expression was upregulated in patients with 
NASH but Okushin et al. (2015) observed downregulation of MRP2 mRNA expression in liver 
tissue. It must be noted that mRNA expression does not always correlate with protein expression, 
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so it is unclear how the findings from Okushin et al. (2015) translate to MRP2 protein 
expression, and more importantly to MRP2 function (Maier et al., 2009; Vogel et al., 2012). 
Furthermore, MRP2 appears mislocalized off the canalicular membrane, presumably internalized 
to intracellular vesicles in the subapical domain (Hardwick et al. 2011). Vesicular retrieval of 
Mrp2/MRP2 has been demonstrated in lipopolysaccharide-induced oxidative stress and in 
several forms of human liver injury such as autoimmune hepatitis, primary sclerosing 
cholangitis, and obstructive jaundice (Kojima et al., 2003; Kojima et al., 2008; Saeki et al., 
2011). More recently, Dzierlenga et al. (2016) demonstrated that radixin and Rab11-mediated 
active insertion of Mrp2 is impaired in a rodent model of NASH, providing a mechanistic basis 
for these observations. Therefore, the objective of Aim #1 was to evaluate the pharmacokinetics 
of 
99m
Tc-mebrofenin (MEB), an OATP, MRP2 and MRP3 substrate, in patients with biopsy-
confirmed NASH compared to healthy volunteers. The evaluation of systemic pharmacokinetics, 
coupled with liver scintigraphy to assess hepatic exposure, provides a powerful approach to 
assess, for the first time, the functional effects of OATP, MRP2, and/or MRP3 modulation due to 
NASH. 
MEB was selected as a phenotypic probe substrate to assess the effect of altered OATP, 
MRP2, and MRP3 function in patients with NASH compared to healthy volunteers. To date, 
quantitative scintigraphy and pharmacokinetic analysis of MEB have only been conducted in 
healthy volunteers (Ghibellini at al., 2008; Pfeifer et al., 2013a). In vitro studies indicate that 
MEB is a substrate for OATP1B1, OATP1B3, MRP2, and MRP3 (de Graaf et al., 2011; 
Ghibellini at al., 2008); OATP1B1-mediated intrinsic clearance (i.e. Vmax/Km) of MEB is ~1.5-
fold higher compared to OATP1B3 and pharmacokinetic modeling indicated that MRP2-
mediated excretion of MEB is ~3-4-fold greater compared to MRP3-mediated efflux (Ghibellini 
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at al., 2008; Pfeifer et al., 2013a). In humans, MEB is efficiently extracted by the liver (~98% of 
dose) and excreted into bile with minimal urinary excretion (~1-2% up to 24 hrs) and negligible 
metabolism (Krishnamurthy et al., 1990; Choletec package insert). Altered function of OATP- 
and MRP2-mediated transport would be expected to impact the systemic and hepatic exposure of 
MEB. Indeed, inhibition of OATP by ritonavir increased the systemic concentrations of MEB in 
healthy volunteers although hepatic exposure was unaffected by ritonavir because intracellular 
hepatic concentrations were below concentrations necessary to inhibit MRP2-mediated biliary 
excretion (Pfeifer et al., 2013a). Furthermore, increased hepatic exposure of MEB and other 
iminodiacetic acid analogs due to genetic impairment in Mrp2-deficient rats and patients with 
Dubin-Johnson syndrome is well established and supports the use of MEB as a phenotypic probe 
for MRP2 (Bhargava et al., 2009; Doo et al., 1991; Hendrikse et al., 2004; Pinós et al., 1990; 
Pinós et al., 1991). It must be noted that MRP3 also has been shown to transport MEB. MRP3-
mediated clearance of MEB appears to be significantly lower compared to MRP2-mediated 
clearance, but increased MRP3 expression and/or function may impact systemic concentrations 
or liver exposure of MEB (Ghibellini et al., 2008; Pfeifer et al., 2013a). To date, altered function 
of MRP3-mediated transport has been demonstrated in patients with NASH. Ferslew et al. 
(2015) reported increased serum concentrations of morphine glucuronide, an MRP3 substrate, in 
patients with NASH; similarly, Canet et al. (2015) also demonstrated that acetaminophen 
glucuronide serum concentrations, another MRP3 substrate, were increased in pediatric patients 
with NASH.  
Although systemic concentrations are routinely measured to estimate drug exposure, it 
has become increasingly evident that drug exposure in a particular compartment or tissue may be 
altered without significantly affecting systemic concentrations (Rose et al., 2014; Swift et al., 
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2009). Gamma scintigraphy is a powerful imaging technique that enables the direct visualization 
of a radiolabeled molecule in real time. Apart from their routine use as diagnostic agents, gamma 
emitting radionuclides have been used for drug development purposes (e.g. capsule 
disintegration, drug disposition) (Damle et al., 2002; Fischman et al., 2002; Newman et al., 
1995). Therefore, administration of MEB, coupled with gamma scintigraphy, provides a 
noninvasive method to quantify tissue exposure (i.e. liver exposure) in vivo. This approach 
allows for simultaneous evaluation of blood and liver pharmacokinetics; this will improve the 
elucidation of the functional consequences of NASH-associated changes in transporter function 
compared to the use of blood sampling alone. 
Autosomal dominant polycystic kidney disease (ADPKD) 
ADPKD is a monogenic inheritable disease characterized by progressive renal cyst 
development, often leading to end-stage renal disease. Supportive care and surgical interventions 
represent the mainstay of ADPKD treatment because no Food and Drug Administration (FDA)-
approved therapy currently exists. Tolvaptan, an orally available vasopressin V2-receptor 
antagonist, recently has shown promise for delaying renal cyst progression in ADPKD (Torres et 
al., 2012). In the pivotal clinical trial, however, tolvaptan was associated with liver injury evident 
by increased liver enzymes and bilirubin in some patients (Torres et al., 2012; Watkins et al., 
2015). The etiology of liver injury in this patient population, to date, is unknown. Furthermore, it 
is also unclear whether DILI observed in ADPKD patients is due to the parent compound, a 
metabolite of tolvaptan (e.g. DM-4103 or DM-4107), or some other specie(s). Bile acid-mediated 
hepatotoxicity is one mechanism of drug-induced liver injury (DILI). Although bile acids are 
important in digestion/absorption and normal hepatic function, they can be hepatotoxic when 
present at high concentrations due to drug- and/or patient-specific mechanism(s). Therefore, Aim 
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#2 of this dissertation was designed to test the hypothesis that altered bile acid homeostasis is an 
underlying mechanism in tolvaptan-associated liver injury in patients with ADPKD. 
DILI is one of the most frequent adverse events that can lead to market withdrawal, 
additional labeling requirements, or failure during clinical development (Senior et al., 2014). 
Although many mechanisms have been implicated in the pathogenesis and development of DILI 
(e.g. reactive metabolites, mitochondrial toxicity, adaptive and innate immunity), bile acids can 
accumulate and induce cholestasis and/or liver injury in humans (Rodrigues et al., 2016; Yang et 
al., 2013). The bile salt export pump (BSEP) plays a major role in the biliary clearance of bile 
acids. Thus, inhibition of BSEP by drugs and/or metabolites, which may lead to subsequent 
accumulation of bile acids, has been associated with DILI (Morgan et al., 2010). In addition to 
the inhibition of BSEP, inhibition of other bile acid transporters (e.g. MRP2-4) correlated with 
evidence of DILI in humans (Morgan et al., 2013). Therefore, inhibition of bile acid transporters 
by tolvaptan and two major metabolites (i.e. DM-4103 and DM-4107) was evaluated in Subaim 
#2a, which may help elucidate the biological etiology of tolvaptan-associated liver injury.  
To examine the effect of tolvaptan and metabolites on the transport of bile acids, in vitro 
systems were employed. Membrane vesicles or transfected cell lines that overexpress a 
transporter of interest are widely used to characterize the kinetics (e.g. Michaelis-Menten 
constant, maximal transport velocity) of substrate transport in vitro. To study the kinetics of 
efflux transporters (e.g. BSEP), inside-out membrane vesicles are prepared to orient the 
adenosine triphosphate (ATP) binding site of the transporter to the buffer, which facilitates the 
uptake of substrate(s) into vesicles (Vogel et al., 2013). This assay allows the direct 
measurement of transporter-mediated translocation of a substrate across the cell membrane in a 
high-throughput fashion and is a commonly used approach to detect drug-drug or drug-bile acid 
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interactions (Giacomini et al., 2010; Vogel et al., 2013). Therefore, this model system was used 
in Subaim #2a to evaluate the effect of tolvaptan, DM-4103, and DM-4107 on human bile acid 
transporter function. Although transporter-overexpressing systems are convenient in vitro tools, 
human hepatocytes are the most physiologically-relevant cell-based model to study hepatic drug 
transport. Sandwich-cultured human hepatocytes (SCHH) are useful to study drug disposition 
and hepatotoxicity due to the preservation of cellular architecture and relevant metabolism and 
transporter genes (Marion et al., 2007; Swift et al., 2010). Therefore, SCHH were used as a 
secondary model system to evaluate the disposition of tolvaptan and the effect of tolvaptan on 
bile acid disposition in Subaim #2a. 
Interestingly, no hepatic events were observed in tolvaptan-treated patients with 
hyponatremia, heart failure, or cirrhosis, which may indicate that ADPKD patients may be 
particularly susceptible to liver injury (Watkins et al., 2015). It is possible that impaired 
transporter function and bile acid homeostasis, independent of tolvaptan treatment, may 
predispose this patient population to hepatotoxicity. Indeed, literature reports indicate that bile 
acids are increased in DILI and may contribute to the pathogenesis of liver injury (James et al., 
2015; Luo et al., 2014; Yamazaki et al., 2013). Altered bile acid homeostasis and hepatic 
transporter function in ADPKD have not been systematically evaluated to date, although Salam 
et al. (1989) reported prolonged hepatic retention of MEB, a MRP2 substrate, in a patient with 
ADPKD. To investigate bile acid homeostasis and hepatic transporter function in ADPKD, 
polycystic kidney (PCK) rats were selected as a surrogate model for studies outlined in Subaim 
#2b and #2c.  
 Several rodent models of polycystic kidney disease have been described; however, many 
of these rodent models do not display the progressive hallmarks and natural history of 
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hepatorenal abnormalities observed in human ADPKD (McDonald et al., 2006; Schieren et al., 
1996). For example, the polycystic kidney disease (pcy) and polycystin 2 (pkd2) mouse model 
exhibits progressive enlargement of renal cysts, subsequent renal decline and early death, but 
display mild or no hepatic cyst involvement (Fry et al., 1985; Guay-Woodford et al., 2003; Woo 
et al., 1997). Other models are embryonic lethal (e.g. polycystin 1 mouse) or display skeletal and 
vascular defects (e.g. Oak Ridge polycystic kidney mutation) that are inconsistent with the 
human ADPKD phenotype (Boulter et al., 2001; Moyer et al., 1994). A spontaneous mutation in 
a colony of Sprague-Dawley rats displaying bilateral renal and hepatic cysts, now known as the 
PCK rat, was described by Katsuyama et al. (2000). Subsequent studies indicated that the natural 
progression and hepatorenal features in PCK rats, such as progressive renal cyst growth, biliary 
dysgenesis, and hepatic cyst development, most resemble human ADPKD (Hogan et al., 2015; 
Lager et al., 2001; Mason, et al. 2010; Masyuk et al., 2004). Therefore, the PCK rat model was 
selected to evaluate bile acid homeostasis and hepatic transporter function outlined in Subaim 
#2b and #2c.  
To study hepatic transporter function in PCK rats in Subaim #2c, the isolated perfused 
liver model was selected. The isolated perfused rat liver is an ex vivo or in situ model widely 
used to investigate the physiology and function of the liver. Although hepatocyte cultures and 
liver slices are useful whole-cell models, the primary advantages of the isolated perfused rat liver 
are the retention of normal hepatic architecture, microcirculation, and bile production in a system 
that approaches normal physiology (Bessems et al., 2006). Additionally, the influence of 
extrahepatic mechanism(s) (e.g. hormonal influences, nonhepatic routes of elimination) is 
eliminated. The liver can be perfused in a nonrecirculating (single-pass) or recirculating manner 
(Brouwer and Thurman et al., 1996). Single-pass systems perfuse probe-containing buffer into 
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the liver that enables direct sampling of the outflow perfusate and bile to facilitate the calculation 
of hepatic extraction and biliary excretion, respectively. Furthermore, experimental protocols in 
which the steady-state hepatic extraction ratio is achieved and then switched to blank buffer (i.e. 
perfusate without the probe substrate) for additional sampling is an established experimental 
design to estimate basolateral efflux (Akita et al., 2001; Pfeifer et al., 2013b; Tian et al., 2008). 
Coupled with pharmacokinetic modeling, the isolated perfused rat liver model is a powerful tool 
to study hepatobiliary disposition and the multiplicity of transport in isolation (Chandra et al., 
2005; Pfeifer et al., 2013b; Zamek-Gliszczynski et al., 2003). In addition, this model has been 
applied successfully to study the effect of chemical modulation and naturally occurring mutant 
strains (e.g., Mrp2-deficient rats) on transporter function (Chandra et al., 2005; Pfeifer et al., 
2013b). Given the accompanying pathological changes that are expected in PCK rats (i.e. hepatic 
cysts), the isolated perfused liver model was chosen as a suitable model to test the effect of 
polycystic kidney disease on hepatic transporter function outlined in Subaim #2c. The 
fluorescent probe, 5(6)-carboxy-2’,7’-dichlorofluorescein (CDF), was chosen as the phenotypic 
probe because: (1) it is a substrate for the hepatic uptake transporter Oatp1 and rapidly secreted 
into bile via Mrp2; (2) it is a fluorescent molecule and thus readily detectable using fluorescence 
spectroscopy; (3) the hepatobiliary disposition of CDF is well described (Chandra et al., 2005; 
Zamek-Gliszczynski et al., 2003). Additional review regarding the transport kinetics of CDF is 
provided in Chapter 5. 
Summary 
In summary, the first aim of this research project was to evaluate the pharmacokinetics of 
MEB in patients with biopsy-confirmed NASH compared to age- and sex-matched healthy 
volunteers (Aim #1). The second aim of this research project was to determine whether altered 
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bile acid homeostasis is a biologically plausible mechanism underlying tolvaptan-associated liver 
injury in patients with ADPKD (Aim #2). 
Aim #1. Determine the functional consequences of hepatic transport modulation by non-
alcoholic steatohepatitis (NASH) on the pharmacokinetics of 
99m
Technetium-mebrofenin 
(MEB). 
Hypothesis: NASH modulates the expression/function of OATP, MRP2 and/or MRP3 transport 
proteins responsible for drug disposition. Thus, NASH will affect the systemic and hepatic 
disposition of MEB. 
1.a. Quantify MEB pharmacokinetics in patients with NASH versus healthy human 
volunteers. 
Aim #2. Determine the inhibitory potency of tolvaptan and its metabolites on major efflux 
hepatic transporters; characterize the functional consequences of autosomal dominant 
polycystic disease (ADPKD) on bile acid homeostasis and hepatic transport function using 
polycystic kidney (PCK) rats. 
Hypothesis: Altered bile acid homeostasis is a contributing mechanism underlying tolvaptan-
associated liver injury in patients with ADPKD. 
1.a. Determine the inhibitory potency of tolvaptan and its metabolites on hepatic bile acid 
transporters. 
1.b. Characterize the consequences of ADPKD on bile acid homeostasis using PCK rats. 
1.c. Characterize the functional consequences of ADPKD on hepatic transport function using 
the isolated-perfused rat liver model in PCK rats.  
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CHAPTER 2. Hepatic Disposition of 
99m
Technetium–Mebrofenin is Altered in Patients 
with Non-Alcoholic Steatohepatitis (NASH)
2
 
 
INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is one of the most common forms of liver 
disease in western societies; it is estimated that 20-30% of adults in the general population have 
NAFLD (Bellentani et al., 2010; Younossi et al., 2016). However, for reasons not fully 
elucidated, some patients progress to an inflammatory form of NAFLD known as nonalcoholic 
steatohepatitis (NASH). NASH is an advanced form of NAFLD defined by the histological 
confirmation of hepatic steatosis, hepatocyte ballooning, and lobular inflammation (Chalasani et 
al., 2012). NASH is a significant health concern that can progress to advanced fibrosis, cirrhosis, 
hepatocellular carcinoma, and liver failure (Hasimoto et al., 2009; Hui et al., 2003; Powell et al., 
1990). Several medications (e.g. sulfonylureas, statins, thiazolidinediones) have been evaluated 
to prevent fibrosis and reverse inflammation in this patient population, but studies thus far have 
indicated no or marginal efficacy (Nakahara et al., 2012; Sanyal et al., 20120; Torres et al., 
2001). Hence, no Food and Drug Administration (FDA)-approved pharmacological interventions 
currently exist and diet/weight loss remains the only effective measure to resolve NASH 
(Chalasani et al., 2012; Promrat et al., 2010). Because the liver is the primary site of action of 
medications to treat NASH, it is imperative to understand how NASH alters hepatic drug 
disposition.  
                                                          
2
 This chapter will be submitted to Journal of Hepatology, and is presented in the style of that journal. 
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The significance of hepatic transport proteins in the regulation of systemic and hepatic 
exposure of drugs is well established. Perturbation(s) in these processes, especially when drugs 
are eliminated through a single pathway, have been shown to significantly alter the 
pharmacokinetics, and in some cases, the pharmacodynamics of drugs (Kalliokoski et al., 2008; 
Lau et al., 2007). The expression of important hepatic uptake and efflux transporters is 
dysregulated in patients with NASH. The organic anion transporting polypeptides (OATPs), 
hepatic uptake transporters, are downregulated, while multidrug resistance-associated protein 
(MRP)2, and MRP3,  hepatic efflux transporters, appear to be upregulated in liver biopsies from 
patients with NASH compared to healthy controls (Clark et al., 2014; Hardwick et al., 2011). 
The functional impact of increased MRP3 expression has been evaluated in patients with NASH; 
however, the impact of altered OATP and/or MRP2 expression has yet to be determined (Canet 
et al., 2015; Ferslew et al., 2015). Furthermore, MRP2 appears to be mislocalized from the 
canalicular membrane into the pericanalicular cytoplasm, which makes the impact of NASH on 
MRP2 function unclear (Hardwick et al., 2011). The purpose of the present study was to evaluate 
the functional impact of altered hepatic transporter protein expression in patients with biopsy-
confirmed NASH using non-invasive imaging techniques. 
99m
Technetium–mebrofenin (99mTc-mebrofenin or MEB) is a radiodiagnostic used to 
diagnose or differentiate hepatobiliary abnormalities such as structural disorders, infantile 
jaundice, and biliary obstruction (Balon et al., 1997; Ben-Haim et al. 1995; Doo et al. 1991). 
MEB is highly extracted by the liver; ~98% of the dose taken up by the liver and excreted into 
bile with minimal urinary excretion (~1-2% up to 24 hrs) and negligible metabolism 
(Krishnamurthy et al., 1990; Choletec package insert). MEB was chosen as a phenotypic probe 
because the hepatobiliary transport pathways of this agent are well defined. MEB is primarily 
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taken up by OATP1B1/OATP1B3 and is rapidly excreted by the canalicular transporter MRP2 
(de Graaf et al., 2011; Ghibellini et al., 2008; Swift et al., 2010). Altered function of OATP- and 
MRP2-mediated transport would be expected to impact the systemic and hepatic exposure of 
MEB; this is evidenced by increased systemic exposure of MEB due to drug inhibition of OATP 
and prolonged hepatic exposure of MEB and other iminodiacetic acid analogs due to genetic 
impairment of MRP2/Mrp2 in TR- rats and patients with Dubin-Johnson syndrome (Bhargava et 
al., 2009; Doo et al., 1991; Hendrikse et al., 2004; Pfeifer et al., 2013; Pinós et al., 1990; Pinós et 
al., 1991). MRP3, a basolateral efflux transporter, also has been shown to transport MEB, but 
MRP3-mediated clearance of MEB appears to be significantly lower compared to MRP2-
mediated clearance (Ghibellini et al., 2008; Pfeifer et al., 2013). Therefore, we evaluated the 
systemic concentrations and liver activity of MEB to understand the functional impact of NASH-
associated changes in OATPs, MRP2, and MRP3 on MEB systemic and hepatic disposition.  
PATIENTS AND METHODS 
Patients 
Healthy subjects and patients with biopsy-confirmed NASH, between 18 and 65 years of 
age and of any race and ethnicity who reported drinking less than 20g/day of alcohol were 
eligible for the study. Any subject that had a history of gastrointestinal surgery, autoimmune 
disease, or other gastrointestinal/liver abnormality was excluded. Females were excluded if they 
were, or were trying to become, pregnant. All subjects exhibited normal values for serum 
creatinine, total bilirubin, nonreactive HIV, hepatitis B antigen, and hepatitis C antibody. 
Healthy subjects were eligible if all clinical lab values were within the normal range as 
determined by the University of North Carolina at Chapel Hill (UNC-CH) Hospitals McLendon 
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Laboratories for: sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), fasting 
glucose, calcium, magnesium, phosphorus, albumin, aspartate transaminase (AST), alanine 
transaminase (ALT), and alkaline phosphatase (ALP), coagulation panel (PT/PTT), homeostatic 
model assessment for insulin resistance (HOMA-IR) score <2.5, BMI ≤ 30 kg/m2, not taking any 
concomitant medications other than birth control or a standard multivitamin. Patients with 
NASH were recruited from the UNC-CH Hepatology Clinic and were eligible for enrollment if 
all of the following applied: biopsy confirmed noncirrhotic NASH with nonalcoholic fatty liver 
disease activity score (NAS) >3, BMI ≤ 45 kg/m2, no treatment for type 2 diabetes other than 
metformin, no milk thistle products or high-dose antioxidant treatment during the prior 30 days, 
and absence of prior treatment with NASH-associated drugs (i.e., tamoxifen, amiodarone, 
methotrexate, prednisone, tetracyclines, or valproic acid). Written informed consent was 
obtained from all subjects. This study was approved by the UNC-CH Biomedical Institutional 
Review Board and published on ClinicalTrials.gov (NCT2235233). 
Study design 
This single-center, comparative cohort study, evaluated the pharmacokinetics of MEB in 
healthy subjects and patients with NASH. Subjects and patients who met all inclusion/exclusion 
criteria were admitted to the Clinical and Translational Research Center at UNC-CH Hospitals 
after fasting overnight. Vital signs were assessed and an intravenous catheter was placed in one 
arm delivering a normal saline drip. Prior to MEB administration, a transmission-emission 
acquisition was performed using a cobalt-57 flood source (Isotope Products Laboratories, 
Burbank, CA) positioned posteriorly, and gamma rays were detected in the cobalt window (122 
KeV±15%) for 5-10 min on the anterior detector in the absence and presence of the subject. A 
~2.5 mCi intravenous bolus dose of MEB was administered via an indwelling catheter placed in 
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a contralateral forearm or hand vein, which was removed after drug administration. Blood 
samples (3 mL) were collected at baseline (0), 2.5, 5, 7.5, 10, 15, 20, 40, 60, 80, 100, 120, 140, 
160, 180, 210, 240, 270, and 300 min after administration; urine samples were collected at 
baseline (0) and at 180 min after administration. Anterior and posterior scintigraphic images of 
the abdomen were acquired dynamically in the 
99m
Tc window (140 KeV ± 15%) at 1-min 
intervals using a dual headed gamma camera up to 180 min after administration. Prior to 
discharge, vital signs were assessed and subjects were administered a safety questionnaire.  
Sample processing and analysis 
Blood and urine samples were analyzed for MEB radioactivity with a sodium iodide well 
counter and corrected for decay (
99m
Tc t1/2 = 6.01 hr). A blood sample (3 mL) collected at 20 
min post-dose was centrifuged to obtain serum and ultrafiltrate using the CentrifreeT 
ultrafiltration membrane system (Millipore Ireland Ltd, Tullagreen, Cork Ireland) according to 
the manufacturer’s instructions to determine the unbound fraction of MEB in serum. A subject-
specific correction matrix was obtained as described previously (Pfeifer et al., 2013) and 
multiplied by the geometric mean of the anterior and posterior 
99m
Tc-mebrofenin gamma 
scintigraphy images to generate time-activity curves (excluding the gall bladder) using Syngo MI 
applications version 6.5.9.19 (Siemens, New York, NY). 
Mathematical simulation for sample size calculation 
A previously published semi-physiologically based pharmacokinetic model was used to 
describe the hepatobiliary disposition of MEB (Pfeifer et al., 2013) and simulate altered 
disposition of MEB in a virtual population of healthy subjects and patients with NASH. The 
difference in hepatic exposure (AUC0-∞, liver) was selected as the primary endpoint. Based on the 
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modeling output and estimates of variability from a previous study (Pfeifer et al., 2013), 
feasibility, timeliness, and patient availability, the number of subjects recruited (n=14 healthy 
subjects and n=7 NASH patients) was sufficient to reject the null hypothesis of no difference in 
AUC0-∞, liver between subject groups. 
Pharmacokinetic data analysis 
The pharmacokinetics of MEB were evaluated using noncompartmental analysis (NCA) 
(Phoenix WinNonlin v. 6.3). Pharmacokinetic parameters were estimated using the blood 
concentration-time profile and the liver counts/sec-time profile. The area under the 
concentration-time curve or liver activity-time curve (AUC) from time zero to the last time point 
(AUC0-300,blood or AUC0-180,liver) was determined using a linear-up log-down trapezoidal 
algorithm. Total AUC (AUC0-∞) was calculated as the sum of AUC0-last and Clast/λz where λz was 
estimated using the terminal elimination phase. The terminal half-life (t1/2) was calculated as 
0.693/ λz. Blood clearance (CLblood) of MEB was calculated as the ratio of administered dose to 
AUC0-∞,blood. The percentage of the dose excreted in urine was calculated by dividing the total 
mass of MEB in urine after 180 min (the product of urine concentration and total volume 
collected) by the administered dose. Renal clearance (CLrenal) was calculated as the mass of MEB 
excreted over 180 min divided by the blood AUC from 0 to 180 min. 
Statistical analysis strategy 
MEB blood and liver pharmacokinetics are presented as geometric mean and 95% 
confidence intervals (CIs) with the exception of tmax,liver, which is presented as median and range. 
A two-tailed t-test (α = 0.05) was used to compare the log transformed pharmacokinetic 
parameters between groups; the Wilcoxon Mann-Whitney test was used to detect differences in 
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median the of tmax,liver. Linear regression was used to identify an association between NASH 
severity (defined as the sum of NAS and fibrosis biopsy scores) and blood and hepatic 
pharmacokinetics of MEB (GraphPad Prism, San Diego, CA). 
RESULTS 
Study Subjects  
Twenty-one volunteers (14 healthy subjects and 7 patients with biopsy-confirmed NASH) 
were studied (Table 2.1). Every effort was made to select healthy subjects that were comparable 
to patients with NASH based on age, sex, race, and ethnicity. Albumin, total bilirubin, activated 
partial thromboplastin time (APTT), and creatinine was within normal limits for both groups 
(Table 2.2). ALP was within the normal range for both groups, indicating no underlying 
evidence of cholestasis. Patients with NASH had a higher body weight and body mass index 
(BMI). Additionally, patients with NASH had higher levels of serum aminotransferases (i.e. 
ALT, AST), triglycerides, and insulin resistance as evidenced by elevated levels of fasting 
glucose, insulin, and HOMA-IR scores. Based on biopsy results, patients with NASH had a 
NAFLD activity score (NAS) greater than 3, with a maximum of 5, and fibrosis (F0-F3) (Table 
2.2). 
Blood and urine MEB pharmacokinetics 
After administration of a ~2.5 mCi intravenous dose of MEB, blood concentrations 
declined rapidly followed by a slower terminal elimination phase (Fig. 2.1A). The geometric 
mean of Cmax and area under the MEB blood-concentration time curve (AUC0-∞, blood) was 
significantly increased by 1.9- and 1.7-fold in patients with NASH, respectively. Blood clearance 
(CLblood) in healthy subjects was similar to values reported in healthy control subjects in 
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Ghibellini et al. (2004 and 2008) and Pfeifer et al. (2013); the geometric mean of CLblood was 
significantly decreased by 60% in patients with NASH (Table 2.3). The terminal elimination 
half-life of MEB appeared to increase from 242 min to 314 min in patients with NASH, but there 
was no statistically significant difference in the elimination rate constant (λz,blood) (Table 2.3). 
Although albumin levels were similar between each group, the unbound fraction (fu) of MEB in 
the plasma was evaluated to account for any potential difference in pharmacokinetics; as shown, 
there was no statistically significant difference in MEB fu between healthy subjects and patients 
with NASH (Table 2.3). Urinary recovery of MEB was less than 1% and CLrenal was not different 
between healthy subjects and patients with NASH (Table 2.3). 
Liver pharmacokinetics 
Gamma scintigraphy of MEB over 180 min revealed rapid uptake of MEB by the liver. 
The time-to-maximal activity in the liver (tmax, liver) was 13 min and was comparable between 
both groups (Table 2.3). These results are consistent with previously reported values (Doo et al., 
1991; Krishnamurthy et al., 1989; Pfeifer et al., 2013). The area under the MEB liver-activity 
time curve (AUC0-∞, liver) and maximal liver activity (Xmax) was significantly increased by 2.0-
fold and 1.4-fold in patients with NASH, respectively (Fig. 2.1B). The half-life of MEB in the 
liver (t1/2,liver) also increased from 22.5 to 36.5 min, indicating impaired excretion of MEB 
compared to healthy subjects; the elimination rate constant of MEB in the liver (λz,30-80 min, liver) 
was significantly decreased in patients with NASH (Table 2.3). 
Linear Regression Analysis 
Univariate linear regression detected a moderate association between NASH severity 
score (NAS+fibrosis) and blood exposure (AUC0-∞, blood) (R
2
 = 0.443, p-value = 0.001) (Fig. 
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2A).  Importantly, a strong correlation was detected between NASH severity score and blood 
Cmax (R
2
 = 0.683, p-value < 0.0001) as well as liver exposure (AUC0-∞, liver) (r
2
 = 0.775, p-value < 
0.0001) (Fig. 2.2B and 2.2C). 
DISCUSSION 
This is the first study to employ quantitative γ-scintigraphy techniques to assess the 
impact of NASH-associated alterations in hepatic uptake and efflux function in humans using a 
transporter probe substrate. This study demonstrated that patients with biopsy-confirmed NASH 
exhibited increased systemic and hepatic exposure of MEB, a hepatobiliary imaging agent, 
consistent with literature reports of disease-associated decreases in OATP expression, increases 
in MRP3 expression, and MRP2 mislocalization (Clark et al., 2014b; Dzierlenga et al., 2016; 
Hardwick et al., 2011; Hardwick et al., 2014).  
Lake et al. (2011) first reported global gene expression changes associated with 
absorption, distribution, metabolism, and excretion (ADME) processes, including phase I and II 
drug metabolizing enzymes and hepatic transporters, in patients with NASH. These changes 
appear to be driven by an adaptive hepatoprotective response to prevent further injury. Due to the 
prevalence of comorbidities such as type 2 diabetes mellitus, hypertension, and dyslipidemia in 
this population, many of these patients are taking multiple medications (Portincasa et al., 2006). 
Hence, altered ADME processes may impact the disposition, efficacy, and/or safety of drugs in 
patients with NASH. Subsequent studies revealed increased protein expression of ATP-binding 
cassette (ABC) efflux transporters with NAFLD disease progression, including ABCC2 (MRP2), 
although MRP2 appeared to be mislocalized from the canalicular membrane (Hardwick et al., 
2011). Because MRP2-mediated transport is the rate-limiting step in canalicular efflux of MEB 
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(Araikum et al., 1996; Neyt et al., 2013), altered expression and/or localization of MRP2 would 
be expected to affect MEB liver exposure. Hepatic MEB exposure was significantly increased 
2.0-fold compared to healthy age- and sex-matched subjects. This shift towards hepatic retention 
likely reflects mislocalization of MRP2 as evidenced by immunohistochemistry leading to 
reduced MRP2 function (Canet et al., 2015; Dzierlenga et al., 2015; Dzierlenga et al., 2016). The 
half-life of MEB in the liver increased from 22.5 to 36.5 min in patients with NASH, which 
supports our observations of increased hepatic retention. Linear regression analysis revealed the 
NASH severity score was able to predict hepatic exposure of MEB (Fig. 2.2C). Although 
Hardwick et al. (2011) reported increased MRP2 expression in patients with NASH, Okushin et 
al. (2015) recently reported that hepatic expression levels of MRP2 were inversely correlated 
with NAFLD progression in humans. Therefore, decreased expression of MRP2 cannot be 
dismissed as a contributing mechanism to our observations. Increased hepatic exposure of MEB 
is a novel finding, which is likely due to the functional impairment of MRP2. These data are 
consistent with human studies and experimental rodent models of NASH. For example, patients 
with Dubin-Johnson syndrome who lack functional MRP2 exhibit increased and prolonged 
exposure to MEB (Bar-Meir et al., 1982). In diet-induced rodent models of NASH, magnetic 
resonance imaging (MRI) of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-
EOB-DTPA), an OATP and MRP2 substrate, revealed that liver half-life was significantly 
increased in NASH animals (Tsuda et al., 2007; Tsuda et al. 2011). Enhanced hepatic exposure 
and increased half-life of Gd-EOB-DTPA in NASH rodents are consistent with our findings in 
patients with NASH using MEB. 
Blood Cmax and AUC0-∞,blood were significantly increased by 1.9-fold and 1.7-fold in 
patients with NASH, respectively. This likely reflects decreased hepatic uptake of MEB by 
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OATPs, consistent with reports of OATP downregulation in NASH (Canet et al., 2014; Fisher et 
al., 2009). MEB is also a MRP3 substrate (Ghibellini et al., 2008; Pfeifer et al., 2013). 
Pharmacokinetic studies support increased MRP3-mediated efflux in patients with NASH; 
therefore, MRP3 may contribute to increased systemic concentrations observed in the present 
study (Canet et al., 2015b; Ferslew et al., 2015). Although OATPs and MRP3 mediate the 
basolateral uptake and efflux of MEB, respectively, pharmacokinetic modeling reveal that 
modest changes (i.e. < 5-fold) in these clearance pathways will have a negligible effect on 
hepatic exposure because MRP2-mediated excretion is the rate-limiting step in MEB clearance 
from the liver (Pfeifer et al., 2013). Likewise, systemic exposure is sensitive to alterations in 
OATPs and MRP3-mediated transport of MEB (Pfeifer et al., 2013); thus, increased systemic 
exposure likely reflects altered OATP and/or MRP3-mediated function. 
Altered hepatic transporter function due to disease, genetic polymorphisms, or drug-drug 
interactions (DDIs) can contribute to interindividual variability in drug/metabolite systemic and 
hepatic disposition thereby affecting therapeutic efficacy and/or safety. OATPs (e.g. OATP1B1 
and OATP1B3) have emerged as important determinants of hepatic uptake and consequently, 
systemic pharmacokinetics. For example, elevated concentrations of statins due to OATP 
inhibition are associated with increased prevalence of myopathy which can lead to life-
threatening rhabdomyolysis (Ballantyne et al., 2003; Omar et al., 2001; Omar et al., 2002); 
increased simvastatin concentrations have been observed in a rodent model of NASH (Clarke et 
al., 2014b). Conversely, drugs whose site of action is the liver (e.g. statins) or rely on hepatic 
biotransformation to active metabolites (e.g. morphine) may display altered hepatic exposure 
thereby impacting pharmacodynamic response. Other clinically-relevant examples of OATP 
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substrates that may be impacted by altered OATP expression include repaglinide, enalapril, and 
olmesartan (Kalliokoski et al., 2009). 
Biliary excretion is a major route of elimination for drugs and metabolites. Therefore, 
knowledge about hepatobiliary disposition and its relationship to clearance is essential to 
understanding drug pharmacokinetics .The notion that MRP2 function in NASH is impaired may 
have unintended consequences for drug disposition thereby placing a larger burden on the liver. 
For example, spiramycin has been associated with cholestatic hepatitis despite its favorable 
safety profile relative to other macrolide antibiotics (Denie et al., 1992). In vivo 
pharmacokinetics studies in Mrp2 knockout (KO) mice revealed a ~10-fold decrease in Mrp2-
mediated biliary excretion, which suggests that patients with impaired MRP2 function, such as in 
NASH demonstrated in the current study, may be susceptible to spiramycin-induced liver injury 
(Tian et al., 2007). Interruption of the enterohepatic recirculation of mycophenolate and its 
glucuronide conjugate by the MRP2 inhibitor cyclosporine A unexpectedly decreased 
mycophenolic acid systemic exposure. Hence, it is conceivable that impaired MRP2 function 
could decrease systemic pharmacokinetics of drugs which may alter pharmacodynamic response 
(Pou et al., 2001). However, the dynamic interplay and overlapping substrate specificity between 
multiple uptake and efflux transporters (e.g. P-glycoprotein, breast cancer resistance protein) 
must be considered when predicting the clinical relevance of altered drug disposition (Varma et 
al., 2016). 
Although a relatively low number of volunteers with NASH were enrolled in this study, 
the precision of pharmacokinetic parameters was increased by recruiting 2:1 healthy to NASH 
subjects. Ethical considerations precluded a biopsy to specifically quantify transporter 
expression, but OATP downregulation and MRP2 internalization are well documented in this 
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population. To define a homogenous population and confounding variables, subjects were 
excluded if they had evidence of cirrhosis, portal hypertension, or decompensated liver disease, a 
history of immune-related disease, bariatric surgery, a history of drugs associated with fatty liver 
disease or steatohepatitis, or were taking any type II diabetes medications other than metformin. 
Patients with a histological confirmation of NASH with an NAS score of >3 were enrolled 
because changes in transporter expression are expected after the onset of inflammation 
(Hardwick et al., 2011).  
In conclusion, patients with biopsy-confirmed NASH displayed increased systemic and 
hepatic concentrations of MEB compared to age- and sex-matched healthy subjects. Specifically, 
these changes are consistent with NASH-associated downregulation of OATPs, upregulation of 
MRP3, and mislocalization of MRP2. Given the increasing prevalence of NAFLD and NASH, 
these data indicate that dysregulation of hepatic transporters may alter the systemic and hepatic 
exposure of drugs/metabolites. Further understanding how NASH affects hepatic and 
extrahepatic clearance mechanisms will improve the ability to predict drug disposition, efficacy, 
and safety of new and existing medications in this patient population.  
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Figure 2.1. 
99m
Tc-mebrofenin (MEB) concentrations and liver activity in patients with 
NASH. MEB blood concentration vs. time curves (A); liver scintigraphy vs. time curves (B) in 
healthy subjects (black) and patients with NASH (grey) Data represent mean ± SD. 
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Figure 2.2 Association between NASH severity score and 
99m
Tc-mebrofenin (MEB) 
pharmacokinetics. Association between NASH severity score (NAS+fibrosis) and 
99m
Tc-
mebrofenin (MEB) blood Cmax (A), AUC0-∞,blood (B), and AUC0-∞,liver (C) in healthy subjects 
(black) and patients with NASH (grey). The best-fit line is represented by the solid black line 
while the 5th and 95th confidence intervals are represented by the lower and upper dashed lines, 
respectively. Results from linear regression are presented as the coefficient of determination 
(R
2
), regression parameter estimate (β ± standard deviation of the parameter estimate), and the p-
value.
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Table 2.1. Demographic characteristics of study participants   
Parameter  Healthy (n=14)  NASH (n=7) 
Sex       
  Men  8  4 
  Women  6  3 
Ethnicity  Hispanic  0  1 
  Non-Hispanic  14  6 
Race  White  11  5 
  Hispanic  0  1 
  Asian  1  1 
  Black  3  0 
Age  
(years) 
   
38.9 (15.4)  37.4 (17.4) 
Body weight  
(kg) 
   
72.1 (12.1)  102 (16)* 
Body mass index 
(kg/m
2
) 
   
24.4 (2.2)  33.3 (5.1)* 
Waist 
circumference 
(cm) 
   
81.9 (8.3)  111 (15)* 
Hip circumference 
(cm) 
   
89.3 (8.6)  119 (14)* 
Waist-to-hip ratio  All subjects  0.90 (0.05)  1.00 (0.04)* 
  Men  0.91 (0.06)  1.00 (0.04)* 
  Women  0.88 (0.06)  1.01 (0.06)* 
Data presented as mean (standard deviation); *p < 0.05 using two-tailed Student’s t-test. 
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Table 2.2. Clinical chemistries and liver biopsy grade   
Clinical parameter  Healthy  NASH 
Creatinine (mg/dL)  0.86 (0.17)  0.83 (0.15) 
Albumin (g/dL)  4.2 (0.2)  4.5 (0.4) 
ALP (U/L)  56.3 (17.8)  68.1 (20.0) 
ALT (U/L)  28.7 (9.8)  113 (60)* 
AST (U/L)  25.2 (8.0)  72.9 (34.3)* 
APTT (s)  31.3 (2.7)  33.7 (1.6) 
Bilirubin, total (mg/dL)  0.7 (0.2)  1.0 (0.4) 
Cholesterol (mg/dL)  153 (25)  133 (40) 
Triglycerides ( mg/dL)  73.2 (32.8)  146 (47)* 
HDL (mg/dL)  57.4 (15.9)  42.2 (12.5) 
LDL-direct (mg/dL)  86.1 (22.4)  72.5 (41.1) 
Glucose, fasting (mg/dL)  86.6 (6.3)  142 (81)* 
HOMA-IR  1.56 (0.53)  8.18 (4.56)* 
Serum insulin (μIU/mL)  7.3 (2.8)  24.3 (8.6)* 
Total NAS score  N/A  4 (4-5) 
     Steatosis  N/A  2 (2-3) 
     Hepatocyte ballooning  N/A  1 (0-1) 
     Inflammation  N/A  1 (1-2) 
Fibrosis  N/A  2 (0-3) 
NAS + Fibrosis  N/A  6 (5-8) 
Data are presented as mean (standard deviation); biopsy scoring presented as median (range); *p 
< 0.05 using two-tailed Student’s t-test. ALP, alkaline phosphatase; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; APPT; activated partial thromboplastin time; 
HDL, high-density lipoprotein; HOMA-IR, homeostasis model for assessing insulin resistance; 
LDL, low-density lipoprotein; NAS, nonalcoholic fatty liver disease activity score. 
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Table 2.3. Pharmacokinetics of 
99m
Tc-mebrofenin in healthy subjects and patients with 
NASH  
Parameter  Healthy  NASH 
Administered dose
a
  
(mCi) 
 
2.47  
(0.16) 
 
2.46  
(0.23) 
Cmax (nCi/mL)  
132  
(117-148) 
 
246*  
(188-322) 
AUC0-300,blood  
(nCi*min/mL) 
 
1700  
(1440-2000) 
 
2670*  
(1960-3640) 
AUC0-∞,blood  
(nCi*min/mL) 
 
2150  
(1840-2600) 
 
3760* 
(2590-5450) 
CLblood  
(mL/min/kg) 
 
16.1  
(13.9-18.8) 
 
6.49*  
(4.16-10.1) 
λz,blood 
(min) 
 
0.00286 
(0.00243-0.00337) 
 
0.00221  
(0.00161-0.00303) 
Unbound fraction (fu)
a
  
0.0667  
(0.0310) 
 
0.0855  
(0.0400) 
Urinary recovery
b 
 
(% of dose) 
 
0.515  
(0.390-0.681) 
 
0.794  
(0.557-1.13) 
CLrenal 
(mL/min/kg) 
 
0.117  
(0.088-0.154) 
 
0.082 
(0.063-0.109) 
AUC0-180,liver  
(kcounts*min/sec) 
 
103  
(87-122) 
 
186* 
(157-219) 
AUC0-∞,liver  
(kcounts*min/sec) 
 
105  
(88-124) 
 
210*  
(178-248) 
Xmax,liver 
(counts/sec) 
 
2350  
(2180-2530) 
 
3230*  
(2635-3970) 
tmax,liver
c
 
(min) 
 
13  
(12-15) 
 
13  
(11-17) 
λz,30-80 min, liver 
(min) 
 
0.0309  
(0.0275-0.0345) 
 
.0190* 
(0.0127-0.0284) 
Data presented as geometric mean (95% CI). 
a
Mean (standard deviation). 
b
Total mass excreted 
from 0-180 min. 
c
Median (range). *p < 0.05, Student’s two-tailed t-test of log transformed data 
comparing healthy subjects to patients with NASH. Maximal blood concentration (Cmax), area 
under the blood-concentration time curve (AUCblood), blood clearance (CLblood), blood 
elimination rate constant (λz,blood), area under the liver activity-time curve (AUCliver), maximal 
liver activity (Xmax), renal clearance (CLrenal), time to maximum liver activity (tmax,liver), and liver 
elimination rate constant (λz, 30-80 min,liver)  
 115 
 
 
 
 
CHAPTER 3. Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and 
Metabolites: Contributing Factors to Drug-Induced Liver Injury?
3
 
 
INTRODUCTION 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a monogenic inheritable 
disease characterized by progressive renal cyst development, often leading to end-stage-renal-
disease. Supportive care and surgical interventions represent the mainstay of ADPKD treatment 
because no Food and Drug Administration (FDA)-approved therapy currently exists (Patel et al., 
2014; Torres et al., 2007). Tolvaptan, an orally available benzazepine derivative, is a selective 
vasopressin V2-receptor antagonist (Yamamura et al., 1998) used in the treatment of clinically 
significant hyponatremia (Schrier et al., 2006), volume overload in heart failure (Fukunami et al., 
2011) and liver cirrhosis with edema (Sakaida, 2015). Tolvaptan recently has shown promise for 
delaying renal cyst progression in ADPKD (Boertien et al., 2015; Higashihara et al. 2011; Torres 
et al., 2012) with approvals in Canada and Europe for this indication. In the pivotal clinical trial, 
however, tolvaptan was associated with liver injury evident as increased liver enzymes and 
bilirubin in some patients. No signals of liver injury have been observed in patient populations 
treated with tolvaptan for other indications or in nonclinical studies (Oi et al., 2011; Watkins et 
al. 2015).  The etiology and/or biological mechanism(s) underlying tolvaptan-associated liver 
injury in patients with ADPKD have yet to be elucidated.  
                                                          
3
 This chapter has been published in Toxicological Sciences, and is presented in the style of that journal: Tox Sci 
2016 Jan;149(1):237-50 
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Drug-induced liver injury (DILI) is a frequent safety concern during drug development 
that has led to prescribing restrictions for some drugs (e.g. trovafloxacin) and market withdrawal 
for others (e.g. troglitazone) (Senior, 2014). Cholestatic and hepatocellular liver injury are two 
major forms of DILI, but despite extensive research, the underlying pathophysiological 
mechanism(s) remain ill-defined and are likely compound-specific. Inhibition of bile acid 
transport is one mechanism of DILI leading to intracellular accumulation of hydrophobic bile 
acids that can cause necrotic and/or apoptotic cell death (Marion et al., 2007; Perez and Briz, 
2009; Wagner et al., 2009). The major transport proteins responsible for the basolateral uptake 
and biliary excretion of bile acids in humans are Na+-taurocholate cotransporting polypeptide 
(NTCP/SLC10A1) and the bile salt export pump (BSEP/ABCB11), respectively.  Inhibition of 
BSEP-mediated bile acid transport has been implicated in DILI (Morgan et al., 2010; Woodhead 
et al., 2014). Additionally, multidrug resistance-associated proteins 2, 3 and 4 (MRP2/ABCC2, 
MRP3/ABCC3 andMRP4/ABCC4) also transport bile acids and may represent compensatory 
pathways for hepatic bile acid excretion under duress (Akita et al., 2001; Akita et al., 2002; Rius 
et al., 2006; Zelcer et al., 2003b). Recently, our group demonstrated that inhibition of MRP4, in 
addition to BSEP, may be a risk factor for the development of cholestatic DILI (Köck et al., 
2014). Despite the association between bile acid inhibition and DILI, not all bile acid inhibitors 
cause DILI, suggesting that other mechanism(s) or patient-specific susceptibility factors may 
play a role in the development of DILI (Morgan et al., 2013). 
In humans, tolvaptan exhibits dose-linear pharmacokinetics with an apparent elimination 
half-life ranging from 3 to 12 hours depending on the dose (Kim et al. 2011; Shoaf et al. 2007) 
and an oral bioavailability of ~50% following a 30 mg dose (Shoaf et al., 2012a). Tolvaptan is 
eliminated primarily by extensive CYP3A metabolism (Shoaf et al., 2012b) with several 
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metabolites detectable in the plasma including an oxybutyric acid metabolite (DM-4103) and a 
hydroxybutyric acid metabolite (DM-4107) (Fig. 3.1; Tammara et al., 1999; Sorbera et al., 
2002). DM-4103 has a long half-life (~180 hours) in humans.  Following a single, 60 mg oral 
dose of 14C-tolvaptan, plasma concentrations of DM-4103 are measurable for as long as 456 
hours and account for ~52% of plasma radioactivity. While circulating concentrations of DM-
4107 are lower than tolvaptan (which represents <3% of plasma radioactivity), approximately 
20% of a tolvaptan dose is excreted in urine and feces as this metabolite (Tammara et al., 1999; 
Sorbera et al., 2002). In addition to the unknown etiology of tolvaptan-associated liver injury in 
ADPKD patients, it is also unclear whether DILI observed in ADPKD patients is due to the 
parent compound, a metabolite of tolvaptan, or some other specie(s). 
These studies were designed to elucidate the interaction of tolvaptan and two metabolites, 
DM-4103 and DM-4107, with several proteins involved in the hepatic transport of bile acids. In 
addition, the accumulation and vectorial transport of selected bile acids in the absence and 
presence of tolvaptan was examined in sandwich-cultured human hepatocytes (SCHH). The 
results of this investigation, in combination with other ongoing research examining alternative 
potential mechanisms of hepatotoxicity (e.g., mitochondrial toxicity, adaptive immune 
response.), may provide important information to aid in determining the mechanism(s) 
underlying liver injury in tolvaptan-treated ADPKD patients. 
MATERIALS AND METHODS 
Materials. 
[
3
H]Taurocholic acid (TCA, 15.4 Ci/mmol), [
3
H]estradiol-17β-glucuronide (E217G, 41.4 
Ci/mmol), and [
3
H]dehydroepiandrosterone sulfate (DHEAS, 60 Ci/mmol) were purchased from 
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PerkinElmer (Schwerzenbach, Switzerland). Unlabeled substrates (TCA, E217G, and DHEAS) 
were purchased from Cayman Chemicals (Ann Arbor, MI) or Sigma-Aldrich (St. Louis, MO). 
Stable-labeled taurocholic acid (d8-TCA) and chenodeoxycholic acid (d5-CDCA) were purchased 
from Martex Inc. (Minnetonka, MN). GCDCA (glycochenodeoxycholic acid), TCDCA 
(taurochenodeoxycholic acid), and erythromycin-estolate were purchased from Sigma-Aldrich 
(St. Louis, MO). MK-571 was purchased from Cayman Chemicals (Ann Arbor, MI).  A/E Type 
glass filters (25mm) used in membrane vesicle studies were purchased from Pall Life Sciences 
(Ann Arbor, MI). Supplements added to culture NTCP-CHO cells were purchased from 
Invitrogen (Zug, Switzerland). Tolvaptan, DM-4103, and DM-4107 were provided by Otsuka 
Pharmaceutical Co. Ltd (Tokyo, Japan). The purity of these compounds was >99%. 
Cell Culture 
Chinese Hamster Ovary (CHO) cells.  
CHO cells expressing human NTCP seeded in a 96-well format were obtained from 
Solvo Biotechnology (Szeged, Hungary). Cells were stored in a humidity-controlled incubator 
(37°C, 5% CO2) until used. If possible, studies were completed on the day CHO cells arrived. In 
the event that experiments were not conducted on the arrival day, the media was replaced 
according to the supplier’s protocol and the experiment was conducted within 24 hours. 
Sandwich-Cultured Human Hepatocytes (SCHH).  
SCHH were prepared by Qualyst Transporter Solutions (Durham, NC) using Transporter 
Certified
TM 
cryopreserved human hepatocytes from donor S-1099 (Kaly-Cell, Plobsheim, 
France) or donor HUM4059 (Triangle Research Laboratories, Durham, NC).  Cryopreserved 
hepatocytes were thawed following the supplier’s thawing instructions.  SCHH were prepared by 
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plating hepatocytes suspended in propriety hepatocyte QualGro
TM
 Seeding Medium (Qualyst 
Transporter Solutions, Durham, NC) at a density of 0.7x10
6
 viable cells/mL onto BioCoat
®
 24-
well cell culture plates (BD Biosciences, San Jose, CA). Following plating, cells were allowed to 
attach for 2-4 hours, rinsed and fed with warm (37
o
C) seeding medium. Eighteen to 24 hours 
later, cells were fed and over-laid with the appropriate species-specific propriety culture medium 
(Qualyst Transporter Solutions, Durham, NC) supplemented with the extracellular matrix (ECM) 
Matrigel
®
 (BD Biosciences, San Jose, CA). Cells were maintained in culture medium in a 
humidity-controlled incubator (37°C, 5% CO2) until experiments were conducted on day 5 of 
culture.  
Assays 
Membrane Vesicle Assay.  
BSEP, MRP2, and MRP4 membrane vesicles were obtained from GenoMembrane 
(Kanagawa, Japan) and MRP3 membrane vesicles were obtained from Solvo Biotechnology 
(Szeged, Hungary). Membrane vesicles (10 µg BSEP, 5 µg MRP2, 10 µg MRP3, 5 µg MRP4, or 
control vesicles) were incubated at 37°C with the substrate [
3
H]TCA, [
3
H] E217G, or 
[
3
H]DHEAS (2 µCi/mL) supplemented with the unlabeled substrate to achieve a concentration of 
2 µM TCA (for BSEP), 50 µM E217G (for MRP2), 10 µM E217G  (for MRP3), or 2 µM DHEAS 
(for MRP4) in transport buffer (10 mM Hepes-Tris for BSEP; 40 mM MOPS-Tris for MRP2 and 
MRP4; 10 mM Tris-HCl for MRP3) containing MgCl2 (10 mM), sucrose (50 mM for BSEP or 
250 mM for MRP3) and adenosine triphosphate (ATP) or adenosine monophosphate (AMP) (4 
mM) in a final volume of 50 µL. Dimethyl sulfoxide (DMSO) was used to solubilize tolvaptan, 
DM-4103, and DM-4107; the final concentration of DMSO was < 1% v/v. After incubation for 2 
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min (for BSEP and MRP4), 3 min (for MRP2), or 5 min (for MRP3) with vehicle or increasing 
concentrations of tolvaptan, DM-4103, or DM-4107, the reaction was stopped by the addition of 
800 µL ice-cold transport buffer and immediately filtered using A/E glass fiber filters presoaked 
in transport buffer overnight. The tested concentrations and incubation time points were 
determined by the limit of solubility for each compound and from preliminary data (data not 
shown). For the BSEP uptake studies, the filters were presoaked with 1 mM TCA solution to 
minimize nonspecific binding. For the MRP2, MRP3, and MRP4 uptake studies, the filters were 
presoaked with 3 mM reduced glutathione and 10mM dithiothreitol solution to minimize 
nonspecific binding.  The filters were washed three times with ice-cold transport buffer using a 
vacuum filtration system. The filters were transferred to glass vials, and 10 mL liquid 
scintillation cocktail was added and mixed by vortex before analysis using the Tri-Carb 3100 TR 
liquid scintillation analyzer (PerkinElmer, Waltham, MA). The ATP-dependent uptake of 
substrate was calculated by subtracting substrate uptake in the presence of AMP from substrate 
uptake in the presence of ATP. The assays were performed in triplicate in three separate 
experiments. 
CHO Transport Studies.  
CHO cells were rinsed twice with 100 µL of prewarmed (37°C) Krebs-Henseleit uptake 
buffer with or without Na
+
. A third aliquot of 100 µL transport buffer was left on the cells and 
incubated at 37°C for 15 min. The media was then aspirated and discarded. Uptake was initiated 
by the addition of prewarmed (37°C) uptake buffer containing the substrate [
3
H]TCA (2 µCi/mL)  
supplemented with unlabeled TCA to achieve a concentration of 1 µM. Increasing concentrations 
of tolvaptan (0-50 µM), DM-4103 (0-75 µM), and DM-4107 (0-200 µM) were added to the 
substrate solution; the highest concentrations approached the limit of solubility for each 
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compound. DMSO was used to solubilize tolvaptan, DM-4103, and DM-4107; the final 
concentration of DMSO was < 1% v/v. The cells were incubated for 5 min at 37°C. Transport 
was stopped by quick aspiration of the radiolabeled solution; the cells were rinsed three times 
with 100 µL of ice-cold uptake buffer to stop the reaction. The cells were solubilized by adding 
100 µL of 100 mM NaOH and left at room temperature for 2 min; 80 µL of the cell suspension 
was mixed with 5 mL scintillation fluid for radioactivity counting using the Tri-Carb 3100 TR 
liquid scintillation analyzer (PerkinElmer, Waltham, MA). NTCP-mediated uptake of TCA was 
calculated by subtracting substrate uptake in the absence of sodium from substrate uptake in the 
presence of sodium. The assays were performed in three separate experiments in triplicate. 
Sandwich-Cultured Human Hepatocyte Studies. 
Time-, Temperature-, and Na
+
-Dependent Uptake of Tolvaptan in SCHH. 
On day 5 of culture, media was aspirated and the SCHH were rinsed with 0.5 mL/well of 
standard or Ca
2+
-free Hank’s Balanced Salt Solution (HBSS). For Na+-dependent uptake studies, 
Na
+
-containing or Na
+
- free (choline) HBSS buffers were used instead. After the second rinse, 
HBSS buffers were aspirated completely and SCHH were incubated with 0.5 mL of standard or 
Ca
2+
-free HBSS buffers for 10 min (or Na
+
-containing or Na
+
- free HBSS buffers for the NTCP-
mediated uptake studies). After 10 min, HBSS buffers were aspirated and then incubated with 
standard HBSS buffer containing tolvaptan (15 μM) at 37ºC for 5, 10, or 20 min, or 4ºC for 10 
min. DMSO was used to solubilize tolvaptan; the final concentration of DMSO was 0.2% v/v.  
For the Na
+
-dependent uptake studies, tolvaptan was incubated at 37ºC for 10 min. A tolvaptan 
concentration of 15 µM was selected because it was the highest concentration in the linear range 
for tolvaptan uptake (data not shown). After incubation, the HBSS buffer was aspirated from all 
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wells and rinsed three times with ice-cold standard HBSS buffer. Plates were sealed and stored at 
-80ºC until analysis. 
Hepatobiliary Disposition of Taurocholic Acid (TCA), Chenodeoxycholic Acid (CDCA), 
Taurochenodeoxycholic Acid (TCDCA), and Glycochenodeoxycholic Acid (GCDCA) in the 
Presence of Tolvaptan. 
On day 7 of culture, culture media was aspirated completely and SCHH were rinsed with 
0.5 mL/well of standard or Ca
2+
-free HBSS buffers. After the second rinse, HBSS buffers were 
aspirated completely and SCHH were incubated with 0.5 ml of standard or Ca
2+
-free HBSS 
buffers for 10 min. After 10 min, HBSS buffers were aspirated completely and then incubated 
with the standard HBSS containing 2.5 µM of the probe substrate (d8-TCA, d5-CDCA, TCDCA, 
or GCDCA) with or without tolvaptan (15µM) for 10 min. After incubation, the incubation 
solutions were aspirated from all wells and rinsed three times with ice-cold standard HBSS 
buffer. Plates were sealed and stored at -80ºC until analysis. 
Analysis of Tolvaptan, DM-4103, and DM-4107 in SCHH and Media by Liquid 
Chromatography-Tandem Mass Spectrometry (LC-MS/MS). 
A volume of 500 µL of lysis solution (70:30 methanol:water (v:v) containing 27.5 nM 
internal standard) was added to each well of previously frozen 24-well plates containing study 
samples. Plates were shaken for approximately 15 min and the cell lysate solution was 
transferred to a Whatman
®
 96-well Unifilter® 25 µm MBPP / 0.45 µm PP filter plate 
(Maidstone, England) stacked on a 96-well deepwell plate.  Lysate was filtered into the deepwell 
plate by centrifugation (2000 x g for 5 min). The sample filtrate was evaporated to dryness and 
the samples were reconstituted in 200 µL sample diluent (70:30 methanol:water containing 0.1% 
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formic acid) and mixed for 15 min on a plate shaker. The reconstituted samples were transferred 
to a 0.45 µm filter plate (Millipore, Billerica, MA) and filtered into a 96-well plate by 
centrifugation (2000 x g for 2 min) and sealed with a silicone capmat prior to LC-MS/MS 
analysis. Analytical controls for tolvaptan, DM-4103, and DM-4107 were measured using 
standard curves. Analytical standards were prepared over a range of concentrations to deliver, 
with the addition of a 10 µL volume per well, the range of mass 0.5 – 5000 pmoles/well for 
tolvaptan, DM-4103, and DM-4107. Cell lysates from SCHH were utilized for the generation of 
standard curves and related quality control (QC) samples. QC lysate samples were prepared at 
the lower limit of quantitation (LLQ) and the upper limit of quantitation (ULQ). These lysate 
controls were further processed as described above. A binary HPLC system (Shimadzu, 
Columbia, MD) composed of LC-10ADvp pumps, a CTO-10Avp oven, and an HTc – 96-well 
autosampler was used. The chromatographic column was a Hypersil Gold™ C18 (100 x 1.0 mm, 
3 µm) with matching guard (5 µm) and pre-column filter (Thermo Scientific, Bellefont, PA). 
Column temperature was maintained at 35°C. A mobile phase gradient composed of A = 50% 
methanol with 0.1% formic acid and B = 90% methanol with 0.01% formic acid was used at a 
flow rate of 50 µL/min and a total run time of 10 min. All test compounds were 
chromatographically resolved. The gradient profile was: initial 25% B for 2.0 minutes; from 2.0 
– 5.0 minutes ramp to 100% B and hold for 0.9 minute; step back to 25% B at 6.0 minutes and 
re-equilibrate for 4.0 minutes. An injection volume of 5 µL was used. Tandem mass 
spectrometry with positive ion electrospray ionization was conducted with a Thermo Electron 
TSQ
®
 Quantum Discovery MAX™ (Thermo Fisher, Waltham, MA) with an Ion Max ESI 
source. The transitions monitored (parent m/z > product m/z) at unit resolution for tolvaptan, the 
internal standard, DM-4103, and DM-4107 were 449.2 > 252.0, 463.2 > 266.0, 479.0 > 252.0 
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and 481.0 > 252.0, respectively. The analytical run was typically conducted with a standard 
curve at the beginning of the run. A ULQ QC and a LLQ QC sample were placed in the middle 
of the run and at the end of the run. Analyte and internal standard peak area responses were 
determined for the standards, QC’s, and unknown samples, and the unknown and QC samples 
(pmoles/well) were calculated utilizing the standard curve. Analytical run ruggedness was 
evaluated based on percent accuracy of the back calculated values for the standards and QC’s.  
Acceptance criteria for percent accuracy of back calculated values were typically 15 - 20%. 
Analysis of TCA, CDCA, TCDCA, and GCDCA. 
Analysis of d8-TCA, d5-CDCA, TCDCA and GCDCA was performed using LC-MS/MS 
as described previously (Marion et al., 2012). Assay acceptance criteria were similar to those 
defined above. For the analysis of TCDCA and GCDCA only, the relative amounts (no standard 
curve) were determined by measuring the peak area ratios from the unknown LC-MS/MS peak 
area and the area of the corresponding internal standard. Relative changes were determined for 
individual treatments. 
Data Analysis and Statistics.  
Membrane Vesicle and CHO Cell Assays. 
Transporter-mediated uptake was normalized to vehicle control values (without 
inhibitor). IC50 values were determined by nonlinear regression techniques using the following 
equation in GraphPad Prism 6 (San Diego, CA): 
Y=100/[1+10^((X-LogIC50))] 
where X represents the log concentration of inhibitor and Y represents the percentage of control 
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activity. Data are reported as the point estimate and 95% confidence interval (CI).  If the 
inhibitor did not reduce substrate transport by >50% at the highest tested concentration, 
nonlinear regression to estimate an IC50 value was not conducted. The type of inhibition and 
inhibition constant (Ki) for BSEP-mediated TCA transporter was determined by fitting 
competitive, noncompetitive, and uncompetitive models to the untransformed data by nonlinear 
regression analysis using GraphPad Prism 6 (San Diego, CA). The best-fit model was assessed 
based on visual inspection of the observed versus predicted data and the Akaike Information 
Criteria (Akaike, 1974). Equations used for each inhibition model were as follows:  
Competitive: 𝑣 =
𝑉𝑚𝑎𝑥  × S
𝐾𝑚  ×  1 + 
𝐼
𝐾𝑖
   + S
 
Noncompetitive: 𝑣 =
𝑉𝑚𝑎𝑥  × S
𝐾𝑚  ×  1 + 
𝐼
𝐾𝑖
   + S ×  1 + 
𝐼
𝐾𝑖
  
 
Uncompetitive: 𝑣 =
𝑉𝑚𝑎𝑥  × S
𝐾𝑚  + S ×  1 + 
𝐼
𝐾𝑖
   
  
Where S represents the concentration of TCA, I represents the concentration of tolvaptan or DM-
4103, ν represents the rate of TCA transport, νmax represents the maximal rate of TCA transport, 
𝐾𝑚  represents the TCA concentration that yields half maximal TCA transport, and 𝐾𝑖  represents 
the dissociation constant for the BSEP-inhibitor complex. Data are from n=3 independent 
experiments in triplicate. 
Sandwich-Cultured Hepatocyte Studies.  
All mass values were normalized to the mean protein (mg) content per well from SCHH.  
Protein content was determined using the Pierce BCA protein assay kit. Cellular accumulation 
determined in Ca
2+
-free HBSS buffer was assumed to represent the total mass of analyte inside 
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the hepatocyte at the end of the incubation time period. Total accumulation determined in 
standard HBSS buffer represents the total mass of compound taken up and excreted (cells + bile). 
The biliary excretion index (BEI) was calculated according to the following equation (Liu et al., 
1999a): 
BEI  % =  
AccumulationStandard  HBSS −  AccumulationCa 2+−free  HBSS
AccumulationStandard  HBSS
 × 100 
The in vitro biliary clearance (Clbiliary) was determined using the following equation (Ghibellini 
et al. 2007; Liu et al., 1999b) and was scaled to body weight using scaling factors (Qualyst 
Transporter Solutions Technical Application Bulletin, 2011). 
𝐶𝑙𝑏𝑖𝑙𝑖𝑎𝑟𝑦 =  
𝐴𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑  𝐻𝐵𝑆𝑆 −  𝐴𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛𝐶𝑎2+−𝑓𝑟𝑒𝑒  𝐻𝐵𝑆𝑆
𝑡𝑖𝑚𝑒 × 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑚𝑒𝑑𝑖𝑎
  
The biliary clearance for DM-4103 and DM-4107 could not be determined because the 
metabolites were generated endogenously.  The intracellular concentration of each test 
compound was calculated by dividing the mass of compound in cells by the respective 
hepatocyte intracellular fluid volume for human hepatocytes (7.69 µl/mg protein; Qualyst 
Transporter Solutions Technical Application Bulletin, 2011). All calculations were performed 
using Microsoft Excel (Redmond, Washington). 
RESULTS 
NTCP- and BSEP-Mediated TCA Transport. 
TCA was used as a substrate to study the interaction of tolvaptan, DM-4103, and DM-
4107 with the basolateral uptake transporter NTCP. TCDCA (100 µM) was used as a positive 
control and inhibited NTCP-mediated uptake by >98% (data not shown). The estimated IC50 
values for tolvaptan, DM-4103 and DM-4107 were ~41.5, 16.3 and 95.6 µM, respectively (Fig. 
3.2A-C; Table 3.1). TCA was used as a substrate to study the interaction of tolvaptan, DM-4103, 
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and DM-4107 with the canalicular efflux transporter BSEP. Rifampicin (50 µM) was used as a 
positive control and inhibited BSEP-mediated uptake by >50% (data not shown; Byrne et al., 
2002). BSEP-mediated TCA uptake was reduced to 16.4% of control when incubated with 50 
µM tolvaptan; the estimated IC50 value was 31.6 µM (Fig. 3.2D; Table 3.1). DM-4103 inhibited 
BSEP-mediated TCA uptake with an IC50 value of 4.15 µM, while the IC50 value for DM-4107 
was 119 µM (Fig. 3.2E-F). The Ki was estimated using nonlinear regression by incubating BSEP 
membrane vesicles with TCA (2-30 μM) and designated concentrations of tolvaptan (0-50 μM) 
or DM-4103 (0-20 μM). A Ki for DM-4107 was not determined because it was a less potent 
inhibitor of BSEP-mediated TCA transport based on the estimated IC50 value compared to 
tolvaptan and DM-4103.  Nonlinear regression analysis of the data revealed that tolvaptan was 
best described by a noncompetitive inhibition model (Ki=34.2 μM), while DM-4103 was best 
described by a competitive inhibition model (Ki=3.77 μM) (Fig. 3.3). 
MRP2- and MRP3-Mediated E217G Transport, and MRP4-Mediated DHEAS Transport.  
E217G and DHEAS were used as substrates to study the interaction of tolvaptan, DM-
4103, and DM4107 with the efflux transporters MRP2, MRP3, and MRP4.  MK-571 (50 μM) 
was used as a positive control and inhibited MRP2-, MRP3- and MRP4-mediated transport by 
>95%, >50%, and >90%, respectively (data not shown). If transporter-mediated uptake of a 
probe substrate was not inhibited by >50%, nonlinear regression analysis was not conducted 
(Fig. 3.4C, D, and G). At the highest concentration of tolvaptan, MRP2-mediated E217G uptake 
was 115% of control, indicating that tolvaptan did not inhibit MRP2 transport (Fig. 3.4A). The 
estimated IC50 value for DM-4103 was ~51.0 µM (Fig. 4B). The estimated IC50 values for DM-
4103 and DM-4107 mediated MRP3 inhibition were ~44.6 and 61.2 µM, respectively (Fig. 3.4E 
and F; Table 3.1). DHEAS was used as a substrate to study the interaction of tolvaptan, DM-
 128 
 
4103 and DM4107 with the basolateral efflux transporter MRP4. At the highest concentration of 
tolvaptan (50 μM), MRP4-mediated DHEAS uptake was 88.0% of control, indicating that 
tolvaptan had minimal impact on MRP4 transport (Fig. 3.4G). The estimated IC50 values for 
DM-4103 and DM-4107 were 4.26 and 37.9 µM, respectively (Fig. 3.4H-I; Table 3.1). DM-4103 
inhibited MRP2-mediated E217G uptake by >50% only at the highest tested concentration (Fig. 
3.4B).  Although a curve was fit to these data to estimate an IC50 of ~51.0 µM, caution must be 
exercised when interpreting this value.  The limits of solubility precluded testing higher 
concentrations of DM-4103. Such was the case with MRP3-mediated inhibition by DM-4103 as 
well as NTCP-mediated inhibition by tolvaptan (Fig. 3.2A and 4E).   
Time- and Temperature-Dependent Uptake of Tolvaptan in Sandwich-Cultured Human 
Hepatocytes (SCHH). 
SCHH were incubated with tolvaptan (15 µM) for 5, 10, or 20 min at 37ºC or for 10 min 
at 4ºC. Tolvaptan accumulated in SCHH reaching a concentration of ~500 µM after 10 min, 
assuming that binding to the hepatocyte surface was negligible and that accumulation 
represented the mass of tolvaptan in the cell. Temperature-dependent uptake suggested that both 
active and passive components are involved in tolvaptan uptake (Fig. 3.5A). The biliary 
excretion index (BEI) for tolvaptan was < 10%, indicating a low potential for biliary excretion of 
tolvaptan. In separate SCHH studies, formation of both DM-4103 and DM-4107 was observed 
during a 10-min incubation with tolvaptan (15 µM) at 37ºC (Fig. 3.5B); the mean total 
(bound+unbound) cellular concentrations of tolvaptan, DM-4103 and DM-4107 were 530, 1.71, 
and 35.6 μM, respectively. 
 
 
 129 
 
Sodium-Dependent (NTCP) Uptake of Tolvaptan in SCHH.  
To determine the sodium-dependent uptake of tolvaptan in SCHH, hepatocytes were 
incubated in the presence or absence of sodium. The total accumulation of tolvaptan and the 
accumulation of generated DM-4103 and DM-4107 were unaffected by the absence of sodium 
(Table 3.2). 
Hepatobiliary Disposition of TCA, CDCA, TCDCA and GCDCA in the Presence of 
Tolvaptan in SCHH.  
The effect of tolvaptan on the hepatobiliary disposition of four model bile acids (TCA, 
CDCA, TCDCA, and GCDCA) was evaluated in SCHH. When co-incubated with 15 µM 
tolvaptan, the total accumulation of TCA was decreased by 32.6% and the BEI was decreased by 
15.7% compared to control (Table 3.3).  The combined effect of the inhibition of both uptake 
and efflux by tolvaptan decreased the biliary clearance of TCA by 0.57-fold to control (Table 
3.3; Fig. 3.6A). In contrast to TCA, the cellular accumulation of CDCA tended to increase by 
1.30-fold relative to control. Tolvaptan-mediated changes in the biliary clearance and BEI of 
CDCA were 0.39 and 0.45-fold of control (Table 3.3). Erythromycin estolate (100 µM), a broad-
spectrum efflux transport inhibitor, was used as a positive control and had no effect on the total 
accumulation (cell + bile) of CDCA, but inhibited the biliary excretion of CDCA (data not 
shown).  Similar to CDCA, tolvaptan had no effect on the total accumulation of TCDCA or 
GCDCA, but did appear to increase the cellular accumulation (cells) of TCDCA and GCDCA by 
1.68 and 2.16-fold, respectively compared to control when co-incubated with tolvaptan (Table 
3.3; Fig. 3.6B). 
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DISCUSSION 
In the present study, the inhibitory effect of tolvaptan, DM-4103, and DM-4107 on 
human hepatic bile acid transporters was investigated. This work was undertaken because 
tolvaptan was associated with liver injury in some patients with ADPKD during clinical 
investigation. Liver injury had not been reported previously for other patient populations, e.g., 
patients treated for hyponatremia, or cardiac and hepatic edema. In the ADPKD pivotal trials and 
the subsequent ongoing open-label safety study (NCT01214421), 4.9% of patients treated with 
tolvaptan had elevated alanine aminotransferase levels compared to 1.2% of those receiving the 
placebo (Torres et al., 2012). Fewer patients treated with tolvaptan than those receiving the 
placebo (0.9% vs. 1.9%) had increased bilirubin levels.  However, two cases of Hy’s Law were 
observed in tolvaptan-treated ADPKD patients, while no Hy’s Law cases were reported in 
placebo-treated patients (Torres et al., 2012). A third case of Hy’s Law was observed in a 
tolvaptan-treated ADPKD patient in an open-label follow on trial (Watkins et al., 2015). 
Furthermore, these observations did not appear to be associated with dose or exposure and 
generally occurred after three months or more of treatment (Watkins et al., 2015).   
Idiosyncratic DILI is, by definition, a rare event.  There was no apparent correlation 
between renal impairment, apparent hepatorenal cyst burden or stage of ADPKD and occurrence 
of hepatic events.  Because of the low number of events, a definitive conclusion about an 
association between cyst burden and DILI cannot be made at this time.  These data were 
described at the FDA Advisory Committee meeting for tolvaptan (August 2013; www.fda.gov) 
but have not been published yet.  Interestingly, systemic tolvaptan exposure based on AUC was 
greater in patients with reduced creatinine clearance (<30 mL/min) than in patients with 
preserved renal function (Shoaf et al., 2014).  Thus, prolonged renal impairment may alter 
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excretory mechanisms thereby placing a larger burden on the liver.  With renal impairment in 
this population, an increase in systemic exposure does occur compared to non-ADPKD patients, 
although the differences are minimal since patients with severe renal impairment were excluded 
from the pivotal clinical trial (Torres et al., 2012). It is worth noting, however, that the liver is 
the primary elimination pathway for tolvaptan/metabolites (metabolism and fecal excretion) and 
not urinary excretion (Shoaf et al., 2012a).  Hence, increasing the hepatic burden could alter 
hepatic exposure to tolvaptan/metabolites and may be associated with bile acid transporter 
inhibition, as shown in the present experiments.  
 BSEP inhibition has been implicated as one mechanism of DILI, although inhibition of 
other efflux transporters such as MRP2 and MRP4 also have been shown to exhibit an 
association with DILI (Köck et al., 2014; Mennone et al., 2006; Morgan et al., 2013). Under 
normal physiological conditions in humans, bile acids, primarily the conjugated bile acids 
taurodeoxycholic acid (TDCA), glycodeoxycholic acid (GDCA), TCDCA, and GCDCA, are 
transported across the canalicular membrane into bile and stored in the gallbladder until released 
into the duodenum (Hofmann et al., 2008; Rodrigues et al., 2013). Bile acids concentrate in the 
bile ducts relative to hepatocytes; active canalicular transport via BSEP is the rate-limiting step 
in bile acid transport and an important determinant of bile flow (Kullak-Ublick et al., 2004; 
Meier et al., 2004). Inhibition of BSEP may lead to accumulation of bile acids within 
hepatocytes and subsequently induce cytotoxicity. 
 Cholestatic DILI is a subset of liver disease that can result from direct damage to hepatic 
parenchyma (e.g. hepatocytes, bile ducts) through toxic or immunogenic mechanisms, and/or by 
impairment of biliary excretory function. Apart from genetic defects [e.g., progressive familial 
intrahepatic cholestasis type 2 (PFIC2)], numerous drugs have been implicated in cholestasis 
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(Padda et al., 2011). Cyclosporine, a prototypical drug that can induce cholestatic liver injury, 
alters bile acid transport function, intrahepatic vesicle transport, canalicular membrane fluidity 
and bile-acid independent bile flow (Böhme et al., 1994; Bramow et al., 2001; Román et al., 
2003; Yasumiba et al., 2001). No cases of hepatotoxicity were reported during the development 
of troglitazone. However, this thiazolidinedione was removed from the market due to 
idiosyncratic liver injury.  Subsequent studies, after market withdrawal, revealed that 
troglitazone and the sulfate conjugate of troglitazone inhibit BSEP.  Further, studies with 
troglitazone revealed that cholestasis was more prevalent in male rats presumably due to sex-
dependent differences in the toxic sulfate-conjugated species (Funk et al., 2001; Kostrubsky et 
al., 2001). These examples highlight the potential multi-mechanistic nature of DILI as well as the 
interplay between the formation and excretion of drug metabolites.  
 These present experiments were designed to test the hypothesis that bile acid transporter 
interference could be a biologically plausible mechanism to explain DILI in tolvaptan-treated 
patients with ADPKD. As shown, DM-4103 was a ~7.5-fold and a ~29-fold more potent 
inhibitor of BSEP (IC50: 4.15 μM) compared to tolvaptan and DM-4107, respectively, based on 
IC50 data (Table 3.1). The ratio between the concentration at steady state (Css) or maximal 
plasma concentration (Cmax) and the inhibitory potency (IC50) is used commonly to understand 
the relationship between drug or metabolite exposure and inhibition (Zhang, 2012; Morgan et al., 
2013). According to FDA guidance, when the estimated [I]/Ki or [I]/IC50 ratio is greater than 0.1, 
where [I] represents the total (bound plus unbound) mean steady-state Cmax after administration 
of the highest proposed clinical dose, an in vivo drug interaction study may be warranted (Huang 
et al., 2008). For BSEP, both tolvaptan and DM-4107 exhibited (total) Cmax/IC50 values < 0.1 
while DM-4103 exhibited a value of 3.78 (Table 3.1), which suggests that DM-4103 may be a 
 133 
 
relevant inhibitor of BSEP at the therapeutic dose of 90 mg tolvaptan. However, cellular rather 
than plasma concentrations of tolvaptan, DM-4103 and DM-4107 would be more relevant for 
predictions of efflux inhibition.  
 To further understand BSEP inhibition, the mechanism of inhibition was interrogated for 
tolvaptan and DM-4103. Inhibition of BSEP by tolvaptan was best described by a 
noncompetitive inhibition model (Ki=34.2 μM) while DM-4103 was best described by a 
competitive inhibition model (Ki=3.77 μM). Unlike competitive inhibition, noncompetitive 
inhibition reduces the rate of transport (e.g. of bile acids) and the resulting effects of depressed 
bile acid transport may lead to accumulation of bile acids, impaired bile flow, and hepatotoxicity. 
This principle is supported by Woodhead et al. (2014) who showed that in a simulated patient 
population treated with CP-724,714, an anti-cancer agent terminated from further development 
due to hepatotoxicity thought to be due, in part, to BSEP inhibition (Guo et al., 2008), clinically-
relevant ALT elevations developed more frequently when BSEP inhibition was noncompetitive 
in nature. Mitochondrial toxicity also was implicated as a mechanism of CP-724,714 toxicity 
(Feng et al., 2009) and clinical findings suggest that CP-724,714 exerted both hepatocellular and 
hepatobiliary cholestatic injury (Guo et al., 2008; Munster et al., 2007). 
 As noted earlier, inhibition of BSEP alone cannot always predict or explain DILI.  This 
may be due, in part, to the adaptive abilities of the liver. When bile acids accumulate in 
hepatocytes, compensatory or salvage pathways are transcriptionally upregulated/downregulated 
that function as hepatoprotective mechanisms (Wagner et al., 2005). MRP4, a sinusoidal bile 
acid efflux transporter, is normally expressed at low levels in human hepatocytes but protein 
expression can be increased significantly during cholestasis (Chai et al., 2012; Teng et al., 2007, 
Wagner et al., 2009; Zollner et al., 2006). Alterations in other bile acid efflux transporter 
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expression/function have been reported including MRP2, MRP3 and organic solute transporters 
(OSTα/OSTβ), indicating a complex adaptive response to cholestasis and/or bile acid-mediated 
toxicity (Boyer et al., 2006; Trauner et al., 1997; Zollner et al., 2001). Because of these potential 
adaptive responses, Morgan et al. (2013) developed decision criteria for bile acid transporter-
mediated hazard identification, which includes evaluating the inhibition of important bile acid 
efflux transporters (i.e. MRP2, MRP3, and MRP4) in addition to BSEP. All evaluated 
compounds that exhibited a BSEP Css/IC50 ratio ≥ 0.1 and either a MRP2, MRP3 or MRP4 
Css/IC50 ratio ≥ 0.1 were associated with some form of liver injury. These findings highlight the 
potential importance of compensatory mechanisms of bile acid transport when BSEP is impaired.  
Because inhibition of MRP-mediated transport function, in addition to BSEP, is associated with 
DILI, we sought to determine the inhibitory potency of tolvaptan, DM-4103 and DM-4107 on 
MRP2-, MRP3- and MRP4-mediated transport function.  
 As shown, tolvaptan and DM-4107 showed no or marginal MRP2 inhibition, respectively 
(Fig. 3.4A-C). Although DM-4103 inhibited MRP2-mediated transport by >50% at the highest 
tested concentration, caution should be exercised when interpreting the IC50 of DM-4103 (~51.0 
μM) because limits of solubility precluded testing the effects of higher tolvaptan concentrations 
on MRP2-mediated transport. Such was the case with DM-4103 on MRP3-mediated transport. 
Tolvaptan showed no effect on MRP3-mediated transport and although the IC50 for DM-4107 
was estimated to be 61.2 μM, the Cmax/IC50 value was 0.04, indicating that DM-4107 may not be 
a relevant inhibitor of MRP3 (Table 3.1). In contrast, the Cmax/IC50 value for DM-4103 was 0.35 
for MRP3-mediated transport. DM-4103 was a ~9-fold more potent inhibitor of MRP4-mediated 
transport based on IC50 when compared to DM-4107 (IC50 of 4.26 vs. 37.9 μM, respectively), 
while tolvaptan exhibited minimal inhibition of MRP4-mediated transport (Fig. 3.4G-I). When 
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taking into account plasma concentrations, DM-4103 exhibited a Cmax/IC50 value of 3.69 for 
MRP4 (Table 3.1), indicating that DM-4103 may be a relevant inhibitor of the basolateral efflux 
transporter MRP4 since this ratio was >0.1. The effects of tolvaptan on BSEP, MRP2 and MRP4 
transport were similar to the IC50 values reported by Morgan et al. (2013) (9.99, >133 and >133 
μM, respectively).  
 Although over-expressing cell lines and inside-out membrane vesicles are used 
commonly to screen for interactions at the transporter level, such systems may not be entirely 
predictive of the interactions that may or may not occur in complex cellular systems (e.g., 
hepatocytes) or in vivo (Byrne et al., 2002; Colombo et al., 2013; Xia et al., 2007). SCHH are a 
promising tool to study drug disposition and hepatotoxicity (Marion et al. 2007; Swift et al., 
2010). Therefore, to further explore the interaction of tolvaptan with hepatocellular bile acid 
transporters, the disposition of tolvaptan and bile acids was evaluated in SCHH. Tolvaptan 
accumulation in SCHH was rapid and appeared to consist of both passive and active uptake 
processes (Fig. 3.5). After a 10-min incubation with 15 μM tolvaptan, the total cellular 
concentration was ~500 μM, assuming that all tolvaptan was localized intracellularly. In SCHH, 
approximately 30% of the tolvaptan dose was metabolized over 10 min, with ~1% and 10% 
representing DM-4103 and DM-4107, respectively. The cellular concentrations of DM-4103 and 
DM-4107 after a 10-min incubation with 15 μM tolvaptan were ~1.73 and ~23.8 μM, 
respectively. Although DM-4107 is formed preferentially compared to DM-4103 in about a 10:1 
ratio (DM-4107:DM4103) after 10 min in SCHH, DM-4103 is the main circulating metabolite in 
vivo (Tammara et al., 1999; Sorbera et al., 2002). This apparent discrepancy may be due to 
differences in metabolite formation rates, i.e., DM-4103 and DM-4107 are downstream 
metabolites of tolvaptan (Tammara et al., 1999). Furthmore, intracellular metabolite 
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concentrations in culture may not be similar to metabolite concentrations circulating in human 
plasma. 
 Four bile acids (TCA, CDCA, TCDCA and GCDCA) were used as probes to determine 
the inhibitory potential of tolvaptan on hepatocellular bile acid transport in SCHH. CDCA, 
TCDCA, and GCDCA are among the most common circulating bile acids in humans and 
alterations in their disposition have been implicated in cholestatic liver injury (Greim et al., 
1973; Ijare et al., 2009; Perwaiz et al., 2001; Roda et al., 1998; Tagliacozzi et al., 2003).  Both 
the BEI and Clbiliary of TCA and CDCA in human SCHH appeared to decrease (0.84- and 0.57-
fold of control, respectively for TCA and 0.39 and 0.45-fold of control, respectively for CDCA) 
when incubated with tolvaptan (Table 3.3). The cellular accumulation of TCA was not altered by 
tolvaptan, indicating that cellular basolateral efflux may be able to compensate for TCA 
accumulation even though TCA Clbiliary was decreased; TCA Clbiliary is approximately 3-fold 
greater than basolateral clearance in SCHH (Yang et al., 2015). Similarly, both the BEI and 
Clbiliary of CDCA in SCHH were modestly decreased (Table 3.3). Unlike TCA, CDCA appeared 
to accumulate intracellularly when co-incubated with tolvaptan (increased by 1.3-fold relative to 
control) (Fig. 3.6A). The cellular accumulation of TCDCA and GCDCA also appeared to 
increase when co-incubated with tolvaptan (increased by 1.68 and 2.16-fold relative to control, 
respectively), which indicates the potential for these bile acids to accumulate, possibly due to 
inhibition of biliary and/or basolateral efflux (Fig. 3.6B).  The BEI for TCDCA and GCDCA 
also appeared to be lower when co-incubated with tolvaptan (Table 3.3).  Inhibition of bile acid 
transport in SCHH is consistent with the observations from the membrane vesicle studies.  These 
data support the hypothesis that accumulation of tolvaptan in hepatocytes may play a role in the 
mechanism(s) of DILI.  
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Although the cellular accumulation of bile acids such as TCDCA has been shown to 
experimentally induce liver injury in vivo (Sokol et al., 1998), the biological importance of such 
changes in bile acid biliary clearance and hepatocyte accumulation in humans is not well 
defined. In sandwich-cultured hepatocytes, Marion et al. (2007) and Griffin et al. (2013) 
demonstrated that some hepatotoxic drugs were associated with impaired bile acid biliary 
clearance and/or increased cellular accumulation of bile acids and subsequent toxicity, similar to 
the present findings. Furthermore, the current study examined bile acid disposition in short-term 
incubations, which may be exacerbated in long-term exposures as shown by the delayed 
presentation of bile acid-mediated toxicity of troglitazone (Yang et al., 2014).  
As described earlier, inhibition of hepatic bile acid transporters may not be the sole 
mechanism of DILI noted in the ADPKD population. Alternative mechanisms of hepatotoxicity 
currently are being explored.  Wu et al. (2015) recently demonstrated that tolvaptan induces in 
vitro cellular apoptosis in HepG2 cells, potentially through several mechanisms including 
mitochondrial dysfunction.  However, considering clinically relevant concentrations of tolvaptan 
and the fact that hepatotoxicity has not been reported in non-ADPKD populations, the clinical 
relevance of these studies remains uncertain.  In addition to direct drug-induced mitochondrial 
dysfunction and oxidative stress, bile acids can cause hepatocellular damage by inducing 
swelling and abnormal mitochondrial cristae, disruption of cellular membranes, and generation 
of reactive oxygen species (Billington et al., 1980; Philips et al., 1987; Sokol et al., 1993).  As 
described by Watkins et al. (2015), the signature pattern of hepatic events occurred after 
approximately 3-4 months of treatment, and resolved over a prolonged period of time following 
discontinuation of tolvaptan. The signature pattern of hepatotoxicity suggested an adaptive 
immune-mediated hepatic event, which continues to be explored in patients. However, multiple 
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mechanisms of DILI cannot be ruled out including the inhibition of bile acid transport, as shown 
here, and mitochondrial toxicity (Feng et al. 2009). The results of studies focused on these 
alternative mechanism(s) will be reported subsequently.  As noted at the outset of this paper, the 
purpose of the current investigation was to test the hypothesis that inhibition of human hepatic 
bile acid transporters by tolvaptan and metabolites could play a role in tolvaptan-associated 
DILI.  
It has been suggested that inhibition of NTCP-mediated bile acid uptake may provide 
some cellular protection from hepatic accumulation of bile acids, such as shown with bosentan 
(Leslie et al. 2007).  However, the NTCP IC50 value for tolvaptan (~41.5 μM) was >2-fold higher 
than the dose concentration in the SCHH studies, indicating that tolvaptan would have little 
impact on TCA uptake in hepatocytes; this is consistent with the data obtained in SCHH (Fig. 
3.6A). DM-4103 and DM-4107 concentrations in the media were negligible after a 10-min 
incubation (data not shown); these metabolites likely had little impact on TCA uptake in the 
present study.  Based on Cmax concentrations achieved with therapeutic doses of tolvaptan, only 
DM-4103 exhibited an I/IC50 > 0.1 for NTCP (Table 3.1). However, when taking into account the 
unbound fraction (assuming fu ~1%, similar to that of tolvaptan, Shoaf et al., 2014), an 
interaction at the level of NTCP would not be expected. Tolvaptan did not appear to be a 
substrate of NTCP (Table 3.2). While NTCP is considered the primary hepatic bile acid 
transporter in humans, OATPs also may transport endogenous anions including bile acids and 
bilirubin (Cui et al., 2001; Meier et al., 1997; Tamai et al., 2000). Although inhibition of OATPs 
is a concern for the interaction of concomitantly administered drugs (Zhang et al., 2012), 
inhibition of OATPs has not been associated with DILI and thus, may not be relevant to 
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understanding bile acid-mediated toxicity/disposition. Furthermore, OATP drug-drug 
interactions with tolvaptan have not been reported in humans (Bhatt et al., 2014). 
In conclusion, results of the present studies demonstrate that tolvaptan and metabolites 
inhibited multiple human hepatic proteins involved in bile acid transport (i.e. NTCP, BSEP, 
MRP2, MRP3 and MRP4). Impaired bile acid transport by tolvaptan and/or its metabolites may 
negatively impact bile acid homeostasis, which may explain, in part, the mechanism(s) behind 
liver injury in tolvaptan-treated ADPKD patients. However, the fact that liver injury has been 
observed only in patients with ADPKD, and that no evidence of cholestasis (i.e., no clinically 
significant increases in alkaline phosphatase) was observed in the ADPKD clinical trial (Torres 
et al., 2012), suggests that other mechanisms may predispose this patient population to DILI.  
Research into other genetic and non-genetic mechanisms of tolvaptan-induced DILI is on-going.  
  
 140 
 
REFERENCES 
Akaike, H. (1974). A new look at the statistical model identification. IEEE Trans. Auto. Ctrl. 
AC-19, 716-723. 
 
Akita, H., Suzuki, H., Hirohashi, T., Takikawa, H., Sugiyama, Y.  (2002). Transport activity of 
human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm. Res. 19, 34-41. 
 
Bhatt, P.R., McNeely, E.B., Lin, T.E., Adams, K.F., Patterson, J.H. (2014). Review of 
tolvaptan's pharmacokinetic and pharmacodynamic properties and drug interactions. J Clin Med. 
3, 1276-1290. 
 
Billington, D., Evans, C.E., Godfrey, P.P., Coleman, R. (1980). Effects of bile salts on the 
plasma membranes of isolated rat hepatocytes. Biochem J, 188, 321-327. 
 
Bramow, S., Ott, P., Thomsen Nielsen, F., Bangert, K., Tygstrup, N., Dalhoff, K. (2001). 
Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver 
following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol. 89, 
133-139. 
 
Boertien, W.E., Meijer, E., de Jong PE, Ter., Horst, G.J., Renken, R.J., van der Jagt, E.J., 
Kappert, P., Ouyang, J., Engels, G.E., van Oeveren, W., Struck, J., Czerwiec, F.S., Oberdhan, D., 
Krasa, H.B., Gansevoort, R.T.  (2015). Short-term effects of tolvaptan in individuals with 
autosomal dominant polycystic kidney disease at various levels of kidney function. Amer. J. 
Kidney Dis.  65, 833-841. 
 
Boyer, J.L., Trauner, M., Mennone, A., Soroka, C.J., Cai, S.Y., Moustafa, T., Zollner, G., Lee, 
J.Y., Ballatori, N. (2006). Upregulation of a basolateral FXR-dependent bile acid efflux 
transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest 
Liver Physiol. 290, G1124–G1130. 
Böhme, M., Müller, M., Leier, I., Jedlitschky, G., Keppler, D.  (1994).  Cholestasis caused by 
inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterol. 
107, 255-265. 
 
Byrne, J.A., Strautnieks, S.S., Mieli-Vergani, G., Higgins, C.F., Linton, K.J., Thompson, R.J. 
(2002). The human bile salt export pump: characterization of substrate specificity and 
identification of inhibitors. Gastroenterol. 123, 1649-1658. 
 
Chai, J., H.e, Y., Cai, S.Y., Jiang, Z., Wang, H., Li, Q., Chen, L., Peng, Z., He, X., Wu, X., Xiao, 
T., Wang, R., Boyer, J.L., Chen, W. (2012).  Elevated hepatic multidrug resistance-associated 
protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is 
mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated 
protein kinase-signaling pathway. Hepatol. 55, 1485-1494. 
 
Colombo, F., Poirier, H., Rioux, N., Montecillo, M.A., Duan, J., Ribadeneira, M.D. (2013). A 
 141 
 
membrane vesicle-based assay to enable prediction of human biliary excretion. Xenobiotica. 43, 
915-919. 
 
Cui, Y., König, J., Leier, I., Buchholz, U., Keppler, D. (2001) Hepatic uptake of bilirubin and its 
conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 276, 9626-9630. 
 
Feng, B., Xu, J.J., Bi, Y.A., Mireles, R., Davidson, R., Duignan, D.B., Campbell,S., Kostrubsky, 
V.E., Dunn, M.C., Smith, A.R., Wang, H.F. (2013). Role of hepatic transporters in the 
disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol Sci. 108, 
492-500. 
 
Fukunami, M., Matsuzaki, M., Hori, M., Izumi, T., Tolvaptan Investigators. (2011). Efficacy and 
safety of tolvaptan in heart failure patients with sustained volume overload despite the use of 
conventional diuretics: a phase III open-label study. Cardiovas Drugs Ther. 25, S47-56. 
 
Funk, C., Pantze, M., Jehle, L., Ponelle, C., Scheuermann, G., Lazendic, M., Gasser, R. (2001). 
Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of 
bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate 
formation and the inhibition of the canalicular bile salt export pump (BSEP) by troglitazone and 
troglitazone sulfate. Toxicol. 167, 83-98. 
 
Ghibellini, G., Vasist, L.S., Leslie, E.M., Heizer, W.D., Kowalsky, R.J., Calvo, B.F., Brouwer, 
K.L. (2007).  In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin 
Pharmacol Ther. 81, 406-413. 
 
Greim, H., Czygan, P., Schaffner, F., Popper, H. (1973). Determination of bile acids in needle 
biopsies of human liver. Biochem. Med. 8, 280–286. 
 
Griffin, L.M., Watkins, P.B., Perry, C.H., St Claire, R.L. 3rd, Brouwer, K.L. (2013). 
Combination lopinavir and ritonavir alter exogenous and endogenous bile acid disposition in 
sandwich-cultured rat hepatocytes. Drug Metab Dispos. 41, 188-196. 
 
Guo, F., Letrent, S. P., Munster, P. N., Britten, C. D., Gelmon, K., Tolcher, A. W., Sharma A. 
(2008). Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with 
advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and 
safety. Cancer Chemother. Pharmacol. 62, 97–109. 
 
Higashihara, E., Torres, V.E., Chapman, A.B., Grantham, J.J., Bae, K., Watnick, T.J., Horie, S., 
Nutahara, K., Ouyang, J., Krasa, H.B., Czerwiec, F.S.  (2011). TEMPO Formula and 156-05-002 
study investigators. Tolvaptan in autosomal dominant polycystic kidney disease: three years' 
experience. Clin. J. Amer. Soc. Nephrol. 6, 2499-2507. 
 
Hofmann A.F., Hagey L.R. (2008). Bile Acids: Chemistry, Pathochemistry, Biology, 
Pathobiology, and Therapeutics. Cell Mol Life Sci. 65, 2461-2483. 
 
Huang S.M., Strong, J.M., Zhang, L., Reynolds, K.S., Nallani, S., Temple, R., Abraham, S., 
 142 
 
Habet, S.A., Baweja, R.K., Burckart, G.J., Chung, S., Colangelo, P., Frucht, D., Green, M.D., 
Hepp, P., Karnaukhova, E., Ko, H.S., Lee, J.I., Marroum, P.J., Norden, J.M., Qiu, W., Rahman, 
A., Sobel, S., Stifano, T., Thummel, K., Wei, XX., Yasuda, S., Zheng, J.H., Zhao, H., Lesko, L.J. 
(2008). New era in drug interaction evaluation: US Food and Drug Administration update on 
CYP enzymes, transporters, and the guidance process. J Clin Pharmacol. 48, 662-670. 
 
Ijare, O.B., Bezabeh, T., Albiin, N., Arnelo, U., Bergquist, A., Lindberg, B., Smith, I.C. (2009).  
Absence of glycochenodeoxycholic acid (GCDCA) in human bile is an indication of cholestasis: 
a 1H MRS study. Absence of glycochenodeoxycholic acid (GCDCA) in human bile is an 
indication of cholestasis: a 1H MRS study. NMR Biomed. 22, 471-479. 
 
Kim, S.R., Hasunuma, T., Sato, O., Okada, T., Kondo, M., Azuma, J. (2011). Pharmacokinetics, 
pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor 
antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. 
Cardiovasc Drugs Ther. 25, S5-17. 
 
Köck, K., Ferslew, B.C., Netterberg, I., Yang, K., Urban, T.J., Swaan, P.W., Stewart, P.W., 
Brouwer, K.L. (2014). Risk factors for development of cholestatic drug-induced liver injury: 
inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 
and 4. Drug Metab Dispos. 42, 665-674. 
 
Kostrubsky, V.E., Vore, M., Kindt, E., Burliegh, J., Rogers, K., Peter, G., Altrogge, D., Sinz, 
M.W. (2001).  The effect of troglitazone biliary excretion on metabolite distribution and 
cholestasis in transporter-deficient rats. Drug Metab Dispos. 29, 1561-1566. 
 
Kullak-Ublick, G.A., Stieger, B., Meier, P.J. (2004). Enterohepatic bile salt transporters in 
normal physiology and liver disease. Gastroenterology. 126, 322-342. 
 
Leslie, E.M., Watkins, P.B., Kim, R.B., Brouwer, K.L. (2007).  Differential inhibition of rat and 
human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a 
mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther. 321, 1170-1178. 
 
Liu, X., LeCluyse, E.L., Brouwer, K.R., Gan, L.S., Lemasters, J.J., Stieger, B., Meier, P.J., 
Brouwer, K.L. (1999a). Biliary excretion in primary rat hepatocytes cultured in a collagen-
sandwich configuration. Am J Physiol. 277, G12-G21. 
 
Liu, X., Chism, J.P., LeCluyse, E.L., Brouwer, K.R., Brouwer, K.L. (1999b).  Correlation of biliary 
excretion in sandwich-culture rat hepatocytes and in vivo in rats, Drug Metab. Dispos. 27, 637-644.  
 
Marion, T.L., Leslie, E.M., Brouwer, K.L.  (2007). Use of sandwich-cultured hepatocytes to evaluate 
impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol. Pharm. 4, 911-918. 
 
Marion TL, Perry CH, St Claire RL 3rd, Brouwer KL. (2012). Endogenous bile acid disposition in rat and 
human sandwich-cultured hepatocytes. Toxicol Appl Pharmacol. 261, 1-9. 
 
Meier, P.J., Eckhardt, U., Schroeder, A., Hagenbuch, B., Stieger, B. (1997). Substrate specificity of 
sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatol. 26, 1667-1677. 
 143 
 
 
Meier, P.J., Stieger, B. (2002). Bile salt transporters. Annu Rev Physiol. 64, 635-661. 
 
Mennone, A., Soroka, C.J., Cai, S.Y., Harry, K., Adachi, M., Hagey, L., Schuetz, J.D., Boyer, 
J.L. (2006). Mrp4
-/-
 mice have an impaired cytoprotective response in obstructive cholestasis. 
Hepatol. 43, 1013-1021. 
 
Morgan, R.E., Trauner, M., van Staden, C.J., Lee, P.H., Ramachandran, B., Eschenberg, M., 
Afshari, C.A., Qualls, C.W. Jr., Lightfoot-Dunn, R., Hamadeh, H.K. (2010).  Interference with 
bile salt export pump function is a susceptibility factor for human liver injury in drug 
development. Toxicol. Sci. 118, 485-500. 
 
Morgan, R.E., van Staden, C.J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R.T., Afshari, 
C.A., Hamadeh, H.K.  (2013). A multifactorial approach to hepatobiliary transporter assessment 
enables improved therapeutic compound development. Toxicol Sci. 136, 216-2141.  
 
Munster, P. N., Britten, C. D., Mita, M., Gelmon, K., Minton, S. E., Moulder, S., Slamon, D. J., 
Guo, F., Letrent, S. P., Denis, L., et al. (2007). First study of the safety, tolerability, and 
pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing 
tumors. Clin. Cancer Res. 13, 1238–1245. 
 
Oi, A., Morishita, K., Awogi, T., Ozaki, A., Umezato, M., Fujita, S., Hosoki, E., Morimoto, H., 
Ishiharada, N., Ishiyama, H., Uesugi, T., Miyatake, M., Senba, T., Shiragiku, T., Nakagiri, N., 
Ito, N. (2011). Nonclinical safety profile of tolvaptan. Cardiovasc Drugs Ther. 1, S91-S99. 
 
Padda, M.S., Sanchez, M., Akhtar, A.J., Boyer, J.L. (2011).  Drug-induced cholestasis. Hepatol. 
53, 1377-1387. 
 
Patel, M.S., Kandula, P., Wojciechowski, D., Markmann, J.F., Vagefi, P.A. (2014).  Trends in 
the management and outcomes of kidney transplantation for autosomal dominant polycystic 
kidney disease. J. Transplant. 2014, 675-697. 
 
Perez, M.J., Briz, O. (2009).  Bile-acid-induced cell injury and protection. World J. 
Gastroenterol. 14 15, 1677-1689. 
 
Perwaiz, S., Tuchweber, B., Mignault, D., Gilat, T., Yousef, I.M. (2001). Determination of bile 
acids in biological fluids by liquid chromatography-electrospray tandem mass spectrometry. J 
Lipid Res. 42, 114-119. 
 
Phillips, M.J., Poucell, S., Patterson, J., Valencia, P. Cholestasis. In: Phillips, M.J., Poucell, S., 
Patterson, J., Valencia, P. (1987). The liver: an atlas and text of ultrastructural pathology. New 
York: Raven Press, 101-158. 
 
Qualyst Transporter Solutions Technical Application Bulletin TAB Biol 005. (2011). TAB Biol 
005v2. 
 
 144 
 
Rius, M., Hummel-Eisenbeiss, J., Hofmann, A.F., Keppler, D. (2006).  Substrate specificity of 
human ABCC4 (MRP4)-mediated co-transport of bile acids and reduced glutathione. Amer. J. 
Physiol. Gastrointest. Liver Physiol. 290, G640-G649. 
 
Roda, A., Piazza, F., Baraldini, M., Speroni, E., Guerra, M.C., Cerré, C., Cantelli Forti, G. 
(1998).  Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced 
cholestasis in the rat. Hepatol. 27, 520-525. 
 
Rodrigues, A.D., Lai, Y., Cvijic, M.E., Elkin, L.L., Zvyaga, T., Soars, M.G. (2014). Drug-
induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic 
considerations beyond the direct inhibition of the bile salt export pump. Drug Metab Dispos. 42, 
566-74. 
 
Román, I.D., Fernández-Moreno, M.D., Fueyo, J.A., Roma, M.G. (2003). Coleman R 
Cyclosporin A induced internalization of the bile salt export pump in isolated rat hepatocyte 
couplets. Toxicol Sci. 71, 76-81. 
 
Sakaida, I. (2014). Tolvaptan for the treatment of liver cirrhosis oedema. Expert Rev 
Gastroenterol Hepatol. 8, 461-70. 
 
Schrier, R.W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J.G., Czerwiec, F.S., Orlandi, C. 
(2006).  SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for 
hyponatremia. N. Engl. J. Med. 355, 2099-2112. 
 
Senior, J.R.  (2014).  Evolution of the Food and Drug Administration approach to liver safety 
assessment for new drugs: current status and challenges. Drug Saf. 37 Suppl 1, S9-S17. 
 
Shoaf, S.E., Wang, Z., Bricmont, P., Mallikaarjun, S.  (2007).  Pharmacokinetics, 
pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending 
single-dose studies in healthy subjects. J. Clin. Pharmacol. 47, 1498-1507. 
 
Shoaf, S.E., Bricmont, P., Mallikaarjun, S.  (2012a).  Absolute bioavailability of tolvaptan and 
determination of minimally effective concentrations in healthy subjects.  Int. J. Clin. Pharmacol. 
Ther.  50, 150-156. 
 
Shoaf, S.E., Bricmont, P., Mallikaarjun, S.   (2012b).  Effects of CYP3A4 inhibition and 
induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP 
antagonist in healthy subjects.  Br. J. Clin. Pharmacol. 73, 579-587. 
 
Shoaf, S.E., Bricmont, P., Mallikaarjun, S. (2014). Pharmacokinetics and pharmacodynamics of 
oral tolvaptan in patients with varying degrees of renal function. Kidney Int. 85, 953-61. 
 
Sokol RJ.., Devereaux M., Khandwala R., O'Brien K. (1993). Evidence for involvement of 
oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatol, 17, 869-881. 
 
Sokol R.J., McKim J.M. Jr., Goff M.C., Ruyle S.Z., Devereaux M.W., Han D., Packer L., 
 145 
 
Everson G. (1998). Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of 
taurochenodeoxycholic acid in the rat. Gastroenterol. 114, 164-74. 
 
Sorbera, L.A., Castaner, J., Bayes, M., Silvestre, J.  (2002). Tolvaptan: Treatment for heart 
failure Vasopressin V2 antagonist. Drugs of the Future. 27, 350-357. 
 
Swift, B., Pfeifer, N.D., Brouwer, K.L. (2010).  Sandwich-cultured hepatocytes: an in vitro 
model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug 
Metab Rev. 42, 446-471. 
 
Tagliacozzi, D., Mozzi, A.F., Casetta. B., Bertucci, P., Bernardini, S., Di Ilio, C., Urbani, A., 
Federici, G. (2003). Quantitative analysis of bile acids in human plasma by liquid 
chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. 
Clin Chem Lab Med. 41, 1633-1641. 
 
Tamai, I., Nezu, J., Uchino, H., Sai, Y., Oku, A., Shimane, M., Tsuji, A. 2000. Molecular 
identification and characterization of novel members of the human organic anion transporter 
(OATP) family. Biochem Biophys Res Commun. 273, 251-60. 
 
Tammara, B.K., Sekar, K.S., Brumer, S.L. (1999). The disposition of a single dose of 
14
C OPC-
41061 in healthy male volunteers. Ann. Meeting Amer. Assoc. Pharm. Sci. Abstract 2025. 
 
Teng, S., Piquette-Miller, M. (2007).  Hepatoprotective role of PXR activation and MRP3 in 
cholic acid-induced cholestasis. Br J Pharmacol. 151, 367-376. 
 
Torres, V.E., Harris, P.C., Pirson, Y. (2007).  Autosomal dominant polycystic kidney disease. 
Lancet. 369, 1287‐1301. 
 
Torres, V.E., Chapman, A.B., Devuyst, O., Gansevoort, R.T., Grantham, J.J., Higashihara, E., 
Perrone, R.D., Krasa, H.B., Ouyang, J., Czerwiec, F.S. (2012).  TEMPO 3:4 trial investigators. 
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 
2407-2418. 
 
Trauner, M., Arrese, M., Soroka, C.J, Ananthanarayanan M., Koeppel T.A., Schlosser S.F., 
Suchy F.J., Keppler D., Boyer J.L. (1997). The rat canalicular conjugate export pump (Mrp2) is 
down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology. 113, 255-64. 
 
Wagner, M., Trauner, M. (2005). Transcriptional regulation of hepatobiliary transport systems in 
health and disease: implications for a rationale approach to the treatment of intrahepatic 
cholestasis. Ann Hepatol. 4, 77–99. 
 
Wagner, M., Zollner, G., Trauner, M.  (2009).  New molecular insights into the mechanisms of 
cholestasis. J Hepatol. 51, 565-580. 
 
Watkins, P.B., Lewis, J.H., Kaplowitz, N., Alpers, D.H., Blais, J.D., Smotzer, D.M., Krasa, H., 
Ouyang, J., Torres, V.E., Czerwiec, F.S., Zimmer, C.A. (2015). Clinical Pattern of Tolvaptan-
 146 
 
Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: 
Analysis of Clinical Trials Database. Drug Saf. 2015 Jul 19. [Epub ahead of print] 
 
Woodhead, J.L., Yang, K., Siler, S.Q., Watkins, P.B., Brouwer, K.L., Barton, H.A., Howell, 
B.A. (2014).  Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-
induced liver injury. Front Pharmacol. 7, 5-240.  
 
Wu, Y., Beland, F.A., Chen, S., Liu, F., Guo, L., Fang, J-L. (2015).  Mechanisms of tolvaptan-
induced toxicity in HepG2 cells. Biochem. Pharmacol. 95, 324-336. 
 
Xia, C.Q., Milton, M.N., Gan, L.S. (2007). Evaluation of drug-transporter interactions using in 
vitro and in vivo models. Curr Drug Metab. 8, 341-363. 
 
Yamamura, Y., Nakamura, S., Itoh, S., Hirano, T., Onogawa, T., Yamashita, T., Yamada, Y., 
Tsujimae, K., Aoyama, M., Kotosai, K., Ogawa, H., Yamashita, H., Kondo, K., Tominaga, M., 
Tsujimoto, G., Mori, T.  (1998). OPC-41061, a highly potent human vasopressin V2-receptor 
antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in 
rats. J. Pharmacol. Exp. Ther. 287, 860-867. 
 
Yang K., Woodhead J.L., Watkins P.B., Howell B.A., Brouwer K.L. (2014). Systems 
pharmacology modeling predicts delayed presentation and species differences in bile acid-
mediated troglitazone hepatotoxicity. Clin Pharmacol Ther. 96, 589-598. 
 
Yang, K., Pfeifer, N.D., Kock, K., Brouwer, K.L. (2015). Species differences in hepatobiliary 
disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: Implications for 
drug-induced liver injury. J Pharmacol Exp Ther. 353, 415-423. 
 
Yasumiba, S., Tazuma, S., Ochi, H., Chayama, K., Kajiyama, G. (2001). Cyclosporin A reduces 
canalicular membrane fluidity and regulates transporter function in rats. Biochem J. 2001 354, 
591-596. 
 
Zelcer, N., Reid, G., Wielinga, P., Kuil, A., van der Heijden, I., Schuetz, J.D., Borst, P.  (2003).  
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 
(ATP-binding cassette C4). Biochem. J. 71, 361-367. 
 
Zhang, L. (2012).  Guidance for Industry: Drug Interaction Studies – Study Design, Data 
Analysis, Implications for Dosing, and Labeling Recommendations. Silver Spring, MD: Office of 
Clinical Pharmacology, Food and Drug Administration. 
 
Zollner, G., Fickert, P., Zenz, R., Fuchsbichler, A., Stumptner, C., Kenner, L., Ferenci, P., 
Stauber, R.E., Krejs, G.J., Denk, H., Zatloukal, K., Trauner, M. (2001). Hepatobiliary transporter 
expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology. 
33, 633-46. 
 
Zollner, G., Marschall, H.U., Wagner, M., Trauner, M. (2006).  Role of nuclear receptors in the 
 147 
 
adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol 
Pharm 3, 231–251. 
 148 
 
Figure 3.1. Chemical structures of tolvaptan, DM-4103, and DM-4107. 
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Figure 3.2. Inhibition of NTCP- and BSEP-mediated uptake by tolvaptan, DM-4103, and 
DM4107. NTCP-overexpressing cells were co-incubated with tolvaptan (0-50 μM), DM-4103 
(0-75 μM), or DM4107 (0-200 μM) and [³H]TCA (2 µCi/ml; 1 µM) for 5 min at 37°C (A-C); 
BSEP vesicles were co-incubated with tolvaptan (0-50 μM), DM-4103 (0-75 μM), or DM4107 
(0-200 μM) and [³H]TCA (2 µCi/ml; 2 µM) for 2 min at 37°C (D-F). NTCP-mediated uptake of 
TCA was calculated by subtracting substrate uptake in the absence of sodium from substrate 
uptake in the presence of sodium. BSEP-mediated transport was calculated by subtracting TCA 
uptake in the presence of AMP from TCA uptake in the presence of ATP. Values are expressed 
as percentage of vehicle control; each value represents the mean ± SD from three independent 
experiments. The curve represents the best fit line using nonlinear regression techniques. See 
Materials and Methods for further details.   
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Figure 3.3. BSEP Ki determination. Uptake of TCA (2, 5, 10, 20, or 30 µM) was determined in 
the presence of 0 µM (●), 10 µM (○), 25 µM (▲), or 50 µM (Δ) tolvaptan (A) or  0 µM (●), 2 
µM(○), 5 µM (▲), or 20 µM (Δ) of DM-4103 (B). TCA uptake was measured after an 
incubation of 2 min at 37ºC in the presence or absence of inhibitor. BSEP-mediated transport 
was calculated by subtracting TCA uptake in the presence of AMP from TCA uptake in the 
presence of ATP; each value represents the mean ± SD from three independent experiments. The 
curves represent the best fit model using nonlinear regression techniques. See Materials and 
Methods for further details. 
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Figure 3.4. Inhibition of MRP2-, MRP3-, and MRP4-mediated uptake by tolvaptan, DM-
4103, and DM4107. MRP2 (A-C), MRP3 (D-F) or MRP4 (G-I) vesicles were co-incubated with 
tolvaptan (0-50 μM), DM-4103 (0-50 μM for MRP2 and MPR3, and 0-20 μM for MRP4), or 
DM-4107 (0-200 μM) and [³H]E217G (2 µCi/ml; 50 µM) (A-C) for 2 min, [³H]E217G (2 µCi/ml; 
10 µM) (D-F) for 5 min, or [³H]DHEAS (2 µCi/ml; 2 µM) (G-I) for 2 min at 37°C. MRP-
mediated transport was calculated by subtracting substrate uptake in the presence of AMP from 
substrate uptake in the presence of ATP. Values are expressed as percentage of vehicle control; 
each value represents the mean ± SD from three independent experiments. If the inhibitor did not 
reduce substrate transport by >50% at the highest tested concentration, nonlinear regression to 
estimate an IC50 value was not conducted. The curve represents the best fit line using nonlinear 
regression techniques. See Materials and Methods for further details.    
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Figure 3.5. Time- and temperature-dependent accumulation of tolvaptan in sandwich-
cultured human hepatocytes (SCHH). Accumulation of tolvaptan in cells + bile (black bars) 
and cells (white bars) was measured by incubating SCHH with 15 µM of tolvaptan for 5, 10, or 
20 min at 37ºC, or for 10 min at 4 ºC (A). Accumulation of tolvaptan, and the generated 
metabolites DM-4103 and DM-4107 in cells+bile (black bars) and cells (white bars) was 
measured by incubating SCHH with 15 µM of tolvaptan for 10 min at 37ºC (B). *Cellular 
concentrations were calculated using the total mass of tolvaptan, DM-4103, or DM-4107 in cells 
(white bars) and hepatocyte fluid volume as described in Materials and Methods; each value 
represents the mean ± SD from n= 1 liver in triplicate. 
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Figure 3.6. Accumulation of TCA, CDCA, TCDCA, and GCDCA after incubation in the 
presence or absence of tolvaptan in sandwich-cultured human hepatocytes (SCHH). 
Accumulation of d8-TCA (2.5 µM) and d5-CDCA (2.5 µM) (A), or TCDCA (2.5 µM) and 
GCDCA (2.5 µM) (B) in cells+bile (black bars) and cells (white bars) was measured after 
incubating SCHH with designated bile acids in the presence or absence of tolvaptan (15 µM) for 
10 min at 37ºC; each value represents the mean ± SD from n= 1 liver in triplicate. 
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Table 3.1. Inhibitory potency of tolvaptan, DM-4103, and DM-4107 on transporter-
mediated uptake.  
Transporter  Inhibitor  IC50 (µM)  95% CI (µM)  Cmax/IC50 
NTCP 
 Tolvaptan  ~41.5  26.0-66.3  0.03 
 DM-4103  16.3  11.1-24.0  0.96* 
 DM-4107  95.6  58.7-156  0.02 
BSEP 
 Tolvaptan  31.6  16.5-60.3  0.04 
 DM-4103  4.15  3.45-4.99  3.78* 
 DM-4107  119  86.2-163  0.02 
MRP2 
 Tolvaptan  
>50 
 NC  
NC 
 DM-4103  ~51.0  32.0-81.3  
0.31* 
 DM-4107  >200  NC  
NC 
MRP3 
 Tolvaptan  
>50 
 NC  
NC 
 DM-4103  
~44.6 
 30.9-64.5  
0.35* 
 DM-4107  
61.2 
 51.5-72.8  
0.04 
MRP4 
 Tolvaptan  
>50 
 NC  
NC 
 DM-4103  4.26  3.32-5.47  
3.69* 
 DM-4107  37.9  32.1-44.7  
0.06 
CI: confidence interval; mean Cmax following a 90 mg dose in humans. In cases where substrate 
uptake was inhibited by >50% only at the highest tested inhibitor concentration, the data were 
curve fit in the usual manner, but the estimated IC50 value was designated as an approximation 
(~). If the inhibitor did not reduce substrate transport by >50% at the highest tested 
concentration, nonlinear regression to estimate an IC50 value was not conducted and the value 
was reported as greater than the highest tested concentration. *Cmax values were not determined 
in clinical trials therefore, concentrations at steady-state were used instead. 
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Table 3.2. Sodium-dependent uptake of tolvaptan, DM-4103 and DM-4107 in sandwich-
cultured human hepatocytes (SCHH).  
    Tolvaptan  DM-4103  DM-4107 
Tolvaptan 
Dose 
Concentration 
 Buffer  
Total 
Accumulation 
(pmol/mg) 
 
Total 
Accumulation 
(pmol/mg) 
 
Total 
Accumulation 
(pmol/mg) 
15 µM 
 Sodium  2730 ± 397  7.82 ± 0.84  121 ± 19 
 Choline  3460 ± 684  8.35 ± 0.83  136 ± 16 
Data represent mean ± SD (n= 1 liver in triplicate) 
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Table 3.3. Hepatobiliary disposition of bile acids in the absence or presence of tolvaptan in 
sandwich-cultured human hepatocytes (SCHH).Hepatobiliary disposition of 2.5 µM 
taurocholic acid (TCA), chenodeoxytaurocholic acid (CDCA), taurochenodeoxycholic acid 
(TCDCA) or glycochenodeoxycholic acid (GCDCA) in the absence or presence of tolvaptan (15 
µM) in sandwich-cultured human hepatocytes (SCHH). 
 
Probe  Inhibitor  
Total 
Accumulation
#
 
 
Cellular 
Accumulation
#
 
 
Clbiliary 
(mL/min/kg) 
 
BEI 
(%) 
TCA 
 
Vehicle 
Control 
 215 ± 27  43.3 ± 4.4  20.3  79.8 
 Tolvaptan  145 ± 16  47.5 ± 2.1  11.6  67.3 
CDCA 
 
Vehicle 
Control 
 580 ± 67  469 ± 60  13.1  19.1 
 Tolvaptan  658 ± 86  608 ± 31  5.86  7.52 
TCDCA 
 
Vehicle 
Control 
 3.37 ±0.55  0.545 ± 0.049  NC*  83.8 
 Tolvaptan  3.32 ± 0.27  0.915 ± 0.22  NC*  71.0 
GCDCA 
 
Vehicle 
Control 
 8.82 ± 0.98  0.892 ± 0.065  NC*  89.2 
 Tolvaptan  7.55 ± 1.28  1.93 ± 0.28  NC*  74.5 
#
Accumulation of TCA and CDCA is expressed as pmol/mg protein; accumulation of TCDCA 
and GCDCA is expressed as peak area ratio; BEI=biliary excretion index; Data represent mean ± 
SD (n=1 liver in triplicate); *NC: not calculable, see Materials and Methods. 
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CHAPTER 4. Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic 
Kidney Disease 
4
 
 
INTRODUCTION 
Polycystic kidney disease (PKD) is a class of ciliopathic disorders that arise from 
abnormalities in the primary cilium in many epithelial organs that lead to the development of 
fluid-filled cysts (Igarashi et al., 2007). These inheritable diseases are genetically transmitted in 
either a dominant form (autosomal dominant polycystic kidney disease; ADPKD) or a recessive 
form (autosomal recessive polycystic kidney disease; ARPKD) from mutations in the PKD1/2 or 
PKDH1 gene, respectively (Torres et al., 2007; Ward et al., 2002). ADPKD is the most common 
form of PKD and occurs between 1 in 400 and 1 in 1000 live births (Ecder et al., 2006; Torres et 
al., 1998). The destruction/displacement of renal tubules as a result of cystic growth and 
subsequent decline in renal function is central to the morbidity and mortality in patients with 
ADPKD. However, cysts occur in other epithelial organs such as the spleen, pancreas, lungs, and 
liver (Danaci et al., 1998; Levine et al., 1985, Perrone, 1997; Torra et al., 1997). 
The liver is the most frequently affected extrarenal organ in ADPKD. A recent study by 
Hogan et al. (2015) reported that ~70% of men and ~80% of women with ADPKD have liver 
cysts. Although increases in serum γ-glutamyl transferase (GGT) or alkaline phosphatase (ALP) 
of ~2-5 times the upper limit of normal have been observed in some patients, typical biochemical 
measures of liver impairment, as with many liver diseases, are not sensitive or specific to detect 
                                                          
4
 This chapter was submitted to Toxicology and Applied Pharmacology and is presented in the style of that journal. 
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liver injury (Alempijevic et al. 2009; Giannini et al. 2005; Mofrad et al. 2003; Pohl et al. 2001). 
Therefore, there is value in establishing more sensitive and/or specific molecular biomarker(s) 
that may be useful in staging, diagnosis/prognosis, and/or clinical response to intervention(s) in 
ADPKD and related polycystic liver diseases (PLD).  Several rodent models of PKD have been 
described with some animal models displaying isolated renal disease whereas others exhibit 
isolated hepatic abnormalities (McDonald et al., 2006; Schieren et al., 1996). In 2000, a 
spontaneous mutation in a colony of Sprague-Dawley rats displaying bilateral renal and hepatic 
cysts, now known as the polycystic kidney (PCK) rat, was described by Katsuyama et al. (2000). 
Although the inheritance of PKD in PCK rats is autosomal recessive, the renal and hepatic 
histopathological features resemble human ADPKD (Lager et al., 2001). For example, the kidney 
in PCK rats and human ADPKD are normal at birth but exhibit slow, progressive renal cyst 
growth. Furthermore, liver ductal plate abnormalities, biliary dysgenesis, and hepatic cyst 
development in PCK rats are consistent with the natural history of human ADPKD (Lager et al., 
2001; Mason, et al. 2010; Masyuk et al., 2004).  Hence, the PCK rat has been a valuable tool to 
understand the progression of ADPKD as well as to evaluate therapeutic interventions (Blazer-
Yost et al., 2010; Lager et al., 2001; Sabbatini et al., 2014). Therefore, the PCK rat model was 
selected in the present study to evaluate the association between potential biomarkers and liver 
impairment in ADPKD. 
Bile acids are a diverse, but structurally similar group of cholesterol-derived acidic 
steroids important in digestion/absorption and normal hepatic function. They also act as 
signaling molecules and play a critical role in the regulation of lipid metabolism and 
inflammation (Marin et al., 2015). Bile acids have been evaluated as biomarkers in various liver 
diseases such as cirrhosis, hepatocellular carcinoma, and nonalcoholic steatohepatitis (Chen et 
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al., 2011; Ferslew et al., 2015; Mannes et al., 1986).  However, the association between bile 
acids and severity of liver impairment in ADPKD has yet to be established. Thus, this study was 
designed to investigate the association between liver impairment and bile acid concentrations in 
an established rodent model of ADPKD. These data may provide justification for future research 
in ADPKD patients. 
MATERIALS AND METHODS 
Materials.  
All bile acid standards were obtained from Steraloids Inc. (Newport, RI) and TRC 
Chemicals (Toronto, ON, Canada).  Nine stable isotope- labeled standards were obtained from 
C/D/N Isotopes Inc. (Quebec, Canada) and Steraloids Inc. (Newport, RI). Methanol (Optima LC-
MS), acetonitrile (Optima LC-MS) and formic acid (Optima LC-MS) were purchased from 
Thermo-Fisher Scientific (FairLawn, NJ). Ultrapure water was produced by a Mill-Q Reference 
system equipped with a LC-MS Pak filter (Millipore, Billerica, MA). 
Animals.  
Male Sprague-Dawley (SD) or polycystic kidney disease (PCK/Crlj Crl-Pkhd1pck/Cr) 
rats were purchased from Charles River Laboratories (Wilmington, MA). Rats were housed in a 
constant alternating 12-hr light/dark cycle and allowed water and food ad libitum and acclimated 
for a minimum of 1 week prior to experimentation. All animal procedures complied with the 
guidelines of the Institutional Animal Care and Use Committee (University of North Carolina, 
Chapel Hill, NC). 
Magnetic resonance imaging.  
Magnetic resonance images (MRI) were acquired with a 9.4T Bruker Biospec 94/30USR 
(Bruker BioSpin, Billerica, MA) controlled with ParaVision software (v5.1. Billerica, MA). Rats 
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were anesthetized with 2% isoflurane in an air/oxygen mix. Respiratory-gated axial images were 
acquired with a 2D FLASH sequence with a repetition time of 533ms and an echo time of 10ms. 
Axial slices covered a 6x6 cm
2
 field of view with a 256x256 matrix at a separation of 2mm and 
utilized two averages. The region of interest was multiplied by the slice thickness to estimate the 
volume of the liver tissue or cysts using the following equation: 
 
Vliver or Vcyst = (Aliver or Acyst in slice 1)●(Thickness) + (Aliver or Acyst in slice 2)●(Thickness) + 
(Aliver or Acyst in slice 3)●(Thickness) +…+ (Aliver or Acyst in slice n)●(Thickness) 
 
Where Vliver is the volume of the liver, Vcyst is the volume of cysts; Aliver is the area of the liver 
MRI slice; Acyst is the area of cyst in the MRI slice and the thickness is the thickness of each 
slice (2mm). Cyst segmentation and volume were measured using ImageJ 1.48v (National 
Institutes of Health, USA). 
Sample collection.  
After 72 hrs following MRI, rats were fasted overnight and anesthetized with 
ketamine:xylazine (60:12 mg/kg IP). Bile was collected by cannulating the bile duct using PE-10 
tubing; urine was collected from the bladder by cystocentesis; liver samples were excised from 
the median lobe; whole blood was collected and spun down at 1500g for 10 min to collect serum. 
All samples were immediately frozen at -80
○
C until bioanalysis. 
Sample preparation and bioanalysis.  
Sample preparation and bile acid quantification methodology were adapted from Xie et 
al. (2015). Briefly, an internal standard solution containing nine internal standards (100 nM for 
d4-GCA, d4-TCA, d9-TCDCA, d4-UDCA, d4- CA, d4-GCDCA, d4-GDCA, d4-DCA, and 200 
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nM for d4-LCA) was added to serum, urine, bile, liver homogenate, or standard solution and 
centrifuged. Liver tissue was homogenized with 100 µL of 50% methanol using a Bullet Blender 
Tissue Homogenizer (Next Advance, Inc., Averill Park, NY). After centrifugation, the 
supernatant was evaporated to dryness using a freeze dryer system (Labconco, Kansas City, 
MO). The residue was reconstituted in 1:1 (v/v) mobile phase B (acetonitrile / methanol =95:5, 
v/v) and mobile phase A (water with formic acid, pH=3.25), and centrifuged at 13,500g (4°C) for 
20 min. The supernatant was transferred to a 96-well plate for analysis. An ultra-performance 
liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) system 
(ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA) was used to quantify bile acids in 
the rat bile, serum, urine, and liver homogenate samples. Calibration solutions containing all 
analytes prepared at a series of concentrations in pooled naïve serum and urine depleted of bile 
acids using activated charcoal were used to generate standard curves using TargetLynx 
application manager (Waters Corp, Milford, MA). The limit of quantification was 1.024 nM for 
all bile acid species, except for a limit of 2.56 nM for cholic acid (CA), murocholic acid (MCA), 
glycodeoxycholic acid (GDCA), glycochenodeoxycholic acid (GCDCA), ursodeoxycholic acid 
(UDCA), α-hyodeoxycholic acid (HDCA), 6-ketolithocholic acid (6-keto-LCA), 
tauroursodeoxycholic acid (TUDCA), taurohyodeoxycholic acid (THDCA), and 
chenodeoxycholic acid 24-acyl-β-D-glucuronide (CDCA-24G); the limit of quantification for 
tauro-ω-muricholic acid, tauro-α-muricholic acid, tauro-β-muricholic acid, and taurocholic acid 
was 12.8 nM. 
Immunohistochemistry (IHC). 
Liver samples from the median lobe were excised and immediately placed in 4% 
paraformaldehyde for 48 h, processed, embedded in paraffin, serially sectioned at 4 µm thickness 
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and placed on coated glass slides. Sectioned slides were used for IHC immediately or unstained 
slides were stored in the nitrogen gas chamber if staining was not done immediately. Goat 
polyclonal anti-BSEP antibody sc-17292 was purchased from Santa Cruz Biotechnology (Dallas, 
TX). IHC was carried out in the Bond fully automated immunostainer (Leica Biosystems Inc., 
Vista, CA). Slides were dewaxed in Bond Dewax solution (AR9222) and hydrated in Bond Wash 
solution (AR9590). Antigen retrieval was performed for 30 min at 100ºC in Bond-Epitope 
Retrieval Solution 1 pH-6.0 (AR9961). The antigen retrieval was followed with 5 min Bond 
peroxide blocking (DS9800) and 10 min protein blocking (PV6122, Leica) steps. After 
pretreatment, slides were incubated with the antibody (1:50) for 4 hrs. Bond polymer was 
supplemented with ImmPRESS HRP anti-Goat secondary antibody (MP-7405-15, Vector Labs; 
Burlingame, CA Bond™) and detected using the Polymer Refine Detection system (DS9800). 
Stained slides were dehydrated and covered with a coverslip. Positive and negative controls (no 
primary antibody) were evaluated. 
Data and statistical analysis. 
The molar sum of all measured bile acids is reported as total bile acids. Total 
unconjugated and glycine- and taurine-conjugated bile acids were calculated as the sum of all 
unconjugated or glycine- or taurine-conjugated species of CA, CDCA, hyocholic acid (HCA), 
HDCA, MCA, deoxycholic acid (DCA), lithocholic acid (LCA), and UDCA. The relative 
abundance of each group of bile acid species was calculated as the total molar mass for that 
particular species divided by the total bile acid molar mass. Measured bile acid concentrations 
below the limit of quantification, but above the limit of detection, were imputed as one-half of 
the limit of quantification; concentrations measured below the limit of detection were imputed as 
zero. Statistical significance was determined using the nonparametric Mann-Whitney test, with 
 163 
 
α=0.05 using GraphPad Prism (v.6.0 GraphPad Software, La Jolla, CA) to compare PCK versus 
wild-type rats. Given the number, complexity, and potential intercorrelation(s) between data in 
large metabolomic data sets, a multivariate statistical approach was utilized to reduce the 
dimensionality of the bile acid data to detect differences in the bile acid metabolome between 
wild-type and PCK rats. Without multivariate analysis, this may lead to false positives if 
traditional methods of statistical hypothesis testing are used alone (e.g. t-tests, ANOVAs) 
(Ringnér et al., 2008) Therefore, Principal component analysis (PCA) was performed to visualize 
the bile acid metabolome in PCK compared to wild-type rats (SIMCA 14, Umetrics, Umea, 
Sweden). Spearman correlation coefficients (two-tailed) were determined using GraphPad Prism 
(v.6.0 GraphPad Software, La Jolla, CA) where p-values ≤ 0.05 were considered statistically 
significant. Multiple analysis of variance (MANOVA) was conducted using R package (v. 3.3.1). 
RESULTS 
Rat Characteristics. 
Hepatic cyst volume was measured at 12, 16, and 20 weeks in PCK rats to monitor the 
progression of cystic volume. Cystic disease is progressive and these time frames are consistent 
with the presentation of hepatic cysts and liver dysfunction in PCK rats (Lager et al., 2001; 
Katsuyama et al., 2000). Furthermore the mortality in PCK rats is high after 20 weeks of age 
(Katsuyama et al., 2000). The cystic volume (mean ± standard deviation) in PCK rats increased 
from 2.83 ± 1.42 to 3.92 ± 1.98 to 5.20 ± 2.61 at 12, 16 and 20 weeks, respectively. 
Representative magnetic resonance images are shown in Fig. 4.1. At 20 weeks, liver and total 
kidney weights were significantly increased in PCK rats compared to wild-type rats (Table 4.1). 
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Bile Acid Composition. 
Under fasting conditions, 42 bile acids were measured in the liver, bile, serum, and urine 
of wild-type and PCK rats. Total liver and serum bile acids were significantly increased in PCK 
rats by 13.2- and 5.5-fold compared to wild-type rats, respectively (p < 0.05; Fig. 4.2A and 
4.2C). Total urine bile acids also were increased 3.0-fold in PCK rats but differences did not 
reach statistical significance (Fig. 4.2D).  There was no apparent different in total biliary bile 
acids (Fig. 4.2B). As shown, the difference in liver bile acids was driven by similar fold 
increases in unconjugated, taurine- and glycine-conjugated bile acids (p < 0.05; Fig. 4.3A). In 
contrast, unconjugated bile acids were significantly increased (p < 0.05) and appeared to increase 
to a greater extent (6.6-fold) compared to taurine conjugates (3.8-fold) in the serum of PCK rats 
(Fig. 4.3C). In urine, taurine and glycine conjugates increased by 7.4- and 5.1-fold compared to a 
2.8-fold increase of unconjugated bile acids in PCK rats (Fig. 4.3D), although these differences 
did not reach statistical significance. No apparent differences in unconjugated or glycine or 
taurine-conjugated bile acids were observed in the bile between wild-type and PCK rats. Hepatic 
sulfate (i.e. lithocholic acid -3-sulfate) and glucuronide (i.e. CDCA 24-acyl-β-D-glucuronide and 
CDCA 3-acyl-β-D-glucuronide) bile acid conjugates also were significantly increased in PCK 
rats by 5.1-fold and 6.9-fold, respectively (p < 0.05; Supplement Table 4.1). Serum and urine 
glucuronide conjugates also were significantly increased by 15.5-fold and 12.2-fold (p < 0.05), 
respectively, in PCK rats. Serum and urine sulfate conjugates appeared to increase in PCK rats 
but differences did not reach statistical significance; no differences were apparent in biliary 
sulfate or glucuronide bile acid conjugates.  
To determine whether the relative abundance of bile acid species was different between 
wild-type and PCK rats, the relative amounts (expressed as a % of the total molar sum) of total 
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unconjugated and glycine- and taurine-conjugated species of CDCA, CA, DCA, LCA, and 
UDCA were evaluated in each matrix. Few notable differences between wild-type and PCK rats 
were observed.  For example, LCA species decreased in the liver of PCK rats (p < 0.05; Table 
4.2). In contrast, the relative abundance of DCA (serum and urine) and LCA (liver) species 
increased in PCK rats (p < 0.05). The remaining species in each matrix appeared to be 
unchanged. Secondary bile acids (e.g. glycohyodeoxycholic acid (GHDCA), HDCA, and MCA 
were among bile acids species that displayed the greatest-fold change in PCK compared to wild-
type rats (Supplement Table 4.2). 
Bile Acids Associated with Hepatotoxicity.  
Due to their detergent-like effects, bile acid hydrophobicity is positively associated with 
liver injury (Attili et al., 1986). Generally recognized hepatotoxic bile acids include the glycine 
and taurine conjugates of DCA and CDCA (Perez et al., 2009). When bile acids associated with 
hepatotoxicity (i.e. TDCA, TCDCA, GDCA, and GCDCA) were analyzed separately, total toxic 
bile acids were significantly increased in PCK rat liver and serum by 8.4-fold and 3.3-fold, 
respectively (Fig.4.4A and 4C). GCDCA was increased as much as 22.8-fold in the liver of PCK 
rats, whereas in serum, TDCA, TCDCA, GDCA, and GCDCA were increased to a similar extent 
(i.e. ~2-5-fold). Total toxic bile acids tended to increase in the urine (2.8-fold) but differences 
failed to reach statistical significance (Fig. 4.4D). No notable differences were observed in 
biliary bile acids (Fig. 4.4B). LCA, one of the most hydrophobic bile acids, was significantly 
increased by ~2.5-fold in the liver and serum, but not in the urine or bile of PCK rats 
(Supplementary Table 4.3). DCA concentrations did not reach statistically significant differences 
in the liver; however, DCA was significantly increased by 5.2 and 30.5-fold in the serum and 
urine of PCK rats, respectively (Supplementary Table 4.3). 
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Principal Component Analysis. 
Separate PCA score plots for bile acids in each matrix were used to evaluate differences 
in the profile of individual bile acid species in wild-type and PCK rats. PCA score plots indicated 
that PCK rats clearly separated from wild-type rats (liver cumulative r
2
 = 0.874; bile cumulative 
r
2
 = 0.707; serum cumulative r
2
 = 0.804; urine cumulative r
2
 = 0.652) under fasting conditions 
(Fig. 4.5).  
Correlation Analysis and Multivariate Analysis of Variance (MANOVA) 
Correlation analysis was used first to evaluate the correlation between serum bile acids 
and markers of liver impairment (i.e. liver weight, total liver bile acids, total toxic liver bile 
acids, and cystic volume) to test the hypothesis that serum bile acids correlated with markers of 
liver impairment (α = 0.05). Serum bile acids positively correlated with liver weight (r = 0.919, 
95% CI = 0.650-0.985), total liver bile acids (r = 0.976; 95% CI = 0.869-0.995), total toxic liver 
bile acids (r = 0.950; 95% CI = 0.743-0.991), and cystic volume (r = 0.939; 95% CI = 0.693-
0.989) (Fig. 4.6); p-values were < 0.01. After adjusting using the Bonferroni correction, p-values 
remained statistically significant. As a follow-on assessment, a MANOVA model was used to: 
(1) obtain the point and interval estimates of the mean levels, (2) estimate correlations among the 
five variables, and (3) perform a test of the overall multi-dimensional null hypothesis that the 
two strains (i.e. wild-type and PCK) do not differ based on mean values for any of the five 
variables (i.e. serum bile acids, total liver weight, total liver bile acids, total toxic liver bile acids, 
and cystic volume) of interest. Wild-type and PCK rats were different for all five variables and a 
statistically significant MANOVA effect was obtained, Pillais Trace = 0.977 F (32.1, 4) p < 
0.001. Subsequently, a series of one-way analysis of variances (ANOVAs) on each of the four 
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dependent variables was conducted as follow-up tests to the MANOVA. The ANOVA values for 
liver weight (F-value = 32.5; p = 0.00126), total liver bile acids (F-value = 34.4; p = 0.00109), 
total hepatotoxic liver bile acids (F-value = 15.1; p = 0.0081), and cyst volume (F-value = 43.9; p 
= 0.000570) were statistically significant. 
Immunohistochemistry (IHC).  
Visualization of Bsep in wild-type and PCK rats using immunohistochemical techniques 
revealed similar expression and distribution of Bsep throughout the liver acinus (Fig. 4.7). 
DISCUSSION 
Serum bile acids have been used as a clinical index of liver pathology. To our knowledge, 
this is the first study to examine the relationship between serum bile acids and markers of liver 
impairment in a rodent model of ADPKD, which may provide justification for future research in 
ADPKD patients. As shown, total liver bile acids were increased by 13.2-fold compared to wild-
type rats (Fig. 4.2A). During the analysis of these data, Munoz-Garrido et al. (2015) reported that 
hepatic bile acids were elevated in PCK rats, a finding that is in agreement with the current data 
presented. Elevated hepatic bile acids are consistent with cholestasis in PCK rats; in addition, 
total serum and urine bile acids were increased by 5.5- and 3.0-fold, respectively, in PCK rats 
(Fig. 4.2C and 2D).  
A functional alteration in Bsep, the rate-limiting step in the translocation of bile acids 
from hepatocytes to the bile canaliculus, is one mechanism of impaired biliary secretion that can 
lead to bile acid accumulation, acute liver toxicity, and fibrosis (Kisseleva et al., 2011). Bsep was 
internalized and transport function was impaired in a taurolithocholate-induced model of 
cholestasis (Crocenzi et al., 2003). In the present study, taurolithocholate was increased by 27.3 
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and 22.4-fold in the liver and serum, respectively, of PCK rats (Supplementary Table 4.3), which 
suggests that elevated concentrations of taurolithocholate (and other bile acids) could decrease 
bile acid transport through internalization and/or downregulation of Bsep. Therefore, we 
hypothesized that Bsep expression and/or localization may be impaired in PCK rats, which may, 
in part, explain elevated liver bile acid concentrations. However, IHC analysis failed to detect 
any apparent difference in Bsep expression and/or localization (Fig. 4.7). Although mechanisms 
of bile acid-mediated internalization of Bsep have been demonstrated in vitro, Bsep expression is 
maintained in models of chronic cholestasis in the rat (Buscher et al., 1989; Lee et al., 2000), 
consistent with the current data. Moreover, we did not observe significant differences in biliary 
bile acid concentrations, which further support the relative preservation of Bsep function (Fig. 
4.2B). 
Although the purpose of this study was not to elucidate the mechanisms underlying 
altered bile acid homeostasis, the data generated raise several questions. Using gene expression 
analysis, Ruh et al. (2013) first reported down-regulation of primary bile acid synthesis 
pathways, a compensatory mechanism aimed at reducing hepatic bile acid concentrations. 
However, this would not explain increased hepatic taurocholic acid concentrations reported by 
Ruh et al. (2013) as well as increased concentrations of most bile acid species in the liver, as 
observed in the present study and reported by Munoz-Garrido et al. (2015). Furthermore, 
Cyp7a1, the rate-limiting step in bile acid synthesis, was not altered in PCK rats (Munoz-Garrido 
et al., 2015). These data suggest that increased bile acid synthesis may not account for elevated 
hepatic bile acid concentrations, although other enzymes are involved in bile acid metabolism 
and should be considered (e.g. Cyp27A1, Cyp8B1, and bile acid– coenzyme A:amino acid N-
acyltransferase) (Chiang et al., 2009; Pellicoro et al., 2007). Altered function of other 
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hepatobiliary bile acid transporters may explain the observations reported here. For example, 
NTCP/Ntcp and OATP/Oatp are responsible for the sinusoidal uptake of bile acids from the 
blood to hepatocytes, and are downregulated in obstructive cholestasis, which may explain 
elevated serum bile acid concentrations observed in the present study (Geier, et al. 2007; Lee et 
al., 2000; Moseley et al. 1996; Trauner et al. 1997). In addition, MRP3/Mrp3 is upregulated in 
cholestasis to provide an additional compensatory route for hepatic bile acid efflux (Chai et al., 
2012; Donner et al., 2001). IHC analysis revealed that Mrp3 appears to be upregulated in PCK 
rats consistent with a cholestatic state (Slizgi et al., manuscript in preparation) and further work 
quantifying the protein expression of relevant transporters in PCK rats is currently underway. It 
must be noted that canalicular membrane fluidity and cholesterol content can affect Bsep 
function without affecting localization or expression, which could contribute to the observations 
reported here and should be explored in future mechanistic studies (Kanno et al., 2003; Kis et al., 
2009). 
High concentrations of bile acids can be cytotoxic, which may lead to hepatocellular 
damage and acute liver injury (Alnouti 2008; Hoffman et al., 2009). Because of the positive 
relationship between hydrophobicity and detergent effects, hydrophobic bile acid (e.g. LCA, 
DCA, CDCA and their glycine and taurine conjugates) are considered the most cytotoxic (Attili 
et al., 1986). Mechanistic studies indicate that hydrophobic bile acids can disrupt cell 
membranes, promote the generation of reactive oxygen species, and cause mitochondrial and 
endoplasmic reticulum stress triggering hepatocyte apoptosis and necrosis (Perez et al., 2009). 
Therefore, the disposition of hepatotoxic bile acids in PCK rats that may contribute to liver 
dysfunction was evaluated. Although the relative abundance of bile acid species was generally 
similar between wild-type and PCK rats (Table 4.2), concentrations of total bile acids associated 
 170 
 
with hepatotoxicity (i.e. GDCA, GCDCA, TDCA, and GCDCA) were increased by 8.3- and 3.3-
fold in the liver and serum of PCK rats, respectively. Secondary bile acids associated with 
hepatotoxicity (i.e. LCA and DCA), also were increased in the serum of PCK rats, albeit to a 
lesser extent relative to the glycine and taurine conjugates of DCA and CDCA (Supplementary 
Table 4.3). Studies have shown that accumulation of bile acids in the systemic circulation can 
promote endothelial cell injury, such as in the kidney (Bomzon et al., 1997; Hofmann et al., 
2002). In accordance with increased hepatotoxic bile acids, liver biochemical abnormalities are 
generally observed in PCK rats. For example, GGT and glutamate dehydrogenase (GLDH), 
markers for hepatocellular damage, were increased in PCK rats (Ruh et al., 2013). Additionally, 
elevated levels of bilirubin and transaminases also may indicate hepatocellular damage (Mason 
et al., 2010; Shimomura et al., 2015). Contrasting observations of increased or unchanged levels 
of ALP, a marker of bile duct obstruction and cholestasis, have been reported (Munoz-Garrido et 
al., 2015; Mason et al., 2010; Shimomura et al., 2015).  
Although liver tests (e.g. transaminases, bilirubin, ALP) are used routinely in clinical 
practice, these measures are generally not sensitive, specific, and/or may display large 
interindividual variability in the presence of liver impairment, thus making diagnoses 
challenging. Therefore, we sought to determine whether serum bile acids were associated with 
markers of liver impairment to justify their evaluation as biomarkers in PKD. Total liver bile 
acids and total toxic liver bile acids were chosen as markers of liver impairment because elevated 
bile acids are associated with hepatotoxicity. Liver weight was chosen as a marker of liver 
impairment because hepatomegaly may indicate vascular swelling, inflammation, and portal 
hypertension, which can lead to cirrhosis (Dooley et al., 2011). Finally, cystic volume was used 
as a marker of liver impairment because cysts are associated with infection, hemorrhaging, liver 
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cancer, and in some cases, cholangitis (Chauveau et al., 1997; Chauveau et al., 2000; Dooley et 
al., 2011; Suwabe et al., 2012; Yazdanpanah et al., 2013). 
As shown, serum bile acids correlated with liver weight, total liver bile acids, total toxic 
liver bile acids, and cystic volume (r > 0.9; p < 0.01; Fig. 4.6). Because there are potential 
intercorrelation(s) between markers of liver impairment (e.g. liver weight would be expected to 
increase with an increase in cystic volume), subsequent MANOVA revealed a statistically 
significant effect (p < 0.0085). Follow-on ANOVAs also revealed a statistically significant 
effect, indicating that markers of liver impairment independently associated with total serum bile 
acids. An association between serum bile acids and hepatic cyst bile acid concentrations was 
reported in patients with ADPKD (Garrido-Munoz et al., 2015). The present data indicate that 
total toxic bile acids are increased in the livers of PCK rats and that elevated serum bile acids are 
associated with elevated liver bile acids. Given the similar hepatorenal abnormalities observed 
between PCK rats and human ADPKD, hepatotoxic bile acids also may be increased in ADPKD 
patients; thus, metabolomic profiling in ADPKD patients is warranted to test this hypothesis.  
In a recent clinical trial, some patients with ADPKD experienced drug-induced liver 
injury (DILI) while being treated with tolvaptan, a vasopressin V2-receptor antagonist (Watkins 
et al., 2015). Inhibition of bile acid transporters by tolvaptan/metabolites leading to intrahepatic 
accumulation of bile acids and subsequent hepatotoxicity has been explored as a biologically 
plausible mechanism underlying tolvaptan-associated DILI (Slizgi et al., 2016). However, 
tolvaptan was not associated with hepatotoxicity in other patient populations, which suggests that 
patients with ADPKD may be more susceptible to liver injury (Watkins et al., 2015). It is 
possible that elevated concentrations of hepatic bile acids in ADPKD due to liver pathology (e.g. 
hepatic cyst burden) may predispose some patients to bile acid-mediated hepatotoxicity. In the 
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context of tolvaptan-associated liver injury, the present data suggest that some ADPKD patients 
may be susceptible to bile acid-mediated hepatotoxicity if their hepatic bile acid load is 
characteristically elevated. Inhibition of bile acid transporter function by tolvaptan and/or 
metabolites, as reported in Slizgi et al. (2016), may further increase hepatic bile acid 
concentrations and lead to hepatotoxicity. It must be noted, however, that no evidence of 
cholestasis (e.g. no clinically significant increases in ALP) was apparent in ADPKD trials, which 
may suggest that alternative and/or contributing mechanism(s) may predispose this patient 
population to tolvaptan-associated DILI (Torres et al., 2012).  
In conclusion, the results of these studies indicate that bile acids are increased in the liver 
and the serum of PCK rats, including bile acids associated with hepatotoxicity. Total serum bile 
acids are correlated with markers of liver impairment, which suggests that serum bile acids may 
be useful biomarkers of hepatic impairment in ADPKD.  
 173 
 
REFERENCES 
Alempijevic T, Krstic M, Jesic R, Jovanovic I, Sokic Milutinovic A, Kovacevic N, Krstic S, 
Popovic D. Biochemical markers for non-invasive assessment of disease stage in patients with 
primary biliary cirrhosis. World J Gastroenterol. 2009 Feb 7;15(5):591-4. 
 
Alnouti Y. Bile Acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol 
Sci. 2009 Apr;108(2):225-46. 
 
Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L. Bile acid-induced liver toxicity: 
relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses. 1986 
Jan;19(1):57-69. 
 
Blazer-Yost BL, Haydon J, Eggleston-Gulyas T, Chen JH, Wang X, Gattone V, Torres VE. 
Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease. 
PPAR Res. 2010; 2010:274376. 
 
Bomzon A, Holt S, Moore K. Bile acids, oxidative stress, and renal function in biliary 
obstruction. Semin Nephrol. 1997 Nov;17(6):549-62. 
 
Buscher HP, Miltenberger C, Macnelly S, Gerok W. The histoautoradiographic localization of 
taurocholate in rat liver after bile ductligation. J Hepatol. 1989 Mar;8(2):181-91. 
 
Chai J, He Y, Cai SY, Jiang Z, Wang H, Li Q, Chen L, Peng Z, He X, Wu X, Xiao T, Wang R, 
Boyer JL, Chen W. Elevated hepatic multidrug resistance-associated protein 3/ATP-binding 
cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor 
necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling 
pathway. Hepatology. 2012 May;55(5):1485-94. 
 
Chauveau D, Fakhouri F, Grunfeld JP. Liver Involvement in Autosomal-Dominant Polycystic 
Kidney Disease: Therapeutic Dilemma. J Am Soc Nephrol. 2000 Sep;11(9):1767-75. 
 
Chauveau D, Pirson Y, Le Moine A, Franco D, Belghiti J, Grünfeld JP. Extrarenal 
manifestations in autosomal dominant polycystic kidney disease. Adv Nephrol Necker Hosp. 
1997;26:265-89. 
 
Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M, Wang X, Xu LX, Yen Y, 
Liu P, Jia W. Serum and urine metabolite profiling reveals potential biomarkers of human 
hepatocellular carcinoma. Mol Cell Proteomics. 2011 Jul;10(7):M110.004945. 
 
Chiang J. Bile acids: regulation of synthesis. J Lipid Res. 2009 Oct;50(10):1955-66. 
 
Crocenzi FA, Mottino AD, Sánchez Pozzi EJ, Pellegrino JM, Rodríguez EA, Garay, Milkiewicz 
P, Vore M, Coleman R, and Roma MG. Impaired localisation and transport function of 
canalicular Bsep in taurolithocholate induced cholestasis in the rat. Gut. 2003 Aug; 52(8): 1170–
1177. 
 174 
 
 
Danaci M, Akpolat T, Baştemir M, Sarikaya S, Akan H, Selçuk MB, Cengiz K. The prevalence 
of seminal vesicle cysts in autosomal dominant polycystic kidney disease. Nephrol Dial 
Transplant. 1998 Nov;13(11):2825-8. 
 
Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in 
cholestatic rat liver. Hepatology. 2001 Aug;34(2):351-9. 
 
Dooley J, Lok A, Andrew K. Burroughs AK, Jenny Heathcote J. Sherlock's Diseases of the Liver 
and Biliary System, 12th Edition. 2011 Blackwell Publishing Ltd. 
 
Ecder T, Fick-Brosnahan G, Schrier RW. Polycystic kidney disease: diseases of the kidney and 
urinary tract. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. 
 
Ferslew BC, Xie G, Johnston CK, Su M, Stewart PW, Jia W, Brouwer KL, Sidney Barritt A 4th. 
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci. 2015 
Nov;60(11):3318-28. 
 
Giannini E, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005 
Feb 1; 172(3): 367–379. 
 
Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter 
regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta. 2007 
Mar;1773(3):283-308. 
 
Hofmann AF. Cholestatic liver disease: pathophysiology and therapeutic options. Liver. 2002;22 
Suppl 2:14–19. 
 
Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman 
TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, 
Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW. Liver involvement in early 
autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015 Jan;13(1):155-
64.  
 
Igarashi P, Somlo S. Polycystic Kidney Disease. JASN. 2007 vol. 18 no. 5 1371-1373. 
 
Kanno K, Tazuma S, Niida S, Chayama K. Unique reciprocal changes of hepatocellular 
membrane transporter expression and fluidity in rats with selective biliary obstruction. Hepatol 
Res. 2003 Jun;26(2):157-163. 
 
Katsuyama M, Masuyama T, Komura I, Hibino T, Takahashi H. Characterization of a novel 
polycystic kidney rat model with accompanying polycystic liver. Exp Anim. 2000 Jan;49(1):51-
5. 
 
 175 
 
Kis E, Ioja E, Nagy T, Szente L, Herédi-Szabó K, Krajcsi P. Effect of membrane cholesterol on 
BSEP/Bsep activity: species specificity studies for substrates and inhibitors. Drug Metab Dispos. 
2009 Sep;37(9):1878-86. 
 
Kisseleva T, Brenner DA. Anti-fibrogenic strategies and the regression of fibrosis. Best Pract 
Res Clin Gastroenterol. 2011;25:305–317. Aquaporins: their role in cholestatic liver disease. 
World J Gastroenterol. 2008 Dec 14;14(46):7059-67. 
 
Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE. The pck rat: a new model that resembles 
human autosomal dominant polycystic kidney and liver disease. Kidney Int. 2001 Jan;59(1):126-
36. 
 
Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL. Expression of the bile salt export 
pump is maintained after chronic cholestasis in the rat. Gastroenterology. 2000 Jan;118(1):163-
72. 
 
Levine E, Cook LT, Grantham JJ. Liver cysts in autosomal-dominant polycystic kidney disease: 
clinical and computed tomographic study. AJR Am J Roentgenol. 1985 Aug;145(2):229-33. 
 
Mannes GA, Thieme C, Stellaard F, Wang T, Sauerbruch T, Paumgartner G. Prognostic 
significance of serum bile acids in cirrhosis. Hepatology. 1986 Jan-Feb;6(1):50-3. 
 
Marin JJ, Macias RI, Briz O, Banales JM, Monte MJ. Bile Acids in Physiology, Pathology and 
Pharmacology. Curr Drug Metab. 2015;17(1):4-29. 
 
Mason SB, Liang Y, Sinders RM, Miller CA, Eggleston-Gulyas T, Crisler-Roberts R, Harris PC, 
Gattone VH 2nd. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK 
rat model of ARPKD. Anat Rec (Hoboken). 2010 Aug;293(8):1279-88. 
 
Masyuk TV, Huang BQ, Masyuk AI, Ritman EL, Torres VE, Wang X, Harris PC, Larusso NF. 
Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic 
kidney disease. Am J Pathol. 2004 Nov;165(5):1719-30. 
 
McDonald RA, Avner ED. Watson ML, editor. New York: Oxford University Press; Mouse 
Models of Polycystic Kidney Disease. 1996:pp 63–87. 
 
Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty 
liver disease associated with normal ALT values. Hepatology. 2003;37:1286–1292. 
 
Moseley RH, Wang W, Takeda H, Lown K, Shick L, Ananthanaray anan M, Suchy FJ. Effect of 
endotoxin on bile acid transport in rat liver: a potential model for sepsis-associated cholestasis. 
Am J Physiol 1996;271:G137–G146. 
 
Munoz-Garrido P, Marin JJ, Perugorria MJ, Urribarri AD, Erice O, Sáez E, Úriz M, Sarvide S, 
Portu A, Concepcion AR, Romero MR, Monte MJ, Santos-Laso Á, Hijona E, Jimenez-Agüero R, 
Marzioni M, Beuers U, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Drenth JP, Banales JM. 
 176 
 
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver 
disease. J Hepatol. 2015 Oct;63(4):952-61. 
 
Pellicoro A, van den Heuvel FA, Geuken M, Moshage H, Jansen PL, Faber KN. Human and rat 
bile acid-CoA:amino acid N-acyltransferase are liver-specific peroxisomal enzymes: 
implications for intracellular bile salt transport. Hepatology. 2007 Feb;45(2):340-8. 
 
Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009 Apr 
14;15(14):1677-89. 
 
Perrone RD. Extra-renal manifestations of autosomal dominant polycystic kidney disease. 
Kidney Int 1997:51:2022-36 
 
Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels 
and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J 
Gastroenterol. 2001 Nov;96(11):3142-6. 
 
Ringnér M. What is principal component analysis? Nature Biotechnology. 2008 26, 303–304. 
 
Ruh H, Salonikios T, Fuchser J, Schwartz M, Sticht C, Hochheim C, Wirnitzer B, Gretz N, Hopf 
C. MALDI imaging MS reveals candidate lipid markers of polycystic kidney disease. J Lipid 
Res. 2013 Oct;54(10):2785-94. 
 
Sabbatini M, Russo L, Cappellaio F, Troncone G, Bellevicine C, De Falco V, Buonocore P, 
Riccio E, Bisesti V, Federico S, Pisani A. Effects of combined administration of rapamycin, 
tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. Am J Physiol 
Renal Physiol. 2014 May 15;306(10):F1243-50. 
 
Schieren G, Pey R, Bach J, Hafner M, Gretz N. Murine models of polycystic kidney disease. 
Nephrol Dial Transplant. 1996;11 Suppl 6:38-45. 
 
Shimomura Y, Brock WJ, Ito Y, Morishita K. Age-Related Alterations in Blood Biochemical 
Characterization of Hepatorenal Function in the PCK Rat: A Model of Polycystic Kidney 
Disease. Int J Toxicol. 2015 Nov-Dec;34(6):479-90. 
 
Slizgi JR, Lu Y, Brouwer KR, St Claire RL, Freeman KM, Pan M, Brock WJ, Brouwer KL. 
Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing 
Factors to Drug-Induced Liver Injury? Toxicol Sci. 2016 Jan;149(1):237-50. 
 
Suwabe T, Ubara Y, Sumida K, Hayami N, Hiramatsu R, Yamanouchi M, Hasegawa E, Hoshino 
J, Sawa N, Saitoh S, Okuda I, Takaichi K. Clinical features of cyst infection and hemorrhage in 
ADPKD: new diagnostic criteria. Clin Exp Nephrol. 2012 Dec;16(6):892-902. 
 
Torra R, Nicolau C, Badenas C, Navarro S, Pérez L, Estivill X, Darnell A. Ultrasonographic 
study of pancreatic cysts in autosomal dominant polycystic kidney disease. Clin Nephrol. 1997 
Jan;47(1):19-22.  
 177 
 
 
Torres VE, Chapman AB, Devuyst, O, Gansevoort RT, Grantham JJ, Higashihara, E, Perrone, 
RD, Krasa HB, Ouyang J, and Czerwiec, FS. TEMPO 3:4 trial investigators. Tolvaptan in 
patients with autosomal dominant polycystic kidney disease. N.Engl.J.Med. 2012 367,2407–
2418. 
 
Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007 
Apr 14;369(9569):1287-301. 
 
Torres VE. New insights into polycystic kidney disease and its treatment. Curr Opin Nephrol 
Hypertens. 1998 Mar;7(2):159-69. 
 
Trauner M, Arrese M, Soroka C, Ananthanarayanan M, Koeppel TA,  Schlosser  SF,  Suchy  FJ,  
Keppler  D,  Boyer  JL.  The rat canalicular conjugate export pump (mrp 2) is down-regulated in 
intrahepatic and obstructive cholestasis. Gastroenterology. 1997 Jul;113(1):255-64. 
 
Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, Kubly V, Cunningham JM, 
Bacallao R, Ishibashi M, Milliner DS, Torres VE, Harris PC. 2002. The gene mutated in 
autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet. 
2002 Mar;30(3):259-69. 
 
Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, 
Torres VE, Czerwiec FS, Zimmer CA. Clinical Pattern of Tolvaptan-Associated Liver Injury in 
Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials 
Database. Drug Saf. 2015 Nov;38(11):1103-13. 
 
Xie G, Wang Y, Wang X, Zhao A, Chen T, Ni Y, Wong L, Zhang H, Zhang J, Liu C, Liu P, Jia 
W. Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS. J 
Proteome Res. 2015 Feb 6;14(2):850-9. 
 
Yazdanpanah K, Manouchehri N, Hosseinzadeh E, Emami MH, Mehdi Karami, Sarrami AH. 
Recurrent Acute Pancreatitis and Cholangitis in a Patient with Autosomal Dominant Polycystic 
Kidney Disease. Int J Prev Med. 2013 February; 4(2): 233–236. 
 178 
 
Figure 4.1. Magnetic resonance images of the hepatic parenchyma and cystic regions in 
wild-type and three different PCK rats at 20 weeks of age. Representative magnetic 
resonance images of the hepatic parenchyma and cystic regions in wild-type (A) and three 
different PCK (B-D) rats at 20 weeks of age. 
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Figure 4.2. Total bile acid concentrations in the liver, bile, serum, and urine in wild-type 
and PCK rats. Total bile acid concentrations in the liver (A), bile (B), serum (C), and urine (D) 
in wild-type (white) and PCK (grey) rats. Data represent the mean, first and third quartiles, and 
the maximum and minimum values (n=4/cohort except n=3 in bile of wild-type). Individual 
values are shown (black circles); ** p < 0.05 comparing wild-type versus PCK rats. 
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Figure 4.3. Unconjugated and conjugated bile acids in the liver, bile, serum, and urine in 
wild-type and PCK rats. Unconjugated and conjugated bile acids in the liver (A), bile (B), 
serum (C), and urine (D) in wild-type (white) and PCK (grey) rats. Data represent the mean, first 
and third quartiles, and the maximum and minimum values (n=4/cohort except n=3 in bile of 
wild-type). Individual values are shown (black circles); ** p < 0.05, wild-type vs. PCK rats. 
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Figure 4.4. Bile acids associated with hepatotoxicity in the liver, bile, serum, and urine in 
wild-type and PCK rats. Bile acids associated with hepatotoxicity (i.e. glycochenodeoxycholic 
acid (GCDCA),  glycodeoxycholic acid (GDCA), taurochenodeoxycholic acid (TCDCA), 
taurodeoxycholic acid (TDCA)) in the liver (A), bile (B), serum (C), and urine (D) in wild-type 
(white) and PCK (grey) rats. Data represent the mean, first and third quartiles, and the maximum 
and minimum values (n=4/cohort except n=3 in bile of wild-type). Individual values are shown 
(black circles); ** p < 0.05, wild-type vs. PCK rats. 
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Figure 4.5. Principle component analysis (PCA) score plots. Score plots of the PCA models 
of bile acid profiles in the liver (A), bile (B), serum (C), and urine (D) of wild-type (black 
circles) and PCK (open circles) rats. 
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Figure 4.6. Correlation between serum bile acids and markers of liver impairment. 
Correlation between liver weight (A), total liver bile acids (B), total liver bile acids associated 
with hepatotoxicity (C), cystic volume (D) and total serum bile acids in wild-type (black circles) 
and PCK (open circles) (n=4/cohort). The best-fit line is represented by the solid black line. 
Cystic volume was assumed to be zero in wild-type rats.  
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Figure 4.7. Immunohistochemical (IHC) staining of Bsep in wild-type and PCK rats. 
Representative immunohistochemical staining of Bsep in liver tissue from male wild-type (A) 
and PCK (B) rats (20X magnification). 
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Table 4.1. Body weight, organ weight, and estimated cyst volume in wild-type and PCK 
rats at 20 weeks of age.  
Parameter  Wild-type  PCK 
Body weight (g) 
 
409 ± 87 
 
501 ± 21   
  
Liver weight (g) 
 
10.1 ± 1.9 
 
20.2 ± 3.5**   
  
 
Liver weight/ body 
weight (%) 
 2.49 ± 0.17  4.16 ± 0.74** 
Total kidney weight (g) 
 
  2.50 ± 0.30 
 
6.97 ± 0.45**   
  
Total kidney weight/ 
body weight (%) 
 0.620 ± 0.069  1.29 ± 0.18** 
Estimated cyst volume 
(mL)
a
 
 
N/A 
 
5.20 ± 2.61   
  
Data represent the mean ± SD (n=4/cohort); ** p < 0.05, wild-type vs. PCK rats; N/A: no liver 
cysts were apparent in wild-type rats. 
a
Estimated using MRI as described in Materials and 
Methods . 
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Table 4.2. Relative abundance of bile acids in wild-type and PCK rats as a percentage of 
total bile acid concentrations in each matrix.  
Matrix  Bile Acid Species  
Wild-type  
(% of total) 
 
PCK  
(% of total) 
Liver 
 
CDCA species 
 
  0.272 ± 0.169 
 
  0.0746 ± 0.0303 
 
CA species 
 
77.6 ± 8.3 
 
        84.8 ± 3.61 
 
DCA species 
 
18.7 ± 8.3 
 
        13.3 ± 3.6 
 
LCA species 
 
  1.90 ± 0.24 
 
     0.816 ± 0.179** 
 
UDCA species 
 
  1.46 ± 0.59 
 
  1.01 ± 0.17 
Bile 
 
CDCA species 
 
0.200 ± .207 
 
  0.376 ± 0.090 
 
CA species 
 
  81.5 ± 3.03 
 
  84.6 ± 1.45 
 
DCA species 
 
  16.6 ± 2.76 
 
13.8 ± 1.4 
 
LCA species 
 
  0.660 ± 0.131 
 
  0.374 ± 0.062 
 
UDCA species 
 
  0.986 ± 0.387 
 
  0.823 ± 0.044 
Serum 
 
CDCA species 
 
  8.72 ± 9.30 
 
  2.03 ± 0.44 
 
CA species 
 
80.9 ± 9.5 
 
65.9 ± 6.2 
 
DCA species 
 
  7.73 ± 1.94 
 
   27.0 ± 5.8** 
 
LCA species 
 
  1.10 ± 0.63 
 
    3.75 ± 0.65** 
 
UDCA species 
 
  1.53 ± 0.52 
 
 1.28 ± 0.11 
Urine 
 
CDCA species 
 
  1.30 ± 0.82 
 
 1.56 ± 0.89 
 
CA species 
 
  83.7 ± 11.7 
 
        77.3 ± 5.1 
 
DCA species 
 
  5.96 ± 4.19 
 
        18.3 ± 4.3** 
 
LCA species 
 
  7.36 ± 5.62 
 
  1.98 ± 0.63 
 
UDCA species 
 
  1.63 ± 1.38 
 
  0.857 ± 0.203 
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Data are presented as mean ± SD (n=4/cohort except n=3 in bile of wild-type rats); ** p < 0.05, 
wild-type vs. PCK rats. 
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Supplementary Materials 
Supplementary Table 4.1. Sulfate and glucuronide conjugates in wild-type and PCK rats. Data 
are presented as mean ± SD (n=4/cohort except n=3 in bile of wild-type rats); * p < 0.05, wild-
type vs. PCK rats. 
Matrix  BA species  Wild-type   PCK  
Liver  
(pmol/g) 
 
Sulfate conjugates
a
 
 
    0.645 ± 0.265 
 
  3.26 ± 1.27* 
 Glucuronide 
conjugates
b
 
 
   25.1 ± 8.6 
 
174 ± 53* 
Bile (µM) 
 
Sulfate conjugates
a
 
 
  12.7 ± 8.7 
 
8.00 ± 6.11 
 Glucuronide 
conjugates
b
 
 
    2.55 ± 3.30 
 
6.15 ± 1.54 
Serum (nM) 
 
Sulfate conjugates
a
 
 
    0.651 ± 0.278 
 
10.1 ± 14.6 
 Glucuronide 
conjugates
b
 
 
    9.66 ± 4.66 
 
118 ± 68* 
Urine (nM) 
 
Sulfate conjugates
a
 
 
0.512 ± 0.0 
 
1.29 ± 0.75 
 Glucuronide 
conjugates
b
 
 
    1.45 ± 0.21 
 
 7.01 ± 2.70* 
a
Lithocholic acid-3-sulfate (LCA-S); 
b
sum of chenodeoxycholic acid-3-β-D-glucuronide 
(CDCA-3G); chenodeoxycholic acid 24-acyl-β-D-glucuronide (CDCA-24G) 
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Supplementary Table 4.2. Bile acids exhibiting the greatest fold-increase compared to wild-
type rats. The relative fold-change was calculated by dividing the mean bile acid concentration in 
PCK rats by the mean bile acid concentration in wild-type rats. 
Matrix  Bile acid species  Relative fold change  
Liver  
 
GHDCA 
 
317 
 
HDCA 
 
213 
 
THDCA 
 
185 
 
MCA 
 
47.3 
Bile 
 
6-ketoLCA 
 
53.9 
 
HDCA 
 
43.2 
 
THDCA 
 
20.9 
 
MCA 
 
16.0 
Serum 
 
HDCA 
 
1710 
 
GHDCA 
 
154 
 
6-ketoLCA 
 
122 
 
THDCA 
 
52.9 
Urine 
 
DCA 
 
30.5 
 
β-MCA 
 
26.5 
 
MCA 
 
25.0 
 
HDCA 
 
24.9 
6-ketolithocholic acid (6-ketoLCA), deoxycholic acid (DCA), glycohyodeoxycholic acid 
(GHDCA), hyodeoxycholic acid (HDCA), muricholic acid (MCA), taurohyodeoxycholic acid 
(THDCA).  
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Supplementary Table 4.3. Bile acid concentrations in liver (nmol/g), bile (μM), serum (nM), 
and urine (nM) of fasting wild-type and PCK rats. Data are presented as mean ± standard 
deviation (n=4/cohort except n=3 in bile of wild-type rats). 
BA species  Matrix  Wild-type  PCK 
ACA  
Liver    0.217 ± 0.005  0.360 ± 0.308 
Bile    1.29 ± 1.36  1.01 ± 0.19 
Serum    81.0 ± 35.2  474 ± 102 
Urine    23.5 ± 23.7  45.9 ± 34.5 
CA  
Liver    0.420 ± 0.204  7.77 ± 6.63 
Bile    33.3 ± 29.5  24.3 ± 5.2 
Serum  2170 ± 970  9660 ± 1340 
Urine    198 ± 211  651 ± 681 
3β-CA  
Liver   0.0174 ±0.0004  0.0677 ± 0.0344 
Bile    0.413 ± 0.179  0.274 ± 0.057 
Serum  11.1 ± 8.3  47.2 ± 20.5 
Urine  BQL  BQL 
norCA  
Liver  0.0251 ± 0.0142  0.0636 ± 0.0224 
Bile  0.757 ± 0.282  0.294 ± 0.150 
Serum  2.88 ± 2.17  4.52 ± 2.97 
Urine  9.90 ± 11.2  6.15 ± 2.68 
muroCA  
Liver  0.0573 ± 0.0253  2.71 ± 1.16 
Bile  0.0786 ± 0.0432  1.26 ± 0.34 
Serum  36.9 ± 22.1           1170 ± 550 
Urine  1.81 ± 1.05   45.2 ± 48.3 
CDCA 
 Liver       0.0961 ±0.0741   0.217 ± 0.061 
 Bile  0.218 ± 0.105   0.0622 ± 0.0197 
 Serum  647 ± 224           1120 ± 170 
 Urine  4.63 ± 3.73   37.0 ± 42.1 
CDCA-3G 
 Liver     0.00517 ±0.00133     0.110 ± 0.0326 
 Bile  2.55 ± 3.30   6.15 ± 1.54 
 Serum  7.16 ± 3.97             117 ± 68 
 Urine  1.45 ± 0.21  7.01 ± 2.73 
CDCA-24G 
 Liver  0.0199 ± 0.0092  0.0639 ± 0.0217 
 Bile  BQL  BQL 
 Serum  2.50 ± 0.86  1.28 ± 0.00 
 Urine  BQL  BQL 
DCA 
 Liver   1.37 ± 2.27   0.707 ± 0.268 
 Bile   0.187 ± 0.106   0.205 ± 0.055 
 Serum             212 ± 68           1100 ± 230 
 Urine   1.13 ± 1.24  34.5 ± 40.1 
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BA species  Matrix  Wild-type  PCK 
norDCA 
 Liver  0.00188 ±0.00165  0.0146 ± 0.0030 
 Bile   0.00240 ± 0.00296  0.000828 ± 0.000632 
 Serum  BQL  BQL 
 Urine  BQL  BQL 
3-DHCA 
 Liver  0.00774 ± 0.00130   0.0475 ± 0.0316 
 Bile  0.222 ± 0.228   0.0900 ± 0.0388 
 Serum  30.7 ± 13.3   58.9 ± 11.2 
 Urine  20.0 ± 16.5   45.5 ± 46.6 
7-DHCA 
 Liver  0.0411 ± 0.0238   0.229 ± 0.259 
 Bile  2.72 ± 2.19   0.919 ± 0.145 
 Serum  165 ± 198   92.1 ± 37.5 
 Urine  20.1 ± 26.4   21.1 ± 13.3 
GCA 
 Liver  2.79 ± 1.23   39.6 ± 23.7 
 Bile            156 ± 79             164 ± 44 
 Serum  900 ± 560  3200 ± 1240 
 Urine  5.88 ± 3.75  32.8 ± 16.2 
GCDCA 
 Liver  0.207 ± 0.026   4.73 ± 3.98 
 Bile  29.2 ± 10.5            17.3 ± 5.9 
 Serum           13.9 ± 4.1   79.3 ± 30.8 
 Urine  3.42 ± 1.58   12.7 ± 10.1 
GDCA 
 Liver  0.659 ± 0.256   7.19 ± 5.83 
 Bile  21.1 ± 16.6            28.3 ± 8.7 
 Serum            104 ± 67   548 ± 177 
 Urine  4.92 ± 3.29   3.14 ± 2.21 
GHCA 
 Liver  0.00863 ± 0.00479   0.127 ± 0.131 
 Bile    0.310 ± 0.0530   0.0815 ± 0.0636 
 Serum         0.844 ± 1.03   3.59 ± 2.16 
 Urine  BQL  BQL 
GHDCA 
 Liver  0.0489 ± 0.0201   15.5 ± 12.2 
 Bile  4.69 ± 2.92   62.5 ± 17.8 
 Serum  15.4 ± 11.3   2360 ± 1450 
 Urine  BQL   29.7 ± 23.8 
GLCA 
 Liver  0.0235 ± 0.0041   0.183 ± 0.199 
 Bile  0.812 ± 0.484   0.500 ± 0.166 
 Serum  2.89 ± 2.14            10.5 ± 3.3 
 Urine  BQL  BQL 
GUDCA 
 Liver  0.0654 ± 0.0203    39.6 ± 23.7 
 Bile  3.01 ± 0.97    3.42 ± 1.21 
 Serum  6.37 ± 5.37             26.2 ± 8.9 
 Urine  BQL  BQL 
HCA 
 Liver  0.00716 ± 0.00249    0.0317 ± 0.0248 
 Bile  0.119 ± 0.100    0.0763 ± 0.0393 
 Serum  24.1 ± 12.3    33.7 ± 17.9 
 Urine  1.59 ± 2.15    4.46 ± 5.36 
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BA species  Matrix  Wild-type  PCK 
HDCA 
 Liver  0.0163 ± 0.0148    3.47 ± 1.68 
 Bile  0.0492 ± 0.0778    2.12 ± 0.45 
 Serum  6.77 ± 7.49  11600 ± 5000 
 Urine  15.5 ± 1.44    386 ± 360 
LCA 
 Liver  0.0149 ± 0.0037    0.0399 ± 0.0104 
 Bile  0.0306 ± 0.0090    0.0282 ± 0.0019 
 Serum           18.5 ± 7.7  43.9 ± 8.4 
 Urine  3.90 ± 1.51    13.0 ± 14.7 
LCA-S 
 Liver  0.000645 ± 0.000265    0.00326 ± 0.00127 
 Bile  0.0127 ± 0.0087    0.00972 ± 0.00354 
 Serum  0.641 ± 0.277    10.1 ± 14.6 
 Urine         0.512 ± 0.00    1.28 ± 0.75 
6-ketoLCA 
 Liver  0.0515 ± 0.0156    2.41 ± 1.19 
 Bile  0.0351 ± 0.0187    1.89 ± 0.65 
 Serum           17.3 ± 3.6  2110 ± 840 
 Urine           16.3 ± 5.0  22.6 ± 7.8 
7-ketoLCA 
 Liver  BQL    0.0124 ± 0.0077 
 Bile  0.00716 ± 0.00070    0.0147 ± 0.0082 
 Serum  24.3 ± 26.2  116 ± 36 
 Urine         0.512 ± 0.00    1.25 ± 0.88 
12-ketoLCA 
 Liver  BQL    0.125 ± 0.061 
 Bile  0.00903 ± 0.00274    0.0388 ± 0.0251 
 Serum  13.3 ± 13.2    67.8 ± 10.8 
 Urine  2.25 ± 0.79    1.30 ± 0.76 
alloLCA 
 Liver  0.00573 ± 0.00202    0.0132 ± 0.0068 
 Bile  0.00515 ± 0.00243    0.00358 ± 0.00088 
 Serum  1.57 ± 2.12    8.40 ± 5.29 
 Urine  BQL           0.563 ± NC 
dehydroLCA 
 Liver  0.00193 ±0.00058    0.00356 ± 0.00059 
 Bile  0.00247 ± 0.00081    0.00215 ± 0.00125 
 Serum  3.55 ± 2.14    3.89 ± 0.33 
 Urine  0.778 ± 0.532    0.901 ± 0.459 
αMCA 
 Liver  0.108 ± 0.037    0.388 ± 0.229 
 Bile  4.30 ± 2.81    2.63 ± 0.18 
 Serum  523 ± 199  1728 ± 230 
 Urine  27.7 ± 38.9    133 ± 111 
βMCA 
 Liver  0.380 ± 0.134    4.13 ± 2.75 
 Bile  2.20 ± 1.87    4.91 ± 1.72 
 Serum  349 ± 146    4590 ± 2860 
 Urine  10.4 ± 11.1    275 ± 310 
tαMCA 
 Liver  4.99 ± 2.32    28.8 ± 14.9 
 Bile            126 ± 41    85.5 ± 32.7 
 Serum  787 ± 535  1490 ± 650 
 Urine  6.40 ± 0.00    12.7 ± 12.6 
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BA species  Matrix  Wild-type  PCK 
tβMCA 
 Liver  2.52 ± 0.86  117 ± 95 
 Bile           29.8 ± 3.2  233 ± 95 
 Serum  244 ± 146    3570 ± 2050 
 Urine  6.40 ± 0.00    32.7 ± 17.9 
tωMCA 
 Liver  1.12 ± 1.09  14.2 ± 9.7 
 Bile  7.95 ± 5.98    26.8 ± 8.0 
 Serum  80.4 ± 80.7    518 ± 244 
 Urine  6.40 ± 0.00    6.40 ± 0.00 
ωMCA 
 Liver  0.145 ± 0.085   0.429 ± 0.300 
 Bile  1.39 ± 1.12   0.975 ± 0.174 
 Serum  499 ± 364           1420 ± 624 
 Urine  234 ± 413   468 ± 452 
TCA 
 Liver           21.7 ± 8.1             212 ± 72 
 Bile  621 ± 114   651 ± 250 
 Serum  3380 ± 2480   8210 ± 4000 
 Urine  6.40 ± 0.00             108 ± 18 
TCDCA 
 Liver  3.94 ± 1.65            28.4 ± 8.3 
 Bile            106 ± 32   80.1 ± 38.6 
 Serum  270 ± 282   598 ± 386 
 Urine  0.512 ± 0.000   5.18 ± 4.11 
TDCA 
 Liver  2.71 ± 1.16            22.5 ± 6.7 
 Bile  61.7 ± 28.4   69.4 ± 29.7 
 Serum  421 ± 335           1470 ± 530 
 Urine  0.512 ± 0.000   5.18 ± 4.11 
THDCA 
 Liver  0.442 ± 0.145   81.5 ± 42.2 
 Bile           10.2 ± 0.8             213 ± 44 
 Serum  86.7 ± 65.3  4590 ± 1430 
 Urine  2.41 ± 1.31  56.6 ± 58.5 
TLCA 
 Liver  0.771 ± 0.255  1.95 ± 0.58 
 Bile  7.24 ± 1.12  4.02 ± 1.57 
 Serum  22.4 ± 19.2            27.3 ± 7.5 
 Urine  BQL  BQL 
TUDCA 
 Liver  0.588 ± 0.448    6.13 ± 3.83 
 Bile           11.7 ± 3.2            14.0 ± 4.2 
 Serum  94.9 ± 77.8             180 ± 83 
 Urine  2.09 ± 0.94   3.47 ± 1.71 
UCA 
 Liver  0.0529 ± 0.0492   0.0893 ± 0.0786 
 Bile  1.45 ± 0.31   0.136 ± 0.116 
 Serum  114 ± 142   86.6 ± 21.9 
 Urine  211 ± 377   50.6 ± 43.3 
UDCA 
 Liver  0.0346 ± 0.0154   0.264 ± 0.182 
 Bile  0.0621 ± 0.0367   0.0933 ± 0.0255 
 Serum  81.2 ± 57.1   627 ± 220 
 Urine  4.14 ± 2.61   18.5 ± 19.2 
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Allocholic acid (ACA); below quantitation limit (BQL); cholic acid (CA); 23-norcholic acid 
(norCA); murocholic acid (muroCA); chenodeoxycholic acid (CDCA); chenodeoxycholic acid-
3-β-D-glucuronide (CDCA-3G); chenodeoxycholic acid 24-acyl-β-D-glucuronide (CDCA-24G); 
deoxycholic acid (DCA); 23-nordeoxycholic acid (norDCA); 3-dehydrocholic acid (3-DHCA); 
7-ketodeoxycholic acid (7-DHCA); glycocholic acid (GCA); glycochenodeoxychol ic acid 
(GCDCA); glycodeoxycholic acid (GDCA); glycohyocholic acid  (GHCA); glycohyodeoxychol 
ic acid (GHDCA); glycolithocholic acid  (GLCA); glycoursodeoxycholic acid (GUDCA); 
hyocholic acid (HCA); α-hyodeoxycholic acid (HDCA); lithocholic acid (LCA); lithocholic 
acid-3-sulfate (LCA-S); 6-ketolithocholic acid (6-ketoLCA); 7-ketolithocholic acid (7-
ketoLCA); 12-ketolithocholic acid (12-ketoLCA); allolithocholic acid (alloLCA); 
dehydrolithocholic acid (dehydroLCA); α-muricholic acid (αMCA); β-muricholic acid (βMCA); 
tauro- α-muricholic acid (tαMCA); tauro-β-muricholic acid (tβMCA); tauro-ω-muricholic acid 
(tωMCA); ω-muricholic acid (ωMCA); not calculable (NC); taurocholic acid (TCA); 
taurochenodeoxycholic acid (TCDCA); taurodeoxycholic acid (TDCA); taurohyodeoxycholic 
acid (THDCA); taurolithocholic acid (TLCA); tauroursodeoxycholic acid (TUDCA); ursocholic 
acid (UCA); ursodeoxycholic acid (UDCA). The limit of quantification was 1.024 nM for all bile 
acid species, except for a limit of 2.56 nM for cholic acid, murocholic acid, glycodeoxycholic 
acid, glycochenodeoxycholic acid, ursodeoxycholic acid, α-hyodeoxycholic acid, 6-
ketolithocholic acid, tauroursodeoxycholic acid, taurohyodeoxycholic acid, and 
chenodeoxycholic acid 24-acyl-β-D-glucuronide; the limit of quantification for tauro-ω-
muricholic acid, tauro-α-muricholic acid, tauro-β-muricholic acid, and taurocholic acid was 12.8 
nM. 
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CHAPTER 5. Altered Hepatobiliary Disposition of the Mrp2 Probe Substrate 
Carboxydichlorofluorescein in Isolated Perfused Livers from a Rat Model of Polycystic 
Kidney Disease
5
 
INTRODUCTION 
Polycystic kidney disease (PKD) is the most common class of inheritable genetic diseases 
characterized by the progressive development of kidney cysts and subsequent decline in renal 
function (Harris et al., 2009). Autosomal dominant polycystic kidney disease (ADPKD) is the 
most common form of PKD. ADPKD is primarily due to a germline mutation in the polycystin-1 
(PKD1) or polycystin-2 (PKD2) gene located on the arm of chromosome 16 and 4, respectively, 
while autosomal recessive polycystic kidney disease (ARPKD) is due to a mutation in the 
polycystic kidney and hepatic disease 1 (PKHD1) gene located on chromosome 6 (Igarashi et al., 
2002). Despite the clinical and genetic heterogeneity of ADPKD and ARPKD, both these 
ciliopathies manifest themselves in the formation and progression of fluid-filled cysts that alter 
and destroy renal nephrons. While it is clear that the decline in renal function is central to 
morbidity and mortality of PKD, this disease is a multisystem disorder that affects other 
epithelial organs (Danaci et al., 1998; Levine et al., 1985, Torra et al., 1997). 
The liver is the most common extrarenal organ affected in patients with ADPKD. One 
study showed that the prevalence of hepatic cysts increased with age and was as high as 94% in 
35- to 46-year-old patients with ADPKD (Bae et al., 2006). While hepatic biochemical 
abnormalities have been reported, liver synthetic function typically is preserved, and the 
presence of liver cysts is generally considered benign (Everson et al., 1999; Hogan et al., 2015, 
                                                          
5
 This chapter will be submitted to Molecular Pharmacology and is presented in the style of that journal. 
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Qian et al., 2003). This is likely due to the fact that hepatic parenchymal volume is maintained 
(Everson et al., 1999), although a recent report by Hogan et al. (2015) showed that parenchymal 
volume may contribute to hepatomegaly in humans. However, in some patients, particularly with 
severe hepatomegaly, increases in serum γ-glutamyl transferase or alkaline phosphatase ~2-5 
times the upper limit of normal have been reported (Chauveau et al., 1997).  
Although renal cyst progression and functional decline have been associated with 
decreased elimination of renally-cleared drugs, the same observation has not been established for 
drugs that undergo hepatic elimination – despite the prevalence of cysts, and in some cases, the 
burden of cysts in the liver. Surprisingly, the impact of PKD on the hepatobiliary disposition of 
drugs has not been evaluated. Bile acids were reported to be increased in serum, and decreased in 
bile, of rats with polycystic kidney disease (i.e., PCK rats), a rodent model that resembles human 
ADPKD (Lager et al., 2001; Munoz-Garrido et al. 2015; Ruh et al. 2013). Although the exact 
mechanism of altered bile acid disposition in PCK rats has yet to be determined, studies so far 
have excluded any difference in the rate and/or extent of bile acid metabolism, suggesting that 
altered bile acid transporter function may be involved. 
Hepatocyte uptake of bile acids is mediated primarily by the Na
+
-taurocholate co-
transporting polypeptide (NTCP) and the organic anion transporting polypeptide (OATP) family 
of transporters. Bile acids are efficiently secreted into bile by the ATP-dependent bile salt export 
pump (BSEP). Bile acid conjugates also are excreted into bile by the multidrug resistance–
associated protein (MRP) 2. Additionally, bile acids can undergo transport from hepatocytes into 
sinusoidal blood by the basolateral efflux transporters MRP3, MRP4, and the heteromeric 
organic solute transporter (OST)α-OSTβ (Boyer et al., 2006). To this end, this study was 
designed to examine the effect of PKD on the hepatobiliary disposition of 5(6)-carboxy-2’,7’-
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dichlorofluorescein (CDF), a fluorescent MRP2/Mrp2 probe, in isolated perfused livers from 
PCK rats compared to healthy Sprague Dawley (SD) rats (Heredi-Szabo et al., 2008; Myint et 
al., 2015; Zamek-Gliszczynski et al., 2003). CDF was chosen because it is excreted unchanged 
into bile by Mrp2 in rats (Zamek-Gliszczynski et al., 2003); CDF is also a substrate for Oatps 
and the basolateral efflux transporter  Mrp3 (Chandra et al., 2005).  
The isolated perfused rat liver is an established ex vivo model that has been used to 
investigate the physiology and function of the liver including the assessment of ischemia-
reperfusion injury, synthesis of proteins, oxygen consumption, and metabolism and transport of 
drugs and metabolites (Dahn  et al., 1999; Haussinger et al., 1986; Khezrian et al., 2015; Lindell 
et al., 1994; Pfeifer et al., 2013) . The primary advantages of the isolated perfused rat liver model 
are the retention of normal hepatic architecture, microcirculation, and bile production in a system 
that approaches normal physiology (Bessems et al., 2006; Brouwer and Thurman, 1996). Given 
the accompanying pathological changes that are expected in PCK rats, the isolated perfused liver 
model was chosen to test the effect of PKD on hepatic organic anion transporter function. 
MATERIALS AND METHODS 
Materials. 
CDF was obtained from Sigma-Aldrich (St. Louis, MO). All other chemicals and 
reagents were of analytical grade or higher and were readily available from commercial sources. 
Animals. 
Male Sprague-Dawley (SD) or polycystic kidney disease (PCK/Crlj Crl-Pkhd1pck/Cr) 
rats were purchased from Charles River Laboratories (Wilmington, MA). Rats were housed in a 
constant alternating 12-h light/dark cycle and allowed water and food ad libitum and acclimated 
for a minimum of 1 week prior to experimentation. All animal procedures complied with the 
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guidelines of the Institutional Animal Care and Use Committee (University of North Carolina, 
Chapel Hill, NC). Isolated perfused liver procedures and liver tissue samples were collected at 16 
weeks of age because the expected pathological changes (e.g., hepatic cysts) in PCK rats are well 
defined at this age (Lager et al., 2001, Mason et al., 2010). 
Isolated perfused liver experiments. 
Wild-type and PCK rat livers were perfused in a single-pass manner as described 
previously (Brouwer and Thurman, 1996; Chandra et al., 2005). Briefly, animals were 
anesthetized with ketamine:xylazine (60:12 mg/kg i.p.) and the portal vein and bile duct were 
cannulated. Following cannulation, the liver was removed from the carcass and transferred to a 
humidified 37ºC perfusion chamber, and perfused with oxygenated Krebs-Ringer bicarbonate 
buffer containing 15 μM taurocholate for ~10 min at a flow rate of 38 mL/min. Following the 
~10-min equilibration period, the perfusate was switched to 1 µM CDF-containing buffer for 30 
min (approximately steady-state). The perfusate was then switched to CDF-free buffer for a 30-
min washout phase. Liver viability was assessed by monitoring inflow perfusion pressure (< 15 
cm H2O), gross morphology, and maintenance of bile flow. Bile volume was determined 
gravimetrically in pre-weighed tubes. Bile and perfusate samples were collected from 0 to 60 
min and frozen at -80ºC until analysis. A blank perfusion (without liver) was performed to assess 
adsorption to the tubing and apparatus; adsorption was negligible (data not shown). A liver was 
perfused with 0.1% triton-X and served as a positive control for the viability assessment.  
Lactate dehydrogenase (LDH) assay. 
Leakage of LDH into the outflow perfusate during perfusions was determined using the 
LDH cytotoxicity detection kit (Thermo Fisher Scientific, Waltham, MA). Briefly, outflow 
perfusate samples were thawed and aliquots were dispensed into a 96-well format. LDH 
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substrate mixture was prepared per the manufacturer’s protocol and incubated for 30 min. LDH 
released from hepatocytes into the perfusate reduced the tetrazolium salt 2-(4-iodophenyl)-3-(4- 
nitrophenyl)-5-phenyl-2H-tetrazolium chloride (INT) to formazan by a coupled enzymatic 
reaction. After incubation, formazan was measured by using the Fluoroskan Ascent FL 
Fluorometer (Thermo Scientific, Waltham, MA) at wavelengths of 492 nm per the 
manufacturer’s protocol. Data were converted to percentage of positive control from a liver 
perfused with 0.1% triton-X.  
CDF sample preparation.  
Perfusate and bile samples were thawed and appropriately diluted with buffer and 
analyzed for CDF by fluorescence spectroscopy using the Fluoroskan Ascent FL Fluorometer 
(Thermo Scientific, Waltham, MA) at wavelengths of 485 nm (excitation) and 518 nm 
(emission). Standard curves were prepared daily by diluting CDF in buffer. The linear range was 
determined to be 1.95-125 nM; the lower limit of quantitation was 1.95 nM. 
Pharmacokinetic analyses. 
Pharmacokinetic models were developed to describe the disposition of CDF in wild-type 
and PCK rat livers. Various models were evaluated to simultaneously fit the outflow perfusate 
rate and biliary excretion rate vs. time data by nonlinear least-squares regression using a 
1/Ypredicted
2
 weighting scheme (Phoenix WinNonlin 4.3, Pharsight, Mountain View, CA). 
Selection criteria included coefficients of variation on the estimated parameters, distribution of 
residuals, and Akaike’s information criterion (Akaike, 1976). Model structures describing the 
hepatocellular space as one or two compartments (Fig. 5.1) were compared. Based on the 
goodness-of-fit criteria, the model scheme presented in Fig. 5.1B best described the data.  The 
differential equations used to describe the disposition of CDF are provided below: 
 200 
 
 1 
d𝑋𝑠𝑖𝑛
dt
=  Q●Cin −  Q●Cout  +  kperfusate ●XL1 −  CLup ●Cout                                  X°sin = 0 
 2 
d𝑋𝐿1
dt
=  CLup ●Cout  −  kperfusate ●XL1 −  k12●XL1 +  k21●XL2   t ≤ 30 min  X°sin = 0 
(3)
d𝑋𝐿1
dt
=  k21●XL2 −   kperfusate ●XL1 −  k12●XL1                             t > 30 𝑚𝑖𝑛    X°sin = 0 
(4)
d𝑋𝐿2
dt
=  k12●XL1 −  k21●XL2 −  kbile ●XL2                                                                  X°sin = 0 
 5 
d𝑋𝑏𝑖𝑙𝑒
dt
=  kbile ●XL2                                                                                                                  X°sin = 0 
where Cin is the concentration of CDF in the inflow perfusate, Cout is the concentration of CDF in 
the outflow perfusate, Q is the flow rate (38 mL/min), Xsin is the amount of CDF in the 
sinusoidal space, CLup is the uptake clearance into the liver, kperfusate is the first-order rate 
constant for basolateral excretion, XL1 and XL2 are the amounts of CDF in the two compartments 
representing the hepatocellular space of the liver, k12 is the first-order rate constant for 
movement from liver compartment 1 to liver compartment 2, k21 is the first-order rate constant 
for movement from liver compartment 2 to liver compartment 1, and kbile is the first-order rate 
constant for biliary excretion. The model was constructed assuming that CDF was not 
metabolized, and that all processes were linear and were represented by either an uptake 
clearance (i.e., CLup) or a first-order rate constant (i.e., kperfusate, k12, k21, and kbile). The perfusate 
outflow rate was calculated as the product of the flow rate and the outflow perfusate 
concentration at each designated time point; similarly, the biliary excretion rate was calculated as 
the product of bile flow during the specified collection interval and the biliary concentration at 
each designated time point. The extraction ratio was calculated by subtracting Cin from Cout and 
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then dividing by Cin. The area under the concentration-time curve (AUC) was determined using a 
linear-up log-down trapezoidal algorithm (Phoenix WinNonlin 4.3, Pharsight, Mountain View, 
CA). Simulations were performed to evaluate the effects of perturbations in CLup and kperfusate on 
the extent of CDF biliary excretion using the final model structure (Fig. 5.1B) and equations (1)-
(5) listed above. Simulations were conducted assuming a constant infusion rate of CDF into the 
liver (1 μM at 38 mL/min for 30 min) by modulating parameter estimates based on the mean 
values from wild-type rats (Table 5.1) using Phoenix WinNonlin (v. 4.3 Pharsight, Mountain 
View, CA). 
Immunoblot analysis. 
Liver samples from the median lobe were excised, snap frozen, and immediately placed 
in -80 ºC. Liver samples were thawed in 2 mL protease-containing radioimmunoprecipitation 
assay (RIPA) buffer (Santa Cruz Biotechnology, Inc. Dallas, TX) and sonicated for 30 sec on 
ice. Homogenates were centrifuged at 1500g for 10 min at 4ºC; the supernatant was removed and 
subsequently centrifuged at 100,000g for 30 min, and the remaining pellet was suspended in 
protease-containing RIPA buffer and stored at -80 ºC until use. Protein concentration was 
determined using the bicinchoninic acid method (Smith et al., 1985). Samples for Western blots 
were prepared according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA); 40 μg 
(for MRP2) or 30 μg (for MRP3) was loaded onto 4-12% Bis-Tris gels. After electrophoresis, 
proteins were transferred to polyvinylidene fluoride membranes according to standard 
procedures. The membranes were probed with anti-MRP2 antibody (MC-206, 1:100, Kamiya 
Biochemical Company, Seattle, WA) or anti-MRP3 antibody (sc-5776, 1:200, Santa Cruz 
Biotechnology, Dallas, TX) overnight in diluted 5% (w/v) milk- tris-buffered saline tween 20 
(TBS-T). After washing three times in TBS-T for 10 min, the blots were probed with horseradish 
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peroxidate-conjugated anti-mouse or anti-goat IgG secondary antibody (Santa Cruz 
Biotechnology, Dallas, TX) for 2 hr at room temperature. Detection was enhanced using 
chemiluminescence reagents (SuperSignal/West Dura; Pierce Chemical, Rockford IL). Actin was 
used as the loading control (sc-1615, Santa Cruz Biotechnology, Dallas, TX). The data were 
normalized to loading control (actin) using densitometric analysis to compare protein expression 
between wild-type and PCK rats with ImageLab software version 4.1 (Bio-Rad, Hercules, CA). 
Immunohistochemical (IHC) staining. 
Liver samples from the median lobe were excised and immediately placed in 4% 
paraformaldehyde for 48 hr, processed, embedded in paraffin, serially sectioned at 4 µm 
thickness, and placed on coated glass slides. Sectioned slides were used for IHC immediately or 
unstained slides were stored in the nitrogen gas chamber if staining was not done immediately. 
Mouse monoclonal anti-MRP2 (MC-206, Kamiya Biochemical Company, Seattle, WA) and goat 
polyclonal anti-MRP3 (sc-5776, Santa Cruz Biotechnologies, Dallas, TX) antibodies were used 
for IHC. IHC was carried out in the Bond fully automated immunostainer (Leica Biosystems 
Inc., Vista, CA). Slides were dewaxed in Bond Dewax solution (AR9222) and hydrated in Bond 
Wash solution (AR9590). Antigen retrieval was performed for 30 min at 100ºC in Bond-Epitope 
Retrieval solution 1 pH-6.0 (AR9961). Antigen retrieval was followed with 5 min Bond peroxide 
blocking (DS9800) step; for MRP3 protein blocking reagent (PV6122, Leica) was added for 10 
min. After pretreatment, slides were incubated with anti-MRP2 (1:50) and anti-MRP3 (1:100) 
antibodies for 30 min and 4 hr, respectively. Bond™ Polymer Refine Detection system 
(DS9800) was used to detect both antibodies; for MRP3, Bond polymer was supplemented with 
ImmPRESS HRP anti-goat secondary antibody (MP-7405-15, Vector Labs; Burlingame, CA). 
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Stained slides were dehydrated and covered with a coverslip. Positive and negative controls (no 
primary antibody) were evaluated. 
Statistical analysis.  
The data were reported as the mean ± SD. Five rat livers per cohort were used in the 
isolated perfused liver experiments; three rat livers per cohort were used in western blot and IHC 
analysis. Statistically significant differences between the generated parameters for each cohort 
were determined by the nonparametric two-tailed Wilcoxon rank sum test using GraphPad Prism 
6 (San Diego, CA). Statistical significance was determined at the α = 0.05 level. 
RESULTS 
Isolated-perfused liver experiments. 
The body weight of wild-type and PCK rats was similar although the liver weight was 
significantly increased in PCK rats (Table 5.1). Liver viability was maintained as evidenced by 
negligible LDH release (< 0.1% toxicity; data not shown) and constant bile flow throughout the 
60-min perfusion (Fig. 5.2). Bile flow was ~0.9 µL/min/g liver in wild-type rat livers, which is 
similar to previously reported values (Beckh, et al., 1991; Beckh et al., 1994). Although bile flow 
appeared to be increased in PCK rat livers, when normalized by liver weight, bile flow was lower 
in PCK rat livers (~0.5-0.7 µL/min/g) (Fig. 5.2). The outflow perfusate excretion rate vs. time 
data were similar between both cohorts (Fig. 5.3A); notably, the biliary excretion rate vs. time 
data were lower in PCK rat livers (Fig. 5.3B). The total dose of CDF perfused (mean ± SD) was 
similar between wild-type (1140 ± 30 nmol) and PCK (1130 ± 30 nmol) rat livers. The extraction 
ratio (mean ± SD) of CDF in PCK rat livers appeared to decrease (0.0672 ± 0.0203) compared to 
wild-type rat livers (0.0965 ± 0.0143) but this difference was not statistically significant. The 
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total mass of CDF recovered in bile (mean ± SD) was significantly higher in wild-type (33.5 ± 
8.8 nmol) compared to PCK (0.108 ± 0.171 nmol) perfused rat livers. The mass in the perfusate 
washout phase (30-60 min) (mean ± SD) was significantly increased in PCK (25.2 ± 9.0 nmol) 
compared to wild-type (11.1 ± 6.0 nmol) rat livers. The total mass of CDF collected in the 
perfusate (mean ± SD) throughout the 60-min perfusion was similar between wild-type (1040 ± 
30 nmol) and PCK (1070 ± 40 nmol) rat livers. 
Pharmacokinetic modeling. 
Pharmacokinetic parameters estimated based on a model with either one or two 
compartments representing the hepatocellular space (Fig. 5.1) were compared. In wild-type and 
PCK perfused rat livers, the CV% of the parameter estimates tended to be smaller using a two-
compartment liver model (Table 5.2). The weighted residuals for the outflow perfusate excretion 
rate vs. time data were similar for both model structures and both cohorts (data not shown). 
Representative weighted residuals for the biliary excretion rate vs. time data using the model 
with two compartments to describe the hepatocellular space tended to be evenly distributed and 
centered around zero (Fig. 5.5D) more so than for the one-compartment model for PCK rat livers 
(Fig. 5.5B). This observation was consistent for all PCK rats (data not shown). Furthermore, AIC 
values were lower using the two-compartment model (AIC = -22.3) compared to the one-
compartment model (AIC = -12.3) in PCK rat livers. Therefore, the pharmacokinetic model with 
two compartments representing the hepatocellular space was selected as the final model structure 
(Fig. 5.1B) to describe the CDF perfusate outflow rate- and biliary excretion rate-time data. A 
representative fit of the final model scheme is shown in Fig. 5.4 and the final parameter estimates 
are summarized in Table 5.1. PCK rat liver #3 and wild-type rat liver #1 were used as 
representative data in Fig. 5.4 and Fig. 5.5. The uptake clearance of CDF (CLup) (mean ± SD) 
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appeared to decrease in PCK rat livers (2.64 ± 0.51 mL/min) compared to wild-type rat livers 
(3.23 ± 0.23 mL/min). The rate constant for biliary excretion (kbile) (mean ± SD) was 
significantly decreased in PCK (0.00146 ± 0.00223 min
-1
) compared to wild-type (0.176 ± 0.012 
min
-1
) rat livers. Conversely, the basolateral excretion rate constant of CDF (kperfusate) (mean ± 
SD) was significantly increased in PCK (0.0538 ± 0.0112 min
-1
) compared to wild-type (0.0184 
± 0.0012 min
-1
) rat livers. Intercompartmental rate constants between wild-type and PCK rat 
livers were similar for both k12 and k21.  
Simulations were performed to evaluate the effects of perturbations in CLup and kperfusate , 
reflecting Oatp-mediated uptake and Mrp3-mediated basolateral efflux, respectively, on the 
extent of CDF biliary excretion using the model structure in Fig. 5.1B.  Simulations were 
conducted assuming a constant infusion rate of CDF into the liver for 30 min (1 μM; 38 mL/min) 
using parameter estimates based on the mean values from wild-type isolated perfused rat livers 
(Table 5.1). Simulations revealed that the basolateral efflux rate constant would need to be 
increased by more than 100-fold to account for the observed decrease in CDF biliary excretion 
(Table 5.3; Supplementary Table 5.1). Although CLup was not statistically different between 
PCK and wild-type rat livers, it is possible that CLup was decreased in some PCK rat livers, 
which might explain the decreased biliary excretion of CDF in PCK isolated perfused rat livers. 
Based on simulations, a 2-fold decrease in CLup combined with a 10-fold increase in kperfusate 
would not reduce the biliary excretion of CDF in PCK rat livers to the negligible levels observed 
in the present study (Table 5.3; Supplementary Table 5.1). A 10-fold increase in kperfusate was 
chosen for this simulation because Mrp3 protein expression has been reported to be induced by 
as much as ~5-10-fold in rodents (Ogawa et al., 2000; Xiong et al., 2000). 
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Protein expression and immunohistochemical analysis (IHC). 
To address the molecular basis for decreased biliary excretion of CDF in the livers of 
PCK rats, the expression of hepatic Mrp2 and Mrp3 was quantified. Immunoblots did not detect 
a significant difference between Mrp2 expression in wild-type and PCK rat liver tissue using 
densitometric analysis (Fig. 5.6A and Fig. 5.6C). IHC indicated proper localization of Mrp2 to 
the canalicular membrane in wild-type (Fig. 5.7A) and PCK rat livers (Fig. 5.7B). Interestingly, 
immunoblots revealed that Mrp3 was significantly increased by 2.7-fold in PCK rat liver tissue 
using densitometric analysis (Fig. 5.6B and Fig. 5.6D). IHC also indicated an increase in Mrp3 
expression in PCK (Fig.5.7D) compared to wild-type (Fig. 5.7C) rat livers, although Mrp3 did 
not appear to be predominantly localized to the basolateral membrane. 
DISCUSSION 
Liver cysts are a common liver pathology observed in human ADPKD. The effect of 
hepatic impairment (e.g., liver cysts) on hepatobiliary drug disposition in ADPKD, however, has 
not been studied. To address this knowledge gap, hepatic transporter function was evaluated in 
PCK rats using the isolated perfused rat liver model. The PCK rat was chosen because it displays 
hepatorenal abnormalities that are phenotypically consistent with human ADPKD (Chauveau et 
al., 2000; Hogan et al., 2010; Lager et al., 2001; Masyuk et al., 2004; Mason et al., 2010). 
Similar to human ADPKD, the PCK rat is characterized by remodeling of the biliary tree and 
formation of multiple biliary microhamartomas that progress to form distinct cysts with 
advancing age. The effect of these hepatic pathological findings on drug disposition, to date, is 
unknown. 
CDF is a fluorescent anionic probe used to study the excretory function of Mrp2, a 
hepatic transporter localized on the canalicular membrane of hepatocytes. CDF is not 
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metabolized and is transported from hepatocytes to the bile via Mrp2, as evidenced by impaired 
CDF excretion in perfused livers from Mrp2-deficient TR
-
 rats (Jansen et al., 1987; Swift et al., 
2010; Zamek-Gliszczynski et al., 2003). In the present study, PCK rat livers displayed a 
significant decrease in the biliary excretion rate vs. time data of CDF compared to wild-type rat 
livers (Fig. 5.3B). Weight-normalized bile flow was lower in PCK rat livers (Fig. 5.2), although 
absolute bile flow was higher in PCK rat livers, consistent with reports of enhanced bile 
secretion in PCK rats (Mason et al., 2010; Masyuk et al., 2004).  
A pharmacokinetic model with either one or two compartments representing the 
hepatocellular space was evaluated to describe the hepatobiliary disposition of CDF. The 
precision of the parameter estimates tended to increase (i.e., lower CV%) using the two-
compartment model structure compared to the model structure with one compartment (Table 
5.2). CV% values < 30% are generally desirable when modeling pharmacokinetic data (Mould et 
al., 2013). Furthermore, weighted residuals using the two compartment model in PCK rats were 
randomly distributed around the mean (and centered around zero) (Fig. 5.5D), whereas the 
weighted residuals did not appear to be randomly distributed using the one-compartment model 
structure in PCK perfused rat livers (Fig. 5.5B). Hence, the model structure with two 
compartments representing the hepatocellular space was used as the final model structure (Fig. 
5.1B).  
To prevent further hepatic injury, decreased expression of hepatic bile acid uptake 
transporters in rats (e.g., Ntcp and Oatp) has been documented in cholestasis (Pauli-Magnus et 
al., 2006). Serum and hepatic bile acids were increased in PCK rats (Munoz-Garrido et al. 2015), 
consistent with a cholestatic-like state. A decrease in Oatp-mediated CDF uptake could explain, 
in part, decreased biliary excretion of CDF in PCK rats (Zamek-Gliszczynski et al., 2003). 
 208 
 
Although uptake clearance (CLup) of CDF tended to be lower in PCK rat livers, the differences 
were not statistically significant (Table 5.1). Furthermore, while Oatp1a1 is decreased during 
cholestatic-like conditions in rodents, Oatp1a4 and Oatp1b2 expression are maintained (Dumont 
et al., 1997; Geier et al., 2001); hence, it is possible that overlapping substrate specificity of CDF 
for multiple Oatps may explain why differences in the CDF CLup values in PCK rat livers failed 
to reach statistical significance. It should be noted that CLup values for CDF were higher in the 
single-pass isolated perfused rat liver study reported by Chandra et al. (2005). Differences in the 
strain of rats (i.e., Wistar vs. Sprague-Dawley), pre-treatment with vehicle (e.g., 90% propylene 
glycol/10% ethanol for up to four days by Chandra et al., (2005)) prior to liver perfusion, or 
age/liver weight-related alterations in transporter function may account for the ~2.5-fold higher 
Clup values reported by Chandra et al. (2005). Decreased hepatic transporter expression (e.g. 
Oatp1a1) has been reported in aging rodents (Fu et al., 2012).   
To understand the mechanism(s) responsible for the decreased biliary excretion rate of 
CDF in PCK rat livers, the expression of Mrp2 was quantified. Immunblot and densitometric 
analysis did not detect a difference in the expression of Mrp2 between PCK and wild-type rat 
livers (Fig. 5.6A and 5.6C). Furthermore, IHC analysis corroborated these findings and indicated 
that Mrp2 appeared to be properly localized to the canalicular membrane of hepatocytes in both 
wild-type and PCK rat livers (Fig. 5.7A and 5.7B). When biliary excretion is compromised, 
basolateral efflux can play an important role in the egress of compounds from hepatocytes 
(Pfeifer et al., 2014). The basolateral organic anion transporter Mrp3 is a compensatory 
transporter involved in the efflux of bile acids and drug conjugates; Mrp3 also transports CDF 
(Nezasa et al. 2006; Xiong et al., 2000; Zelcer et al. 2003; Zamek-Gliszczynski et al., 2003). 
Pharmacokinetic modeling revealed that the basolateral efflux rate constant (kperfusate) was 
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increased ~3-fold in isolated perfused PCK rat livers (Table 5.1). Furthermore, the mass of CDF 
recovered during the washout phase was ~2-fold greater from PCK perfused rat livers, consistent 
with increased basolateral efflux. These data are also consistent with increased basolateral efflux 
of CDF in Mrp2-knockout rodents that exhibit increased Mrp3 expression (Nezasa et al., 2006). 
Correspondingly, immunoblot analysis indicated a strong upregulation of Mrp3 in PCK rat livers 
(Fig. 5.6B and 5.6D), which is consistent with the inducible nature of Mrp3 under a cholestatic-
like state and increased basolateral efflux (kperfusate) of CDF (Donner et al., 2001; Soroka et al. 
2001). IHC staining corroborated these findings and indicated that Mrp3 expression was 
increased in PCK (Fig. 5.7D) compared to wild-type (Fig. 5.7C) rat livers. 
Increased kperfusate and/or decreased CLup may contribute to decreased CDF biliary 
excretion. Simulations were performed to test the hypothesis that impaired biliary excretion of 
CDF was due solely to increased kperfusate and/or decreased CLup. Simulations revealed that a 
~200-fold increase in kperfusate would be required to decrease the amount of CDF excreted into 
bile to values measured in isolated perfused PCK rat livers (Table 5.3; Supplementary Table 
5.1). Mrp3 protein expression has been reported to be induced by as much as ~5-10-fold in 
rodents (Ogawa et al., 2000; Xiong et al., 2000). Based on these reports, it may not be 
biologically plausible for Mrp3-mediated kperfusate to increase ~200-fold to account alone for the 
decrease in CDF biliary excretion observed in isolated perfused PCK rat livers. Although there 
was no statistically significant difference in CLup between wild-type and PCK rat livers, the 
effect of a decrease in CLup and an increase in kperfusate on CDF biliary excretion also was 
simulated. A 50% decrease in CLup and a 10-fold increase in kperfusate reduced the amount of CDF 
in the bile to 2.09 nmol (Table 5.3), suggesting that alterations in these parameters can contribute 
to the decreased biliary excretion of CDF in PCK rat livers, but changes in these parameters 
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alone cannot account for the marked decrease in CDF biliary excretion observed (Supplementary 
Table 5.1). Therefore, a decrease in kbile is necessary to explain the decreased CDF biliary 
excretion in isolated perfused PCK rat livers. 
The mechanism(s) responsible for decreased biliary excretion of CDF in PCK rat livers, 
despite the apparent preservation of Mrp2 expression and localization, is unclear. Cholangiocytes 
also express Mrp3 (Donner et al., 2001; Konig et al., 1999; Soroka et al., 2001). Because liver 
cysts in PCK rats are derived from the biliary epithelium, it is conceivable that CDF may be 
actively transported into cysts, thereby decreasing the apparent biliary excretion. However, focal 
hepatic lesions, such as liver cysts and biliary hamartomas, are hypointense and do not 
accumulate contrast agent when using magnetic resonance imaging-based contrast agents such as 
gadolinium-ethoxibenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA), an established 
Mrp2 and Mrp3 substrate (Campos et al., 2012; Kitao et al., 2010). Alternatively, increased 
cholangiocyte uptake could decrease CDF accumulation in the common bile duct. Carrier-
mediated transport of Mrp2/Mrp3 substrates (i.e. conjugated bile acids) has been demonstrated 
using fluorescent assays in biliary epithelial cell culture (Bendedetti et al., 1997). In fact, 
cholangiocyte-mediated bile acid transport is increased in bile duct ligated rodents, a model of 
chronic cholestasis (Alpini et al., 2001). Interestingly, this observation was not attributable to 
marked increases in transporter expression per cholangiocyte, but rather to increased intrahepatic 
bile duct surface area (e.g., increased number of cholangiocytes). Masyuk et al. (2004) reported 
extensive remodeling of the biliary tree in PCK rats that increased the intrahepatic biliary volume 
~20-40-fold. It should be noted that CDF was not measurable in the liver homogenate due to 
high background fluorescence. Based on the mass of CDF not recovered in either the perfusate or 
bile, the estimated CDF remaining in the liver was similar between wild-type and PCK rat livers 
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(66.6 vs. 53.0 nmol, respectively; Supplementary Table 5.1).  Although Mrp2 has been 
extensively studied in the context of biliary excretion of drugs, Mrp2 also transports endogenous 
substances such as bilirubin-glucuronide and conjugated bile acids (Akita et al., 2001; Keppler, 
2014). Increased concentrations of serum bilirubin have been reported in PCK rats, suggestive of 
impaired Mrp2 function (Mason et al., 2010; Shimomura et al. 2015). Furthermore, recent 
literature reports indicate that hepatocellular concentrations of bile acids are significantly 
increased in PCK rats, consistent with a cholestatic-like state and with our finding of increased 
Mrp3 in the present study (Munoz-Garrido et al., 2015). It is possible that elevated 
concentrations of hepatic bile acids in PCK rats directly compete for Mrp2-mediated transport of 
CDF. The current study provides mechanistic data to support this hypothesis. For example, the 
sulfate conjugates of taurochenodeoxycholate and taurolithocholate are actively transported in an 
ATP-dependent manner in Mrp2-overexpressing membrane vesicles and have been shown to 
inhibit bile acid transport (Akita et al., 2001). Furthermore, inhibition of bile acid transport was 
potentiated when vesicles were pre-incubated with sulfated bile acids, indicating that these 
conjugates may trans-inhibit bile acid transport. Taurolithocholate also inhibits canalicular 
secretion of sodium fluorescein and sulfobromophthalein, both Mrp2 substrates, in in vivo 
studies (Roma et al., 1994; Ryan et al., 2014). Studies by Gerk et al. (2007; 2004) also revealed 
that tauroursodeoxycholate, glycoursodeoxycholate, and estrogen glucuronides associated with 
cholestasis (i.e., β-estradiol 3-β-d-glucuronide and β-estradiol 17-β-d-glucuronide) inhibit 
MRP2-mediated transport. Hence, increased bile acid concentrations in PCK rats may play a role 
in the apparent decrease in Mrp2-mediated CDF excretion as reported in the present study. 
Evidence of cholestasis in ADPKD patients is rare and biliary stenosis is usually 
associated with a physical stricture by overlaying cyst(s) (Kolodziejski et al., 2004; Lerner et al., 
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1992). Interestingly, Salam et al. (1989) reported prolonged hepatic retention of 
99m
Tc–
mebrofenin, a clinical hepatobiliary diagnostic agent and MRP2 substrate in a patient with 
ADPKD, which suggests that MRP2-mediated biliary excretion is impaired, consistent with our 
findings in PCK rats (Ghibellini et al., 2008; Pfeifer et al., 2013). Delayed visualization or 
inability to visualize the gallbladder using λ-scintigraphy has been reported in patients with 
choledochal cysts of various or unknown origin (Gad et al., 1992; Huang et al., 1982). 
The impact of pathophysiological disease states, such as the presence of hepatic cysts, on 
transporter-mediated drug disposition is under recognized.  Negligible biliary excretion of the 
Mrp2 substrate CDF in PCK rat livers was an unexpected and novel finding. Impaired Mrp2 
function may impact the hepatobiliary disposition of Mrp2 substrates that have pharmacologic 
and/or toxicological effects. For example, the biliary excretion of spiramycin, an antibiotic 
associated with cholestatic hepatitis, was decreased ~10-fold in Mrp2-deficient rats, which 
suggests that elevated hepatic concentrations of spiramycin may increase the susceptibility to 
liver injury when Mrp2 function is impaired (Denie et al., 1992; Tian et al., 2007). Further 
investigations are warranted to evaluate the impact of altered MRP2/Mrp2 function on drug 
efficacy and/or safety in polycystic kidney diseases with hepatic involvement. 
 213 
 
REFERENCES 
Akaike H. An information criterion. Math Sci. 1976 14:5–9. 
 
Akita H, Suzuki H, Ito K, Kinoshita S, Sato N, Takikawa H, Sugiyama Y. Characterization of 
bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export 
pump. Biochim Biophys Acta. 2001 Mar 9;1511(1):7-16. 
 
G Alpini SG, Phinizy JL, Kanno N. et al. Regulation of cholangiocyte apical bile acid transporter 
(ABAT) activity by biliary bile acids: Different potential compensatory changes for intrahepatic 
and extrahepatic cholestasis. Gastroenterology. 2001;120:A6. 
 
Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, 
King BF Jr, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang 
X, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney 
Disease (CRISP). Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-
dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of 
Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006 Jan;1(1):64-9. Epub 2005 Oct 
26. 
 
Beckh K, Kneip S, Arnold R. Direct regulation of bile secretion by prostaglandins in perfused rat 
liver. Hepatology. 1994 May;19(5):1208-13. 
 
Beckh K, Arnold R. Regulation of bile secretion by sympathetic nerves in perfused rat liver. Am 
J Physiol. 1991 Nov;261(5 Pt 1):G775-80. 
 
Benedetti A, Di Sario A, Marucci L. et al. Carrier-mediated transport of conjugated bile acids 
across the basolateral membrane of biliary epithelial cells. Am J Physiol. 1997 Jun;272(6 Pt 
1):G1416-24. 
 
Bessems M, 't Hart NA, Tolba R, Doorschodt BM, Leuvenink HG, Ploeg RJ, Minor T, van Gulik 
TM. The isolated perfused rat liver: standardization of a time-honoured model. Lab Anim. 2006 
Jul;40(3):236-46. 
 
Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, Moustafa T, Zollner G, Lee JY, Ballatori 
N. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta 
in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol. 2006 
Jun;290(6):G1124-30. 
 
Brouwer KLR and Thurman RG.Isolated perfused liver.Pharm Biotechnol. 1996; 8:161–192 
 
Campos JT, SirlinCB, Choi JY Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the 
atlas. Insights Imaging. 2012 Oct; 3(5): 451–474.  
 
Chandra P, Johnson BM, Zhang P, Pollack GM, and Brouwer KLR. Modulation of hepatic 
canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic 
 214 
 
anion in the isolated perfused rat liver. Drug Metab Dispos. 2005 33:1238–1243 
 
Chauveau D, Pirson Y, Le Moine A, Franco D, Belghiti J, Grünfeld JP. Extrarenal 
manifestations in autosomal dominant polycystic kidney disease. Adv Nephrol Necker Hosp. 
1997;26:265-89. 
 
Chauveau D, Fakhouri F, Grünfeld JP. Liver involvement in autosomal-dominant polycystic 
kidney disease: therapeutic dilemma. J Am Soc Nephrol. 2000 Sep;11(9):1767-75. 
 
Dahn MS, Lange MP, Benn S. The influence of hepatic venous oxygen saturation on the liver’s 
synthetic response to metabolic stress. Proc Soc Exp Biol Med. 1999 May;221(1):39-45. 
 
Danaci M, Akpolat T, Baştemir M, Sarikaya S, Akan H, Selçuk MB, Cengiz K. The prevalence 
of seminal vesicle cysts in autosomal dominant polycystic kidney disease. Nephrol Dial 
Transplant. 1998 Nov;13(11):2825-8. 
 
Denie C, Henrion J, Schapira M, Schmitz A, Heller FR. Spiramycin-induced cholestatic 
hepatitis. J Hepatol. 1992 Nov;16(3):386. 
 
Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in 
cholestatic rat liver. Hepatology. 2001 Aug;34(2):351-9. 
 
Dumont M, Jacquemin E, D'Hont C, Descout C, Cresteil D, Haouzi D, Desrochers M, Stieger B, 
Hadchouel M, Erlinger S. Expression of the liver Na+-independent organic anion transporting 
polypeptide (oatp-1) in rats with bile duct ligation. J Hepatol. 1997 Dec;27(6):1051-6. 
 
Everson GT, Scherzinger A, Berger-Leff N, Reichen J, Lezotte D, Manco-Johnson M, Gabow P. 
Polycystic liver disease: quantitation of parenchymal and cyst volumes from computed 
tomography images and clinical correlates of hepatic cysts. Hepatology. 1988 Nov-
Dec;8(6):1627-34. 
 
Fu ZD, Csanaky IL, Klaassen CD. Effects of aging on mRNA profiles for drug-metabolizing 
enzymes and transporters in livers of male and female mice. Drug Metab Dispos. 2012 
Jun;40(6):1216-25. 
 
Gad MA, Krishnamurthy GT, Glowniak JV. Identification and differentiation of congenital 
gallbladder abnormality by quantitative technetium-99m IDA cholescintigraphy. J Nucl Med. 
1992 Mar;33(3):431-4. 
 
Geier A, Matern S., Gartung C. Regulation of sinusoidal transporters in cholestasis and liver 
regeneration. Hepatobiliary Transport: From Bench to Bedside, Kluwer Academic Publishers, 
Dordrecht. 2001, pp. 32–36. 
 
Gerk PM, Li W, Megaraj V, Vore M. Human multidrug resistance protein 2 transports the 
therapeutic bile salt tauroursodeoxycholate. J Pharmacol Exp Ther. 2007 Feb;320(2):893-9. 
 
 215 
 
Gerk PM, Li W, Vore M. Estradiol 3-glucuronide is transported by the multidrug resistance-
associated protein 2 but does not activate the allosteric site bound by estradiol 17-glucuronide. 
Drug Metab Dispos. 2004 Oct;32(10):1139-45. 
 
Ghibellini G, Leslie EM, Pollack GM, Brouwer KL. Use of tc-99m mebrofenin as a clinical 
probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, 
and simulation studies. Pharm Res. 2008 Aug;25(8):1851-60. 
 
Haussinger D, Gerok W, Sies H. The effect of urea synthesis on extracellular pH in isolated 
perfused rat liver. Biochem J. 1986 May 15; 236(1): 261–265. 
 
Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009;60:321-37. 
 
Heredi-Szabo K, Kis E, Molnar E, Gyorfi A, Krajcsi P. Characterization of 5(6)-carboxy-2,'7'-
dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate 
for LTC4. J Biomol Screen. 2008 Apr;13(4):295-301. 
 
Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman 
TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, 
Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW. Liver involvement in early 
autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015 Jan;13(1):155-
64.e6.  
 
Huang   MJ,   Liaw  TF. Intravenous cholescintigraphy using Tc-99m-Labeled agents in the 
diagnosis of choledochalcyst. J Nucl Med. 1982 Feb;23(2):113-6. 
 
Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol. 
2002 Sep;13(9):2384-98. 
 
Jansen PL, Groothuis GM, Peters WH, and Meijer DF. Selective hepatobiliary 
transport  defect  for  organic  anions  and  neutral  steroids  in  mutant  rats  with hereditary-
conjugated hyperbilirubinemia. Hepatology. 1987 Jan-Feb;7(1):71-6. 
 
Keppler D. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated 
hyperbilirubinemia. Drug Metab Dispos. 2014 Apr;42(4):561-5. 
 
Khezrian M, Sheikholeslami B, Dadashzadeh S, Lavasani H, Rouini M.Effects of cyclosporine A 
on the hepatobiliary disposition and hepatic uptake of etoposide in an isolated perfused rat liver 
model. Cancer Chemother Pharmacol. 2015 May;75(5):961-8.  
 
Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, Kozaka K, Yoneda N, Yamashita 
T, Kaneko S, Nakanuma Y.. Hepatocellular carcinoma: signal intensity at gadoxetic acid-
enhanced MR Imaging--correlation with molecular transporters and histopathologic features. 
Radiology. 2010 Sep;256(3):817-26. 
 
 216 
 
Kolodziejski TR, Safadi BY, Nakanuma Y, Milkes DE, Soetikno RM. Bile duct cysts in a patient 
with autosomal dominant polycystic kidney disease. Gastrointest Endosc. 2004 Jan;59(1):140-2. 
 
Konig J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein 
isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology. 1999 
Apr;29(4):1156-63. 
 
Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE. The pck rat: a new model that resembles 
human autosomal dominant polycystic kidney and liver disease. Kidney Int. 2001 Jan;59(1):126-
36. 
 
Lerner ME, Roshkow JE, Smithline A, Ng C. Polycystic liver disease with obstructive jaundice: 
treatment with ultrasound-guided cyst aspiration. Gastrointest Radiol. 1992 Winter;17(1):46-8. 
 
Levine E, Cook LT, Grantham JJ. Liver cysts in autosomal-dominant polycystic kidney disease: 
clinical and computed tomographic study. AJR Am J Roentgenol. 1985 Aug;145(2):229-33. 
 
Lindell SL, Southard JH, Vreugdenhil P, Belzer FO. Kupffer cells depress hepatocyte protein 
synthesis on cold storage of the rat liver. Transplantation. 1994 Oct 27;58(8):869-74. 
 
Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology. 
2006 Oct;44(4):778-87. 
 
Mason SB, Liang Y, Sinders RM, Miller CA, Eggleston-Gulyas T, Crisler-Roberts R, Harris PC, 
Gattone VH 2nd. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK 
rat model of ARPKD. Anat Rec (Hoboken). 2010 Aug;293(8):1279-88. 
 
McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. 
Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor 
antibodies. Arch Pathol Lab Med. 1985 Aug;109(8):716-21. 
 
Masyuk TV, Huang BQ, Masyuk AI, Ritman EL, Torres VE, Wang X, Harris PC, Larusso NF. 
Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic 
kidney disease.Am J Pathol. 2004 Nov;165(5):1719-30.  
 
Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based 
drug development-part 2: introduction to pharmacokinetic modeling methods. CPT 
Pharmacometrics Syst Pharmacol. 2013 Apr 17;2:e38. 
 
Munoz-Garrido P, Marin JJ, Perugorria MJ, Urribarri AD, Erice O, Sáez E, Úriz M, Sarvide S, 
Portu A, Concepcion AR, Romero MR, Monte MJ, Santos-Laso Á, Hijona E, Jimenez-Agüero R, 
Marzioni M, Beuers U, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Drenth JP, Banales JM. 
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver 
disease. J Hepatol. 2015 Oct;63(4):952-61. 
 
 217 
 
Myint K, Li Y, Paxton J, McKeage M. Multidrug Resistance-Associated Protein 2 (MRP2) 
Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 
1;10(7):e0130727. 
 
Nezasa K, Tian X, Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, Brouwer KL. Altered 
hepatobiliary disposition of 5 (and 6)-carboxy-2',7'-dichlorofluorescein in Abcg2 (Bcrp1) and 
Abcc2 (Mrp2) knockout mice. Drug Metab Dispos. 2006 Apr;34(4):718-23. 
 
Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M, 
Sugiyama Y. Characterization of inducible nature of MRP3 in rat liver. Am J Physiol 
Gastrointest Liver Physiol. 2000 Mar;278(3):G438-46. 
 
Roma MG, Penalva GL, Agüero RM, Rodríguez Garay EA. Hepatic transport of organic anions 
in taurolithocholate-induced cholestasis in rats. J Hepatol. 1994 May;20(5):603-10. 
 
Ryan JC, Dunn KW, Decker BS. Effects of chronic kidney disease on liver transport: 
quantitative intravital microscopy of fluorescein transport in the rat liver. Am J Physiol Regul 
Integr Comp Physiol. 2014 Dec 15;307(12):R1488-92. 
 
Pfeifer ND, Hardwick RN, Brouwer KL. Role of hepatic efflux transporters in regulating 
systemic and hepatocyte exposure to xenobiotics. Annu Rev Pharmacol Toxicol. 2014;54:509-
35. 
 
Pfeifer ND, Bridges AS, Ferslew BC, Hardwick RN, Brouwer KL. Hepatic basolateral efflux 
contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by 
basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. J Pharmacol 
Exp Ther. 2013 Dec;347(3):737-45. 
 
Pfeifer ND, Goss SL, Swift B, Ghibellini G, Ivanovic M, Heizer WD, Gangarosa LM, and 
Brouwer  LR. Effect of Ritonavir on 99mTechnetium–Mebrofenin Disposition in Humans: A 
Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs. CPT 
Pharmacometrics Syst Pharmacol. 2013 Jan 2;2:e20. 
 
Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston J 3rd, Shub C, Davila S, Somlo S, Torres 
VE. Clinical profile of autosomal dominant polycystic liver disease. Hepatology. 2003 
Jan;37(1):164-71. 
 
Ruh H, Salonikios T, Fuchser J, Schwartz M, Sticht C, Hochheim C, Wirnitzer B, Gretz N, Hopf 
C. MALDI imaging MS reveals candidate lipid markers of polycystic kidney disease. J Lipid 
Res. 2013 Oct;54(10):2785-94. 
 
Salam M, Keeffe EB. Liver cysts associated with polycystic kidney disease: role of Tc-99m 
hepatobiliary imaging. Clin Nucl Med. 1989 Nov;14(11):803-7. 
 
 218 
 
Shimomura Y, Brock WJ, Ito Y, Morishita K. Age-Related Alterations in Blood Biochemical 
Characterization of Hepatorenal Function in the PCK Rat: A Model of Polycystic Kidney 
Disease. Int J Toxicol. 2015 Nov-Dec;34(6):479-90. 
 
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, 
Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal 
Biochem. 1985 Oct;150(1):76-85. 
 
Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug 
resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis 
in rat liver. Hepatology. 2001 Apr;33(4):783-91. 
 
Swift B, Pfeifer ND, Brouwer KL. Sandwich-cultured hepatocytes: an in vitro model to evaluate 
hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev. 2010 
Aug;42(3):446-71. 
 
Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, 
Brouwer KL. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in 
mice. Antimicrob Agents Chemother. 2007 Sep;51(9):3230-4. 
 
Torra R, Nicolau C, Badenas C, Navarro S, Pérez L, Estivill X, Darnell A. Ultrasonographic 
study of pancreatic cysts in autosomal dominant polycystic kidney disease. Clin Nephrol. 1997 
Jan;47(1):19-22. 
 
Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur 
J Clin Pharmacol. 2008 Dec;64(12):1147-61. 
 
Xiong H, Turner KC, Ward ES, Jansen PL, and Brouwer KLR. Altered hepatobiliary 
disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resis- 
tance-associated protein 2-deficient TR rats. J Pharmacol Exp Ther. 2000 Nov;295(2):512-8. 
 
Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL. 
Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in 
the liver. J Pharmacol Exp Ther. 2003 Feb;304(2):801-9.  
 
Zelcer N, Saeki T, Bot I, Kuil A, Borst P. Transport of bile acids in multidrug-resistance-protein 
3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. 
Biochem J. 2003 Jan 1;369(Pt 1):23-30. 
 
  
 219 
 
Figure Legends 
Figure 5.1. Model schemes of CDF disposition in the isolated perfused rat liver. 
Compartmental model scheme of CDF disposition in rat isolated perfused livers. Q, flow; Xsin, 
amount of CDF in sinusoidal space; Cin, concentration of CDF in inflow perfusate; Cout, 
concentration of CDF in outflow perfusate; CLup, uptake clearance of CDF from the sinusoidal 
space into the liver compartment; first-order rate constant for basolateral excretion, kperfusate; XL1 
and XL2, amount of CDF in liver compartments 1 and 2, respectively; k12, first-order rate constant 
for movement from XL1 to XL2; k21, first-order rate constant for movement from XL2 to XL1; kbile, 
first-order rate constant for biliary excretion; Xbile, amount of CDF in bile. The model scheme 
with two compartments representing the hepatocellular space (B) was selected as the final model. 
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Figure 5.2. Bile flow in isolated perfused livers from wild-type and PCK rats. Bile flow rate 
in wild-type (closed circles, solid black line) and PCK (open circles, long dashed line) rat livers 
(n=5 per cohort, mean ± SD). Livers were perfused with 1 µM CDF-containing perfusate for 30 
min and then switched to CDF-free perfusate for an additional 30 min as described in Materials 
and Methods. 
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Figure 5.3. CDF outflow perfusate rate and biliary excretion rate vs. time data. CDF 
outflow perfusate rate (A) and CDF biliary excretion rate (B) in wild-type (closed circles) and 
PCK (open circles) rat livers (n=5 per cohort, mean ± SD). Livers were perfused with 1 µM 
CDF-containing perfusate for 30 min and then switched to CDF-free perfusate for an additional 
30 min as described in Materials and Methods. 
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Figure 5.4. Model fit of the outflow perfusate rate and biliary excretion rate vs. time data. 
Representative fit of the 2-compartment liver model (scheme depicted in Fig. 5.1B) to outflow 
perfusate rate (circles) or biliary excretion rate (triangles) vs. time data in a wild-type (A) and 
PCK (B) rat liver.  
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Figure 5.5. Weighted residuals of the model fit to the biliary excretion rate vs. time data 
depicted in Fig. 5.4 comparing one- and two-compartment model structures representing 
the hepatocellular space. Weighted residuals of the biliary excretion rate vs. time data using a 
model structure with one compartment representing the hepatocellular space (A and B) and two 
compartments representing the hepatocellular space (C and D) in wild-type (A and C) and PCK 
(B and D) isolated perfused rat livers. 
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Figure 5.6. Western blots of Mrp2 and Mrp3. Western blot of Mrp2 in wild-type and PCK 
(A), and Mrp3 in wild-type and PCK (B) rat liver tissue, and relative optical density (OD) of 
Mrp2 (C) and Mrp3 (D) using densitometric analysis as described in Materials and Methods.; 
**p < 0.05, wild-type vs. PCK (n=3 per cohort, mean ± SD). 
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Figure 5.7. Immunohistochemical staining of Mrp2 and Mrp3. Representative expression of 
Mrp2 in wild-type (A) and PCK (B), and Mrp3 in wild-type (C) and PCK (D) rat liver tissue 
using immunohistochemical staining as described in Materials and Methods 
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Tables 
Table 5.1. Physiological parameters and compartmental modeling parameter estimates. 
Physiological and pharmacokinetic parameters describing CDF disposition in single-pass 
isolated perfused livers from wild-type and PCK rats. Pharmacokinetic parameters were 
estimated using nonlinear regression analysis with the two-compartment hepatocellular model 
shown in Fig. 5.1B. 
Parameter  Wild-Type  PCK 
Body weight (g)  539 ± 15  536 ± 34 
Liver weight (g/kg)  33.6 ± 5.7        75.2 ± 27.6** 
Clup (mL/min)    3.23 ± 0.23    2.64 ± 0.51 
kperfusate (min
-1
)    0.0184 ± 0.0012      0.0538 ± 0.0112* 
k12 (min
-1
)  0.0509 ± .0062    0.0628 ± 0.0077 
k21 (min
-1
)   0.0555 ± 0.0192    0.0350 ± 0.0104 
kbile (min
-1
)   0.176 ± 0.012        0.00146 ± 0.00223** 
Data represent mean ± SD (n=5); *p < 0.05; **p < 0.01, wild-type vs. PCK 
  
 
2
2
7 
Table 5.2. Pharmacokinetic parameter estimates determined based on one- or two-compartment models representing the 
hepatocellular space in PCK rat livers. 
 
 
PCK (animal number) 
1  2  3  4  5 
Estimate 
(CV%) 
 
Estimate 
(CV%) 
 
Estimate 
(CV%) 
 
Estimate 
(CV%) 
 
Estimate 
(CV%) 
1 liver 
compartment 
 
Clup 
(mL/min) 
 
3.22 
(8.21) 
 
2.67 
(9.53) 
 
2.80 
(12.2) 
 
2.64 
(13.6) 
 
2.48 
(13.7) 
 
kperfusate 
(min
-1
) 
 
0.0854 
(29.5) 
 
0.0784 
(22.3) 
 
0.0809 
(18.1) 
 
0.0890 
(38.6) 
 
0.103 
(28.0) 
 
k12 
(min
-1
) 
 n/a  n/a  n/a  n/a  n/a 
 
k21 
(min
-1
) 
 n/a  n/a  n/a  n/a  n/a 
 
kbile 
(min
-1
) 
 
0.000744 
(49.1) 
 
0.000632 
(59.1) 
 
0.00079 
(45.2) 
 
0.00865 
(62.5) 
 
0.000967 
(42.0) 
2 liver 
compartments 
 
Clup 
(mL/min) 
 
3.42 
(5.39) 
 
2.34 
(6.65) 
 
2.56 
(8.52) 
 
2.78 
(9.53) 
 
2.10 
(9.60) 
 
kperfusate 
(min
-1
) 
 
0.0524 
(19.4) 
 
0.0421 
(15.6) 
 
0.0498 
(12.7) 
 
0.0523 
(27.0) 
 
0.0723 
(19.6) 
 
k12 
(min
-1
) 
 
0.0562 
(31.4) 
 
0.0668 
(40.0) 
 
0.0739 
(22.9) 
 
0.0558 
(31.5) 
 
0.0613 
(30.2) 
 
k21 
(min
-1
) 
 
0.0329 
(24.8) 
 
0.0509 
(31.5) 
 
0.0220 
(18.0) 
 
0.0262 
(24.8) 
 
0.0330 
(23.8) 
 
kbile 
(min
-1
) 
 
0.000488 
(25.5) 
 
0.000327 
(32.5) 
 
0.000487 
(18.6) 
 
0.00545 
(25.6) 
 
0.000539 
(24.6) 
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Wild-type (animal number) 
1  2  3  4  5 
Estimate 
(CV%) 
 
Estimate 
(CV%) 
 
Estimate 
(CV%) 
 
Estimate 
(CV%) 
 
Estimate 
(CV%) 
1 liver 
compartment 
 
Clup 
(mL/min) 
 
2.95 
(5.53) 
 
3.28 
(6.51) 
 
3.10 
(5.08) 
 
3.12 
(9.40) 
 
2.66 
(6.53) 
 
kperfusate 
(min
-1
) 
 
0.0137 
(14.7) 
 
0.0152 
(17.9) 
 
0.0141 
(26.6) 
 
0.0133 
(22.3) 
 
0.0122 
(17.9) 
 
k12 
(min
-1
) 
 n/a  n/a  n/a  n/a  n/a 
 
k21 
(min
-1
) 
 n/a  n/a  n/a  n/a  n/a 
 
kbile 
(min
-1
) 
 
0.160 
(29.7) 
 
0.161 
(31.5) 
 
0.180 
(33.5) 
 
0.177 
(29.0) 
 
0.179 
(31.5) 
2 liver 
compartments 
 
Clup 
(mL/min) 
 
3.09 
(3.36) 
 
3.59 
(4.55) 
 
3.19 
(3.55) 
 
3.30 
(6.56) 
 
2.98 
(12.5) 
 
kperfusate 
(min
-1
) 
 
0.0189 
(19.0) 
 
0.0187 
(12.5) 
 
0.0198 
(18.6) 
 
0.0168 
(15.5) 
 
0.0176 
(12.5) 
 
k12 
(min
-1
) 
 
0.0455 
(15.0) 
 
0.0542 
(15.9) 
 
0.0600 
(22.0) 
 
0.0452 
(19.6) 
 
0.0497 
(21.6) 
 
k21 
(min
-1
) 
 
0.0756 
(15.4) 
 
0.0342 
(12.6) 
 
0.0541 
(17.4) 
 
0.0741 
(15.5) 
 
0.0392 
(17.0) 
 
kbile 
(min
-1
) 
 
0.161 
(15.4) 
 
0.167 
(12.9) 
 
0.183 
(11.9) 
 
0.187 
(10.9) 
 
0.182 
(11.6) 
n/a: not applicable (i.e., parameter not in the model structure); PCK rat liver #3 was selected as the representative data for Fig. 5.4 and 
Fig. 5.5. 
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Table 5.3. Effect of Modulating kperfusate or CLup on CDF excretion into the bile. 
Parameter   Fold-change in parameter  
CDF in bile after a 30-min 
infusion (nmol) 
kperfusate 
 3  11.9 
 5  9.50 
 10  4.18 
 100  0.161 
 200  0.0532 
CLup and kperfusate 
 
 
CLup: 0.5 
kperfusate: 3 
 5.94 
 
CLup: 0.5 
kperfusate: 10 
 2.09 
Simulations using the final model structure (Fig. 5.1B) were conducted assuming a constant 
infusion rate of CDF into the liver (1 μM at 38 mL/min for 30 min) by modulating parameter 
estimates based on the mean values from wild-type rats (Table 5.1) using Phoenix WinNonlin (v. 
4.3 Pharsight, Mountain View, CA). The mass in bile was calculated by multiplying the rate of 
CDF in bile (nmol/min) by the time interval. 
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Supplementary Data 
Table 5.1. Model Independent Parameter Estimates  
Parameter  Wild-Type  PCK 
Dose (nmol)  1140 ± 30  1130 ± 30 
Total mass in outflow 
perfusate through 60 
min (nmol) 
 1040 ± 30  1070 ± 40 
Mass in perfusate 
during 30 min washout  
(nmol) 
  11.1 ± 6.0    25.2 ± 9.0* 
Mass in bile through 30 
min (nmol) 
   13.3 ± 0.9    0.0576 ± 0.104** 
Mass in bile through 60 
min (nmol) 
   33.5 ± 8.8     0.108 ± 0.171** 
Mass not collected in 
perfusate or bile 
through 60 min (nmol) 
    66.6 ± 27.5     53.0 ± 41.1 
CLH (mL/min)     3.67 ± 0.54     2.55 ± 0.77 
AUC0last  
(nM*min) 
  27400 ± 1000   28300 ±1300 
Data represent mean ± SD (n=5); total mass in the outflow perfusate was calculated throughout 
the 60-min perfusion, including the mass during the 30-min washout; CLH was calculated as the 
product of the flow rate (38 mL/min) and extraction ratio. Mass not collected in the perfusate or 
bile through 60 min was calculated as the difference between the administered dose and the mass 
collected in the perfusate and bile through 60 min; *p < 0.05; **p < 0.01, wild-type vs. PCK 
  
 231 
 
 
 
 
CHAPTER 6. Summary and Future Directions 
This dissertation has focused on the application of preclinical and clinical tools to study 
hepatic transporter function in liver disease. The impact of liver disease-associated alterations in 
hepatic transporter function on the pharmacokinetics and hepatobiliary disposition of drugs and 
endogenous substances is poorly understood. To address this knowledge gap, a 
multiexperimental, translational approach was employed including in vitro studies in human 
transporter expression systems, rat in vivo and isolated perfused liver studies, metabolomic 
profiling, imaging, and a clinical study. The liver plays a central role in the metabolism, 
hepatobiliary transport, and pharmacokinetics of drugs and endogenous substances. 
Consequently, the disposition of such substances may be altered in patients with liver 
dysfunction, which may contribute to the pathophysiology of hepatic and extrahepatic disease, 
require dose adjustments, or impact the safety of medications (Morgan et al., 1995; Palatini et ak, 
2016; Rodighiero et al. 1999). Two types of liver disease were studied: non-alcoholic 
steatohepatitis (NASH) and autosomal dominant polycystic kidney disease (ADPKD).
 
NASH is an advanced form of non-alcoholic fatty liver disease (NAFLD) driven by the 
prevailing obesity epidemic; it is estimated that ~25% and ~2-3% of the general population have 
NAFLD and NASH, respectively (Younossi et al., 2016; Bellentani et al., 2010).
 
Due to NASH-
associated oxidative and inflammatory stress, increasing evidence suggests that absorption, 
distribution, metabolism, and excretion (ADME) genes are dysregulated in this patient 
population (Canet et al., 2014a). For example, uptake transporters (e.g. sodium-dependent 
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taurocholate cotransporting polypeptide (NTCP) and organic anion transporting polypeptide 
(OATPs)) are generally downregulated whereas efflux transporters [e.g. multidrug resistance-
associated protein (MRP)2, MRP3] are generally upregulated in what appears to be a 
hepatoprotective response to liver injury/inflammation in NASH (Canet et al., 2014a Canet et al., 
2014b; Clarke et al., 2014; Hardwick et al., 2011). However, functional studies in humans to 
evaluate altered transporter expression are limited. In Chapter 2, technetium-99m mebrofenin 
(MEB) was used as a clinical probe to assess the function of OATP, MRP2, and MRP3 in 
patients with biopsy-confirmed NASH. MEB is a metabolically stable imaging agent used to 
diagnose dysfunctions associated with the gallbladder and hepatobiliary network, although 
broader applications include the evaluation of hepatocyte viability as well as hepatic transporter 
function (Gencoglu et al., 2002; Ghibellini et al., 2008; Koruk et al., 2003; Pfeifer et al., 2013). 
Given that MEB is predominantly taken up by OATPs and excreted from the hepatocyte by 
MRP2 and MRP3, NASH-associated changes in OATP, MRP2, and MRP3 would be expected to 
alter the systemic and hepatic concentrations of MEB (de Graaf et al., 2011; Neyt et al., 2013).  
Tolvaptan is a competitive vasopressin V2-receptor antagonist that has shown promise in 
treating ADPKD, a monogenetic inheritable disease for which no treatment is currently approved 
by the Food and Drug Administration (FDA) (Torres et al., 2012). During clinical development, 
however, elevated levels of transaminases (i.e. alanine aminotransferase) were disproportionately 
reported in patients taking tolvaptan compared to placebo-controlled patients (Torres et al., 2012; 
Watkins et al., 2015). Furthermore, two patients met the definition of Hy’s Law while an 
additional Hy’s Law case was reported in the TEMPO 4:4 trial while on tolvaptan therapy. 
Hence, the FDA has not granted approval for this indication in the U.S. due, in part, to reports of 
hepatotoxicity in tolvaptan-treated ADPKD patients (Watkins et al., 2015).
 
The mechanistic 
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etiology of these clinical observations are currently unknown. The studies outlined in Chapter 3, 
4, and 5 were designed to evaluate the biological plausibility of bile acid-mediated liver injury as 
a contributing mechanism to tolvaptan-associated hepatotoxicity. Knowledge of the effect of 
tolvaptan and/or metabolites on transporter-mediated bile acid uptake/efflux (Chapter 3) as well 
as disease-contributing alterations in bile acid homeostasis (Chapter 4 and Chapter 5) may 
help implicate bile acid-mediated hepatotoxicity as a mechanism of liver injury. Furthermore, 
these data may identify biomarkers (e.g. bile acids), which may help identify patients susceptible 
to hepatotoxicity.  
This dissertation research has provided valuable contributions to the knowledge of 
hepatic transporter function in NASH and ADPKD, which may enhance our ability to predict 
hepatobiliary bile acid and drug disposition in these patient populations in order to optimize 
pharmacotherapy and minimize toxicity. The following is a summary of the contributions of this 
dissertation research as well as a perspective on opportunities for further investigations.  
Altered Hepatic Disposition of the Transporter Probe 
99m
Technetium–Mebrofenin in 
Patients with Non-Alcoholic Steatohepatitis (NASH) (Chapter 2) 
Hepatobiliary transporters are important determinants of drug disposition and response. 
Many factors contribute to the variability of hepatic transporter expression and function 
including concurrent disease(s), physiological or life-style factors, concomitant medications, or 
genetics (Ho et al., 2005; König et al., 2013). Therefore, significant effort has been directed 
towards quantifying hepatic transporter expression and function, which may aid in predicting 
drug disposition and efficacy. Although animal studies or in vitro studies are valuable research 
tools used to understand hepatobiliary transporter function, clinical probe substrates are highly 
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sought after tools to assess transporter function in humans. This work evaluated the impact of 
altered basolateral uptake and efflux as well as canalicular efflux on the systemic and hepatic 
disposition of the clinical imaging agent MEB. MEB is an OATP, MRP2, and MRP3 substrate 
that has been used as a tool to evaluate impaired hepatobiliary uptake and efflux. (de Graaf et al., 
2011; Geisel et al., 2015; Ghibellini et al., 2008; Pfeifer et al., 2013; Swift et al., 2010). MRP2 is 
the rate-limiting step in biliary excretion of MEB as evidenced by a prolonged half-life and 
increased hepatic exposure in Mrp2-knockout (KO) mice and in patients with Dubin-Johnson 
syndrome (Bar-Meir et al., 1982; Neyt et al., 2013).
 
The objective of using MEB as a probe for 
OATP, MRP2, and MRP3 function was to assess whether reports of dysregulation of OATP, 
MRP2, and MRP3 expression/localization in patients with NASH would lead to altered systemic 
and/or hepatic pharmacokinetics of MEB. By leveraging protein expression data from human 
liver biopsies and modeling and simulation techniques, a comparative cohort study was designed 
to compare the systemic and hepatic disposition of MEB in healthy volunteers and patients with 
NASH (Canet et al., 2014b; Fisher et al., 2009; Geisel et al., 2015; Hardwick et al., 2011). 
A previously published semiphysiologically-based pharmacokinetic (PBPK) model 
describing the disposition of MEB was used to estimate basolateral uptake/efflux and canalicular 
efflux of MEB in healthy human volunteers (Pfeifer et al., 2013). The difference in hepatic 
exposure (AUC0-∞,liver) was selected as the primary endpoint and sample size was estimated. 
Computer-based modeling and simulation, as utilized here, can provide tremendous value to 
predict the effect of altered ADME processes on drug pharmacokinetics. Such mechanistic 
models can explore the impact of biological parameters, drug-drug interactions, and population 
variability, among others, that may improve rationally guided decision making in drug discovery 
and development. This may be of particular use in the design of Phase I and early Phase II trials 
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where in vitro or functional data may be implemented to guide sample size considerations and/or 
dose selection. 
Although systemic concentrations are routinely measured to estimate drug exposure, it 
has become increasingly evident that drug exposure in a particular compartment or tissue may be 
altered without significantly affecting systemic concentrations (Mennone et al., 2006; Swift et 
al., 2009). To address this limitation, quantitative imaging techniques can provide noninvasive 
estimation of drug concentrations and/or pharmacokinetic parameters in organ(s) of interest. 
Altered function of OATP, MRP2, and/or MRP3 in patients with NASH has significant 
implications for drug therapy and safety. Several medications (e.g. sulfonylureas, statins, 
thiazolidinediones) have been evaluated to prevent fibrosis and reverse inflammation in this 
patient population, but studies thus far have indicated no or marginal efficacy (Nakahara et al., 
2012; Sanyal et al., 2010; Torres et al., 2011). Because the liver is the primary site of action of 
medications to treat NASH, it is imperative to understand how NASH alters hepatic drug 
disposition. The notion that MRP2 function in NASH is impaired may have unintended 
consequences for drug disposition thereby placing a larger burden on the liver. For example, 
Mrp2-mediated biliary excretion of spiramycin, an antibiotic been associated with cholestatic 
hepatitis, was impaired in Mrp2-knockout mice (Denie et al., 1992; Tian et al., 2007). These data 
suggest that hepatic exposure to spiramycin may increase in patients with impaired MRP2 
function (e.g. patients with NASH) and that such individuals may be more susceptible to 
spiramycin-induced liver injury.
 
To date, a link between NASH and susceptibility to liver injury 
has not been established. Additionally, the MRP2 inhibitor cyclosporine A unexpectedly 
decreased mycophenolic acid systemic exposure, presumably by interrupting the enterohepatic 
recirculation of mycophenolate and its glucuronide conjugate (Pou, et al., 2001). Hence, it is 
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conceivable that impaired MRP2 function could decrease systemic exposure to drugs (e.g. 
mycophenolate) and alter pharmacodynamic response, which may have clinical significance 
since NASH is projected to become a leading indication for liver transplant in addition to the 
reoccurrence of NASH post-transplant (Patil et al., 20120). Because the efficacy of 
pharmacotherapeutic interventions to treat NASH (e.g. metformin) have been disappointing, it is 
tempting to attribute these failures to altered pharmacokinetics as described by the current study. 
However, metformin is an organic cation transporter (OCT) substrate and it is unknown if the 
expression of OCTs in NASH is altered (Han et al., 2015; Kimuara et al., 2005). 
Pharmacokinetic-pharmacodynamic modeling may be required to extrapolate the findings from 
the current study to clinical efficacy in NASH. 
Gamma scintigraphy is a well-established noninvasive functional imaging technique used 
in nuclear medicine to quantify the distribution of a radiotracer over time. Several probes for 
drug transporters have been developed for the pharmacokinetic analysis of transporter function in 
tissues such as the liver and the blood-brain-barrier (Mairinger et al., 2011). Advantages of γ-
imaging include low costs, commercial availability of clinical probes, and the potential for 
imaging with two different radioisotopes simultaneously (e.g. technetium-99m, iodine-123), 
among others. However, some limitations do exist. For example, γ-scintigraphy has lower 
sensitivity and spatial resolution compared to positron emission tomography (PET), which can 
lead to images of poor quality. Although corrections for body mass attenuation can be applied, 
such as in the current study, attenuation effects in patients with severe obesity (e.g. body mass 
index (BMI) > 45 kg/m
2
) may introduce uncertainty in the estimation of attenuation-corrected 
drug concentrations and therefore, may limit the utility of two-dimensional (2D) planar imaging 
(Lee et al., 2001; Pitcairn et al., 1997).
 
To address this limitation, single photon emission 
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computed tomography (SPECT) imaging can be employed, which allows 360° rotation of γ-
cameras thereby facilitating three-dimensional (3D) imaging. This increases imaging precision 
compared to 2D planar imaging. When SPECT is combined with high-resolution computed 
tomography (HRCT), anatomical information can be aligned to reconstruct a 3D image of the 
organ(s) of interest (e.g. the liver) to provide more accurate quantification of drug distribution 
(Fleming et al., 2011). Furthermore, this technique may be useful when overlying structures can 
obscure and/or confound quantification in an organ (e.g. the gallbladder in the liver). It must also 
be noted that γ-scintigraphy requires the administration of ionizing radiation. The International 
Commission of Radiological Protection (ICRP) recommends a whole body radiation dose of 5 
rem/yr (Radiation Protection Procedures 1978). Although the total radiation dose throughout the 
current study is ~0.2 rem, even low amounts of exposure to ionizing radiation are considered a 
risk and therefore, should be carefully considered when designing studies involving radiation 
exposure in humans.  
Alternative imaging techniques are available that may help overcome quantification 
limitations of organ-specific drug concentrations using γ-scintigraphy. PET imaging has emerged 
as a powerful tool to study the molecular mechanisms of drug distribution and transport (Testa et 
al., 2015). The advantages of PET are its remarkable sensitivity and spatial resolution and low 
tissue attenuation. PET typically requires microdoses (which are less likely to have 
pharmacological or toxic effects), and it exposes subjects to negligible amounts of radiation 
(Rahmim et al., 2008). In the context of drug development, SPECT radiotracers require the 
introduction of chelating moieties, which may significantly affect the physiochemical properties, 
and hence the biodistribution of a radio-labeled drug, whereas chemical structures or properties 
of drugs are less likely to be altered when a PET radioisotope is introduced (Bergstrom et al., 
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2003; Matthews et al., 2012). To avoid ionizing radiation exposure altogether, magnetic 
resonance imaging (MRI) can be employed. It must be noted that the use of noninvasive imaging 
techniques currently lacks the ability to discriminate between an active drug (or probe) and 
formed metabolites. Therefore, in situations involving the dynamic interplay between 
metabolism and transport, alternative sampling techniques may be used to evaluate 
drug/metabolite disposition (e.g. microdialysis).  
Given the heterogeneity of the NASH patient population, more robust studies including a 
larger sample size are warranted to corroborate these findings. Including patients with a dynamic 
range of fibrosis and NAFLD activity score (NAS) may help establish a robust correlation 
between these clinical variables and MEB pharmacokinetics. Association analysis found a 
statistically significant association between NASH severity score and liver exposure, suggesting 
that as disease severity progresses, MRP2-mediated function becomes progressively impaired. 
These data likely implicate inflammation has a key mediator of altered MEB pharmacokinetics. 
Therefore, validated inflammatory markers (e.g. tumor necrosis factor-α, cytokeratin-18, 
interleukin (IL)-6) should be measured to determine if there is an association between serum 
markers of inflammation and altered MEB pharmacokinetics. NASH generally progresses with 
age but there does not appear to be any effect of age on hepatic transporter expression in healthy 
adults (i.e. 18-65 yrs old); therefore, it is not clear if age-related changes in transporter 
expression may independently correlate with NASH progression or altered MEB 
pharmacokinetics. However, differences in expression and function have been reported in 
pediatric and geriatric populations (Badée et al., 2015; Bennink et al., 2016; Mooij et al., 2014). 
Given the increasing prevalence of NAFLD/NASH in adolescents, the effect of age on transporter 
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expression/function in this special population may contribute to altered drug disposition and 
warrants further investigation (Loomba et al., 2009). 
Dynamic SPECT/CT imaging, as mentioned previously, could aid in the precision of 
quantifying MEB concentrations in the liver. The experimental paradigm described herein could 
be applied to more clinically relevant drugs to estimate the impact of NASH on drug 
pharmacokinetics and pharmacodynamics. For example, a novel pravastatin derivative recently 
was synthesized as a PET probe for noninvasive measurement of hepatobiliary transporter 
kinetics (Shingaki et al., 2013).
 
Administration of rifampicin, an Oatp and Mrp2 inhibitor, 
revealed impaired systemic clearance of the pravastatin derivative and decreased canalicular 
efflux clearance consistent with Oatp and Mrp2 inhibition, respectively, although metabolism of 
the pravastatin derivative in rats may confound the interpretation of these results (Shingaki et al., 
2013). Similar findings were observed in rats using the novel tracer 
11
C-rosuvastatin (He et al., 
2014). The data generated in the current study indicate that OATP, MRP2, and MRP3 function 
are altered in patients with NASH. These data could be applied to pharmacokinetic models of 
other drugs/probe substrates if OATP-, MRP2-, and MRP3-mediated clearance values are 
known. Given the multiplicity of substrate selectivity, careful consideration should be given to 
multiple transporters/efflux pathways when selecting a suitable probe substrate. For example, 
MEB is both an OATP1B1 and OATP1B3 substrate; therefore, the current study is unable to 
deconvolute the relative reduction of OATP1B1 or OATP1B3 function in patients with NASH, 
but rather suggests that OATP1B function is decreased. When noninvasive imaging techniques 
prove technically challenging and/or are unavailable, pharmacodynamic measurements may be 
useful surrogate endpoints for hepatic exposure.  
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Studies in humans can be difficult; therefore, it would be advantageous to develop 
preclinical model(s) that recapitulate the pathophysiological changes that occur in human NASH. 
Although several murine models exist, rodents given a diet deficient in both methionine and 
choline (MCD) are one of the most commonly used models of NASH due to the rapid 
development of steatosis, inflammation, oxidative stress, and fibrosis (Morales et al., 2010; 
Takahashi et al., 2012).  However, MCD-deficient animals generally do not gain weight or 
develop insulin resistance, which are common comorbidities in patients with NASH, which may 
limit their translational value (Morales et al., 2010). In vitro NASH models using human 
hepatocyte cultures are promising, however, require further characterization and validation to 
establish their usefulness in translational NASH research (Di Mauro et al., 2016; Neuman et al., 
2016). 
The results of this clinical study evaluated the effect of NASH on OATP, MRP2, and 
MRP3 function using quantitative γ-scintigraphy. Future studies should focus on NASH-
mediated alterations in other clinically-relevant hepatic transporters that may impact drug 
disposition and therapy (Guidance for Industry, 2016).
 
Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: 
Contributing Factors to Drug-Induced Liver Injury? (Chapter 3) 
Bile acids are a family of cholesterol-derived amphipathic molecules synthesized in the 
liver that contribute to numerous physiological functions such intestinal absorption, cholesterol 
elimination, and normal hepatic function (Monte et al., 2009). The bile salt export pump (BSEP) 
is a transport protein located on the canalicular domain of hepatocytes that translocates bile acids 
from hepatocytes to the bile canaliculi, and is a major determinant of bile flow. Due to their 
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detergent-like properties, bile acids can accumulate in the liver when BSEP is inhibited, thus 
leading to cholestasis and bile acid-induced hepatotoxicity. Increasing evidence indicates that 
drugs can inhibit BSEP and other compensatory bile acid transporters (e.g. MRPs) leading to 
liver toxicity (Köck et al., 2014; Morgan et al., 2010; Morgan et al., 2013). Therefore, the 
purpose of Chapter 3 was to evaluate the effect of tolvaptan on bile acid-mediated transporter 
function. It is also unclear whether drug induced liver injury (DILI) observed in ADPKD patients 
is due to the parent compound and/or metabolite(s) of tolvaptan. Thus, tolvaptan, and two major 
tolvaptan metabolites, DM-4103 and DM-4107, were evaluated as inhibitors of bile acid 
transport. 
The current work suggests that tolvaptan and metabolites have the potential to inhibit 
BSEP function using BSEP-overexpressing membrane vesicles (Fig. 3.2). Multifactorial 
approaches incorporating the inhibitory effect of inhibitors on compensatory bile acid 
transporters such as MRP2, MRP3, and MRP4 increase the correlation between bile acid 
inhibition and evidence of liver injury in humans (Dawson et al., 2014; Morgan et al., 2010; 
Morgan et al., 2013). Accordingly, the inhibitory effect of tolvaptan and metabolites on MRP2-, 
MRP3-, and MRP4-mediated transporter revealed the potential for additional cholestatic liability 
(Fig. 3.4). It must be noted that the half maximal inhibitory concentration (IC50) values generated 
could translate to clinical risk; however, exposure levels (e.g. serum concentrations) of the drug 
must be considered. The ratio of the maximal concentration (Cmax) or the concentration at steady 
state (Css) and the inhibitory potency (i.e. IC50) has been proposed as a relevant parameter (i.e. 
Cmax or Css/IC50 >0.1) to establish the potential for a drug interaction (Chu et al., 2013; Huang  et 
al., 2008; Morgan et al., 2013.
 
Interestingly, DM-4103 exhibited a Cmax/IC50 >0.1 for all 
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evaluated transporters, which may specifically implicate this metabolite as having a role in 
tolvaptan-induced DILI (Table 3.1).  
Although transporter panels are becoming rapidly adopted by pharmaceutical companies, 
extrapolating BSEP and MRP inhibition data to clinical risk is challenging. For example, BSEP 
inhibition by metabolite(s) may not be evaluated routinely; hence, the observation that a 
metabolite of tolvaptan (i.e. DM-4103) appears to be a potent inhibitor of bile acid transporters 
supports the need to evaluate the inhibitory potential of metabolite(s). From a technical 
perspective, apparent IC50 values also assume that added drug is available in solution. True 
concentrations of insoluble compounds, or compounds that display nonspecific binding (e.g. to 
plastic tubes), may be lower than expected and thus, may under estimate the inhibitory potency 
of perpetrators (i.e. predict an IC50 value that is greater than its true IC50 value). Additionally, the 
generation of IC50 values does not provide any information on the mechanism of inhibition. 
Alternative modes of inhibition, such as noncompetitive inhibition of BSEP-mediated 
taurocholate uptake by tolvaptan revealed in the current work (Fig. 3.3), could increase the risk 
of toxicity due to the fact that noncompetitive inhibition reduces the rate of transport (e.g., of bile 
acids), which cannot be overcome by accumulating bile acid concentrations, whereas a 
competitive mechanism of inhibition does not affect Vmax (Strelow  et al., 2012). Therefore, the 
mechanism of inhibition should be considered when extrapolating inhibition data to clinical risk. 
Furthermore, membrane vesicle studies cannot address time dependent, irreversible, or trans 
inhibition.  
Perhaps as a result of these limitations, among others, it is unclear what extent of in vitro 
BSEP inhibition is functionally significant in vivo. Because the pore complex of BSEP and 
MRPs face the hepatocyte cytosol, hepatocyte concentrations may be more relevant in contrast to 
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plasma concentrations. Thus, incorporating hepatocellular drug/metabolite concentrations may 
improve the extrapolation of information generated from membrane vesicle studies to its in vivo 
relevance.  
Sandwich-cultured human hepatocytes (SCHH) are a promising tool to study drug 
disposition and hepatotoxicity due the preservation of cellular architecture and relevant ADME 
genes (Marion et al., 2007; Swift et al., 2010). When tolvaptan was incubated in SCHH, the total 
(bound + unbound) cellular concentrations were ~40-fold higher relative to the dosing 
concentration, suggesting that tolvaptan accumulates within hepatocytes. If this correction factor 
is applied to the inhibitory potency of tolvaptan, the Cmax/IC50 ratio for BSEP is >0.1, which may 
indicate a relevant interaction. However, according to the free drug hypothesis, unbound 
concentrations should be most relevant for the disposition and efficacy of drugs. Therefore, 
unbound concentrations of tolvaptan (and metabolites) should be measured in the future to 
translate these findings (Chu et al., 2013; Mariappan et al., 2013). The impact of tolvaptan and 
metabolites revealed an increase in the cellular accumulation of taurocholic acid (TCA), as well 
as bile acids associated with hepatotoxicity (e.g. chenodeoxycholic acid, taurochenodeoxycholic 
acid, and glycochenodeoxycholic acid) in SCHH studies (Table 3.3), which indicates that 
impaired transporter function established in membrane vesicles studies translated to a functional 
impact in a human hepatocyte system. The extrapolation of these data to clinical findings is 
unknown. However, the principle of altered bile acid disposition in SCHH studies has been 
demonstrated with drugs associated with liver injury such as troglitazone, cyclosporine A, and 
glyburide (Ansede et al., 2010). Thus, the data generated in the current experiments provide the 
first evidence of altered bile acid disposition due to tolvaptan administration, which should be 
explored in future mechanistic studies. 
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Although there does not appear to be a dose- and/or exposure-relationship with liver 
injury in patients with ADPKD, the low frequency of elevated transaminases makes it difficult to 
establish a link (Watkins et al., 2015). Furthermore, the novel implication that DM-4103 is a 
potent inhibitor of bile acid transporters should be taken into consideration when evaluating the 
causality of liver injury. Tolvaptan is primarily eliminated by CYP3A to several metabolites, 
mostly notably the oxybutyric acid metabolite (DM-4103) and the hydroxybutyric acid 
metabolite (DM-4107) (Shoaf et al., 2012). Interestingly, DM-4103 has a long half-life (∼180 h) 
and accounts for ∼52% of plasma radioactivity following a single 60-mg oral dose of 14C-
tolvaptan in humans (Shoaf et al., 2012; Tammara et al., 1999). The mechanism underlying the 
extensive half-life of DM-4103 is not known, although enterohepatic recirculation may play a 
role and could increase hepatic exposure over time. Enterohepatic recirculation has been 
implicated as a mechanism for toxicity of drugs in several examples such as damage to the 
gastrointestinal tract by NSAID-containing carboxylic acid moieties (Davies et al., 1997; 
Dobrinska et al., 1989; Ghanem et al., 2009). Although the data generated herein attempts to 
quantify the inhibitory potency and relevant concentrations of tolvaptan/metabolites, in vitro 
systems have limitations that make it difficult to predict in vivo organ exposure and toxicity.  
Physiologically-based pharmacokinetic (PBPK) modeling and systems pharmacology 
approaches are useful in silico tools to address the complex mechanisms governing drug 
disposition, efficacy, and safety in humans (Sager et al., 2015; Schotland et al., 2016; Zhao et al., 
2012). PBPK models mathematically integrate drug characteristics (e.g. molecular weight, logP, 
tissue partitioning, metabolism etc.) and physiological characteristics (e.g. organ weights, blood 
flow etc.) to describe the time-course of drug disposition. Although PBPK models typically 
require extensive data that describe drug and physiological characteristics, an advantage of this 
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approach is that it provides a quantitative framework to leverage in vitro data to estimate 
drug/metabolite exposure levels under various scenarios, which may be further linked to 
pharmacodynamic and/or toxicological endpoints. One key question generated from this work is: 
what are the steady-state hepatocellular concentrations of tolvaptan and metabolites in patients 
with ADPKD? Although SCHH data indicate that tolvaptan rapidly accumulates in hepatocytes, 
cellular concentrations of DM-4103 and DM-4107 were low relative to tolvaptan concentrations 
and negligible when measured in the media. The most likely explanation for these observations 
is that tolvaptan was incubated in SCHH for only 10 minutes. Because DM-4103 and DM-4107 
are downstream metabolites, as opposed to direct metabolites, this suggests that the study design 
may not have captured the time course of tolvaptan uptake and subsequent metabolism. 
Therefore, extrapolating concentrations of DM-4103 and DM-4107 from the current studies may 
not represent true hepatocellular concentrations at steady-state. To address this limitation, a 
PBPK modeling approach could be implemented to estimate relevant hepatic concentrations after 
long term dosing, which may then be compared to IC50 values generated in the current work. 
Alternatively, long-term dosing experiments in SCHH could be employed to estimate 
hepatocellular drug/metabolite concentrations but clinical data do not exist to validate these 
findings. 
Data discussed in Chapter 3 consider the role of direct inhibition of BSEP in the context 
of tolvaptan-associated DILI.  However, considering the complexity of the bile acid pool and the 
dynamic interplay between the formation and excretion of bile acids, alternative and contributing 
bile acid-related mechanisms to DILI must be considered. For example, disruption of nuclear 
hormone receptor function can impair the adaptive ability of the liver to handle increased 
hepatocellular bile acids. Ketoconazole, an antifungal associated with DILI, has been shown to 
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inhibit the activation of pregnane X receptor (Huang et al., 2007). Other mechanisms that can 
impair bile acid homeostasis, such as the modulation of kinases (which can impact transport 
trafficking), maintenance of membrane integrity and phospholipid flux (by transporters such as 
multidrug resistance protein 3 and ATPase phospholipid transporting 8B1), and perturbations in 
gut bacteria, by tolvaptan and/or metabolite(s) should be considered when determining the 
causality of tolvaptan-associated DILI (Rodrigues et al., 2014). 
Wu et al. (2015) demonstrated that tolvaptan was able to inhibit cell growth and induce 
apoptosis through the generation of reactive oxygen species and mitochondrial dysfunction in 
HepG2 cells. Concentrations of tolvaptan greater than 60 μM were required to induce a cytotoxic 
response. However, total maximal concentrations (Cmax) of tolvaptan are ~1 μM after a single 60 
mg dose in humans; hence, the clinical relevance of these findings from Wu et al. (2015) are 
unknown, but cannot be dismissed as a contributing mechanism of toxicity (Shoaf et al., 2012). 
In fact, impaired mitochondrial activity has been proposed as a source of oxidative stress due to 
hepatotoxic bile acids, which may imply that direct effects and bile acid-mediated dysfunction of 
mitochondrial respiration due to tolvaptan/metabolite(s) can contribute to liver injury (Perez et 
al., 2009; Rolo et al., 2000). Systems pharmacology approaches demonstrated that a synergy 
between multiple mechanisms is conceivable (Woodhead et al., 2016).
 
The results from Chapter 3 demonstrated, for the first time, that tolvaptan and metabolites 
can inhibit multiple human hepatic proteins involved in bile acid transport (i.e. NTCP, BSEP, 
MRP2, MRP3, and MRP4). Impaired bile acid transport by tolvaptan and/or its metabolites may 
negatively impact bile acid homeostasis, which may explain, in part, the mechanism(s) behind 
liver injury in tolvaptan-treated ADPKD patients.  
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Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney 
Disease (Chapter 4) 
In Chapter 3, tolvaptan and metabolites (i.e. DM-4103 and DM-4107) were identified as 
inhibitors of major bile acid transporters. Hepatotoxic liability within a drug class indicates that 
physiochemical properties, such as inhibition of bile acid transporters, may play a role in DILI. 
For example, troglitazone was associated with irreversible liver injury in patients whereas 
rosiglitazone and pioglitazone are less harmful and still used in clinical practice today (Jaeschke 
et al., 2007). Although the incidence of DILI is linked to the administration of certain drugs, the 
idiosyncratic nature of some DILI cases suggests that patient-specific factors play an important 
role in the development and/or the pathogenesis of hepatotoxicity (Fontana et al., 2014). No 
hepatic events were observed in tolvaptan-treated patients with hyponatremia, heart failure, or 
cirrhosis, which may indicate that ADPKD patients may be particularly susceptible to liver 
injury (Watkins et al., 2015). It must be noted that patients with hyponatremia typically receive 
lower doses (single daily dose up to 60 mg/day) compared to patients with ADPKD (split daily 
dose up to 120 mg/day), although there does not appear to be a link between exposure and 
hepatotoxicity (Watkins et al., 2015). Given the rarity of hepatotoxic signals, tolvaptan-
associated liver injury has been adjudicated as idiosyncratic in nature. 
It is interesting that patients with cirrhosis do not appear to display signals of liver injury 
compared to patients with ADPKD, which may suggest that underlying liver pathology may 
contribute to tolvaptan-associated liver injury in the ADPKD patient population. Although 
clinical manifestations of ADPKD are typically related to kidney dysfunction (e.g. hypertension, 
urinary tract infection, hematuria, renal functional decline), the liver is the most commonly 
affected extrarenal organ (Hogan et al., 2015; Milutinovic et al., 1990). Hogan et al. (2015) 
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reported that ~70% of men and ~80% of women have liver cysts. Biliary microhamartomas arise 
from the cholangiocyte epithelium and remodeling of the ductal plate. Altered fluid secretion and 
proliferative activity of the cystic epithelium contributes to cystogenesis and hepatomegaly over 
time (Feranchak et al., 2001). The incidence of bile duct dilatation is common in patients with 
ADPKD and obstructive jaundice has been reported (Chauveau et al., 2000; Ishikawa et al., 
1996). Hence, it is conceivable that biliary dysmorphogenesis and progressive cyst development 
impair normal bile formation and/or flow thereby increasing hepatic exposure to cytotoxic bile 
acids.  
The polycystic kidney (PCK) rat, a rodent model of human ADPKD, was used to 
investigate bile acid homeostasis. Total liver bile acids, including bile acids associated with 
hepatotoxicity, were significantly increased in PCK rats compared to wild-type rats (Fig. 4.2 and 
Fig. 4.3). Elevated hepatic bile acids are consistent with cholestasis and further evidenced by 
increased serum and urine bile acids in PCK rats (Fig. 4.2). The retention and accumulation of 
bile acids, particularly hydrophobic (i.e. toxic) bile acids such as DCA, CDCA and their taurine 
and glycine conjugates, is a key feature underlying cholestatic hepatotoxicity. Although the 
cellular biology underlying toxicity continues to be investigated, bile acid-mediated 
hepatotoxicity has been experimentally established using cultured hepatocytes and animal 
models (Perez et al., 2009). These data demonstrate that hepatic accumulation of toxic bile acids, 
independent of tolvaptan treatment, is possible in patients with ADPKD. Therefore, metabolomic 
profiling of bile acids in liver biopsies of patients with ADPKD is warranted. 
Given the number and complexity between data in large metabolomic data sets, a 
multivariate statistical approach was utilized (Ringnér et al., 2008). As shown in Fig. 4.5, wild-
type and PCK rats separated from each other (e.g. did not overlap) in each matrix, indicating that 
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the bile acid metabolome between wild-type and PCK rats are distinctly different from one 
another. Furthermore, the cumulative r
2 
for each matrix was > 0.65, indicating that a two 
principle component model was sufficient to explain the data; a cumulative r
2
 > 0.3 is generally 
considered ideal ((Ringnér et al., 2008). 
Impaired localization and transport function of Bsep in a rodent model of cholestasis has 
been reported (Crocenzi et al., 2003). These data suggest that elevated levels of bile acids could 
decrease bile acid transport through internalization and/or downregulation of Bsep and thereby 
provide an explanation for altered bile acid homeostasis observed in the current study. However, 
immunohistochemical analysis did not detect any apparent difference in Bsep expression and/or 
localization (Fig. 4.7). Moreover, significant differences in biliary bile acids were not observed, 
which further supports the relative preservation of Bsep function (Fig. 4.2). The mechanism(s) 
underlying increased hepatic accumulation of bile acids remains to be fully elucidated.  Cyp7a1, 
the rate limiting step in bile acid synthesis, was unaltered in PCK rats, suggesting that increased 
bile acid synthesis may not account for elevated hepatic bile acid concentrations, although 
functional studies may be needed to corroborate these findings (Munoz-Garrido et al., 2015). The 
alternative (acidic) pathway is initiated by Cyp27A1 and Cyp7B1, which may contribute to total 
bile acid synthesis and could explain alterations in bile acid homeostasis (Chiang et al., 2009). 
Thus, full characterization of proteins/enzymes involved in bile acid synthesis, transport (e.g. 
Ntcp, Oatp), and enterohepatic recirculation are needed. It should be noted that bile flow appears 
to be increased in PCK rats (Mason et al., 2010). Although the exact mechanism has not been 
defined, this is likely due to enhanced cyclic adenosine monophosphate (cAMP)-induced 
expression of cystic fibrosis transmembrane conductance regulator (CFTR) and aquaporin 
(AQP1) that account for increased ion-driven water transport and bile flow (Banales et al., 2008).
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Given the similar hepatorenal abnormalities observed in PCK rats and human ADPKD, 
these data demonstrate that hepatic bile acids may be elevated in this patient population, which 
could implicate ADPKD as a susceptibility factor for bile acid-mediated liver injury. However, 
the rarity of hepatic events indicates the risk of tolvaptan-associated liver injury is low in a 
majority of patients. Why do some ADPKD patients display evidence of liver injury while others 
do not? Because of the positive relationship between intracellular bile acid concentrations and 
toxicity, it is possible that some patients may be more susceptible to liver injury if their hepatic 
bile acid load is characteristically elevated compared to the general ADPKD population 
(Palmeira et al., 2004; Shoda et al., 2014; Yang et al., 2015). The current study demonstrated a 
correlation between total serum bile acids and markers of liver impairment (e.g. total liver 
weight, total liver bile acids, total liver bile acids associated with hepatotoxicity, and cystic 
volume) in PCK rats (Fig. 4.6). If these findings translate to human ADPKD, these data support 
the concept that characteristically elevated bile acid concentrations may be a contributing factor 
to DILI observed in this population. Therefore, evaluation of serum bile acids in tolvaptan-
treated patients at baseline and during a tolvaptan-associated hepatic event (e.g. during increased 
ALT elevations) compared to ADPKD patients that did not display drug-induced hepatotoxicity, 
should be compared. 
 The onset of hepatocellular injury, which occurred between 3 and 18 months after 
tolvaptan therapy, indicates that an adaptive immune response may be involved in tolvaptan-
associated hepatotoxicity. One-half of the subjects experienced no ALT elevations whereas one-
half of the subjects experienced rapid ALT elevations when re-challenged with tolvaptan and 
were permanently withdrawn from therapy (Watkins et al., 2015). Altered bile acid homeostasis 
can result in delayed presentation of hepatocellular injury. For example, delayed ALT elevations 
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of troglitazone were attributed to delayed build-up of toxic hepatic bile acids driven by (1) 
competitive inhibition of biliary bile acid excretion and (2) the inability for FXR-mediated 
regulation of bile acid synthesis/transport to compensate for altered bile acid homeostasis over 
time (Yang et al., 2014). Therefore, it is possible that ADPKD patients are susceptible to 
tolvaptan-associated liver injury related to time on tolvaptan therapy. 
It should be noted that all three Hy’s law cases, and 60% of cases adjudicated as probably 
or highly associated with tolvaptan therapy, occurred in women (Watkins et al., 2015). True sex 
differences in the susceptibility of tolvaptan-associated liver injury cannot be made at this time. 
However, hepatic cysts occur more frequently and in greater size in women; similar findings are 
observed in PCK rats (Hogan et al., 2015; Mason et al., 2010). This observation may be due to 
hormonal differences in women. Postmenopausal estrogen therapy was shown to stimulate 
hepatic cyst enlargement in women; hence, clinicians recommend avoiding hormonal therapy or 
hormone-containing oral contraceptive therapy when symptomatic liver cystic disease presents 
(Chapman et al., 2015; Sherstha et al., 1997). Furthermore, sulfate conjugates of certain 
hormones, such as progesterone for example, are known to inhibit FXR, which can repress the 
expression of BSEP and could contribute to decreased BSEP function and consequently, 
increased concentrations of hepatic bile acids (Chen et al., 2013; Abu-Hayyeh et al., 2013). 
Therefore, sex-differences in hepatic bile acid concentrations in ADPKD patients should be 
evaluated.  
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Altered Hepatobiliary Disposition of the Mrp2 Probe Substrate 
Carboxydichlorofluorescein in Isolated Perfused Livers from a Rat Model of Polycystic 
Kidney Disease (Chapter 5) 
In Chapter 4, altered bile acid homeostasis was established in PCK rats. However, these 
data do not provide any mechanistic explanations for altered bile acid homeostasis. Furthermore, 
the impact of ADPKD on the hepatobiliary disposition of drugs from a pharmacokinetic or 
pharmacologic standpoint has not been addressed, which may aid in understanding the apparent 
susceptibility of ADPKD patients to tolvaptan-associated hepatotoxicity. Therefore, the study 
described in Chapter 5 was designed to examine the effect of PKD on the hepatobiliary 
disposition of 5(6)-carboxy-2’,7’-dichlorofluorescein (CDF), a fluorescent OATP/Oatp, 
MRP2/Mrp2, and MRP3/Mrp3 probe in isolated perfused livers from PCK rats compared to 
healthy Sprague-Dawley (wild-type) rats (Zamek-Gliszczynski et al., 2003). 
The isolated perfused rat liver (IPRL) is an ex vivo model used to investigate the 
physiology and function of the liver. It has been used in the assessment of ischemia-reperfusion 
injury, synthesis of proteins, oxygen consumption, and metabolism and transport of drugs (Dahn 
et al., 1999; Haussinger et al., 1996; Khezrian et al., 2015; Lindell et al., 1994). Although 
hepatocyte cultures and liver slices are useful whole-cell models, the primary advantages of the 
IPRL are the retention of normal hepatic architecture, microcirculation, and bile production in a 
system that approaches normal physiology (Bessems et al., 2006).
 
Wild-type and PCK rats were 
perfused with CDF in a single-pass manner for a 30-min loading phase followed by a 30-min 
washout phase to evaluate the hepatic and biliary clearance of CDF. The extraction ratio was not 
different between the two cohorts but interestingly, the biliary excretion rate was significantly 
decreased in PCK rats. The most logical explanation for decreased biliary excretion of CDF is 
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decreased Mrp2 expression and function. Indeed, Mrp2 expression is decreased in models of 
cholestasis and in some cases, appears to be removed from the canalicular membrane into the 
pericanalicular cytoplasm (Ban et al., 2009; Trauner et al., 1997). However, western blot analysis 
failed to detect a difference in Mrp2 expression in the present studies. Immunohistochemical 
(IHC) analysis corroborated these findings and also indicated proper localization of Mrp2 on the 
canalicular membrane. Although we established a cholestatic-like state in PCK rats as evidenced 
by significantly increased hepatic bile acids in Chapter 4, cyclic adenosine monophosphate 
(cAMP), which has been shown to induce the translocation of Mrp2 to the canalicular 
membrane, is significantly increased in PCK rats (Chebib et al., 2015; Schonhoff et al., 2010).
 
Hence, it is possible that enhanced cAMP activity counteracts bile acid-mediated effects (i.e. 
downregulation) on Mrp2, which accounts for our observations of preserved Mrp2 expression 
and localization in PCK rats. 
CDF can also be transported back into the perfusate by Mrp3 (Zamek-Gliszczynski et al., 
2003). Increased basolateral excretion by Mrp3 in PCK rats is evidenced by increased CDF in 
the dose recovered during the washout phase . Compensatory bile acid transporters (e.g. 
MRP3/Mrp3, MRP4/Mrp4) can be upregulated during hepatocellular stress and cholestasis, 
which could explain these observations (Chai et al., 2012; Donner et al., 2001; Gradhand et al., 
2008; Mennone et al., 2006).
 
Indeed, western blot analysis detected a ~3-fold increase in Mrp3 
protein expression, which was corroborated using IHC analysis. Although decreased hepatic 
uptake and a shift from biliary to basolateral excretion could help explain decreased biliary 
excretion, the observation that Mrp2 expression and localization is preserved despite negligible 
biliary excretion is paradoxical and unexplained by the data generated herein.  
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In Chapter 4, increased hepatocellular bile acid concentrations were observed in PCK 
rats. It is possible that increased concentrations of bile acids in PCK rats inhibit Mrp2-mediated 
transport of CDF. The current study provides mechanistic data to support this hypothesis. For 
example, the sulfate conjugates of taurochenodeoxycholate and taurolithocholate are actively 
transported in an ATP-dependent manner in Mrp2-overexpressing membrane vesicles and have 
been shown to inhibit bile acid transport (Akita et al., 2001). Furthermore, bile acid inhibition 
was potentiated when vesicles were pre-incubated with sulfated bile acids, indicating that these 
conjugates may trans-inhibit Mrp2-mediated transport. Studies by Gerk et al. (2007) and Gerk et 
al. (2004) also revealed that tauroursodeoxycholate, glycoursodeoxycholate, and estrogen 
glucuronides associated with cholestasis (i.e. β-estradiol 3-β-d-glucuronide and β-estradiol 17-β-
d-glucuronide) are able to inhibit MRP2-mediated transport. Hence, increased bile acid 
concentrations in PCK rats may play a role in the apparent decrease in Mrp2-mediated biliary 
clearance of CDF. Mechanistic studies (e.g. using membrane vesicles) should be evaluated to 
determine if this mechanism can explain these observations. Other hepatocellular mechanisms 
that could explain decreased biliary clearance of CDF include enhanced cellular sequestration 
mediated by PCK-related alterations in intracellular binding to cytosolic proteins, organelles, or 
vesicles (e.g. mitochondria, microsomes, and nuclei). Quantitative intravital microscopy and 
digital analysis could be employed to specifically monitor the transport of fluorescent substrates 
from the hepatocyte into the bile canaliculi (Ryan et al., 2014). In addition, other substrates (e.g. 
fluorescent bile acids) could be evaluated in PCK rats to corroborate the findings generated in 
Chapter 5 (Holzinger et al., 1998). 
Considering the significant remodeling of the biliary tree and biliary dysgenesis in PCK 
rats, extrahepatocellular mechanism(s) may contribute to decreased biliary clearance of CDF. 
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Much like hepatocytes themselves, cholangiocytes interact with bile acids and anionic 
compounds in many ways. In vitro studies indicate the bile acids are vectorially transported into 
the peribiliary vascular plexus in an apical-to-basolateral manner by several transporters 
including the apical sodium dependent bile acid transporter (ASBT), MRP3, multidrug resistance 
transporter 3 (MDR3), and organic solute transporter (OST) alpha and OST beta (Ballatori et al., 
2005; Ballatori et al., 2009; Benedetti et al., 1997; Hirohashi et al., 2000; Lazaridis et al., 2000; 
Tabibian et al., 2013). The exchange of bile acids between hepatocytes and cholangiocytes is 
known as the cholehepatic shunt pathway, first proposed by Hoffman et al. (1989) to explain the 
hypercholeretic effects of some bile acids. Because cysts are derived from the biliary epithelium, 
it is conceivable that CDF may diffuse or be actively transported into cysts, thereby decreasing 
biliary excretion. However, focal hepatic lesions, such as liver cysts and biliary hamartomas, are 
hypointense (i.e. do not accumulate contrast agents) when using magnetic resonance imaging 
(MRI)-based contrast agents such as gadolinium-ethoxibenzyl-diethylenetriamine pentaacetic 
acid (Gd-EOB-DTPA), a known Mrp2 and Mrp3 substrate (Campos et al., 2012; Kitao et al., 
2010). 
Alternatively, enhanced cholangiocyte uptake by increased Mrp3 expression and/or other 
unidentified CDF transporters (e.g. organic solute transporter Ost alpha-Ost beta, Mrp4) could 
decrease CDF excretion into the common bile duct. Carrier mediated transport of Mrp2/Mrp3 
substrates (i.e. conjugated bile acids) have been demonstrated using fluorescent assays in biliary 
epithelial cell culture (Benedetti et al., 1997). The cholehepatic shunt pathway may provide a 
mechanism to enhance bile acid-dependent secretion from cholangiocytes back to hepatocytes in 
an adaptive response to cholestasis and/or liver injury and thus provide an alternative route of 
bile acid efflux. This hypothetical mechanism is supported by observations of increased 
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hepatocellular bile acids, described in Chapter 4 and increased Mrp3 in the current study. In 
fact, cholangiocyte-mediated bile acid transport is increased in bile duct ligated rodents, a model 
of chronic cholestasis (Alpini et al., 2001). Interestingly, this observation was not attributable to 
marked increases in transporter expression per cholangiocyte, but rather to increased intrahepatic 
bile duct surface area (e.g. increased number of cholangiocytes). Masyuk et al. (2004) reported 
extensive remodeling of the biliary tree in PCK rats that results in an up to ~40-fold increase in 
biliary volume. Hence, significant increases in the cholangiocyte epithelial surface area may 
contribute to enhanced transport of CDF from the biliary lumen.
 
The clinical significance of these findings is uncertain. Evidence of cholestasis in 
ADPKD patients is rare and biliary stenosis is usually associated with a physical stricture by 
overlaying cyst(s) (Kolodziejski et al., 2004; Lerner et al., 1992). Interestingly, Salam et al. 
(1989) reported prolonged hepatic retention of MEB, the clinical diagnostic agent and MRP2 
substrate used in Chapter 2, in a patient with ADPKD. This report suggests that MRP2-
mediated biliary excretion is impaired, similar to the findings in PCK rats reported in Chapter 5. 
Delayed or nonvisualization of the gallbladder using λ-scintigraphy also has been reported in 
patients with choledochal cysts of various or unknown origin (Gad et al., 1992; Huang et al., 
1982).  
The relevance of PCK rats to evaluate the potential of bile acid-mediated toxicity while 
on tolvaptan therapy is unknown, but may have limitations. Liver abnormalities in tolvaptan-
treated wild-type or PCK rats were not reported during nonclinical testing (Oi et al., 2011; Wang 
et al., 2005). Furthermore, preclinical animals are less sensitive to bile acid-mediated injury 
compared to humans (Leslie et al., 2007; Watkins et al., 2005). This is likely due to differential 
bile acid composition. For example, rats have a more hydrophilic (i.e. less toxic) bile acid pool 
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whereas chenodeoxycholic acid, a bile acid implicated in cholestatic liver disease, is a dominant 
bile acid species in humans (Garcia-Canaveras et al., 2012; Greim et al., 1972; Trottier et al., 
2011). Retrospective analysis of nonclinical data has yet to provide sufficient evidence that 
idiosyncratic DILI, such as observed in tolvaptan-treated ADPKD patients, can be reliably 
predicted from nonclinical toxicity studies (Kaplowitz et al., 2005; Ong et al., 2007; Peters et al., 
2005). Therefore, clinically relevant in vitro assays (e.g. human hepatocyte models) and 
mechanistic modeling may have better predictive power for rare DILI at this time. 
The impact of pathophysiological disease state(s) on drug disposition, such as in 
ADPKD, is under recognized. This study demonstrates that the biliary excretion of the Oatp, 
Mrp2 and Mrp3 substrate CDF is impaired in PCK rats. This novel finding may have clinical 
relevance. In the context of tolvaptan-associated livery injury, these data suggest that altered 
hepatobiliary disposition, combined with impaired renal function, may increase hepatic exposure 
to tolvaptan and/or metabolite(s) in patients with ADPKD and place undue burden on the liver 
leading to hepatotoxicity in some patients. 
Concluding Remarks  
This dissertation project focused on two types of liver disease: NASH and ADPKD. Data 
generated herein have resulted in novel contributions to the field of pharmacokinetics and DILI. 
The use of clinical and preclinical tools has advanced the study of drug transport, particularly in 
the context of ADPKD, where data characterizing hepatic transporter expression and function 
has not been evaluated to date. The results of these studies enhance existing knowledge about 
drug disposition in NASH and ADPKD, which may improve the efficacy and safety of drugs 
administered in these patient populations. 
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APPENDIX 
Data Appendix 
Appendix Table 2.1 Individual blood concentrations of MEB in healthy subjects (n=14) or patients with NASH (n=7) 
 
Subject ID (Healthy Subjects) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Time 
(min) 
Concentration (nCi/mL) 
2.5 116 95.3 94.3 83.1 174 42 180 142 145 178 145 105 131 66.1 
5.0 82.7 101 110 96.1 161 149 129 106 70.2 120 79.2 48.2 88.8 112 
7.5 53.2 89.3 76.1 102 104 115 75.7 82.9 46.8 61.8 52.1 31.3 60.7 85.7 
10 40.4 50.9 47.7 59.4 69.6 86.3 47.3 58.5 26.2 39.7 31.9 18.6 36.2 62.7 
15 29.9 28.1 19.4 15.3 32.3 46.8 25.6 32.6 9.87 16.7 15.2 8.34 14.3 25.8 
  
 
2
7
1 
20 19.3 14.2 11.6 11.7 21.9 31.3 14.5 21.5 7.77 10.2 11.3 4.57 10.1 13.1 
40 7.18 6.71 3.94 6.32 7.69 11.1 4.33 6.63 3.04 3.6 4.24 2.08 3.72 5.36 
60 4.38 3.67 2.57 3.96 3.94 6.68 2.42 4.25 2.19 2.97 2.72 1.59 2.89 2.62 
80 4.39 2.73 2.1 3.04 2.77 5.04 1.95 2.75 1.7 2.22 2 1.12 2.46 2.37 
100 3.67 2.66 1.71 2.55 2.25 3.89 1.47 2.32 1.55 2.07 1.65 0.968 1.75 2.4 
120 3.51 2.56 1.27 2.85 1.92 3.1 1.49 2.17 1.36 1.76 1.53 0.789 1.53 2.2 
140 3.53 2.1 1.19 2.85 1.87 3.11 1.17 2.01 1.19 1.84 1.53 0.688 1.48 2.32 
160 4.16 1.64 1.15 2.57 1.6 2.78 1.06 1.76 1.14 1.58 1.36 0.628 1.27 2.09 
180 2.91 1.45 1.02 2.3 1.5 2.21 1.09 1.53 1.01 1.46 1.4 0.577 1.23 1.87 
210 3.18 1.71 1.1 2.71 1.21 1.79 0.871 1.68 1.21 1.49 1.5 0.567 1.07 1.76 
240 1.76 1.61 0.595 2.77 1.22 1.91 0.729 1.36 1 1.46 1.62 0.535 1.04 1.71 
270 2.08 1.62 0.82 2.78 1.06 2.01 0.723 1.34 0.898 1.4 1.56 0.488 0.963 1.7 
300 2.17 1.54 0.863 2.79 1.07 1.88 0.629 1.26 0.932 1.37 1.6 0.464 0.944 1.55 
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Subject ID (NASH) 
1 2 3 4 5 6 7 
Time 
(min) 
Concentration (nCi/mL) 
2.5 287 286 141 210 226 318 314 
5.0 196 151 105 155 159 213 145 
7.5 142 79.3 54.1 78.3 93.1 131 84.9 
10 95.5 51.3 37.7 44.2 73.0 76.6 46.7 
15 54.2 22.7 19.9 18.3 34.9 39.6 22.4 
20 36.8 12.6 13.4 10.9 20.7 22.2 12.7 
40 16.6 5.10 4.93 5.13 10.0 8.44 6.14 
60 12.6 3.84 3.23 3.60 6.14 4.90 3.77 
80 9.48 3.30 2.46 3.45 5.11 3.52 3.16 
100 8.68 2.88 1.87 2.97 4.23 3.33 2.62 
  
 
2
7
3 
120 7.82 2.73 1.94 2.02 3.98 2.61 2.36 
140 8.18 2.60 1.59 2.67 3.52 2.25 2.26 
160 6.49 2.51 1.55 2.22 3.22 1.99 2.13 
180 7.60 2.50 1.35 2.53 2.72 1.96 1.93 
210 6.84 2.19 1.57 2.72 2.63 1.75 1.70 
240 6.83 2.07 1.43 2.50 2.51 1.84 1.61 
270 6.37 2.06 1.37 1.90 2.33 1.59 1.50 
300 6.14 1.98 1.40 2.30 2.33 1.54 1.48 
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Appendix Table 2.2 Liver activity counts of MEB in healthy subjects (n=14) or patients with NASH (n=7) 
 
Subject ID (Healthy Subjects) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Time 
(min) 
Liver Activity (counts/s) 
1 1420 2480 2360 543 555 482 370 540 666 1380 1380 1470 550 772 
2 3180 5450 5800 3390 4510 2350 2900 2690 3320 4770 4840 5160 3690 3820 
3 3890 6920 7890 5760 6680 3840 4470 4120 5080 6770 6910 7350 5600 5580 
4 4500 7830 9360 7180 7980 4820 5490 5110 6300 8070 8160 8810 6860 6540 
5 4980 8310 10500 8290 9100 5600 6450 5970 7360 9020 8980 9980 7820 7520 
6 5350 8570 11300 9030 10100 6190 7120 6470 7970 9880 9840 10900 8370 8290 
7 5640 8760 12000 9410 10900 6630 7520 7450 9180 10400 10100 11700 8820 8690 
8 5940 8630 12500 9610 11600 7010 7540 7920 9760 10900 10700 12100 8990 8600 
9 6100 8700 12300 9810 11900 7330 8240 8140 10000 11100 10500 12500 9320 8660 
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10 6300 8430 13300 10200 12300 7600 8440 8340 10300 11300 10600 12300 9430 8900 
11 6440 8170 13300 10500 12800 7750 8690 8550 10500 11500 10400 12100 9360 8960 
12 6610 7930 13400 10600 13100 7840 8690 8730 10800 11800 10900 12500 8890 8460 
13 6650 7660 12100 10800 13300 7870 8650 8510 10500 11700 10600 12600 9080 8280 
14 6730 7360 11600 10700 13500 7770 8830 8900 11000 11600 10600 12200 8550 8240 
15 6790 6940 12200 10300 13500 7800 8900 9020 11100 11700 10600 12400 8610 8250 
16 6800 6660 12100 9980 12800 7760 8670 8990 11100 11500 9860 12200 8320 8050 
17 6760 6290 12100 9300 13500 7620 8000 8980 11100 11400 9720 11800 8010 7870 
18 6750 6020 12200 8750 12800 7520 8510 8820 10900 11200 9330 12000 7840 7600 
19 6720 5700 11100 8160 11700 7490 8400 8770 10800 10900 9010 10600 7440 7230 
20 6710 5470 11400 7700 11500 7290 7810 8680 10700 10900 8700 10200 7300 6780 
21 6710 5180 10800 7090 10500 7190 7700 8440 10400 10600 8310 10400 6990 6690 
22 6700 4910 9830 6600 10800 7050 7170 8380 10300 10400 8020 9970 6610 6400 
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23 6580 4500 9020 5980 10400 6790 6600 7310 9000 10200 7690 9830 6440 6170 
24 6470 4280 8880 6090 11000 6680 7170 7710 9500 10000 7380 9540 6150 5890 
25 6380 4070 8170 6160 10900 6540 6920 7110 8760 9840 7080 7790 5850 5720 
26 6340 3790 7320 5510 10800 6470 6800 6950 8570 9570 6950 7610 5650 5530 
27 6470 3570 7030 5100 10300 6250 6460 6760 8340 8960 6640 7350 5450 5050 
28 6200 3460 6560 4750 10900 6130 6320 6590 8120 7970 6520 7020 5230 4350 
29 6040 3210 6180 5110 9430 5930 5990 7070 8720 8460 6170 6800 5080 4470 
30 5870 3020 5830 4880 10200 5850 5390 6490 8000 8340 6090 6270 4870 4250 
31 5740 2830 6000 4590 10000 5680 5360 5780 7120 7410 5940 5980 4720 3930 
32 5640 2700 5390 4670 9390 5530 5410 5910 7280 7750 5580 5780 4590 3890 
33 5500 2570 5450 4420 8960 5330 5180 5680 7000 7510 5320 5460 4470 3730 
34 5490 2410 5140 4230 9090 5100 5120 5610 6910 7250 5220 4730 4310 3610 
35 5380 2290 4820 3920 7990 4970 5050 5600 6900 7030 4890 4330 4150 3670 
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36 5230 2170 4530 3820 7700 4790 4680 5320 6560 6740 4590 3310 4080 3520 
37 5140 2060 4320 3580 7490 4670 4510 4910 6050 6590 4310 3400 3960 3580 
38 5050 1950 4230 3650 7120 4560 4430 4730 5830 6270 4250 3250 3850 3370 
39 4860 1880 3800 3460 6780 4400 4160 4690 5780 6060 3990 3380 3690 3090 
40 4570 1750 3740 3310 6390 4260 4150 4530 5580 5840 3530 3170 3610 3110 
41 4570 1640 3500 3310 5970 4120 3960 4430 5460 5510 3470 3100 3500 3170 
42 4460 1610 3460 3130 5900 3950 3990 4460 5500 5460 3200 3110 3370 3110 
43 4260 1510 2980 3030 5540 3850 3830 4220 5200 5070 3270 2910 3330 2850 
44 4020 1450 2850 3030 4860 3770 3440 3680 4530 4970 3040 2820 3200 2530 
45 3840 1390 2530 2850 4960 3650 3380 3890 4800 4930 2790 2710 3180 2810 
46 3710 1320 2290 2830 5060 3520 3220 3320 4090 4750 2590 2630 3040 2520 
47 3530 1270 2480 2720 5190 3330 3230 3700 4560 4580 2540 2400 3020 2590 
48 3310 1210 2330 2600 4690 2880 3060 3520 4340 4290 2590 2280 2940 2670 
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49 3130 1160 2220 2540 4420 3000 3020 3400 4190 4290 2480 2230 2760 2660 
50 3040 1070 2150 2490 4150 2970 2920 3300 4070 4120 2380 2140 2810 2610 
51 2890 1070 2090 2480 3880 2890 2960 3190 3930 3800 2260 2060 2640 2580 
52 2760 999 2020 2370 3890 2820 2910 3050 3760 3730 2140 2030 2680 2350 
53 2690 920 1880 2320 3680 2710 2740 3010 3700 3690 2030 1990 2570 2330 
54 2590 940 1850 2250 3570 2630 2740 2940 3630 3260 1970 1960 2470 2210 
55 2520 923 1810 2160 3320 2550 2500 2760 3400 3410 1870 1860 2420 2040 
56 2410 857 1700 2050 3110 2470 2260 2640 3250 3430 1790 1840 2360 1960 
57 2380 879 1670 2100 2750 2410 2160 2630 3250 3360 1680 1770 2300 1910 
58 2300 867 1600 2000 2600 2330 2060 2580 3180 3190 1660 1720 2270 1870 
59 2240 816 1570 1900 2590 2290 2030 2540 3140 3110 1570 1630 2200 1810 
60 2210 800 1530 1820 2250 2200 1640 2410 2970 2910 1480 1540 2180 1930 
61 2130 762 1520 1740 2280 2130 1570 2430 2990 2830 1510 1510 2110 1810 
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62 2080 742 1430 1720 2120 2030 1560 2410 2980 2670 1450 1500 2040 1760 
63 2000 689 1330 1730 2210 1980 1390 2240 2770 2840 1380 1410 2020 1800 
64 1990 679 1280 1810 1910 1900 1440 2180 2680 2540 1290 1350 1820 1650 
65 1900 700 1260 1860 2020 1800 1370 1880 2320 2570 1180 1480 1860 1570 
66 1890 701 1320 1940 1820 1740 1450 1800 2220 2480 1240 1490 1800 1560 
67 1850 653 1220 1730 1870 1670 1440 1720 2120 2400 1180 1480 1790 1510 
68 1810 664 1110 1770 1850 1620 1340 1690 2080 2290 1190 1040 1670 1510 
69 1690 617 1080 1570 1470 1590 1320 1630 2010 2190 995 1220 1650 1380 
70 1590 660 1070 1450 1840 1510 1320 1610 1980 2190 1000 1140 1680 1340 
71 1650 626 1040 1440 1530 1450 1370 1630 2010 2150 955 1110 1660 1350 
72 1630 590 1020 1470 1390 1430 1290 1590 1960 2070 877 1050 1580 1260 
73 1580 576 995 1390 1430 1410 1330 1550 1910 2000 843 1040 1510 1250 
74 1570 575 947 1330 1220 1360 1310 1480 1830 1970 854 1030 1520 1170 
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75 1550 578 928 1400 1390 1340 1320 1390 1720 1910 799 984 1450 1180 
76 1510 567 918 1270 1220 1300 1350 1330 1640 1800 789 968 1460 1190 
77 1460 567 825 1260 1210 1240 1300 1430 1760 1700 784 963 1410 1240 
78 1410 598 840 1300 1300 1190 1280 1430 1770 1620 761 969 1380 1130 
79 1420 569 785 1290 1250 1150 1230 1460 1800 1580 774 817 1370 1040 
80 1340 577 825 1310 1360 1140 1030 1450 1790 1510 835 1050 1350 972 
81 1320 625 784 1140 1240 1070 1070 1430 1760 1510 729 1120 1300 970 
82 1250 711 779 614 1140 1070 1050 1430 1760 1490 674 1070 1270 980 
83 1280 718 751 604 1110 1050 1170 1340 1650 1470 656 1010 1350 889 
84 1260 736 747 640 1090 992 1030 1240 1530 1340 711 1030 1310 889 
85 1250 710 671 587 1050 959 1000 1220 1510 1270 673 951 1200 846 
86 1230 700 704 569 1270 938 1020 1260 1550 1340 636 858 1170 861 
87 1160 766 671 536 1010 869 994 1300 1610 1360 661 789 1220 715 
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88 1130 758 590 513 1040 854 1040 1070 1320 1360 647 765 1180 694 
89 1090 768 588 530 1100 845 1050 1230 1510 1270 660 725 1120 582 
90 1070 753 576 529 1060 819 1020 1300 1610 1230 620 750 1140 698 
91 1040 783 570 536 1090 810 897 1240 1530 1220 603 715 1080 678 
92 994 748 526 532 920 795 946 1160 1430 1160 616 706 1160 721 
93 1000 797 557 530 949 768 978 1100 1360 1140 589 801 1070 595 
94 949 777 534 457 807 750 970 1150 1420 1120 593 777 1030 591 
95 929 796 548 390 960 741 1000 1080 1330 1140 576 755 1020 641 
96 892 791 514 525 788 704 963 1150 1420 1110 588 729 986 606 
97 884 795 501 531 875 659 937 1130 1390 1140 583 726 1020 499 
98 852 781 509 495 774 660 961 1060 1300 1100 550 689 1010 451 
99 865 820 518 431 822 632 773 1080 1330 1070 570 662 982 412 
100 821 828 533 415 886 617 805 1110 1360 1040 555 636 962 445 
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101 786 814 528 375 817 586 879 1060 1310 1000 631 654 955 432 
102 756 884 557 391 762 581 925 986 1220 1010 594 591 911 312 
103 723 850 558 392 776 542 802 848 1050 999 588 493 921 359 
104 682 880 523 307 799 552 790 819 1010 992 582 502 883 376 
105 678 872 535 337 791 534 800 815 1000 971 594 498 889 339 
106 659 895 483 349 781 513 840 831 1020 952 518 496 882 389 
107 655 950 497 377 767 492 843 779 960 918 530 483 874 382 
108 616 963 452 373 773 492 808 780 961 907 569 455 876 354 
109 611 980 451 330 782 485 840 781 963 870 557 453 876 442 
110 578 974 453 345 684 464 850 745 918 874 545 451 887 373 
111 579 1010 479 333 767 459 828 719 886 930 549 462 863 340 
112 574 989 408 288 732 486 806 749 923 920 560 450 881 356 
113 568 984 383 290 714 457 776 723 891 857 572 460 826 364 
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114 554 1020 420 298 657 433 825 768 946 839 551 487 866 381 
115 523 1020 434 268 650 433 730 799 984 812 534 490 839 398 
116 481 999 391 270 587 436 807 748 922 817 421 491 804 424 
117 523 1010 443 294 638 416 814 704 868 783 376 447 807 78.9 
118 517 1030 439 306 637 430 780 715 881 777 388 472 803 0.439 
119 527 1010 416 296 578 398 794 709 873 783 374 453 792 0.314 
120 491 1040 381 270 533 402 737 736 907 799 440 437 806 507 
121 478 1040 384 258 463 385 692 773 953 755 388 419 782 1100 
122 490 1010 386 248 503 379 863 834 1030 756 359 441 792 1130 
123 464 1040 368 231 430 372 660 874 1080 693 319 443 779 1080 
124 467 1040 369 217 469 362 836 780 961 713 315 426 792 1020 
125 476 1030 339 237 497 367 792 885 1090 701 289 424 794 1020 
126 474 982 352 219 491 342 836 770 949 717 328 412 773 1060 
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127 467 1030 341 220 489 335 846 781 962 729 345 411 810 1060 
128 454 1010 305 267 461 352 820 902 1110 709 325 413 785 1060 
129 457 1040 299 233 432 334 808 880 1080 671 288 382 811 1040 
130 442 1000 272 218 396 320 752 956 1180 635 317 395 790 951 
131 444 1010 344 218 486 312 792 904 1110 626 360 372 786 1030 
132 447 987 331 185 450 330 815 670 826 640 386 367 772 989 
133 455 984 314 182 388 320 694 582 717 625 393 393 742 955 
134 436 924 301 183 449 324 833 572 704 677 326 377 799 1010 
135 448 926 324 185 461 309 785 628 774 695 421 375 786 1010 
136 450 950 311 188 318 312 728 609 750 688 381 365 762 1060 
137 430 957 291 181 412 303 891 792 976 658 405 368 749 907 
138 427 952 281 218 317 296 843 678 835 665 398 364 750 897 
139 405 930 308 186 305 281 819 703 866 653 393 388 732 837 
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140 405 957 310 199 300 264 683 796 981 674 367 337 767 855 
141 370 928 278 192 343 267 619 809 997 678 368 287 773 902 
142 432 932 262 199 327 259 575 733 904 636 377 136 727 745 
143 422 832 255 210 334 265 672 683 842 676 337 216 734 678 
144 405 869 261 216 384 260 648 868 1070 670 303 285 724 702 
145 388 868 244 210 443 271 613 814 1000 643 349 319 753 670 
146 389 883 228 211 394 247 577 817 1010 680 324 264 733 651 
147 379 896 210 203 382 270 609 719 886 576 312 215 713 711 
148 384 891 184 183 405 260 686 748 922 631 288 407 755 758 
149 351 917 185 190 406 253 682 758 934 636 297 409 740 780 
150 379 906 192 184 424 258 585 644 793 673 267 418 724 784 
151 378 946 184 165 480 258 575 606 747 679 274 385 710 811 
152 388 908 201 155 459 263 593 602 742 707 277 355 704 750 
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153 381 885 200 150 472 245 545 677 834 630 271 358 711 760 
154 363 853 169 172 368 240 521 783 965 658 265 370 679 726 
155 359 874 179 144 364 251 508 677 835 672 262 378 705 725 
156 357 920 177 137 418 225 447 704 867 639 244 370 669 620 
157 377 911 168 140 424 239 493 799 985 695 252 373 561 475 
158 352 882 182 144 415 245 510 882 1090 696 276 374 608 432 
159 355 903 168 143 388 232 503 921 1130 693 267 377 629 487 
160 341 865 171 153 374 221 498 1010 1240 659 263 324 591 466 
161 334 897 167 145 360 226 520 846 1040 644 270 321 639 451 
162 337 924 178 138 435 226 516 670 826 630 249 326 677 445 
163 309 877 180 128 441 201 603 636 784 640 283 311 605 384 
164 320 890 184 140 412 206 559 643 792 718 243 303 538 456 
165 316 869 184 160 422 218 527 716 882 697 238 316 495 477 
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166 314 857 165 151 400 227 571 696 858 674 273 317 481 464 
167 312 866 187 140 375 220 553 694 855 644 280 332 467 417 
168 310 842 164 152 454 221 528 742 914 635 259 338 444 452 
169 302 836 160 147 494 222 560 750 924 632 267 329 447 460 
170 307 848 162 146 393 225 553 809 997 597 249 321 402 454 
171 299 851 172 141 465 210 489 910 1120 624 254 319 384 378 
172 300 858 138 153 456 203 551 885 1090 629 248 352 441 374 
173 315 828 158 148 437 206 446 942 1160 645 236 332 492 365 
174 303 852 154 142 454 214 567 897 1110 641 216 310 582 326 
175 310 820 152 140 451 206 561 901 1110 599 241 201 582 518 
176 306 807 146 145 483 200 546 785 967 708 227 265 554 641 
177 275 798 144 122 440 213 542 904 1110 719 199 202 458 519 
178 301 801 134 100 440 212 574 902 1110 680 182 264 429 361 
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179 288 782 138 101 457 215 546 809 997 684 177 236 472 343 
180 294 773 132 110 445 206 509 874 1080 650 167 206 461 420 
 Subject ID (NASH) 
 1 2 3 4 5 6 7 
Time 
(min) 
Liver Activity (counts/s) 
1 1430 2210 2830 815 1980 138 1180 
2 4850 7850 9270 8680 4470 2320 6400 
3 6680 11000 13000 13900 5830 4950 10400 
4 7640 13300 16000 17100 6920 6410 12800 
5 8600 15100 18200 19500 7610 7370 14600 
6 9480 16400 19600 20800 8460 8110 15800 
7 9900 17600 20600 22100 9000 8620 16600 
8 10400 18400 20900 23400 9500 9020 17800 
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9 11100 18900 21500 23800 9150 9210 18700 
10 11200 19400 21700 24300 8830 9610 19200 
11 11600 19700 21400 24300 9460 9400 19200 
12 12000 19700 20800 24300 9280 9320 19100 
13 12200 19700 19600 24400 9410 9310 20100 
14 12400 19800 18800 24400 8840 9360 20000 
15 12500 19400 17600 24000 9800 9070 19600 
16 12500 19300 17400 23700 9720 9130 19700 
17 12600 18900 16900 23400 9040 8770 19600 
18 12600 18900 16000 23200 8840 8630 19600 
19 12700 18500 15300 22700 8660 8510 18900 
20 12500 18200 14600 22300 8480 8320 18400 
21 12800 17800 13900 22000 8780 8440 18000 
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22 12600 17300 13100 21500 7520 7900 17500 
23 12600 17100 12500 20900 7280 7500 16900 
24 12600 16600 12000 20400 7520 7290 16300 
25 12400 16200 11300 19900 7940 6910 16200 
26 12300 15900 10800 19300 7700 6840 15700 
27 12200 15300 10300 18900 6660 6350 15000 
28 12100 15000 9770 18400 6760 6140 14500 
29 12000 14600 9340 18000 6470 6120 14500 
30 11800 14100 8940 17400 4780 5930 13900 
31 11700 13600 8720 16700 4530 5820 13400 
32 11600 13200 8460 16300 4050 5580 13000 
33 11300 12800 8040 15300 3840 5290 13500 
34 11200 12400 7740 15000 3370 5160 12800 
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35 10900 12000 7620 15000 4060 4920 12900 
36 10800 11700 7250 14500 3610 4800 12300 
37 10800 11400 6990 14200 3590 4620 11800 
38 10600 11000 6870 13600 3210 4500 11200 
39 10600 10500 6540 12900 2820 4240 10800 
40 10500 10300 6380 12800 2660 4000 10400 
41 10300 10000 6170 12400 2950 3940 9990 
42 10100 9820 6070 11700 3040 3800 9500 
43 10100 9420 5900 11600 3380 3800 9300 
44 9950 9020 5580 11100 3440 3700 8890 
45 9700 8740 5330 10600 2810 3630 8600 
46 9630 8520 5110 9930 3190 3600 8380 
47 9580 8200 4920 9990 2960 3480 8030 
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48 9420 7920 4880 9760 2750 3400 7730 
49 9380 7620 4670 9380 2810 3300 7860 
50 9130 7350 4390 9030 2500 3200 7700 
51 9130 7220 4290 8830 2730 3170 7260 
52 8980 7100 4200 8550 2500 3070 6660 
53 8810 7000 4200 8320 2850 3010 5950 
54 8850 6630 3970 7720 2880 2900 5480 
55 8620 6470 3690 7560 2920 2840 5290 
56 8560 6220 3760 6950 2960 2780 5120 
57 8360 5920 3700 6600 2950 2660 4950 
58 8320 5910 3610 6360 2530 2640 4850 
59 8280 5660 3520 6470 2370 2440 4780 
60 8060 5500 3330 6020 1980 2390 4880 
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61 7980 5320 3280 6010 1840 2200 4880 
62 7860 5180 3200 5690 2120 2250 4780 
63 7750 4920 3260 5520 1700 2350 4120 
64 7680 4840 3150 5220 1630 2070 4520 
65 7660 4700 3010 5020 1900 2150 4320 
66 7490 4640 2960 4960 2180 2170 4170 
67 7380 4420 2750 4880 2160 2170 4010 
68 7380 4340 2830 4700 2200 2110 3810 
69 7110 4270 2570 4620 2140 2020 3780 
70 7120 4190 2550 4360 2100 2050 3810 
71 6880 3940 2520 4240 1860 1850 3860 
72 6960 3990 2480 4160 2000 1700 3500 
73 6790 4120 2530 3950 1940 1820 3330 
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74 6700 4010 2570 3830 2070 1780 3260 
75 6710 3970 2370 3790 2350 1780 3280 
76 6600 3880 2340 3750 2190 1780 3200 
77 6390 3830 2150 3580 2250 1800 3240 
78 6260 3710 2220 3490 2420 1800 3030 
79 6320 3640 2090 3390 2210 1760 2890 
80 6140 3490 2120 3350 2490 1710 2560 
81 6130 3300 2000 3150 2320 1620 2560 
82 6060 3390 1900 3070 2480 1350 2530 
83 5980 3320 1860 3010 2180 1440 2490 
84 5900 3200 1820 3030 2360 1410 2390 
85 5820 3090 1780 2800 2290 1460 2310 
86 5620 3070 1830 2720 2210 1470 2390 
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87 5670 3060 1730 2560 2220 1420 2150 
88 5520 2980 1740 2610 2100 1400 2090 
89 5530 2790 1740 2470 2110 1320 2180 
90 5480 2790 1540 2480 1960 1360 2210 
91 5310 2660 1520 2390 1800 1340 2250 
92 5240 2620 1590 2380 1910 1310 2220 
93 5080 2890 1500 2450 1890 1280 2250 
94 5100 2930 1530 2270 1970 1490 2100 
95 5140 2730 1470 2260 1890 1600 1770 
96 4900 2720 1480 2110 1400 1580 1950 
97 5020 2520 1490 1970 1700 1580 1930 
98 4870 2380 1360 1960 1600 1630 1970 
99 4770 2510 1380 1960 1630 1580 2030 
  
 
2
9
6 
100 4720 2490 1530 1840 1610 1620 1920 
101 4700 2450 1380 1810 1560 1610 1960 
102 4700 2380 1310 1820 1770 1630 1720 
103 4550 2310 1340 1790 1690 1570 1750 
104 4470 2260 1320 1710 1520 1600 1740 
105 4400 2240 1240 1680 1540 1610 1680 
106 4320 2110 1360 1610 1480 1570 1580 
107 4150 2160 1420 1700 1440 1640 1550 
108 4230 2220 1290 1610 1330 1620 1560 
109 3980 2330 1300 1680 1520 1630 1510 
110 4020 2030 1380 1580 1400 1590 1650 
111 3990 2020 1270 1670 1550 1610 1580 
112 3890 1920 1260 1510 1510 1620 1490 
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113 3880 2030 1220 1500 1540 1680 1390 
114 3770 2020 1180 1500 1540 1630 1380 
115 3600 1920 1230 1470 1560 1660 1500 
116 3490 1810 1250 1490 1600 1600 1500 
117 3510 1720 1220 1520 1710 1600 1600 
118 3360 1670 1170 1500 1690 1590 1650 
119 3370 1640 1170 1540 1590 1630 1700 
120 3310 1580 1240 1340 1430 1620 1790 
121 3140 1530 1180 1320 1380 1660 1890 
122 3070 1500 1220 1230 1560 1730 1740 
123 3090 1500 1250 1150 1700 1730 1740 
124 3000 1470 1210 1200 1580 1660 1790 
125 2920 1480 1150 1230 1220 1690 1800 
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126 2960 1600 1180 1110 1540 1680 1470 
127 2920 1480 1280 1290 1520 1700 1600 
128 2900 1320 1210 1260 1450 1660 1690 
129 2730 1140 1280 1170 1580 1690 1480 
130 2630 1010 1250 1160 1600 1700 1560 
131 2610 1170 1300 1180 1220 1690 1420 
132 2630 1220 1070 1140 1340 1660 1460 
133 2510 1190 1250 1130 1510 1600 1460 
134 2480 1140 1120 1130 1420 1650 1560 
135 2390 1150 1000 1130 1450 1610 1560 
136 2400 1240 1230 1210 1580 1620 1430 
137 2300 1220 1270 1210 1420 1640 1450 
138 2220 1190 1250 1250 1370 1660 1520 
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139 2290 1170 1210 1090 1370 1640 1390 
140 2120 1230 1190 1080 1270 1650 1460 
141 2090 1170 1220 1070 1320 1610 1470 
142 2040 1150 1180 1010 1310 1590 1360 
143 2050 1050 1210 1040 1340 1590 1320 
144 2000 1120 1180 1050 1280 1650 1460 
145 2030 1200 1290 1090 1300 1610 1500 
146 1980 995 1190 1100 1260 1590 1570 
147 1990 1020 1240 1120 1290 1570 1470 
148 1890 1010 1080 1030 1950 1590 1350 
149 1960 1080 1160 999 1930 1630 1210 
150 1860 1070 1180 1020 1620 1640 1320 
151 1830 1050 1180 932 1850 1630 1320 
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152 1830 997 1150 954 1830 1600 1220 
153 1820 1020 1120 948 1750 1700 1320 
154 1790 978 1200 1040 1810 1630 1340 
155 1650 982 1190 973 1310 1670 1460 
156 1780 931 1070 1010 1600 1700 1360 
157 1660 923 1020 1000 1530 1720 1430 
158 1610 915 1120 942 1480 1660 1150 
159 1690 960 1030 921 1630 1690 1170 
160 1680 942 1180 888 1780 1730 1210 
161 1610 1030 1070 866 1610 1760 1270 
162 1680 878 1040 916 1740 1640 1270 
163 1630 1280 1110 896 1600 1710 1200 
164 1630 1140 1230 852 1350 1650 1130 
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165 1590 710 1260 783 1650 1610 1170 
166 1620 780 1230 858 1580 1650 1090 
167 1580 749 1180 776 1380 1610 1230 
168 1580 810 1120 789 1330 1550 1220 
169 1530 737 1100 751 1160 1700 1220 
170 1530 775 1060 805 1780 1750 1160 
171 1550 937 1100 770 1700 1800 1090 
172 1590 932 1160 723 1650 1720 1130 
173 1550 869 1150 728 1880 1680 1170 
174 1560 898 1080 687 1780 1640 1430 
175 1490 993 1270 636 1750 1650 1050 
176 1490 957 1020 679 1620 1510 1110 
177 1470 917 1100 678 1560 1410 1120 
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178 1460 1030 1260 692 1480 1330 1040 
179 1390 995 1190 675 1480 1290 1060 
180 1280 832 1240 584 1360 1230 959 
Data are not corrected for administered dose 
  
  
 
3
0
3 
Appendix Table 2.3 Blood Pharmacokinetics 
Cohort Subject 
Lamdaz 
(1/min) 
Tmax 
(min) 
Cmax 
(nCi/mL) 
AUC0last 
(nCi*min/mL) 
AUC0∞ 
(nCi*min/mL) 
CLblood 
(mL/min/kg) 
fu 
Healthy 
1 192 2.5 116 2070 2670 17.1 0.096 
2 276 5 101 1840 2460 16.7 0.0595 
3 195 5 110 1480 1720 15.5 0.117 
4 210 7.5 102 1940 2780 12.8 0.0722 
5 180 2.5 174 2340 2620 11.0 0.0384 
6 192 5 131 2300 2760 11.9 0.0988 
7 156 2.5 180 1790 1930 16.7 0.047 
8 226 2.5 142 2060 2470 14.0 0.0541 
9 302 2.5 145 1240 1650 19.1 0.0734 
10 380 2.5 178 1730 2480 17.6 0.0253 
11 278 2.5 145 1500 2140 16.8 0.0281 
12 215 2.5 118 937 1100 27.5 0.0715 
13 223 2.5 131 1440 1750 24.4 0.0347 
14 321 5 112 1770 2480 12.5 0.115 
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Cohort Subject 
Lamdaz 
(1/min) 
Tmax 
(min) 
Cmax 
(nCi/mL) 
AUC0last 
(nCi*min/mL) 
AUC0∞ 
(nCi*min/mL) 
CLblood 
(mL/min/kg) 
fu 
NASH 
1 458 2.5 287 4870 8930 2.4 0.149 
2 357 2.5 286 2440 3460 5.59 0.113 
3 460 2.5 141 1660 2600 7.92 0.0425 
4 368 2.5 210 2240 3460 8.00 0.108 
5 219 2.5 226 2910 3640 6.54 0.0845 
6 212 2.5 318 3120 3590 8.42 0.0515 
7 232 2.5 314 2410 2910 10.3 0.0499 
 
 305 
 
Appendix Table 2.4 Urine Pharmacokinetics 
Cohort Subject 
Urinary 
excretion 
(μCi) 
Urinary 
excretion 
(% of dose) 
CLrenal 
(mL/min/kg) 
Healthy 
1 19.9 0.923 0.236 
2 20.8 0.831 0.206 
3 16.7 0.690 0.133 
4 19.4 0.806 0.177 
5 15.7 0.603 0.0787 
6 19.7 0.811 0.127 
7 12.0 0.514 0.0978 
8 13.4 0.549 0.101 
9 13.8 0.567 0.159 
10 6.91 0.274 0.0771 
11 7.60 0.299 0.0818 
12 7.10 0.292 0.102 
13 16.8 0.586 0.189 
14 5.10 0.200 0.0397 
NASH 
1 31.1 1.56 0.0823 
2 13.4 0.535 0.0474 
3 21.6 0.884 0.122 
4 15.3 0.564 0.0816 
5 26.3 1.06 0.0988 
6 17.5 0.663 0.0718 
7 18.5 0.681 0.0941 
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Appendix Table 2.5 Liver Pharmacokinetics 
Cohort Subject 
Lamdaz¶ 
(1/min) 
Half-life 
(min) 
Tmax 
(nCi/mL) 
Xmax 
(counts/s) 
AUC0last 
(kcounts*min/s) 
AUC0∞ 
(kcounts*min/s) 
Healthy 
1 0.0276 25.1 21 2830 174 182 
2 0.0282 24.6 9 2330 67.9 76.1 
3 0.0410 16.9 12 2180 71.1 71.8 
4 0.0267 26.0 13 2540 96.6 98.1 
5 0.0381 18.2 14 2320 106 110 
6 0.0307 22.5 15 2240 118 123 
7 0.0371 18.7 15 1990 76.7 78.6 
8 0.0304 22.8 15 2550 127 135 
9 0.0364 19.1 13 1840 59.7 60.2 
10 0.0312 22.2 12 2600 126 133 
11 0.0363 19.1 15 2630 120 123 
12 0.0323 21.5 12 2770 111 113 
13 0.0219 31.6 11 2080 112 123 
14 0.0239 29 11 2230 91.3 95.9 
  
 
3
0
7 
Cohort Subject 
Lamdaz¶ 
(1/min) 
Half-life 
(min) 
Tmax 
(nCi/mL) 
Xmax 
(counts/s) 
AUC0last 
(kcounts*min/s) 
AUC0∞ 
(kcounts*min/s) 
NASH 
1 0.0103 67.6 21 2840 260 299 
2 0.0257 27.0 14 3690 208 218 
3 0.0259 26.7 10 4220 171 188 
4 0.0259 26.7 10 3970 161 176 
5 0.0116 59.6 15 2800 177 229 
6 0.0149 46.4 10 2270 153 187 
7 0.0290 23.9 13 3300 187 198 
¶Calculated using the terminal slope from 30-80 min 
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Appendix Table 3.1 Effects of Tolvaptan on NTCP-mediated Uptake of 
3
H-TCA 
                               Tolvaptan (µM)  TCDC (µM) 
 0 0.01 0.1 1 5 10 25 50  100 
Exp. Rep. pmol/min/well (% of control) 
1 1 3.02 NE NE 
3.83 
(128) 
NE 
2.10 
(70.0) 
1.72  
(57.3) 
1.96 
(65.4) 
 
0.121 
(4.02) 
1 2 2.95 NE NE 
3.77 
(126) 
NE 
2.03 
(67.6) 
1.92  
(64.0) 
1.28 
(42.5) 
 
0.0921 
(3.07) 
1 3 3.04 NE NE 
3.86 
(129) 
NE 
1.22 
(40.6) 
1.72  
(92.7) 
1.83 
(60.9) 
 
0.197 
(6.55) 
Mean 
 
3.00 
(100) 
 
- - 
3.82 
(127) 
- 
2.78 
(59.4) 
2.14  
(71.3) 
1.69 
(56.3) 
 
0.136 
(4.54) 
SD 
 
0.0487 
(-) 
 
- - 
0.468 
(1.55) 
- 
0.491 
(16.4) 
0.565  
(18.8) 
0.364 
(12.1) 
 
0.0540 
(1.80) 
 pmol/min/well (% of control) 
2 1 1.50 
 
1.56 
(86.2) 
 
1.47 
(81.3) 
 
2.32 
(128) 
 
1.65 
(91.3) 
 
1.55 
(86.1) 
 
1.43  
(79.3) 
 
1.39 
(77.1) 
 BQL 
2 2 2.00 
 
1.47 
(81.3) 
 
1.28 
(70.6) 
 
2.42 
(134) 
 
1.16 
(64.4) 
 
1.25 
(69.3) 
 
1.12  
(61.8) 
 
0.849 
(47.0) 
 BQL 
2 3 1.92 
 
1.43 
(79.3) 
 
1.22 
(67.5) 
 
1.36 
(75.4) 
 
1.47 
(81.4) 
 
1.40 
(77.5) 
 
1.19  
(65.8) 
 
1.04 
(57.7) 
 BQL 
Mean 
 
1.81 
(100) 
 
1.49 
(82.3) 
1.32 
(73.2) 
2.03 
(113) 
1.43 
(79.0) 
1.40 
(77.6) 
1.25  
(69.0) 
1.09 
(60.6) 
 BQL 
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SD 
0.267 
(-) 
0.064 
(3.57) 
0.584 
(7.23) 
0.246 
(32.3) 
0.246 
(13.6) 
0.151 
(8.39) 
0.166  
(9.17) 
0.275 
(15.3) 
 NC 
  pmol/min/well (% of control) 
3 1 1.17 
 
1.33 
(112) 
 
1.25 
(105) 
 
1.18 
(99.6) 
 
1.12 
(94.5) 
 
0.979 
(82.4) 
 
0.653  
(55.0) 
 
0.409 
(34.5) 
 
 
0.00439 
(0.370) 
3 2 0.874 
 
1.29 
(109) 
 
1.22 
(103) 
 
1.22 
(102) 
 
1.01 
(84.8) 
 
0.853 
(71.9) 
 
0.479  
(40.4) 
 
0.411 
(34.6) 
 
 
0.00910 
(0.767) 
                               Tolvaptan (µM)  TCDC (µM) 
  0 0.01 0.1 1 5 10 25 50  100 
Exp. Rep.                               pmol/min/well (% of control) 
 
3 
 
3 
 
1.18 
 
1.36 
(114) 
 
1.23 
(104) 
 
1.24 
(105) 
 
1.19 
(100) 
 
0.904 
(76.1) 
 
0.548  
(46.1) 
 
0.422 
(35.5) 
 
 
0.0105  
(0.888) 
3 4 1.34 - - - - - - -  - 
3 5 1.34 - - - - - - -  - 
3 6 1.22 - - - - - - -  - 
Mean 
 
1.19 
(100) 
 
1.32 
(112) 
 
1.23 
(104) 
 
1.21 
(102) 
 
1.11 
(93.2) 
 
0.912 
(76.8) 
 
0.560  
(47.2) 
 
0.414 
(34.8) 
 
 
0.00801 
(0.675) 
SD 
0.175 
(-) 
 
0.0329 
(2.77) 
 
0.0120 
(1.01) 
0.0306 
(2.58) 
0.0930 
(7.84) 
0.0630 
(5.31) 
0.0878  
(7.39) 
0.00677 
(0.570) 
 
0.00322 
(0.271) 
NE=not evaluated; 2 µM substrate (
3
H-TCA) and < 1% organic solvent; BQL=below quantitation limit; NC=not 
calculable 
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Appendix Table 3.2 Effects of Tolvaptan on NTCP-mediated Uptake of 
3
H-TCA (combined 
data) 
                               Tolvaptan (µM)  TCDC (µM) 
 0 0.01 0.1 1 5 10 25 50  100 
Exp. % of control 
1 100 NE NE 127 NE 59.4 71.3 56.3  4.54 
2 100 82.3 73.2 113 79.0 77.6 70.0 60.6  BQL (0) 
3 100 112 104 102 93.2 76.8 47.2 34.8  0.675 
Mean 100 96.9 88.5 114 86.1 71.3 62.5 50.6  1.74 
SD - *NC *NC 12.6 *NC 10.3 13.3 13.8  *NC 
NE=not evaluated; BQL=below quantitation limit; 2 µM substrate (
3
H-TCA) and < 1% organic solvent; *n=2, 
standard deviation is not calculable (NC) 
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Appendix Table 3.3 Effects of DM-4103 on NTCP-mediated Uptake of 
3
H-TCA 
                               DM-4103 (µM)  TCDC (µM) 
 0 0.01 0.1 1 10 25 50 75  100 
Exp. Rep. pmol/min/well (% of control) 
1 1 0.715 
 
0.551 
(65.1) 
 
0.722 
(85.2) 
 
0.763  
(90.1) 
 
0.562 
(66.4) 
 
0.597 
(70.5) 
 
0.289 
(34.1) 
NE  
 
BQL  
 
1 2 0.946 
 
0.606 
(71.5) 
 
0.524 
(61.8) 
 
0.632  
(74.6) 
 
0.434 
(51.3) 
 
0.463 
(54.7) 
 
0.281 
(33.2) 
NE  
 
0.00384  
(0.453) 
1 3 0.880 
 
0.630 
(74.4) 
 
0.794 
(93.7) 
 
0.649  
(76.6) 
 
0.471 
(55.6) 
 
0.588 
(69.4) 
 
0.197 
(23.3) 
NE  
 
BQL  
 
Mean 
 
0.847 
(100) 
 
0.596 
(70.3) 
0.680 
(80.3) 
0.681  
(80.4) 
0.489 
(57.8) 
0.550 
(64.9) 
0.256 
(30.2) 
-  BQL 
SD 
 
0.119 
(-) 
 
0.0404 
(4.77) 
0.140 
(17.0) 
0.0713  
(8.42) 
0.0658 
(7.77) 
0.0746 
(8.80) 
0.0508 
(6.00) 
-  NC 
 pmol/min/well (% of control) 
2 1 1.70 
 
1.28 
(70.4) 
 
1.50 
(82.7) 
 
1.58  
(87.0) 
 
1.04 
(57.2) 
 
0.743 
(41.0) 
 
0.406 
(22.3) 
 
0.287 
(15.8) 
 
 
BQL  
 
2 2 1.70 
 
1.72 
(94.9) 
 
1.42 
(78.2) 
 
1.74  
(95.8) 
 
0.961 
(52.9) 
 
0.685 
(37.7) 
 
0.438 
(24.1) 
 
0.311 
(17.1) 
 
 
BQL  
 
2 3 1.92 
 
1.71 
(94.5) 
 
1.57 
(86.2) 
 
1.65  
(90.8) 
 
0.973 
(53.6) 
 
0.743 
(40.9) 
 
0.445 
(24.5) 
 
0.346 
(19.1) 
 
 
0.000705 
(0.0389) 
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2 4 
 
1.35 
 
- - - - - - -  - 
2 5 
 
1.62 
 
- - - - - - -  - 
2 6 
 
2.60 
 
- - - - - - -  - 
Mean 
 
1.82 
(100) 
1.57 
(86.6) 
1.49 
(82.4) 
1.66  
(91.2) 
0.991 
(54.6) 
0.724 
(39.9) 
0.430 
(23.7) 
0.315 
(17.3) 
 BQL 
 
SD 
 
 
0.426 
(-) 
 
0.254 
(14.0) 
 
0.0732 
(4.03) 
 
0.806  
(4.44) 
 
0.421 
(2.32) 
 
0.0333 
(1.83) 
 
0.0211 
(1.16) 
 
0.0296 
(1.63) 
 NC 
                               DM-4103 (µM)  TCDC (µM) 
 0 0.01 0.1 1 10 25 50 75  100 
Exp. Rep.                                           pmol/min/well (% of control) 
3 1 0.958 
 
0.950 
(91.0) 
 
1.20 
(115) 
 
0.663  
(63.6) 
 
0.400 
(38.2) 
 
0.518 
(49.6) 
 
0.297 
(28.5) 
 
0.163 
(15.6) 
 
0.00401 
(0.385) 
3 2 1.36 
 
1.17 
(113) 
 
1.27 
(121) 
 
1.16  
(111) 
 
0.576 
(55.3) 
 
0.466 
(44.7) 
 
0.218 
(20.9) 
 
0.150 
(14.3) 
 
0.00375 
(0.359) 
3 3 0.85 
 
1.07 
(102) 
 
1.07 
(103) 
 
1.01  
(97.2) 
 
0.460 
(44.1) 
 
0.435 
(41.7) 
 
0.266 
(25.5) 
 
0.126 
(12.1) 
 
0.00199 
(0.191) 
3 4 0.949 - - - - - - -  - 
3 5 1.10 - - - - - - -  - 
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3 6 MV - - - - - - -  - 
Mean 
 
1.04  
(100) 
 
1.07 
(102) 
1.18 
(113) 
0.946  
(90.7) 
0.478 
(45.9) 
0.473 
(45.4) 
0.260 
(25.0) 
0.146 
(14.0) 
 
0.00325 
(0.311) 
SD 
 
0.200 
(-) 
0.113 
(10.8) 
0.0986 
(9.46) 
0.256  
(24.5) 
0.0903 
(8.66) 
0.0417 
(4.00) 
0.0397 
(3.81) 
0.0185 
(1.77) 
 
0.00110 
(0.105) 
NE=not evaluated; 2 µM substrate (
3
H-TCA) and < 1% organic solvent; BQL=below quantitation limit; 
MV=missing value (pipette error) 
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Appendix Table 3.4 Effects of DM-4103 on NTCP-mediated Uptake of 
3
H-TCA (combined 
data) 
                               DM-4103 (µM)  TCDC (µM) 
 0 0.01 0.1 1 10 25 50 75  100 
Exp.                                                        % of control 
1 100  70.3  80.3  80.4  57.8  64.9  30.2 NE  BQL 
2 100  86.6  82.4  91.2  54.6  39.9  23.7  17.3  BQL 
3 100  102  113  90.7  45.9  45.4  25.0  14.0  0.311 
Mean 100 86.3 92.0 87.4 52.7 50.0 26.3 15.7  BQL 
SD - 15.8 18.2 6.08 6.17 13.1 3.46 *NC  NC 
NE=not evaluated; 2 µM substrate (
3
H-TCA) and < 1% organic solvent; *n=2, standard deviation is not calculable 
(NC) 
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Appendix Table 3.5 Effects of DM-4107 on NTCP-mediated Uptake of 
3
H-TCA 
 
DM-4107 (µM) 
 TCDC 
(µM) 
 0 0.01 0.1 1 10 25 50 100 200  100 
Exp. Rep.                               pmol/min/well (% of control) 
1 1 3.03 
 
3.93 
(124) 
 
3.43 
(108) 
 
4.18 
(131) 
 
3.04 
(95.5) 
 
2.32 
(72.8) 
 
2.04 
(64.20 
 
1.77 
(55.6) 
 
1.26 
(39.7) 
 
0.0738 
(2.34) 
1 2 3.26 
 
4.54 
(143) 
 
3.88 
(122) 
 
4.51 
(142) 
 
3.37 
(106) 
 
2.90 
(91.0) 
 
2.51 
(79.0) 
 
1.50 
(47.2) 
 
1.02 
(32.1) 
 
BQL  
(0) 
1 3 3.26 
 
4.48 
(141) 
 
4.42 
(139) 
 
4.63 
(146) 
 
3.67 
(115) 
 
2.27 
(71.2) 
 
2.79 
(87.7) 
 
1.50 
(47.3) 
 
1.11 
(34.9) 
 
0.0808 
(2.55) 
Mean 
 
3.18 
(100) 
 
4.32 
(136) 
3.91 
(123) 
4.44 
(140) 
3.36 
(106) 
2.49 
(78.4) 
2.45 
(77.0) 
1.59 
(50.0)  
1.13 
(35.6) 
 
0.0515 
(1.62) 
SD 
 
0.135 
(-) 
 
0.335 
(10.5) 
0.496 
(15.6) 
0.233 
(7.32) 
0.315 
(9.91) 
0.350 
(11.0) 
0.377 
(12.0) 
0.154 
(4.86) 
0.122 
(3.82) 
 *NC 
                              pmol/min/well (% of control) 
2 1 1.88 
 
1.66 
(92.9) 
 
1.45 
(80.8) 
 
1.17 
(65.5) 
 
1.30 
(72.5) 
NE 
 
0.890 
(49.8) 
 
0.856 
(47.8) 
 
0.661 
(36.9) 
 
 
0.0111 
(0.620) 
2 2 1.71 
 
1.65 
(92.4) 
 
1.53 
(85.4) 
 
1.33 
(74.6) 
 
1.52 
(84.9) 
NE 
 
1.32 
(74.0) 
 
0.891 
(49.8) 
 
0.728 
(40.7) 
 
0.00861 
(0.481) 
`             
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3 1.78 1.90 
(106) 
1.67 
(93.0) 
1.55 
(86.5) 
1.36 
(75.7) 
NE 1.22 
(68.2) 
0.931 
(52.0) 
0.416 
(23.3) 
0.00927  
(0.518) 
Mean 
 
1.79 
(100) 
 
1.74 
(97.1) 
1.55 
(86.4) 
1.35 
(75.5) 
1.39 
(77.7) 
- 
1.15 
(64.0) 
0.892 
(49.9) 
0.602 
(33.6) 
 
0.00966 
(0.540) 
SD 
 
0.0841 
(-) 
0.139 
(7.79) 
0.111 
(6.21) 
0.189 
(11.0) 
0.115 
(6.42) 
- 
0.227 
(13.0) 
0.0378 
(2.11) 
0.164 
(9.17) 
 
0.00130 
(0.0724) 
                                 pmol/min/well (% of control) 
3 1 1.11 
 
1.27 
(108) 
 
1.33 
(113) 
 
0.935 
(79.3) 
 
0.500 
(42.3) 
NE 
 
0.655 
(55.6) 
 
0.586 
(49.7) 
 
0.451 
(38.2) 
 
 
0.00604 
(0.512) 
3 2 1.18 *MV 
 
1.38 
(117) 
*MV 
 
0.836 
(70.9) 
NE 
 
0.614 
(52.0) 
 
0.584 
(49.5) 
 
0.452 
(38.3) 
 
 
0.00697 
(0.591) 
  DM-4107 (µM) 
 TCDC 
(µM) 
  0 0.01 0.1 1 10 25 50 100 200  100 
Exp. Rep.                               pmol/min/well (% of control)   
3 3 1.25 
 
1.12 
(94.8) 
 
1.18 
(100) 
*MV 
 
0.860 
(72.9) 
NE 
 
0.682 
(57.8) 
 
0.530 
(45.0) 
 
0.455 
(38.5) 
 
 
0.00407 
(0.345) 
Mean 
 
1.18 
(100) 
1.20 
(101) 
1.30 
(110) 
0.935 
(79.3) 
0.731 
(62.0) 
- 
0.650 
(55.1) 
0.567 
(48.1) 
0.453 
(38.4) 
 
0.00569 
(0.483) 
SD 
 
0.0688 
(-) 
*NC 
0.102 
(8.66) 
*NC 
0.201 
(17.1 
- 
0.0343 
(2.90) 
0.0314 
(2.67) 
0.00186 
(0.157) 
 
0.00148 
(0.125) 
NE=not evaluated; *n=1 or 2, standard deviation is not calculable (NC); 2 µM substrate (
3
H-TCA) and < 1% organic 
solvent; BQL=below quantitation limit; *MV=missing value (cells not functional due to loss of cell media during 
shipment and low DPM counts) 
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Appendix Table 3.6 Effects of DM-4107 on NTCP-mediated Uptake of 
3
H-TCA (combined 
data) 
                               DM-4107 (µM)   TCDC (µM) 
 0 0.01 0.1 1 10 25 50 100 200  100 
Exp.                                                  % of control 
1 100 136 123 140 106 78.4 77.0 50.0 35.6  1.62 
2 100 97.1 86.4 75.5 77.7 NE 64.0 49.9 33.6  0.540 
3 100 101 110 79.3 62.0 NE 55.1 48.1 38.4  0.483 
Mean 100 111 106 98.1 81.9 78.4 65.4 49.3 35.8  0.889 
SD - 21.2 18.5 35.9 22.3 *NC 11.0 1.10 2.39  0.635 
NE=not evaluated; 2 µM substrate (
3
H-TCA) and < 1% organic solvent; *n=1, standard deviation is not calculable 
(NC) 
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Appendix Table 3.7 Effects of Tolvaptan on BSEP-mediated 
3
H-TCA Uptake 
                               Tolvaptan (µM) 
 RIF              
(µM) 
  0 0.1 1 2 5 10 20 30 40 50  50 
Exp. Rep. BSEP-Mediated TCA Uptake (pmol/min/mg protein) 
1 1 104 NE NE NE 107 59.2 46.5 43.7 23.3 15.2  38.0 
1 2 106 NE NE NE MV 46.8 37.5 26.9 25.2 16.7  37.0 
1 3 93.8 NE NE NE 116 48.5 44.6 28.6 20.5 9.41  33.4 
Mean  104 - - - 112 50.9 42.4 32.8 22.8 13.6  35.7 
SD  6.35 - - - NC 6.71 4.75 9.25 2.39 3.86  2.40 
Exp. Rep. BSEP-Mediated TCA Uptake (pmol/min/mg protein) 
2 1 56.1 NE NE NE 70.9 100 63.2 34.5 18.5 10.1  NE 
2 2 68.4 NE NE NE 89.1 88.1 68.8 32.4 19.7 9.16  NE 
2 3 71.1 NE NE NE 72.6 86.2 50.1 26.8 18.5 9.83  NE 
Mean  65.2 - - - 77.5 91.4 60.7 31.2 18.9 9.69  - 
SD  8.01 - - - 10.1 7.55 9.59 4.00 0.692 0.480  - 
Exp. Rep. BSEP-Mediated TCA Uptake (pmol/min/mg protein) 
3 1 68.8 89.6 84.8 94.7 99.2 73.1 66.6 43.9 19.0 12.3  24.5 
3 2 69.0 80.5 79.1 89.3 78.8 76.4 54.9 31.3 12.3 19.6  19.7 
3 3 68.7 84.9 68.6 91.3 91.8 82.4 59.4 30.5 6.63 10.9  10.6 
Mean  68.8 85.0 77.5 91.7 81.5 77.3 60.3 36.1 12.6 14.2  18.3 
SD  0.132 4.56 8.20 2.70 10.4 4.71 5.89 7.52 6.17 4.69  7.08 
Exp. Rep. TCA Uptake (% of control) 
1 1 102 NE NE NE 106 58.5 46.0 43.3 23.1 15.0  37.6 
1 2 105 NE NE NE MV 46.2 37.1 26.6 24.9 16.5  36.6 
1 3 92.8 NE NE NE 115 48.0 44.1 28.3 20.2 9.31  33.0 
Mean  100 - - - 110 50.9 42.4 32.8 22.8 13.6  35.7 
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SD  6.28 - - - 6.38 8.68 6.33 11.8 1.30 1.06  0.73 
Exp. Rep.                                                      TCA Uptake (% of control) 
2 1 86.0 NE NE NE 109 153 96.9 52.9 28.4 15.5  NE 
2 2 105 NE NE NE 137 135 105 49.8 30.2 14.0  NE 
2 3 109 NE NE NE 111 132 76.8 41.1 28.4 15.1  NE 
Mean  100 - - - 119 140 93.1 47.9 29.0 14.9  - 
SD  12.3 - - - 15.4 11.6 14.7 6.14 1.06 0.74  - 
Exp. Rep.                                                       TCA Uptake (% of control) 
3 1 99.9 130 123 137 144 106 96.8 63.8 27.5 17.8  35.6 
3 2 100 117 115 130 114 111 79.8 45.5 17.9 28.5  28.6 
3 3 99.8 123 99.7 133 133 120 86.3 44.4 9.64 15.8  15.4 
Mean  100 124 113 133 118 112 87.6 52.4 18.3 20.7  26.5 
SD  0.192 6.63 11.9 3.93 15.0 6.85 8.55 10.9 8.96 6.81  10.3 
2 µM substrate (
3
H-TCA) and < 1% organic solvent; NC=not calculable; NE=not evaluated; MV=missing value 
(due to technical problem). 
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Appendix Table 3.8 Ki  Determination of Tolvaptan on BSEP-mediated 
3
H-TCA Uptake 
Experiment 1 
TCA (µM) 2 2 2 2 5 5 5 5 10 10 10 10 
Tolvaptan(µM) 0 10 25 50 0 10 25 50 0 10 25 50 
Exp.       Rep.  BSEP-mediated TCA Uptake (pmol/min/mg protein) 
1 1 87.0 63.6 44.5 15.2 186 150 63.4 44.5 269 250 175 62.1 
1 2 75.0 79.2 35.9 6.77 165 135 62.4 51.3 179 274 128 26.9 
1 3 83.2 51.2 39.2 8.32 149 114 79.7 36.1 210 216 155 42.9 
Mean 81.7 64.7 39.9 10.1 167 133 68.5 44.0 219 247 153 44.0 
SD 6.17 14.1 4.34 4.51 18.5 18.3 9.73 7.64 45.9 29.6 23.6 17.6 
TCA (µM) 20 20 20 20 30 30 30 30     
Tolvaptan(µM) 0 10 25 50 0 10 25 50     
Exp.       Rep. BSEP-mediated TCA Uptake (pmol/min/mg protein) 
1 1 479 372 211 47.7 316 288 239 153     
1 2 346 430 156 117 391 348 270 131     
1 3 347 335 153 129 358 206 218 48.0     
Mean  391 379 173 97.8 355 281 242 110     
SD 76.5 48.0 32.6 43.8 37.6 71.4 26.0 55.2     
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Experiment 2 
TCA (µM) 2 2 2 2 5 5 5 5 10 10 10 10 
Tolvaptan (µM) 0 10 25 50 0 10 25 50 0 10 25 50 
Exp.       Rep. BSEP-mediated TCA Uptake (pmol/min/mg protein) 
2 1 104 95.5 60.0 20.1 188 185 139 44.9 279 356 238 94.1 
2 2 101 94.2 55.7 23.8 161 195 163 44.5 299 274 216 111 
2 3 99.7 81.8 44.4 17.0 139 285 131 42.0 212 299 207 100 
Mean 101 90.5 53.4 20.3 163 215 144 43.8 257 310 220 102 
SD 2.01 7.56 8.07 3.41 24.1 43.4 16.6 1.60 56.9 42.0 15.6 8.71 
TCA (µM) 20 20 20 20 30 30 30 30     
Tolvaptan (µM) 0 10 25 50 0 10 25 50     
Exp.       Rep. BSEP-mediated TCA Uptake (pmol/min/mg protein) 
2 1 386 377 228 140 589 533 305 271     
2 2 450 306 293 36.9 454 381 363 264     
2 3 353 353 331 36.7 508 446 302 132     
Mean  396 345 284 71.2 517 453 323 222     
SD 49.3 36.0 52.0 59.5 68.1 76.5 34.6 78.0     
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Experiment 3 
TCA (µM) 2 2 2 2 5 5 5 5 10 10 10 10 
Tolvaptan (µM) 0 10 25 50 0 10 25 50 0 10 25 50 
Exp.       Rep. BSEP-mediated TCA Uptake (pmol/min/mg protein) 
3 1 97.7 103 52.5 11.8 156 150 64.3 45.9 325 267 189 52.9 
3 2 82.1 88.8 61.5 21.2 185 150 64.0 30.6 299 225 197 44.5 
3 3 81.4 95.3 50.1 21.0 176 154 102 25.3 287 282 180 58.8 
Mean 87.1 95.5 54.7 18.0 172 151 76.8 33.9 293 258 188 52.1 
SD 9.24 6.87 6.03 5.37 14.6 2.00 21.9 10.7 19.5 29.8 8.46 7.14 
TCA (µM) 20 20 20 20 30 30 30 30     
Tolvaptan (µM) 0 10 25 50 0 10 25 50     
Exp.       Rep. BSEP-mediated TCA Uptake (pmol/min/mg protein) 
3 1 288 422 341 62.2 436 492 367 184     
3 2 389 435 341 92.8 457 426 260 127     
3 3 323 344 253 60.3 437 488 MV 131     
Mean  333 400 312 71.7 444 469 313 147     
SD 51.2 49.3 50.5 18.2 12.0 37.3 NC 31.7     
MV=missing value (due to technical problem); NC=not calculable.  
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Appendix Table 3.9 Effects of DM-4103 on BSEP-mediated 
3
H-TCA Uptake 
                               DM-4103 (µM)   
  0 0.1 0.3 1 2 5 10 20 30 40 50 75   
Exp. Rep.                                       BSEP-mediated TCA Uptake (pmol/min/mg protein) 
1 1 93.3 NE NE NE NE 34.4 20.8 17.2 7.73 7.13 0.7 0   
1 2 95.5 NE NE NE NE 25.4 16.7 11.3 7.28 1.57 0 2.90   
1 3 74.8 NE NE NE NE 26.1 15.9 14.4 6.23 5.09 0 2.04   
Mean  87.9 - - - - 28.6 17.8 14.3 7.08 4.60 0 1.55   
SD  11.4 - - - - 5.02 2.65 2.97 0.77 2.81 NC NC   
  BSEP-mediated TCA Uptake (pmol/min/mg protein) 
2 1 68.7 83.7 64.8 64.5 48.1 37.4 26.6 14.3 NE NE NE NE   
2 2 70.8 74.3 62.0 61.2 50.6 35.2 12.0 9.49 NE NE NE NE   
2 3 67.0 68.7 53.7 55.6 50.4 31.0 20.5 11.7 NE NE NE NE   
Mean  68.9 75.6 60.1 60.4 49.7 34.5 19.7 11.8 - - - -   
SD  1.92 7.60 5.77 4.50 1.40 3.21 7.33 2.40 - - - -   
  BSEP-mediated TCA Uptake (pmol/min/mg protein) 
3 1 72.1 80.2 69.3 57.3 52.1 41.9 34.8 16.1 NE NE NE NE   
3 2 66.6 71.5 62.5 49.8 46.2 31.8 24.9 12.1 NE NE NE NE   
3 3 66.3 66.7 65.5 53.2 43.5 23.6 24.6 9.74 NE NE NE NE   
Mean  68.3 72.8 65.8 53.5 47.3 32.4 28.1 12.6 - - - -   
SD  3.31 6.87 3.39 3.73 4.39 9.16 5.77 3.20 - - - -   
  TCA Uptake (% of control) 
1 1 106 NE NE NE NE 39.1 23.6 19.6 8.79 8.14 1.43 0   
1 2 109 NE NE NE NE 28.8 18.9 12.8 8.28 1.81 0 3.30   
1 3 85.1 NE NE NE NE 29.7 18.0 16.4 7.09 5.81 0 2.33   
Mean  100 - - - - 32.6 20.2 16.3 8.05 5.23 0 1.76   
SD  12.9 - - - - 5.70 3.02 3.38 0.87 3.20 NC 1.69   
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 TCA Uptake (% of control) 
2 1 99.9 121 94.0 93.6 69.8 54.2 38.5 20.7 NE NE NE NE   
2 2 103 108 89.9 88.7 73.5 51.1 17.4 13.7 NE NE NE NE   
2 3 97.4 99.8 77.9 80.6 73.2 45.1 29.8 17.0 NE NE NE NE   
Mean  100 110 87.3 87.8 72.2 50.1 28.6 17.2 - - - -   
SD  2.79 11.0 8.38 6.53 2.04 4.66 10.6 3.48 - - - -   
  TCA Uptake (% of control) 
3 1 106 117 101 83.8 76.3 61.3 50.9 23.5 NE NE NE NE   
3 2 97.4 105 91.5 73.0 67.6 46.5 36.5 17.7 NE NE NE NE   
3 3 97.0 97.6 95.9 77.9 63.7 34.5 36.1 14.3 NE NE NE NE   
Mean  100 107 96.3 78.2 69.2 47.4 41.1 18.5 - - - -   
SD  4.84 10.1 4.96 5.46 6.43 13.4 8.44 4.68 - - - -   
n=1 for initial concentration range (30-75 μM); n=2-3 for lower ranges (0.1-20 μM) used to determine IC50. 
NC=not calculable; NE=not evaluated. 
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Appendix Table 3.10 Determination of Inhibition Constant (Ki) for DM-4103 on BSEP-
mediated 
3
H-TCA Uptake 
Experiment 1 
TCA (µM) 2 2 2 2 5 5 5 5 10 10 10 10 
DM-4103(µM) 0 2 5 20 0 2 5 20 0 2 5 20 
Exp.       Rep. BSEP-mediated TCA Uptake (pmol/min/mg protein) 
1 1 73.0 63.2 40.6 12.4 190 130 84.5 43.9 365 258 100 89.0 
1 2 79.2 53.0 41.3 12.2 203 127 77.1 34.2 274 241 152 82.1 
1 3 80.7 56.5 33.5 9.70 228 141 77.0 28.7 298 297 106 71.7 
Mean 77.6 57.5 38.5 11.4 207 132 79.5 35.6 312 265 119 80.9 
SD 4.10 5.18 4.32 1.50 19.6 7.08 4.32 7.72 47.3 28.5 28.4 8.73 
TCA (µM) 20 20 20 20 30 30 30 30     
DM-4103 (µM) 0 2 5 20 0 2 5 20     
Exp.       Rep. BSEP-mediated TCA Uptake (pmol/min/mg protein) 
1 1 545 353 276 203 600 480 349 160     
1 2 511 380 311 155 530 579 334 217     
1 3 554 402 274 121 458 510 300 147     
Mean  537 378 287 159 529 523 328 175     
SD 22.7 24.5 20.5 41.3 71.3 50.9 25.3 37.0     
 
Experiment 2 
TCA (µM) 2 2 2 2 5 5 5 5 10 10 10 10 
DM-4103(µM) 0 2 5 20 0 2 5 20 0 2 5 20 
Exp.       Rep. BSEP-mediated TCA Uptake (pmol/min/mg protein) 
2 1 85.4 50.4 45.1 17.3 194 145 87.4 26.2 286 225 96.9 63.6 
2 2 85.3 40.8 33.6 11.9 209 111 101 12.6 236 215 164 68.3 
2 3 87.2 40.8 35.9 16.4 183 110 70.2 7.04 232 179 159 61.2 
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Mean 86.0 44.0 38.2 15.2 195 122 86.1 15.3 251 207 140 64.3 
SD 1.07 5.51 6.10 2.87 12.7 20.0 15.4 9.88 30.0 24.0 37.4 3.61 
TCA (µM) 20 20 20 20 30 30 30 30     
DM-4103 (µM) 0 2 5 20 0 2 5 20     
Exp.       Rep. BSEP-mediated TCA Uptake (pmol/min/mg protein) 
2 1 299 347 216 48.7 437 394 350 182     
2 2 419 318 179 MV 516 505 440 188     
2 3 300 363 144 51.8 440 458 465 114     
Mean  340 343 180 50.3 464 452 418 162     
SD 69.1 22.8 35.9 NC 44.9 55.7 60.5 40.9     
MV=missing value (due to technical problem); NC=not calculable. 
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Experiment 3 
TCA (µM) 2 2 2 2 5 5 5 5 10 10 10 10 
DM-4103(µM) 0 2 5 20 0 2 5 20 0 2 5 20 
Exp.       Rep. BSEP-mediated TCA Uptake (pmol/min/mg protein) 
3 1 63.5 55.4 33.9 13.2 155 116 98.3 50.5 288 200 219 53.0 
3 2 60.6 49.5 29.8 9.21 153 127 106 63.5 209 212 179 25.2 
3 3 56.2 54.0 39.4 5.09 186 107 95.5 27.2 247 205 169 37.2 
Mean 60.1 53.0 34.3 9.17 165 117 99.8 47.1 248 206 189 38.5 
SD 3.68 3.09 4.81 4.06 18.5 9.87 5.20 18.4 39.5 6.10 26.5 13.9 
TCA (µM) 20 20 20 20 30 30 30 30     
DM-4103 
(µM) 
0 2 5 20 0 2 5 20     
Exp.       Rep. BSEP-mediated TCA Uptake (pmol/min/mg protein) 
3 1 382 314 202 0 418 394 277 221     
3 2 580 225 293 0 548 296 417 192     
3 3 315 236 242 0 377 434 321 131     
Mean  426 258 246 0 448 375 339 182     
SD 138 48.7 45.4 NC 89.1 70.9 71.6 46.0     
NC=not calculable   
  
 
3
2
8
 
Table 3.11 Effects of DM-4107 on BSEP-mediated 
3
H-TCA Uptake 
                                DM-4107 (µM)  RIF (µM) 
          0 10 20 50 100 150 200  50 
Exp. Rep.                   BSEP-mediated TCA Uptake (pmol/min/mg protein) 
1 1 82.8 83.3 63.9 61.8 29.5 31.8 13.1  35.3 
1 2 82.6 81.2 72.2 63.3 30.4 25.0 25.2  33.0 
1 3 84.4 76.6 53.3 60.2 32.9 47.2 29.8  29.9 
Mean  83.3 80.4 63.1 61.8 31.0 34.7 22.7  32.8 
SD  1.01 3.46 9.43 1.54 1.76 11.4 8.62  2.70 
                          BSEP-mediated TCA Uptake (pmol/min/mg protein) 
2 1 56.1 50.8 56.3 69.0 42.6 19.4 12.3  46.6 
2 2 60.4 49.2 47.6 27.9 51.7 13.4 6.65  30.7 
2 3 57.7 45.0 50.9 47.7 36.3 17.9 MV  23.5 
Mean  58.1 48.3 51.6 48.2 43.5 16.9 9.49  33.6 
SD  2.17 2.97 4.39 20.6 7.73 3.12 NC  11.8 
                          BSEP-mediated TCA Uptake (pmol/min/mg protein) 
3 1 64.9 75.3 61.2 61.4 44.3 34.3 22.3  NE 
3 2 60.9 69.7 50.7 61.2 37.8 36.2 17.9  NE 
3 3 68.0 71.4 65.6 51.6 33.4 32.5 20.0  NE 
  
 
3
2
9
 
Mean  64.6 72.1 59.1 58.1 38.5 34.4 20.1  - 
SD  3.58 2.88 7.64 5.60 5.50 1.83 2.18  - 
  TCA Uptake (% of control) 
1 1 99.4 100 76.7 74.2 35.5 38.2 15.7  42.4 
1 2 99.2 97.5 86.6 76.0 36.5 30.0 30.3  39.7 
1 3 101 92.0 64.0 72.3 39.5 56.7 35.8  35.9 
Mean  100 96.5 75.8 74.2 37.2 41.7 27.3  39.3 
SD  1.22 4.16 11.3 1.85 2.12 13.7 10.4  3.24 
                                    TCA Uptake (% of control) 
2 1 96.6 87.4 97.0 119 73.3 33.4 21.3  76.6 
2 2 104 84.7 82.0 48.0 88.9 23.1 11.5  49.2 
2 3 99.4 77.5 87.7 82.2 62.4 30.8 MV  36.9 
Mean  100 83.2 88.9 83.1 75.0 29.1 16.3  57.9 
SD  3.73 5.12 7.57 35.4 13.3 5.36 NC  20.3 
   TCA Uptake (% of control) 
3 1 101 117 94.7 95.0 68.6 53.1 34.5  NE 
3 2 94.2 108 78.5 94.8 58.5 56.1 27.8  NE 
3 3 105 111 101 79.9 51.7 50.4 31.0  NE 
Mean  100 112 91.6 89.9 59.6 53.2 31.1  - 
  
 
3
3
0
 
SD  5.55 4.45 11.8 8.67 8.51 2.84 3.38  - 
MV=missing value (due to technical problem); NC=not calculable; NE=not evaluated; 2 µM substrate (
3
H-TCA) and < 1% organic solvent 
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Appendix Table 3.12 Effects of Tolvaptan on MRP2-mediated 
3
H-E217G Uptake 
                               Tolvaptan (µM)  
MK-571         
(µM) 
  0 0.1 1 3 10 20 50  50 
Exp. Rep. MRP2-Mediated E217G Uptake (pmol/min/mg protein) 
1 1 2330 2560 2400 2400 3390 3130 2780  171 
1 2 2350 2750 2330 2250 2940 3180 2340  175 
1 3 2030 2290 2530 3290 2960 3030 2890  170 
Mean  2240 2530 2420 2650 3090 3110 2670  172 
SD  183 233 101 558 254 77.0 289  2.46 
Exp. Rep. MRP2-Mediated E217G Uptake (pmol/min/mg protein) 
2 1 2100 2320 3120 3410 4130 3330 2630  45.1 
2 2 2330 2480 3090 3780 3080 2920 2620  135 
2 3 2360 2310 3020 3930 3000 3260 2720  87.1 
Mean  2260 2370 3080 3710 3400 3170 2660  88.9 
SD  146 95.3 51.1 268 628 220 55.9  44.8 
Exp. Rep. MRP2-Mediated E217G Uptake (pmol/min/mg protein) 
3 1 2980 2490 3790 3400 3920 3400 3370  176 
3 2 3170 2490 3220 3720 3630 2830 3220  195 
3 3 2930 2120 3060 3050 3740 2830 3240  133 
Mean  3030 2370 3360 3390 3760 3020 3270  168 
SD  124 215 386 334 150 330 79.9  31.7 
Exp. Rep. MRP2-Mediated E217G Uptake (% of control) 
1 1 104 114 107 108 151 140 124  7.64 
1 2 105 123 104 101 131 142 105  7.82 
1 3 90.6 102 113 147 132 135 129  7.61 
Mean  100 113 108 118 138 139 119  7.69 
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SD  8.18 10.4 4.51 24.9 11.4 3.44 12.9  0.110 
Exp. Rep. MRP2-Mediated E217G Uptake (% of control) 
2 1 93 102 138 151 182 147 116  1.99 
2 2 103 109 137 167 136 129 116  5.95 
2 3 104 102 134 173 133 144 120  3.85 
Mean  100 105 136 164 150 140 117  3.93 
SD  6.45 4.21 2.26 11.8 27.8 9.70 2.47  1.98 
Exp. Rep. MRP2-Mediated E217G Uptake (% of control) 
3 1 98.6 82.1 125 112 130 112 111  5.80 
3 2 105 82.4 106 123 120 93.6 106  6.44 
3 3 96.8 70.0 101 101 123 93.6 107  4.39 
Mean  100 78.2 111 112 124 100 108  5.54 
SD  4.11 7.11 12.7 11.1 4.94 10.9 2.64  1.05 
50 µM substrate (
3
H- E217G) and < 1% organic solvent. 
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Appendix Table 3.13 Effects of Tolvaptan on MRP3-mediated 
3
H- E217G Uptake 
                               Tolvaptan (µM)  
MK-571         
(µM) 
  0 0.1 1 3 10 20 50  50 
Exp. Rep. MRP3-Mediated E217G Uptake (pmol/min/mg protein) 
1 1 126 84.0 139 146 103 101 69.8  38.4 
1 2 98.9 81.4 135 129 ND 95.0 71.5  48.2 
1 3 114 97.9 127 122 123 91.2 65.1  53.5 
Mean  113 87.8 134 132 113 95.8 68.8  46.7 
SD  13.4 8.89 5.87 12.8 NC 5.11 3.30  7.66 
Exp. Rep. MRP3-Mediated E217G Uptake (pmol/min/mg protein) 
2 1 123 136 137 151 102 151 94.2  45.1 
2 2 139 144 143 148 101 128 64.8  135 
2 3 152 149 120 134 133 108 71.5  87.1 
Mean  138 143 133 144 112 129 76.8  88.9 
SD  14.3 6.44 12.0 9.45 18.1 21.3 15.4  44.8 
Exp. Rep. MRP3-Mediated E217G Uptake (pmol/min/mg protein) 
3 1 61.9 49.3 73.5 46.2 53.5 47.6 54.7  ND 
3 2 52.3 50.5 57.3 73.6 48.0 61.3 50.3  6.7 
3 3 43.0 ND 37.2 ND 38.8 39.1 46.4  23.8 
Mean  52.4 49.9 56.0 59.9 46.8 49.4 50.5  15.3 
SD  9.43 NC 18.2 19.3 7.44 11.2 4.14  NC 
Exp. Rep. MRP3-Mediated E217G Uptake (% of control) 
1 1 111    74.5 123 130 91.1 89.9 62.0  34.1 
1 2 87.7    72.3 120 114 ND 84.4 63.5  42.8 
1 3 101    86.9 113 108 109 80.9 57.8  47.5 
Mean  100 77.9 119 117 100 85.1 61.1  41.4 
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SD  11.9 7.89 5.21 11.3 NC 4.54 2.93  6.80 
Exp. Rep. MRP3-Mediated E217G Uptake (% of control) 
2 1 89.3 98.3 99.4 109 73.5 109 68.1  32.4 
2 2 101 104 103 107 73.1 92.3 46.8  27.1 
2 3 110 108 86.6 96.6 96.1 78.4 51.7  22.0 
Mean  100 103 96.3 104 80.9 93.3 55.5  27.2 
SD  10.4 4.66 8.64 6.83 13.1 15.4 11.1  5.23 
Exp. Rep. MRP3-Mediated E217G Uptake (% of control) 
3 1 118 94.0 140 88.2 102 90.9 104  ND 
3 2 99.9 96.4 109 140 91.6 117 95.9  12.9 
3 3 82.1 ND 71.0 ND 74.1 74.6 88.7  45.5 
Mean  100 95.2 107 114 89.3 94.2 96.3  29.2 
SD  18.0 1.63 34.7 NC 14.2 21.4 7.90  NC 
10 µM substrate (
3
H- E217G) and < 1% organic solvent; NC=not calculable; ND=not determined (sample processing 
error) 
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Appendix Table 3.14 Effects of Tolvaptan on MRP4-mediated 
3
H-DHEAS Uptake 
                               Tolvaptan (µM)  
MK-571         
(µM) 
  0 0.1 1 3 10 20 50  50 
Exp. Rep. MRP4-Mediated DHEAS Uptake (pmol/min/mg protein) 
1 1 113 170 152 155 167 148 94.6  BQL (0) 
1 2 128 166 141 154 140 139 120  BQL (0) 
1 3 114 136 127 123 113 135 132  11.5 
Mean  118 157 140 144 140 141 116  NC 
SD  8.07 18.3 12.8 17.8 26.8 6.87 19.2  NC 
Exp. Rep. MRP4-Mediated DHEAS Uptake (pmol/min/mg protein) 
2 1 196 224 189 166 224 259 153  BQL (0) 
2 2 168 285 166 191 185 178 138  7.25 
2 3 143 193 180 169 180 158 135  15.3 
Mean  169 225 178 176 196 198 142  7.68 
SD  26.4 32.5 11.3 13.7 24.1 53.2 9.55  7.53 
Exp. Rep. MRP4-Mediated DHEAS Uptake (pmol/min/mg protein) 
3 1 212 196 221 174 176 190 178  BQL (0) 
3 2 204 221 186 223 177 190 151  0.382 
3 3 183 178 171 171 153 143 164  0.763 
Mean  200 198 193 193 169 174 164  0.382 
SD  14.9 21.5 25.2 35.1 13.6 27.0 13.6  0.382 
Exp. Rep. MRP4-Mediated DHEAS Uptake (% of control) 
1 1 95.4 144 129 131 141 125 80.0  BQL (0) 
1 2 108 140 120 130 119 118 101  BQL (0) 
1 3 96.8 115 107 104 95.9 114 112  9.74 
Mean  100 133 119 122 119 119 97.7  NC 
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SD  6.80 15.4 10.8 15.1 22.7 5.81 16.2  NC 
Exp. Rep. MRP4-Mediated DHEAS Uptake (% of control) 
2 1 116 132 112 98.3 133 153 90.5  BQL (0) 
2 2 99.4 153 98.4 113 109 106 81.6  4.29 
2 3 84.7 114 106 100 107 93.4 80.0  9.07 
Mean  100 133 106 104 116 117 84.0  4.54 
SD  15.6 19.2 6.70 8.09 14.3 31.5 5.65  4.45 
Exp. Rep. MRP4-Mediated DHEAS Uptake (% of control) 
3 1 106 98.2 110 86.9 88.1 95.2 89.1  BQL (0) 
3 2 102 111 93.1 117 88.6 94.8 75.6  0.191 
3 3 91.7 89.1 85.7 85.6 76.6 71.7 81.9  0.382 
Mean  100 99.2 96.4 96.4 84.4 87.2 82.2  0.191 
SD  7.46 10.8 12.6 17.5 6.80 13.5 6.78  0.191 
2 µM substrate (
3
H- DHEAS) and < 1% organic solvent; BQL=below quantitation limit; NC=not calculable 
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Appendix Table 3.15 Effects of DM-4103 on MRP2-mediated 
3
H-E217G Uptake 
                               DM-4103 (µM)  
MK-571         
(µM) 
  0 0.1 1 3 10 20 50  50 
Exp. Rep. MRP2-Mediated E217G Uptake (pmol/min/mg protein) 
1 1 2760 3650 3860 3440 2760 2570 1050  62.7 
1 2 2700 3190 3190 3330 2740 2730 961  92.4 
1 3 3500 3980 3750 3270 2690 2500 1430  190 
Mean  2980 3610 3600 3350 2730 2600 1150  115 
SD  444 396 358 85.8 35.0 119 250  66.9 
Exp. Rep. MRP2-Mediated E217G Uptake (pmol/min/mg protein) 
2 1 3160 3280 3870 2670 3170 2580 1230  103 
2 2 2980 3290 3530 3340 2830 2310 1140  160 
2 3 3140 3270 3910 2800 2660 2100 1210  181 
Mean  3090 3280 3770 2940 2880 2330 1190  148 
SD  100 12.7 209 356 258 244 47.1  40.4 
Exp. Rep. MRP2-Mediated E217G Uptake (pmol/min/mg protein) 
3 1 2720 2770 2530 2700 2740 1670 894  36.1 
3 2 2510 2670 2710 2860 2730 1840 1020  30.3 
3 3 2870 2600 2310 2660 2520 2080 946  14.5 
Mean  2700 2680 2520 2740 2660 1860 954  27.0 
SD  180 88.1 196 107 126 202 63.7  11.2 
Exp. Rep. MRP2-Mediated E217G Uptake (% of control) 
1 1 92.4 122 129 115 92.5 86.1 35.1  2.10 
1 2 90.4 107 107 112 91.9 91.4 32.2  3.10 
1 3 117 133 126 110 90.2 83.6 47.9  6.38 
Mean  100 121 121 112 91.5 87.1 38.4  3.86 
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SD  14.9 13.3 12.0 2.88 1.17 3.99 8.36  2.24 
Exp. Rep. MRP2-Mediated E217G Uptake (% of control) 
2 1 102 106 125 86.3     102 83.5 39.7  3.33 
2 2 96.3 106 114 108 91.3 74.8 36.8  5.18 
2 3 102 106 126 90.4 86.0 67.8 39.1  5.85 
Mean  100 106 122 94.9 93.2 75.3 38.6  4.79 
SD  3.23 0.411 6.77 11.5 8.33 7.88 1.52  1.31 
Exp. Rep. MRP2-Mediated E217G Uptake (% of control) 
3 1 101 103 93.7 99.8 101 61.9 33.1  1.34 
3 2 93.0 98.9 100 106 101 68.2 37.8  1.12 
3 3 106 96.2 85.6 98.3 93.2 76.9 35.0  0.538 
Mean  100 99.2 93.2 101 98.5 69.0 35.3  1.00 
SD  6.65 3.26 7.26 3.96 4.67 7.49 2.36  0.413 
50 µM substrate (
3
H- E217G) and < 1% organic solvent; NC=not calculable 
 
  
 339 
 
Appendix Table 3.16 Effects of DM-4103 on MRP3-mediated 
3
H-E217G Uptake 
                               DM-4103 (µM)  
MK-571     
(µM) 
  0 0.1 1 3 10 20 50  50 
Exp. Rep. MRP3-Mediated E217G Uptake (pmol/min/mg protein) 
1 1 220 176 181 183 177 129 71.1  42.0 
1 2 168 178 135 148 119 80.3 61.1  36.4 
1 3 182 198 140 ND 115 109 62.3  46.8 
Mean  190 184 152 166 137 106 64.8  41.7 
SD  26.8 12.3 25.4 NC 34.9 24.3 5.47  5.20 
Exp. Rep. MRP3-Mediated E217G Uptake (pmol/min/mg protein) 
2 1 163 170 129 106 156 137 56.8  51.7 
2 2 143 131 167 109 121 147 82.6  57.3 
2 3 126 130 194 174 146 98.4 68.0  40.2 
Mean  144 144 163 130 141 127 69.1  49.7 
SD  18.3 23.0 32.9 38.2 17.7 25.7 12.9  8.71 
Exp. Rep. MRP3-Mediated E217G Uptake (pmol/min/mg protein) 
3 1 124 144 124 ND 113 105 43.8  35.9 
3 2 135 144 140 184 136 120 63.9  28.1 
3 3 158 ND 136 119 106 100 59.3  42.6 
Mean  139 144 133 151 118 108 55.7  35.5 
SD  17.4 NC 8.30 NC 15.7 10.3 10.5  7.25 
Exp. Rep. MRP3-Mediated E217G Uptake (% of control) 
1 1 116    92.8 95.3 96.4 93.3 67.7 37.4  22.1 
1 2 88.3    93.9 71.0 78.0 62.9 42.3 32.2  19.2 
1 3 96.1    104 73.6 ND 60.3 57.3 32.8  24.6 
Mean  100 97.1 80.0 87.2 72.2 55.8 34.1  22.0 
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SD  14.1 6.46 13.4 NC 18.4 12.8 2.88  2.74 
Exp. Rep. MRP3-Mediated E217G Uptake (% of control) 
2 1 113 118 89.4 73.2 108 94.8 39.4  35.8 
2 2 99.4 90.7 116 75.9 84.1 102 57.3  39.7 
2 3 87.6 90.5 135 120 101 68.2 47.2  27.9 
Mean  100 99.8 113 89.9 97.7 88.4 47.9  34.5 
SD  12.7 16.0 22.8 26.5 12.3 17.8 8.96  6.04 
Exp. Rep. MRP3-Mediated E217G Uptake (% of control) 
3 1 89.2 104 89.2 ND 81.2 75.4 31.5  25.8 
3 2 97.1 104 101 132 97.6 86.1 46.0  20.2 
3 3 114 ND 97.8 85.6 76.0 71.8 42.7  30.6 
Mean  100 104 95.9 109 84.9 77.8 40.1  25.6 
SD  12.5 NC 5.97 NC 11.3 7.44 7.58  5.22 
10 µM substrate (
3
H- E217G) and < 1% organic solvent; NC=not calculable; ND=not determined (sample processing 
error) 
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Appendix Table 3.17 Effects of DM-4103 on MRP4-mediated 
3
H-DHEAS Uptake 
                               DM-4103 (µM)  
MK-571         
(µM) 
  0 0.1 1 3 10 20   50 
Exp. Rep. MRP4-Mediated DHEAS Uptake (pmol/min/mg protein) 
1 1 183 195 180 110 67.9 25.9   5.26 
1 2 189 194 199 108 67.6 23.4   0.770 
1 3 169 185 179 103 58.5 20.1   1.56 
Mean  180 191 186 107 64.7 23.1   2.53 
SD  10.1 5.53 11.3 3.22 5.32 2.90   2.40 
Exp. Rep. MRP4-Mediated DHEAS Uptake (pmol/min/mg protein) 
2 1 228 237 196 135 63.9 35.0   2.72 
2 2 229 217 181 121 43.2 30.1   3.27 
2 3 217 197 162 124 43.0 20.2   1.30 
Mean  225 217 180 127 50.0 28.4   2.43 
SD  6.93 19.9 17.4 7.31 12.0 7.52   1.02 
Exp. Rep. MRP4-Mediated DHEAS Uptake (pmol/min/mg protein) 
3 1 171 213 147 120 36.2 35.9   BQL (0) 
3 2 155 117 135 107 30.4 33.7   BQL (0) 
3 3 167 145 125 71.1 26.7 26.9   BQL (0) 
Mean  164 158 136 99.6 31.1 32.1   NC 
SD  7.97 49.0 11.1 25.5 4.76 4.69   NC 
Exp. Rep. MRP4-Mediated DHEAS Uptake (% of control) 
1 1 101 108 99.8 60.9 37.7 14.4   2.92 
1 2 105 107 110 59.7 37.5 13.0   0.427 
1 3 93.8 103 99.4 57.4 32.5 11.2   0.863 
Mean  100 106 103 59.3 35.9 12.9   1.40 
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SD  5.61 3.07 6.25 1.79 2.95 1.61   1.33 
Exp. Rep. MRP4-Mediated DHEAS Uptake (% of control) 
2 1 102 106 87.5 60.1 28.5 15.6   1.21 
2 2 102 96.9 80.5 54.0 19.2 13.4   1.46 
2 3 96.4 87.9 72.0 55.3 19.2 9.00   0.578 
Mean  100 96.9 80.0 56.5 22.3 12.7   1.08 
SD  3.08 8.86 7.75 3.26 5.36 3.35   0.454 
Exp. Rep. MRP4-Mediated DHEAS Uptake (% of control) 
3 1 104 129 89.6 73.2 22.0 21.8   BQL (0) 
3 2 94.5 71.5 82.1    65.4 18.5 20.5   BQL (0) 
3 3 102 88.2 76.1 43.2 16.3 16.4   BQL (0) 
Mean  100 96.2 82.6 60.6 18.9 19.6   NC 
SD  4.85 29.8 6.76 15.5 2.90 2.85   NC 
2 µM substrate (
3
H- DHEAS) and < 1% organic solvent; BQL=below quantitation limit; NC=not calculable 
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Appendix Table 3.18 Effects of DM-4107 on MRP2-mediated 
3
H-E217G Uptake 
                               DM-4107 (µM)  
MK-571         
(µM) 
  0 10 20 50 100 200  50 
Exp. Rep. MRP2-Mediated E217G Uptake (pmol/min/mg protein) 
1 1 2600 2510 2590 3180 3170 1950  BQL (0) 
1 2 ND 2470 2380 2930 2380 2630  149 
1 3 ND 2330 2480 3120 2970 2070  BQL (0) 
Mean  2600 2440 2480 3080 2840 2210  NC 
SD  NC 97.7 106 129 416 362  NC 
Exp. Rep. MRP2-Mediated E217G Uptake (pmol/min/mg protein) 
2 1 3290 2530 2850 3040 3050 1980  182 
2 2 3130 2840 3070 2700 2940 1960  201 
2 3 3170 2840 3020 2890 2770 1650  206 
Mean  3200 2740 2980 2880 2920 1860  12.5 
SD  84.2 180 112 173 138 185  196 
Exp. Rep. MRP2-Mediated E217G Uptake (pmol/min/mg protein) 
3 1 2820 1940 2520 2620 2220 1570  187 
3 2 2510 1580 2630 2550 2260 1560  131 
3 3 2890 1520 2420 2350 2070 1610  106 
Mean  2740 1680 2520 2510 2180 1580  141 
SD  201 226 107 137 102 29.7  41.7 
Exp. Rep. MRP2-Mediated E217G Uptake (% of control) 
1 1 100 96.6 100 122 122 74.9  BQL (0) 
1 2 ND 95.0 91.4 113 91.3 101  5.75 
1 3 ND 89.5 95.4 120 114 79.5  BQL (0) 
Mean  100 93.7 95.5 118 109 85.1  NC 
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SD  NC 3.76 4.08 4.95 16.0 13.9  NC 
Exp. Rep. MRP2-Mediated E217G Uptake (% of control) 
2 1 103 79.1 89.2 95.1 95.3 62.0  5.70 
2 2 97.9 88.8 96.0 84.3 91.9 61.2  6.30 
2 3 99.1 88.9 94.3 90.5 86.7 51.6  6.44 
Mean  100 85.6 93.2 90.0 91.3 58.3  6.14 
SD  2.63 5.64 3.50 5.40 4.31 5.77  0.392 
Exp. Rep. MRP2-Mediated E217G Uptake (% of control) 
3 1 103 70.7 92.1 95.7 81.2 57.2  6.83 
3 2 91.6 57.7 96.2 93.1 82.5 57.0  4.77 
3 3 105 55.4 88.3 86.0 75.4 59.0  3.86 
Mean  100 61.3 92.2 91.6 79.7 57.7  5.15 
SD  7.35 8.27 3.93 5.00 3.74 1.09  1.53 
50 µM substrate (
3
H- E217G) and < 1% organic solvent; BQL=below quantitation limit; NC=not calculable; ND=not 
determined (sample processing error) 
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Appendix Table 3.19 Effects of DM-4107 on MRP3-mediated 
3
H- E217G Uptake 
                               DM-4107 (µM)  
MK-571         
(µM) 
  0 10 20 50 100 200  50 
Exp. Rep. MRP3-Mediated E217G Uptake (pmol/min/mg protein) 
1 1 176 194 134 118 61.4 57.8  46.3 
1 2 215 133 122 74.9 63.8 49.3  49.3 
1 3 181 ND 136 ND 59.2 44.0  43.6 
Mean  191 164 131 96.6 61.5 50.4  46.4 
SD  21.0 NC 7.88 NC 2.28 6.94  2.89 
Exp. Rep. MRP3-Mediated E217G Uptake (pmol/min/mg protein) 
2 1 130 123 97.1 86.2 67.4 57.3  57.3 
2 2 155 144 113 70.2 55.0 50.5  55.0 
2 3 168 125 94.3 93.6 47.1 48.6  37.8 
Mean  151 131 101 83.4 56.5 52.1  50.0 
SD  19.2 11.7 10.0 11.9 10.3 4.58  10.6 
Exp. Rep. *MRP3-Mediated E217G Uptake (pmol/min/mg protein) 
3 1 15.5 11.1 9.87 10.6 7.35 2.06  1.59 
3 2 14.8 10.1 9.64 7.59 6.07 6.94  0.802 
3 3 11.6 10.4 12.0 6.65 6.29 3.11  ND 
Mean  14.0 10.5 10.5 8.26 6.57 4.04  1.20 
SD  2.09 0.497 1.29 2.04 0.682 2.57  NC 
Exp. Rep. MRP3-Mediated E217G Uptake (% of control) 
1 1 92.4 102 70.4 62.1 32.2 30.3  24.3 
1 2 113 69.6 63.8 39.3 33.5 25.9  25.9 
1 3 94.9 ND 71.5 ND 31.1 23.1  22.9 
Mean  100 85.8 68.6 50.7 32.2 26.4  24.3 
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SD  11.0 NC 4.14 16.1 1.20 3.64  1.52 
Exp. Rep. MRP3-Mediated E217G Uptake (% of control) 
2 1 86.1 81.3 64.3 57.1 44.6 37.9  37.9 
2 2 103 95.3 74.7 46.5 36.4 33.4  36.4 
2 3 111 82.9 62.4 62.0 31.2 32.2  25.0 
Mean  100 86.5 67.1 55.2 37.4 34.5  33.1 
SD  12.7 7.71 6.63 7.91 6.80 3.03  7.04 
Exp. Rep. *MRP3-Mediated E217G Uptake (% of control) 
3 1 111 79.2 70.6 75.5 52.6 14.8  11.4 
3 2 106 72.2 69.0 54.3 43.4 49.6  5.74 
3 3 83.0 74.6 85.7 47.6 45.0 22.2  ND 
Mean  100 75.3 75.1 59.1 47.0 28.9  8.57 
SD  14.9 3.56 9.22 14.6 4.88 18.4  NC 
10 µM substrate (
3
H- E217G) and < 1% organic solvent; NC=not calculable; ND=not determined (sample processing 
error);*MRP3 lot number 12-Feb-2015 was used for experiment 3 
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Appendix Table 3.20 Effects of DM-4107 on MRP4-mediated 
3
H-DHEAS Uptake 
                               DM-4107 (µM)  
MK-571         
(µM) 
  0 10 20 50 100 200  50 
Exp. Rep. MRP4-Mediated DHEAS Uptake (pmol/min/mg protein) 
1 1 164 139 109 57.2 38.5 23.4  7.57 
1 2 124 122 61.6 67.2 36.8 20.9  7.21 
1 3 121 107 108 68.3 34.4 15.7  3.29 
Mean  136 123 93.0 64.3 36.6 20.0  6.02 
SD  23.8 15.9 27.2 6.12 2.03 3.90  2.37 
Exp. Rep. MRP4-Mediated DHEAS Uptake (pmol/min/mg protein) 
2 1 259 184 136 89.0 38.9 27.0  8.1 
2 2 226 187 139 82.2 63.0 20.6  BQL (0) 
2 3 220 172 134 88.4 49.2 19.0  BQL (0) 
Mean  235 181 136 86.5 50.4 22.2  NC 
SD  20.8 7.75 2.42 3.78 12.1 4.22  NC 
Exp. Rep. MRP4-Mediated DHEAS Uptake (pmol/min/mg protein) 
3 1 186 149 119 92.4 63.5 32.3  8.71 
3 2 175 189 127 70.2 40.1 18.5  8.82 
3 3 152 131 108 64.6 24.8 30.0  BQL (0) 
Mean  171 157 118 75.7 42.8 26.9  5.85 
SD  17.5 29.8 9.37 14.7 19.5 7.43  5.06 
Exp. Rep. MRP4-Mediated DHEAS Uptake (% of control) 
1 1 120 101 80.0 41.9 28.2 17.1  5.55 
1 2 91.0 89.7 45.1 49.3 27.0 15.3  5.28 
1 3 88.9 78.2 79.4 50.1 25.2 11.5  2.41 
Mean  100 89.8 68.2 47.1 26.8 14.6  4.41 
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SD  17.4 11.7 20.0 4.49 1.49 2.86  1.74 
Exp. Rep. MRP4-Mediated DHEAS Uptake (% of control) 
2 1 110 78.2 57.7 37.8 16.5 11.5  3.44 
2 2 96.2 79.3 58.9 34.9 26.8 8.75  BQL (0) 
2 3 93.7 73.2 56.8 37.6 20.9 8.07  BQL (0) 
Mean  100 76.9 57.8 36.8 21.4 9.44  NC 
SD  8.86 3.29 1.03 1.61 5.14 1.79  NC 
Exp. Rep. MRP4-Mediated DHEAS Uptake (% of control) 
3 1 109 87.1 69.4 54.1 37.2 18.9  5.10 
3 2 102 111 74.4 41.1 23.5 10.8  5.16 
3 3 88.8 76.9 63.4 37.8 14.5 17.6  BQL (0) 
Mean  100 91.6 69.1 44.3 25.0 15.8  3.42 
SD  10.2 17.4 5.48 8.60 11.4 4.35  2.96 
2 µM substrate (
3
H- DHEAS) and < 1% organic solvent; BQL=below quantitation limit; NC=not calculable 
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Appendix Table 3.21 Time- and temperature-dependent accumulation of tolvaptan in SCHH. 
Time (min) 
TVP 
(μM) 
Total 
Accumulation 
(pmol/mg) 
Cell 
Accumulation 
(pmol/mg) 
BEI 
CLbiliary 
(mL/min/kg) 
Intracellular 
concentration 
(μM) 
5 15  3670 ± 260   3710 ± 250 <0 <0 483 
10 15 3880 ± 79   3750 ± 480 4.4 2.7 488 
20 15   3250 ± 520 3050 ± 60 6.1 2.2 396 
10* 15   2970 ± 320   2740 ± 200 7.7 4.6 357 
Data represent mean ±SD (n=3 replicates); *incubated at 4
o
C 
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Appendix Table 3.22 Time-dependent accumulation of tolvaptan, DM-4103, and DM-4107 in 
SCHH. 
Time 
(min) 
TVP 
(μM) 
Species 
Total 
Accumulation 
(pmol/mg) 
Cell 
Accumulation 
(pmol/mg) 
BEI 
CLbiliary 
(mL/min/kg) 
Intracellular 
concentration 
(μM) 
10 15 
Tolvaptan 4240 ± 350 4080 ± 550 3.82 16.7 530 ± 71 
DM-4103 11.6 ± 1.6 13.3 ± 2.2 0 NC   1.71 ± 0.28 
DM-4107 206 ± 34 183 ± 36 10.9 NC 35.6 ± 4.6 
Data represent mean ±SD (n=3 replicates); NC=not calculable 
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Appendix Table 3.23 Accumulation of TCA, CDCA, TCDCA, and GCDCA in the presence and absence of tolvaptan in SCHH 
Species 
TVP 
(μM) 
Total Accumulation 
(pmol/mg) 
Cell Accumulation 
(pmol/mg) 
BEI CLbiliary (mL/min/kg) 
Intracellular 
concentration (μM) 
TCA 
0 215 ± 27 43.3 ± 4.5 79.8 20.3    5.64 ± 0.58 
15 145 ± 16 47.5 ± 2.1 67.3 11.6   6.18 ± 2.77 
CDCA 
0 580 ± 67 469 ± 60 19.1 13.1      61 ± 7.83 
15 658 ± 86 608 ± 31 7.52 5.86 79.1± 4.0 
TCDCA 
0 3.37 ± 0.37   0.545 ± 0.049 83.8 NC NC 
15 3.32 ± 0.26   0.915 ± 0.224 71.0 NC NC 
GCDCA 
0 8.28 ± 0.98   0.892 ± 0.065 89.2 NC NC 
15 7.55 ± 1.28   1.93 ± 0.28 74.5 NC NC 
Data represent mean ±SD (n=3 replicates); BEI=biliary excretion index; NC=not calculable 
  
  
 
3
5
2 
Appendix Table 5.1 CDF (nM) in Outflow Perfusate of Wild-type or PCK rats 
  Wild-type (animal number)  PCK (animal number) 
Time 
(min) 
 1 2 3 4 5  1 2 3 4 5 
2  851 908 927 852 871  811 929 890 922 910 
5  874 932 899 847 881  841 982 941 900 964 
10  881 939 897 939 892  815 933 845 925 966 
15  903 963 903 901 889  885 967 934 920 939 
20  905 965 899 928 920  847 892 934 1000 964 
25  848 904 903 908 895  845 1000 935 876 948 
30  883 942 891 918 894  913 932 819 951 910 
32  55.5 59.7 161 20.2 64.70  299 179 177 110 202 
34  21.7 23.3 46.90 7.54 BQL  58.8 44.5 24 32.3 44.7 
36  15.3 16.4 24.30 6.06 12.94  38.8 27.3 13.2 13.7 26.7 
38  11 11.7 11.30 4.48 11.99  27.4 20.3 8.31 7.70 23.9 
40  8.66 9.26 8.42 3.14 9.92  18.6 15.4 6.93 5.57 19.6 
42  6.62 7.1 5.29 3.12 8.53  18.3 11.9 5.55 3.96 9.39 
`             
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 Wild-type (animal number)  PCK (animal number) 
 1 2 3 1 2 3 1 2 3 1 2 
44  5.26 5.66 4.51 2.49 6.93  12 11 3.5 3.00 5.74 
46  4.04 4.380 3.93 2.13 5.28  9.27 8.65 3.17 2.12 4.52 
48  2.39 2.66 2.71 BQL 5.59  9.16 8.74 2.7 2.21 3.62 
50  BQL BQL 1.85 BQL 5.29  6.32 6.36 2.27 2.00 2.52 
52  BQL BQL 2.22 BQL 4.44  6.48 5.74 2.28 BQL 2.43 
54  BQL BQL 2.63 BQL 3.64  5.70 6.42 BQL BQL 2.19 
56  BQL BQL BQL BQL 2.98  4.26 4.77 BQL BQL BQL 
58  BQL BQL BQL BQL 2.25  3.50 4.09 BQL BQL BQL 
60  BQL BQL BQL BQL BQL  2.36 3.66 BQL BQL BQL 
Below quantitation limit (BQL); missing value (MV)  
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Appendix Table 5.2 CDF (nM) in Bile of Wild-type or PCK rats 
Time 
(min) 
 Healthy (animal number)  PCK (animal number) 
 1  2  3  4  5  1  2  3  4  5 
2.5  636  672  346  29.0  12.0  24.0  2.97  24.9  18.2  28.5 
7.5  8820  9240  13700  9750  7650  BQL  2.43  26.1  267  6.88 
12.5  15800  16500  27800  23600  11100  BQL  3.21  22.3  551  24.7 
17.5  24200  25300  44100  35900  41200  18.7  6.09  21.8  657  27.3 
22.5  28200  29500  59000  46800  62200  9.61  9.98  22.1  561  17.4 
27.5  27800  29100  64500  56000  76200  10.5  14.7  24.6  602  23.0 
32.5  57900  60600  74500  94400  99700  14.6  13.1  28.0  592  42.9 
37.5  47700  50000  53600  73700  99100  14.4  13.0  23.8  335  73.6 
42.5  26500  27600  35500  72300  81000  12.2  12.1  28.0  241  125 
47.5  12100  12700  21800  28500  40500  11.4  10.2  22.8  213  130 
52.5  7490  7850  13500  13900  28100  10.2  9.68  24.8  170  111 
57.5  5970  6260  9190  8600  20500  7.66  8.44  19.1  151  91.0 
Below quantitation limit (BQL)  
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Appendix Table 5.3 Bile Flow Rate 
Time 
(min) 
 Wild-type (animal number)  PCK (animal number) 
 1  2  3  4  5  1  2  3  4  5 
2.5  1.22  1.36  0.561  0.653  0.793  0.37  0.713  0.789  0.619  0.619 
7.5  1.47  1.64  0.473  0.604  0.734  0.417  0.646  0.801  0.59  0.590 
12.5  1.08  1.21  0.668  0.582  0.707  0.447  0.735  0.857  0.612  0.612 
17.5  1.18  1.32  0.749  0.781  0.994  0.440  0.734  0.845  0.518  0.518 
22.5  1.35  1.51  0.680  0.689  0.710  0.408  0.713  0.783  0.785  0.785 
27.5  1.11  1.25  0.795  0.850  1.03  0.364  0.766  0.699  0.756  0.756 
32.5  1.13  1.26  0.698  0.746  0.894  0.367  0.654  0.705  0.713  0.713 
37.5  0.972  1.09  0.802  0.719  0.863  0.331  0.625  0.635  0.683  0.683 
42.5  1.04  1.16  0.702  0.621  0.717  0.307  0.495  0.589  0.770  0.770 
47.5  1.21  1.34  0.724  0.714  0.842  0.449  0.597  0.861  0.711  0.711 
52.5  1.15  1.28  0.688  0.552  0.670  0.368  0.543  0.706  0.676  0.676 
57.5  1.09  1.21  0.741  0.625  0.760  0.369  0.589  0.709  0.639  0.639 
Data expressed as μL/min/g liver 
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Appendix Table 5.4 Rat Physiological Parameters 
 
Wild-type (animal number)  PCK (animal number) 
1  2  3  4  5  1  2  3  4  5 
Body 
weight 
(g) 
 525  534  564  542  532  494  506  572  558  548 
Liver 
weight 
(g) 
 18.4  17.3  16.4  23.0  15.4  55.0  48.5  28.7  27.9  37.5 
Total 
Kidney 
weight 
(g) 
 3.01  2.88  2.98  4.06  3.02  5.70  7.45  5.26  5.19  6.07 
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Appendix Table 5.5 Simulated Bile Rate (nmol/min) 
Time (min) Control Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 Scenario 6 Scenario 7 
0.27252 0.0000000 0.0000000 0.0000000 0.0000000 0.0000000 0.0000000 0.0000000 0.0000000 
1.02252 0.0000000 0.0000000 0.0000000 0.0000000 0.0000000 0.0000000 0.0000000 0.0000000 
1.77252 2.58E-09 2.46E-09 2.58E-09 2.58E-09 3.03E-09 1.61E-09 1.29E-09 3.28E-11 
2.52252 2.58E-05 2.46E-05 2.58E-05 2.58E-05 3.03E-05 1.61E-05 1.29E-05 3.28E-07 
2.58258 0.002754 0.002236 0.001786 0.000786 5.63E-05 0.001115 0.000393 9.99E-06 
2.64264 0.00512 0.004157 0.00332 0.001461 8.23E-05 0.002072 0.000731 1.86E-05 
2.7027 0.007486 0.006078 0.004853 0.002136 0.000108 0.003029 0.001069 2.72E-05 
2.76276 0.009853 0.008 0.006388 0.002811 0.000134 0.003987 0.001407 3.57E-05 
2.82282 0.012219 0.009921 0.007922 0.003487 0.00016 0.004944 0.001745 4.43E-05 
2.88288 0.014585 0.011842 0.009456 0.004162 0.000186 0.005901 0.002083 5.29E-05 
2.94294 0.016952 0.013764 0.010991 0.004837 0.000212 0.006859 0.002421 6.15E-05 
3.003 0.019318 0.015685 0.012525 0.005512 0.000238 0.007817 0.002759 7.01E-05 
3.06306 0.021685 0.017607 0.014059 0.006188 0.000264 0.008774 0.003097 7.87E-05 
3.12312 0.024051 0.019528 0.015593 0.006863 0.00029 0.009732 0.003435 8.72E-05 
3.18318 0.026417 0.021449 0.017127 0.007538 0.000316 0.010689 0.003773 9.58E-05 
3.24324 0.028784 0.02337 0.018662 0.008213 0.000342 0.011647 0.004111 0.000104 
3.3033 0.03115 0.025291 0.020196 0.008888 0.000368 0.012604 0.004448 0.000113 
3.36336 0.033516 0.027212 0.02173 0.009564 0.000394 0.013562 0.004787 0.000122 
3.42342 0.035883 0.029134 0.023264 0.010239 0.00042 0.014519 0.005125 0.00013 
3.48348 0.038249 0.031055 0.024798 0.010914 0.000446 0.015476 0.005462 0.000139 
3.54354 0.040615 0.032976 0.026332 0.011589 0.000472 0.016434 0.0058 0.000147 
3.6036 0.042982 0.034898 0.027867 0.012265 0.000498 0.017392 0.006139 0.000156 
3.66366 0.045348 0.036819 0.029401 0.01294 0.000524 0.018349 0.006476 0.000165 
3.72372 0.047715 0.038741 0.030936 0.013615 0.00055 0.019307 0.006814 0.000173 
3.78378 0.050081 0.040662 0.03247 0.01429 0.000576 0.020265 0.007152 0.000182 
3.84384 0.052447 0.042583 0.034004 0.014965 0.000602 0.021222 0.00749 0.00019 
3.9039 0.054814 0.044505 0.035538 0.015641 0.000628 0.022179 0.007828 0.000199 
3.96396 0.05718 0.046426 0.037072 0.016316 0.000654 0.023137 0.008166 0.000207 
4.02402 0.059546 0.048347 0.038606 0.016991 0.00068 0.024094 0.008504 0.000216 
4.08408 0.061913 0.050268 0.040141 0.017666 0.000706 0.025052 0.008842 0.000225 
4.14414 0.064279 0.052189 0.041675 0.018342 0.000732 0.026009 0.00918 0.000233 
4.2042 0.066645 0.05411 0.043209 0.019017 0.000758 0.026967 0.009518 0.000242 
4.26426 0.069012 0.056032 0.044743 0.019692 0.000784 0.027924 0.009856 0.00025 
4.32432 0.071378 0.057953 0.046277 0.020367 0.00081 0.028881 0.010194 0.000259 
4.38438 0.073745 0.059875 0.047812 0.021043 0.000836 0.029839 0.010532 0.000268 
4.44444 0.076111 0.061796 0.049346 0.021718 0.000862 0.030797 0.01087 0.000276 
4.5045 0.078477 0.063717 0.05088 0.022393 0.000888 0.031754 0.011208 0.000285 
4.56456 0.080844 0.065639 0.052415 0.023068 0.000914 0.032712 0.011546 0.000293 
4.62462 0.08321 0.06756 0.053949 0.023743 0.00094 0.03367 0.011883 0.000302 
4.68468 0.085576 0.069481 0.055483 0.024418 0.000966 0.034627 0.012221 0.00031 
4.74474 0.087943 0.071403 0.057017 0.025094 0.000992 0.035584 0.01256 0.000319 
4.8048 0.090309 0.073324 0.058551 0.025769 0.001018 0.036542 0.012897 0.000328 
4.86486 0.092675 0.075245 0.060085 0.026444 0.001044 0.037499 0.013235 0.000336 
4.92492 0.095042 0.077167 0.06162 0.02712 0.00107 0.038457 0.013574 0.000345 
4.98498 0.097408 0.079088 0.063154 0.027795 0.001096 0.039414 0.013911 0.000353 
5.04505 0.099775 0.081009 0.064688 0.02847 0.001122 0.040372 0.014249 0.000362 
5.10511 0.102141 0.08293 0.066222 0.029145 0.001148 0.041329 0.014587 0.000371 
5.16517 0.104508 0.084852 0.067757 0.029821 0.001174 0.042287 0.014925 0.000379 
5.22523 0.106874 0.086773 0.069291 0.030496 0.0012 0.043245 0.015263 0.000388 
5.28529 0.10924 0.088694 0.070825 0.031171 0.001226 0.044202 0.015601 0.000396 
5.34535 0.111607 0.090616 0.07236 0.031846 0.001252 0.04516 0.015939 0.000405 
5.40541 0.113973 0.092537 0.073894 0.032521 0.001278 0.046117 0.016277 0.000413 
5.46547 0.11634 0.094459 0.075428 0.033197 0.001304 0.047075 0.016615 0.000422 
5.52553 0.118706 0.09638 0.076962 0.033872 0.00133 0.048032 0.016953 0.000431 
5.58559 0.121072 0.098301 0.078496 0.034547 0.001356 0.048989 0.017291 0.000439 
5.64565 0.123439 0.100223 0.080031 0.035222 0.001382 0.049947 0.017629 0.000448 
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5.70571 0.125805 0.102144 0.081565 0.035897 0.001408 0.050905 0.017966 0.000456 
5.76577 0.128171 0.104065 0.083099 0.036573 0.001434 0.051862 0.018305 0.000465 
5.82583 0.130538 0.105987 0.084633 0.037248 0.00146 0.052819 0.018643 0.000474 
5.88589 0.132904 0.107908 0.086167 0.037923 0.001486 0.053777 0.01898 0.000482 
5.94595 0.13527 0.109829 0.087701 0.038598 0.001512 0.054734 0.019318 0.000491 
6.00601 0.137637 0.11175 0.089236 0.039274 0.001538 0.055692 0.019657 0.000499 
6.06607 0.140003 0.113671 0.09077 0.039949 0.001565 0.05665 0.019994 0.000508 
6.12613 0.14237 0.115593 0.092304 0.040624 0.001591 0.057607 0.020332 0.000516 
6.18619 0.144736 0.117514 0.093838 0.041299 0.001617 0.058564 0.02067 0.000525 
6.24625 0.147102 0.119435 0.095372 0.041974 0.001643 0.059522 0.021008 0.000534 
6.30631 0.149469 0.121357 0.096907 0.04265 0.001669 0.06048 0.021346 0.000542 
6.36637 0.151835 0.123278 0.098441 0.043325 0.001695 0.061437 0.021684 0.000551 
6.42643 0.154201 0.125199 0.099975 0.044 0.001721 0.062394 0.022022 0.000559 
6.48649 0.156568 0.127121 0.10151 0.044675 0.001747 0.063352 0.02236 0.000568 
6.54655 0.158934 0.129042 0.103044 0.045351 0.001773 0.06431 0.022698 0.000577 
6.60661 0.1613 0.130963 0.104578 0.046026 0.001799 0.065267 0.023036 0.000585 
6.66667 0.163667 0.132885 0.106112 0.046701 0.001825 0.066225 0.023374 0.000594 
6.72673 0.166033 0.134806 0.107646 0.047376 0.001851 0.067182 0.023712 0.000602 
6.78679 0.1684 0.136728 0.109181 0.048052 0.001877 0.06814 0.02405 0.000611 
6.84685 0.170766 0.138649 0.110715 0.048727 0.001903 0.069097 0.024388 0.000619 
6.90691 0.173132 0.14057 0.112249 0.049402 0.001929 0.070055 0.024726 0.000628 
6.96697 0.175499 0.142491 0.113783 0.050077 0.001955 0.071012 0.025064 0.000637 
7.02703 0.177865 0.144412 0.115317 0.050752 0.001981 0.071969 0.025401 0.000645 
7.08709 0.180231 0.146333 0.116851 0.051428 0.002007 0.072927 0.02574 0.000654 
7.14715 0.182598 0.148255 0.118386 0.052103 0.002033 0.073885 0.026078 0.000662 
7.20721 0.184964 0.150176 0.11992 0.052778 0.002059 0.074842 0.026415 0.000671 
7.26727 0.18733 0.152097 0.121454 0.053453 0.002085 0.075799 0.026753 0.00068 
7.32733 0.189697 0.154019 0.122989 0.054129 0.002111 0.076757 0.027092 0.000688 
7.38739 0.192063 0.15594 0.124523 0.054804 0.002137 0.077715 0.027429 0.000697 
7.44745 0.19443 0.157862 0.126057 0.055479 0.002159 0.078672 0.027767 0.000705 
7.50751 0.196491 0.159535 0.127393 0.056067 0.002185 0.079506 0.028062 0.000713 
7.56757 0.198822 0.161428 0.128905 0.056732 0.00221 0.08045 0.028394 0.000721 
7.62763 0.201152 0.16332 0.130415 0.057397 0.002236 0.081392 0.028727 0.00073 
7.68769 0.203482 0.165211 0.131926 0.058062 0.002262 0.082335 0.02906 0.000738 
7.74775 0.205813 0.167104 0.133437 0.058727 0.002287 0.083278 0.029393 0.000747 
7.80781 0.208143 0.168996 0.134948 0.059392 0.002313 0.084221 0.029726 0.000755 
7.86787 0.210473 0.170888 0.136459 0.060057 0.002339 0.085164 0.030059 0.000763 
7.92793 0.212804 0.17278 0.13797 0.060722 0.002364 0.086107 0.030391 0.000772 
7.98799 0.215134 0.174672 0.13948 0.061387 0.00239 0.087049 0.030724 0.00078 
8.04805 0.217464 0.176564 0.140991 0.062052 0.002415 0.087992 0.031057 0.000789 
8.10811 0.219795 0.178456 0.142502 0.062717 0.002441 0.088935 0.03139 0.000797 
8.16817 0.222125 0.180348 0.144013 0.063382 0.002467 0.089879 0.031723 0.000806 
8.22823 0.224455 0.18224 0.145524 0.064047 0.002492 0.090822 0.032056 0.000814 
8.28829 0.226786 0.184132 0.147035 0.064712 0.002518 0.091765 0.032388 0.000823 
8.34835 0.229116 0.186024 0.148546 0.065376 0.002543 0.092708 0.032721 0.000831 
8.40841 0.231446 0.187916 0.150056 0.066041 0.002569 0.09365 0.033054 0.00084 
8.46847 0.233777 0.189809 0.151568 0.066706 0.002595 0.094594 0.033386 0.000848 
8.52853 0.236107 0.1917 0.153078 0.067371 0.00262 0.095536 0.033719 0.000856 
8.58859 0.238437 0.193592 0.154589 0.068036 0.002646 0.096479 0.034052 0.000865 
8.64865 0.240768 0.195485 0.1561 0.068701 0.002671 0.097422 0.034385 0.000873 
8.70871 0.243098 0.197376 0.157611 0.069366 0.002697 0.098365 0.034718 0.000882 
8.76877 0.245428 0.199268 0.159121 0.070031 0.002723 0.099307 0.035051 0.00089 
8.82883 0.247759 0.201161 0.160633 0.070696 0.002748 0.100251 0.035383 0.000899 
8.88889 0.250089 0.203053 0.162143 0.071361 0.002774 0.101193 0.035716 0.000907 
8.94895 0.252419 0.204944 0.163654 0.072026 0.002799 0.102137 0.036049 0.000916 
9.00901 0.25475 0.206837 0.165165 0.072691 0.002825 0.10308 0.036382 0.000924 
9.06907 0.25708 0.208729 0.166676 0.073356 0.002851 0.104023 0.036715 0.000933 
9.12913 0.25941 0.21062 0.168186 0.074021 0.002876 0.104965 0.037048 0.000941 
9.18919 0.261741 0.212513 0.169698 0.074686 0.002902 0.105909 0.03738 0.000949 
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9.24925 0.264071 0.214405 0.171208 0.075351 0.002927 0.106851 0.037713 0.000958 
9.30931 0.266401 0.216297 0.172719 0.076015 0.002953 0.107794 0.038046 0.000966 
9.36937 0.268732 0.218189 0.17423 0.076681 0.002979 0.108737 0.038379 0.000975 
9.42943 0.271062 0.220081 0.175741 0.077345 0.003004 0.10968 0.038711 0.000983 
9.48949 0.273392 0.221973 0.177252 0.07801 0.00303 0.110623 0.039044 0.000992 
9.54955 0.275723 0.223865 0.178763 0.078675 0.003056 0.111566 0.039377 0.001 
9.60961 0.278053 0.225757 0.180274 0.07934 0.003081 0.112509 0.03971 0.001009 
9.66967 0.280383 0.227649 0.181784 0.080005 0.003107 0.113451 0.040043 0.001017 
9.72973 0.282714 0.229542 0.183295 0.08067 0.003132 0.114394 0.040375 0.001026 
9.78979 0.285044 0.231433 0.184806 0.081335 0.003158 0.115337 0.040708 0.001034 
9.84985 0.287374 0.233325 0.186317 0.082 0.003184 0.11628 0.041041 0.001042 
9.90991 0.289705 0.235218 0.187828 0.082665 0.003209 0.117224 0.041374 0.001051 
9.96997 0.292035 0.237109 0.189339 0.08333 0.003235 0.118167 0.041707 0.001059 
10.03 0.294364 0.239 0.190849 0.083995 0.00326 0.119109 0.04204 0.001068 
10.0901 0.296696 0.240894 0.192361 0.08466 0.003286 0.120053 0.042372 0.001076 
10.1502 0.299028 0.242787 0.193873 0.085325 0.003312 0.120996 0.042705 0.001085 
10.2102 0.301356 0.244677 0.195382 0.08599 0.003337 0.121938 0.043038 0.001093 
10.2703 0.303688 0.246571 0.196894 0.086655 0.003363 0.122882 0.043371 0.001102 
10.3303 0.306016 0.248461 0.198403 0.087319 0.003388 0.123823 0.043703 0.00111 
10.3904 0.308348 0.250354 0.199915 0.087985 0.003414 0.124767 0.044036 0.001119 
10.4505 0.310679 0.252247 0.201426 0.08865 0.00344 0.12571 0.044369 0.001127 
10.5105 0.313007 0.254137 0.202936 0.089314 0.003465 0.126652 0.044702 0.001135 
10.5706 0.315339 0.25603 0.204448 0.08998 0.003491 0.127596 0.045035 0.001144 
10.6306 0.317667 0.25792 0.205957 0.090644 0.003516 0.128538 0.045367 0.001152 
10.6907 0.319999 0.259814 0.207469 0.091309 0.003542 0.129481 0.0457 0.001161 
10.7508 0.322331 0.261707 0.208981 0.091975 0.003568 0.130425 0.046033 0.001169 
10.8108 0.324659 0.263597 0.21049 0.092639 0.003593 0.131367 0.046366 0.001178 
10.8709 0.326991 0.265491 0.212002 0.093304 0.003619 0.132311 0.046699 0.001186 
10.9309 0.329319 0.267381 0.213511 0.093969 0.003645 0.133252 0.047031 0.001195 
10.991 0.331651 0.269274 0.215023 0.094634 0.00367 0.134196 0.047364 0.001203 
11.0511 0.333983 0.271168 0.216535 0.095299 0.003696 0.13514 0.047697 0.001212 
11.1111 0.336311 0.273058 0.218045 0.095964 0.003721 0.136082 0.04803 0.00122 
11.1712 0.338643 0.274951 0.219557 0.096629 0.003747 0.137026 0.048363 0.001228 
11.2312 0.340971 0.276842 0.221066 0.097293 0.003773 0.137967 0.048695 0.001237 
11.2913 0.343302 0.278734 0.222577 0.097959 0.003798 0.13891 0.049028 0.001245 
11.3514 0.345634 0.280628 0.224089 0.098624 0.003824 0.139854 0.049361 0.001254 
11.4114 0.347962 0.282518 0.225598 0.099288 0.003849 0.140796 0.049694 0.001262 
11.4715 0.350294 0.284411 0.22711 0.099954 0.003875 0.141739 0.050027 0.001271 
11.5315 0.352622 0.286301 0.22862 0.100618 0.003901 0.142682 0.050359 0.001279 
11.5916 0.354954 0.288195 0.230132 0.101283 0.003926 0.143625 0.050692 0.001288 
11.6517 0.357286 0.290088 0.231644 0.101949 0.003952 0.144569 0.051025 0.001296 
11.7117 0.359614 0.291978 0.233153 0.102613 0.003977 0.145511 0.051358 0.001304 
11.7718 0.361946 0.293872 0.234665 0.103279 0.004003 0.146454 0.051691 0.001313 
11.8318 0.364274 0.295762 0.236174 0.103943 0.004029 0.147396 0.052023 0.001321 
11.8919 0.366606 0.297655 0.237686 0.104608 0.004054 0.14834 0.052356 0.00133 
11.952 0.368938 0.299548 0.239198 0.105274 0.00408 0.149284 0.05269 0.001338 
12.012 0.371266 0.301439 0.240707 0.105938 0.004105 0.150225 0.053022 0.001347 
12.0721 0.373597 0.303331 0.242219 0.106603 0.004131 0.151169 0.053355 0.001355 
12.1321 0.375925 0.305221 0.243728 0.107267 0.004157 0.152111 0.053687 0.001364 
12.1922 0.378257 0.307115 0.24524 0.107933 0.004182 0.153054 0.05402 0.001372 
12.2523 0.380589 0.309008 0.246752 0.108598 0.004208 0.153998 0.054353 0.001381 
12.3123 0.382917 0.310898 0.248261 0.109262 0.004234 0.15494 0.054686 0.001389 
12.3724 0.385249 0.312792 0.249773 0.109928 0.004259 0.155883 0.055019 0.001397 
12.4324 0.387577 0.314682 0.251283 0.110592 0.004285 0.156826 0.055351 0.001406 
12.4925 0.389909 0.316575 0.252794 0.111258 0.00431 0.157769 0.055685 0.001414 
12.5526 0.392241 0.318469 0.254306 0.111923 0.004336 0.158712 0.056017 0.001423 
12.6126 0.394569 0.320359 0.255816 0.112587 0.004362 0.159655 0.05635 0.001431 
12.6727 0.396901 0.322252 0.257328 0.113253 0.004387 0.160598 0.056683 0.00144 
12.7327 0.399229 0.324142 0.258837 0.113917 0.004413 0.16154 0.057015 0.001448 
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12.7928 0.401561 0.326036 0.260349 0.114582 0.004438 0.162484 0.057348 0.001457 
12.8529 0.403893 0.327929 0.261861 0.115248 0.004464 0.163428 0.057682 0.001465 
12.9129 0.406221 0.329819 0.26337 0.115912 0.00449 0.164369 0.058014 0.001474 
12.973 0.408552 0.331712 0.264882 0.116577 0.004515 0.165313 0.058347 0.001482 
13.033 0.41088 0.333602 0.266391 0.117241 0.004541 0.166255 0.058679 0.00149 
13.0931 0.413212 0.335496 0.267903 0.117907 0.004566 0.167198 0.059012 0.001499 
13.1532 0.415544 0.337389 0.269415 0.118572 0.004592 0.168142 0.059345 0.001507 
13.2132 0.417872 0.339279 0.270924 0.119237 0.004618 0.169084 0.059678 0.001516 
13.2733 0.420204 0.341172 0.272436 0.119902 0.004643 0.170027 0.060011 0.001524 
13.3333 0.422532 0.343063 0.273945 0.120566 0.004669 0.170969 0.060343 0.001533 
13.3934 0.424864 0.344956 0.275457 0.121232 0.004694 0.171913 0.060677 0.001541 
13.4535 0.427196 0.346849 0.276969 0.121897 0.00472 0.172856 0.061009 0.00155 
13.5135 0.429524 0.34874 0.278479 0.122561 0.004746 0.173799 0.061342 0.001558 
13.5736 0.431856 0.350633 0.279991 0.123227 0.004771 0.174742 0.061675 0.001567 
13.6336 0.434184 0.352523 0.2815 0.123891 0.004797 0.175684 0.062007 0.001575 
13.6937 0.436516 0.354417 0.283012 0.124556 0.004822 0.176628 0.06234 0.001583 
13.7538 0.438847 0.356309 0.284523 0.125222 0.004848 0.177571 0.062674 0.001592 
13.8138 0.441175 0.358199 0.286032 0.125886 0.004874 0.178513 0.063006 0.0016 
13.8739 0.443507 0.360093 0.287544 0.126551 0.004899 0.179456 0.063339 0.001609 
13.9339 0.445835 0.361983 0.289054 0.127216 0.004925 0.180399 0.063672 0.001617 
13.994 0.448167 0.363876 0.290566 0.127881 0.004951 0.181342 0.064004 0.001626 
14.0541 0.450499 0.36577 0.292078 0.128546 0.004976 0.182286 0.064337 0.001634 
14.1141 0.452827 0.36766 0.293587 0.129211 0.005002 0.183228 0.06467 0.001643 
14.1742 0.455159 0.369553 0.295099 0.129876 0.005027 0.184171 0.065003 0.001651 
14.2342 0.457487 0.371443 0.296608 0.13054 0.005053 0.185113 0.065335 0.00166 
14.2943 0.459819 0.373337 0.29812 0.131206 0.005079 0.186057 0.065669 0.001668 
14.3544 0.462151 0.37523 0.299632 0.131871 0.005104 0.187 0.066001 0.001676 
14.4144 0.464479 0.37712 0.301141 0.132536 0.00513 0.187942 0.066334 0.001685 
14.4745 0.466811 0.379014 0.302653 0.133201 0.005155 0.188886 0.066667 0.001693 
14.5345 0.469139 0.380904 0.304163 0.133865 0.005181 0.189828 0.066999 0.001702 
14.5946 0.47147 0.382796 0.305674 0.13453 0.005207 0.190771 0.067332 0.00171 
14.6547 0.473802 0.38469 0.307186 0.135196 0.005232 0.191715 0.067666 0.001719 
14.7147 0.47613 0.38658 0.308695 0.13586 0.005258 0.192657 0.067998 0.001727 
14.7748 0.478462 0.388473 0.310207 0.136525 0.005283 0.1936 0.068331 0.001736 
14.8348 0.48079 0.390363 0.311716 0.13719 0.005309 0.194542 0.068664 0.001744 
14.8949 0.483122 0.392257 0.313228 0.137855 0.005335 0.195486 0.068996 0.001753 
14.955 0.485454 0.39415 0.31474 0.138521 0.00536 0.196429 0.06933 0.001761 
15.015 0.487782 0.39604 0.31625 0.139185 0.005386 0.197372 0.069662 0.001769 
15.0751 0.490114 0.397934 0.317762 0.13985 0.005411 0.198315 0.069995 0.001778 
15.1351 0.492442 0.399824 0.319271 0.140515 0.005437 0.199257 0.070328 0.001786 
15.1952 0.494774 0.401717 0.320783 0.14118 0.005463 0.200201 0.070661 0.001795 
15.2553 0.497106 0.403611 0.322295 0.141845 0.005488 0.201144 0.070993 0.001803 
15.3153 0.499434 0.405501 0.323804 0.14251 0.005514 0.202086 0.071326 0.001812 
15.3754 0.501766 0.407394 0.325316 0.143175 0.005539 0.20303 0.071659 0.00182 
15.4354 0.504094 0.409284 0.326825 0.143839 0.005565 0.203972 0.071991 0.001829 
15.4955 0.506425 0.411177 0.328337 0.144504 0.005591 0.204915 0.072324 0.001837 
15.5556 0.508757 0.413071 0.329849 0.14517 0.005616 0.205859 0.072658 0.001846 
15.6156 0.511085 0.414961 0.331358 0.145834 0.005642 0.206801 0.07299 0.001854 
15.6757 0.513417 0.416854 0.33287 0.1465 0.005668 0.207744 0.073323 0.001862 
15.7357 0.515745 0.418744 0.334379 0.147164 0.005693 0.208686 0.073656 0.001871 
15.7958 0.518077 0.420638 0.335891 0.147829 0.005719 0.20963 0.073988 0.001879 
15.8559 0.520409 0.422531 0.337403 0.148495 0.005744 0.210573 0.074322 0.001888 
15.9159 0.522737 0.424421 0.338913 0.149159 0.00577 0.211516 0.074654 0.001896 
15.976 0.525069 0.426315 0.340424 0.149824 0.005796 0.212459 0.074987 0.001905 
16.036 0.527397 0.428205 0.341934 0.150489 0.005821 0.213401 0.07532 0.001913 
16.0961 0.529729 0.430098 0.343446 0.151154 0.005847 0.214345 0.075653 0.001922 
16.1562 0.532061 0.431992 0.344958 0.15182 0.005872 0.215288 0.075986 0.00193 
16.2162 0.534389 0.433882 0.346467 0.152484 0.005898 0.21623 0.076318 0.001938 
16.2763 0.53672 0.435774 0.347978 0.153149 0.005924 0.217173 0.076651 0.001947 
 361 
 
16.3363 0.539048 0.437664 0.349488 0.153813 0.005949 0.218116 0.076983 0.001955 
16.3964 0.54138 0.439558 0.351 0.154479 0.005975 0.219059 0.077317 0.001964 
16.4565 0.543712 0.441451 0.352511 0.155144 0.006 0.220002 0.07765 0.001972 
16.5165 0.54604 0.443341 0.354021 0.155808 0.006026 0.220945 0.077982 0.001981 
16.5766 0.548372 0.445235 0.355533 0.156474 0.006052 0.221888 0.078315 0.001989 
16.6366 0.5507 0.447125 0.357042 0.157138 0.006077 0.22283 0.078648 0.001998 
16.6967 0.553032 0.449018 0.358554 0.157803 0.006103 0.223774 0.07898 0.002006 
16.7568 0.555364 0.450912 0.360066 0.158469 0.006128 0.224717 0.079314 0.002015 
16.8168 0.557692 0.452802 0.361575 0.159133 0.006154 0.225659 0.079646 0.002023 
16.8769 0.560024 0.454695 0.363087 0.159799 0.00618 0.226603 0.079979 0.002031 
16.9369 0.562352 0.456585 0.364597 0.160463 0.006205 0.227545 0.080312 0.00204 
16.997 0.564684 0.458479 0.366109 0.161128 0.006231 0.228489 0.080645 0.002048 
17.0571 0.567015 0.460371 0.36762 0.161793 0.006257 0.229432 0.080977 0.002057 
17.1171 0.569343 0.462262 0.369129 0.162458 0.006282 0.230373 0.08131 0.002065 
17.1772 0.571675 0.464155 0.370641 0.163123 0.006308 0.231317 0.081643 0.002074 
17.2372 0.574003 0.466045 0.37215 0.163787 0.006333 0.232259 0.081975 0.002082 
17.2973 0.576335 0.467938 0.373662 0.164453 0.006359 0.233203 0.082309 0.002091 
17.3574 0.578667 0.469832 0.375174 0.165118 0.006385 0.234146 0.082642 0.002099 
17.4174 0.580995 0.471722 0.376684 0.165782 0.00641 0.235089 0.082974 0.002108 
17.4775 0.583327 0.473615 0.378196 0.166448 0.006436 0.236032 0.083307 0.002116 
17.5375 0.585655 0.475506 0.379705 0.167112 0.006461 0.236974 0.08364 0.002124 
17.5976 0.587987 0.477399 0.381217 0.167778 0.006487 0.237918 0.083973 0.002133 
17.6577 0.590319 0.479292 0.382729 0.168443 0.006513 0.238861 0.084306 0.002141 
17.7177 0.592647 0.481183 0.384238 0.169107 0.006538 0.239803 0.084638 0.00215 
17.7778 0.594979 0.483076 0.38575 0.169773 0.006564 0.240747 0.084971 0.002158 
17.8378 0.597307 0.484966 0.387259 0.170437 0.006589 0.241688 0.085304 0.002167 
17.8979 0.599639 0.486859 0.388771 0.171102 0.006615 0.242632 0.085637 0.002175 
17.958 0.60197 0.488752 0.390283 0.171768 0.006641 0.243576 0.08597 0.002184 
18.018 0.604298 0.490642 0.391792 0.172432 0.006666 0.244517 0.086302 0.002192 
18.0781 0.60663 0.492536 0.393304 0.173097 0.006692 0.245461 0.086635 0.002201 
18.1381 0.608958 0.494426 0.394813 0.173762 0.006717 0.246403 0.086968 0.002209 
18.1982 0.61129 0.496319 0.396325 0.174427 0.006743 0.247346 0.087301 0.002217 
18.2583 0.613622 0.498213 0.397837 0.175092 0.006769 0.24829 0.087634 0.002226 
18.3183 0.61595 0.500103 0.399346 0.175757 0.006794 0.249232 0.087966 0.002234 
18.3784 0.618282 0.501996 0.400858 0.176422 0.00682 0.250176 0.088299 0.002243 
18.4384 0.62061 0.503886 0.402368 0.177086 0.006846 0.251118 0.088632 0.002251 
18.4985 0.622942 0.50578 0.40388 0.177752 0.006871 0.252062 0.088965 0.00226 
18.5586 0.625274 0.507673 0.405392 0.178417 0.006897 0.253005 0.089298 0.002268 
18.6186 0.627602 0.509563 0.406901 0.179081 0.006922 0.253947 0.08963 0.002277 
18.6787 0.629934 0.511457 0.408413 0.179747 0.006948 0.254891 0.089963 0.002285 
18.7387 0.632262 0.513347 0.409922 0.180411 0.006974 0.255832 0.090296 0.002294 
18.7988 0.634593 0.515239 0.411433 0.181076 0.006999 0.256775 0.090629 0.002302 
18.8589 0.636925 0.517133 0.412945 0.181742 0.007025 0.257719 0.090962 0.00231 
18.9189 0.639253 0.519023 0.414455 0.182406 0.00705 0.258661 0.091294 0.002319 
18.979 0.641585 0.520916 0.415967 0.183071 0.007076 0.259605 0.091627 0.002327 
19.039 0.643913 0.522807 0.417476 0.183736 0.007102 0.260547 0.09196 0.002336 
19.0991 0.646245 0.5247 0.418988 0.184401 0.007127 0.26149 0.092293 0.002344 
19.1592 0.648577 0.526593 0.4205 0.185066 0.007153 0.262434 0.092626 0.002353 
19.2192 0.650905 0.528484 0.422009 0.185731 0.007178 0.263376 0.092958 0.002361 
19.2793 0.653237 0.530377 0.423521 0.186396 0.007204 0.264319 0.093291 0.00237 
19.3393 0.655565 0.532267 0.425031 0.18706 0.00723 0.265262 0.093624 0.002378 
19.3994 0.657897 0.53416 0.426542 0.187726 0.007255 0.266205 0.093957 0.002387 
19.4595 0.660229 0.536054 0.428054 0.188391 0.007281 0.267149 0.09429 0.002395 
19.5195 0.662557 0.537944 0.429564 0.189056 0.007306 0.268091 0.094623 0.002403 
19.5796 0.664888 0.539837 0.431075 0.189721 0.007332 0.269034 0.094955 0.002412 
19.6396 0.667216 0.541727 0.432584 0.190385 0.007358 0.269976 0.095288 0.00242 
19.6997 0.669548 0.54362 0.434096 0.19105 0.007383 0.270919 0.095621 0.002429 
19.7598 0.67188 0.545514 0.435608 0.191716 0.007409 0.271863 0.095954 0.002437 
19.8198 0.674208 0.547404 0.437118 0.19238 0.007435 0.272805 0.096286 0.002446 
 362 
 
19.8799 0.67654 0.549297 0.438629 0.193046 0.00746 0.273748 0.09662 0.002454 
19.9399 0.678868 0.551187 0.440139 0.19371 0.007486 0.274691 0.096952 0.002463 
20 0.6812 0.553081 0.441651 0.194375 0.007511 0.275634 0.097285 0.002471 
20.0601 0.683532 0.554974 0.443163 0.195041 0.007537 0.276578 0.097618 0.002479 
20.1201 0.68586 0.556864 0.444672 0.195705 0.007563 0.27752 0.09795 0.002488 
20.1802 0.688192 0.558758 0.446184 0.19637 0.007588 0.278463 0.098283 0.002496 
20.2402 0.69052 0.560648 0.447693 0.197035 0.007614 0.279405 0.098616 0.002505 
20.3003 0.692852 0.562541 0.449205 0.1977 0.007639 0.280349 0.098949 0.002513 
20.3604 0.695184 0.564435 0.450717 0.198365 0.007665 0.281293 0.099282 0.002522 
20.4204 0.697512 0.566325 0.452227 0.19903 0.007691 0.282235 0.099615 0.00253 
20.4805 0.699843 0.568217 0.453738 0.199695 0.007716 0.283178 0.099947 0.002539 
20.5405 0.702171 0.570107 0.455247 0.200359 0.007742 0.28412 0.10028 0.002547 
20.6006 0.704503 0.572001 0.456759 0.201025 0.007767 0.285063 0.100613 0.002556 
20.6607 0.706835 0.573894 0.458271 0.20169 0.007793 0.286007 0.100946 0.002564 
20.7207 0.709163 0.575784 0.45978 0.202354 0.007819 0.286949 0.101278 0.002572 
20.7808 0.711495 0.577678 0.461292 0.20302 0.007844 0.287892 0.101612 0.002581 
20.8408 0.713823 0.579568 0.462802 0.203684 0.00787 0.288835 0.101944 0.002589 
20.9009 0.716155 0.581461 0.464314 0.204349 0.007895 0.289778 0.102277 0.002598 
20.961 0.718487 0.583355 0.465826 0.205015 0.007921 0.290722 0.10261 0.002606 
21.021 0.720815 0.585245 0.467335 0.205679 0.007947 0.291664 0.102942 0.002615 
21.0811 0.723147 0.587138 0.468847 0.206344 0.007972 0.292607 0.103275 0.002623 
21.1411 0.725475 0.589028 0.470356 0.207009 0.007998 0.293549 0.103608 0.002632 
21.2012 0.727807 0.590922 0.471868 0.207674 0.008023 0.294493 0.103941 0.00264 
21.2613 0.730138 0.592814 0.473379 0.208339 0.008049 0.295436 0.104274 0.002649 
21.3213 0.732466 0.594704 0.474889 0.209004 0.008075 0.296378 0.104607 0.002657 
21.3814 0.734798 0.596598 0.476401 0.209669 0.0081 0.297322 0.104939 0.002665 
21.4414 0.737126 0.598488 0.47791 0.210333 0.008126 0.298264 0.105272 0.002674 
21.5015 0.739458 0.600381 0.479422 0.210999 0.008152 0.299207 0.105605 0.002682 
21.5616 0.74179 0.602275 0.480934 0.211664 0.008177 0.300151 0.105938 0.002691 
21.6216 0.744118 0.604165 0.482443 0.212328 0.008203 0.301093 0.10627 0.002699 
21.6817 0.74645 0.606058 0.483955 0.212994 0.008228 0.302036 0.106604 0.002708 
21.7417 0.748778 0.607949 0.485464 0.213658 0.008254 0.302978 0.106936 0.002716 
21.8018 0.75111 0.609842 0.486976 0.214323 0.00828 0.303922 0.107269 0.002725 
21.8619 0.753442 0.611735 0.488488 0.214989 0.008305 0.304865 0.107602 0.002733 
21.9219 0.75577 0.613625 0.489998 0.215653 0.008331 0.305808 0.107934 0.002742 
21.982 0.758102 0.615519 0.49151 0.216319 0.008356 0.306751 0.108268 0.00275 
22.042 0.76043 0.617409 0.493019 0.216983 0.008382 0.307693 0.1086 0.002758 
22.1021 0.762761 0.619302 0.49453 0.217648 0.008408 0.308636 0.108933 0.002767 
22.1622 0.765093 0.621195 0.496042 0.218313 0.008433 0.30958 0.109266 0.002775 
22.2222 0.767421 0.623085 0.497551 0.218978 0.008459 0.310522 0.109599 0.002784 
22.2823 0.769753 0.624979 0.499063 0.219643 0.008484 0.311465 0.109931 0.002792 
22.3423 0.772081 0.626869 0.500573 0.220307 0.00851 0.312408 0.110264 0.002801 
22.4024 0.774413 0.628762 0.502085 0.220973 0.008536 0.313351 0.110597 0.002809 
22.4625 0.776745 0.630656 0.503597 0.221638 0.008561 0.314295 0.11093 0.002818 
22.5225 0.779073 0.632546 0.505106 0.222303 0.008587 0.315237 0.111263 0.002826 
22.5826 0.781405 0.634439 0.506618 0.222968 0.008612 0.31618 0.111596 0.002835 
22.6426 0.783733 0.636329 0.508127 0.223632 0.008638 0.317122 0.111928 0.002843 
22.7027 0.786065 0.638223 0.509639 0.224298 0.008664 0.318066 0.112261 0.002851 
22.7628 0.788397 0.640116 0.511151 0.224963 0.008689 0.319009 0.112594 0.00286 
22.8228 0.790725 0.642006 0.51266 0.225627 0.008715 0.319951 0.112926 0.002868 
22.8829 0.793057 0.6439 0.514172 0.226293 0.00874 0.320895 0.11326 0.002877 
22.9429 0.795385 0.64579 0.515682 0.226957 0.008766 0.321837 0.113592 0.002885 
23.003 0.797716 0.647682 0.517193 0.227622 0.008792 0.32278 0.113925 0.002894 
23.0631 0.800048 0.649576 0.518705 0.228288 0.008817 0.323724 0.114258 0.002902 
23.1231 0.802376 0.651466 0.520214 0.228952 0.008843 0.324666 0.114591 0.002911 
23.1832 0.804708 0.653359 0.521726 0.229617 0.008869 0.325609 0.114923 0.002919 
23.2432 0.807036 0.655249 0.523236 0.230282 0.008894 0.326552 0.115256 0.002928 
23.3033 0.809368 0.657143 0.524748 0.230947 0.00892 0.327495 0.115589 0.002936 
23.3634 0.8117 0.659036 0.526259 0.231612 0.008945 0.328438 0.115922 0.002944 
 363 
 
23.4234 0.814028 0.660926 0.527769 0.232277 0.008971 0.329381 0.116255 0.002953 
23.4835 0.81636 0.66282 0.529281 0.232942 0.008997 0.330324 0.116588 0.002961 
23.5435 0.818688 0.66471 0.53079 0.233606 0.009022 0.331266 0.11692 0.00297 
23.6036 0.82102 0.666603 0.532302 0.234272 0.009048 0.33221 0.117253 0.002978 
23.6637 0.823352 0.668497 0.533814 0.234937 0.009073 0.333153 0.117586 0.002987 
23.7237 0.82568 0.670387 0.535323 0.235601 0.009099 0.334095 0.117918 0.002995 
23.7838 0.828011 0.67228 0.536835 0.236267 0.009125 0.335039 0.118252 0.003004 
23.8438 0.830339 0.67417 0.538344 0.236931 0.00915 0.335981 0.118584 0.003012 
23.9039 0.832671 0.676063 0.539856 0.237596 0.009176 0.336924 0.118917 0.00302 
23.964 0.835003 0.677956 0.541368 0.238262 0.009201 0.337868 0.11925 0.003029 
24.024 0.837331 0.679847 0.542877 0.238926 0.009227 0.33881 0.119583 0.003037 
24.0841 0.839663 0.68174 0.544389 0.239591 0.009253 0.339753 0.119915 0.003046 
24.1441 0.841991 0.68363 0.545898 0.240256 0.009278 0.340695 0.120248 0.003054 
24.2042 0.844323 0.685524 0.54741 0.240921 0.009304 0.341639 0.120581 0.003063 
24.2643 0.846655 0.687417 0.548922 0.241587 0.009329 0.342582 0.120914 0.003071 
24.3243 0.848983 0.689307 0.550432 0.242251 0.009355 0.343525 0.121247 0.00308 
24.3844 0.851315 0.6912 0.551944 0.242916 0.009381 0.344468 0.12158 0.003088 
24.4444 0.853643 0.693091 0.553453 0.24358 0.009406 0.34541 0.121912 0.003097 
24.5045 0.855975 0.694984 0.554965 0.244246 0.009432 0.346354 0.122245 0.003105 
24.5646 0.858306 0.696877 0.556476 0.244911 0.009458 0.347297 0.122578 0.003113 
24.6246 0.860634 0.698767 0.557985 0.245575 0.009483 0.348238 0.12291 0.003122 
24.6847 0.862966 0.70066 0.559497 0.246241 0.009509 0.349182 0.123244 0.00313 
24.7447 0.865294 0.70255 0.561007 0.246905 0.009534 0.350125 0.123576 0.003139 
24.8048 0.867626 0.704444 0.562519 0.24757 0.00956 0.351068 0.123909 0.003147 
24.8649 0.869958 0.706337 0.564031 0.248236 0.009586 0.352012 0.124242 0.003156 
24.9249 0.872286 0.708227 0.56554 0.2489 0.009611 0.352954 0.124575 0.003164 
24.985 0.874618 0.710121 0.567052 0.249566 0.009637 0.353897 0.124908 0.003173 
25.045 0.876946 0.712011 0.568561 0.25023 0.009662 0.354839 0.12524 0.003181 
25.1051 0.879278 0.713904 0.570073 0.250895 0.009688 0.355783 0.125573 0.00319 
25.1652 0.88161 0.715798 0.571585 0.251561 0.009714 0.356726 0.125906 0.003198 
25.2252 0.883938 0.717688 0.573094 0.252225 0.009739 0.357668 0.126239 0.003206 
25.2853 0.88627 0.719581 0.574606 0.25289 0.009765 0.358612 0.126571 0.003215 
25.3453 0.888598 0.721471 0.576116 0.253555 0.00979 0.359554 0.126904 0.003223 
25.4054 0.89093 0.723365 0.577628 0.25422 0.009816 0.360498 0.127237 0.003232 
25.4655 0.893261 0.725257 0.579139 0.254885 0.009842 0.361441 0.12757 0.00324 
25.5255 0.895589 0.727148 0.580648 0.255549 0.009867 0.362382 0.127902 0.003249 
25.5856 0.897921 0.729041 0.58216 0.256215 0.009893 0.363326 0.128236 0.003257 
25.6456 0.900249 0.730931 0.58367 0.256879 0.009918 0.364269 0.128568 0.003266 
25.7057 0.902581 0.732824 0.585181 0.257545 0.009944 0.365212 0.128901 0.003274 
25.7658 0.904913 0.734718 0.586693 0.25821 0.00997 0.366155 0.129234 0.003283 
25.8258 0.907241 0.736608 0.588203 0.258874 0.009995 0.367098 0.129566 0.003291 
25.8859 0.909573 0.738501 0.589715 0.25954 0.010021 0.368041 0.1299 0.003299 
25.9459 0.911901 0.740392 0.591224 0.260204 0.010047 0.368983 0.130232 0.003308 
26.006 0.914233 0.742285 0.592736 0.260869 0.010072 0.369927 0.130565 0.003316 
26.0661 0.916565 0.744178 0.594248 0.261535 0.010098 0.37087 0.130898 0.003325 
26.1261 0.918893 0.746068 0.595757 0.262199 0.010123 0.371812 0.131231 0.003333 
26.1862 0.921225 0.747962 0.597269 0.262864 0.010149 0.372756 0.131563 0.003342 
26.2462 0.923553 0.749852 0.598778 0.263529 0.010175 0.373697 0.131896 0.00335 
26.3063 0.925884 0.751745 0.60029 0.264194 0.0102 0.374641 0.132229 0.003359 
26.3664 0.928216 0.753638 0.601802 0.264859 0.010226 0.375585 0.132562 0.003367 
26.4264 0.930544 0.755528 0.603311 0.265524 0.010251 0.376526 0.132895 0.003376 
26.4865 0.932876 0.757422 0.604823 0.266189 0.010277 0.37747 0.133228 0.003384 
26.5465 0.935204 0.759312 0.606332 0.266853 0.010303 0.378412 0.13356 0.003392 
26.6066 0.937536 0.761205 0.607844 0.267519 0.010328 0.379355 0.133893 0.003401 
26.6667 0.939868 0.763099 0.609356 0.268184 0.010354 0.380299 0.134226 0.003409 
26.7267 0.942196 0.764989 0.610866 0.268848 0.010379 0.381242 0.134558 0.003418 
26.7868 0.944528 0.766882 0.612377 0.269514 0.010405 0.382185 0.134892 0.003426 
26.8468 0.946856 0.768772 0.613887 0.270178 0.010431 0.383127 0.135224 0.003435 
26.9069 0.949188 0.770666 0.615399 0.270844 0.010456 0.384071 0.135557 0.003443 
 364 
 
26.967 0.95152 0.772559 0.616911 0.271509 0.010482 0.385014 0.13589 0.003452 
27.027 0.953848 0.774449 0.61842 0.272173 0.010507 0.385956 0.136223 0.00346 
27.0871 0.956179 0.776342 0.619931 0.272838 0.010533 0.386899 0.136555 0.003469 
27.1471 0.958507 0.778232 0.621441 0.273503 0.010559 0.387841 0.136888 0.003477 
27.2072 0.960839 0.780125 0.622953 0.274168 0.010584 0.388785 0.137221 0.003485 
27.2673 0.963171 0.782019 0.624465 0.274833 0.01061 0.389729 0.137554 0.003494 
27.3273 0.965499 0.783909 0.625974 0.275498 0.010636 0.39067 0.137887 0.003502 
27.3874 0.967831 0.785802 0.627486 0.276163 0.010661 0.391614 0.13822 0.003511 
27.4474 0.970159 0.787692 0.628995 0.276827 0.010687 0.392556 0.138552 0.003519 
27.5075 0.972491 0.789586 0.630507 0.277493 0.010683 0.393499 0.138885 0.003528 
27.5676 0.972151 0.78931 0.630287 0.277396 0.010694 0.393362 0.138837 0.003526 
27.6276 0.973151 0.790122 0.630935 0.277681 0.010694 0.393767 0.138979 0.00353 
27.6877 0.973151 0.790122 0.630935 0.277681 0.010705 0.393767 0.138979 0.00353 
27.7477 0.974151 0.790934 0.631583 0.277967 0.010705 0.394171 0.139123 0.003534 
27.8078 0.974151 0.790934 0.631583 0.277967 0.010716 0.394171 0.139123 0.003534 
27.8679 0.975151 0.791745 0.632232 0.278252 0.010716 0.394576 0.139265 0.003537 
27.9279 0.975151 0.791745 0.632232 0.278252 0.010727 0.394576 0.139265 0.003537 
27.988 0.976151 0.792557 0.63288 0.278537 0.010727 0.39498 0.139408 0.003541 
28.048 0.976151 0.792557 0.63288 0.278537 0.010738 0.39498 0.139408 0.003541 
28.1081 0.977151 0.793369 0.633528 0.278823 0.010738 0.395385 0.139551 0.003545 
28.1682 0.977151 0.793369 0.633528 0.278823 0.010749 0.395385 0.139551 0.003545 
28.2282 0.978151 0.794181 0.634177 0.279108 0.010749 0.39579 0.139694 0.003548 
28.2883 0.978151 0.794181 0.634177 0.279108 0.01076 0.39579 0.139694 0.003548 
28.3483 0.979151 0.794993 0.634825 0.279393 0.01076 0.396194 0.139836 0.003552 
28.4084 0.979151 0.794993 0.634825 0.279393 0.010771 0.396194 0.139836 0.003552 
28.4685 0.980151 0.795805 0.635473 0.279679 0.010771 0.396599 0.139979 0.003555 
28.5285 0.980151 0.795805 0.635473 0.279679 0.010782 0.396599 0.139979 0.003555 
28.5886 0.981151 0.796617 0.636122 0.279964 0.010782 0.397004 0.140122 0.003559 
28.6486 0.981151 0.796617 0.636122 0.279964 0.010793 0.397004 0.140122 0.003559 
28.7087 0.982151 0.797429 0.63677 0.280249 0.010793 0.397408 0.140265 0.003563 
28.7688 0.982151 0.797429 0.63677 0.280249 0.010804 0.397408 0.140265 0.003563 
28.8288 0.983151 0.798241 0.637418 0.280535 0.010804 0.397813 0.140408 0.003566 
28.8889 0.983151 0.798241 0.637418 0.280535 0.010815 0.397813 0.140408 0.003566 
28.9489 0.984151 0.799053 0.638067 0.28082 0.010815 0.398218 0.14055 0.00357 
29.009 0.984151 0.799053 0.638067 0.28082 0.010826 0.398218 0.14055 0.00357 
29.0691 0.985151 0.799865 0.638715 0.281105 0.010826 0.398622 0.140693 0.003574 
29.1291 0.985151 0.799865 0.638715 0.281105 0.010837 0.398622 0.140693 0.003574 
29.1892 0.986151 0.800677 0.639363 0.281391 0.010837 0.399027 0.140836 0.003577 
29.2492 0.986151 0.800677 0.639363 0.281391 0.010848 0.399027 0.140836 0.003577 
29.3093 0.987151 0.801489 0.640012 0.281676 0.010848 0.399432 0.140979 0.003581 
29.3694 0.987151 0.801489 0.640012 0.281676 0.010859 0.399432 0.140979 0.003581 
29.4294 0.988151 0.802301 0.64066 0.281961 0.010859 0.399836 0.141122 0.003584 
29.4895 0.988151 0.802301 0.64066 0.281961 0.01087 0.399836 0.141122 0.003584 
29.5495 0.989151 0.803112 0.641308 0.282247 0.01087 0.40024 0.141265 0.003588 
29.6096 0.989151 0.803112 0.641308 0.282247 0.010881 0.40024 0.141265 0.003588 
29.6697 0.990151 0.803924 0.641957 0.282532 0.010881 0.400645 0.141407 0.003592 
29.7297 0.990151 0.803924 0.641957 0.282532 0.010892 0.400645 0.141407 0.003592 
29.7898 0.991151 0.804736 0.642605 0.282817 0.010892 0.40105 0.14155 0.003595 
29.8498 0.991151 0.804736 0.642605 0.282817 0.010903 0.40105 0.14155 0.003595 
29.9099 0.992151 0.805548 0.643253 0.283103 0.010903 0.401454 0.141693 0.003599 
29.97 0.992151 0.805548 0.643253 0.283103 0.010914 0.401454 0.141693 0.003599 
30.03 0.993151 0.80636 0.643902 0.283388 0.01025 0.401859 0.141836 0.003603 
27.5676 0.972151 0.78931 0.630287 0.277396 0.010694 0.393362 0.138837 0.003526 
27.6276 0.973151 0.790122 0.630935 0.277681 0.010694 0.393767 0.138979 0.00353 
27.6877 0.973151 0.790122 0.630935 0.277681 0.010705 0.393767 0.138979 0.00353 
27.7477 0.974151 0.790934 0.631583 0.277967 0.010705 0.394171 0.139123 0.003534 
27.8078 0.974151 0.790934 0.631583 0.277967 0.010716 0.394171 0.139123 0.003534 
27.8679 0.975151 0.791745 0.632232 0.278252 0.010716 0.394576 0.139265 0.003537 
27.9279 0.975151 0.791745 0.632232 0.278252 0.010727 0.394576 0.139265 0.003537 
 365 
 
27.988 0.976151 0.792557 0.63288 0.278537 0.010727 0.39498 0.139408 0.003541 
28.048 0.976151 0.792557 0.63288 0.278537 0.010738 0.39498 0.139408 0.003541 
28.1081 0.977151 0.793369 0.633528 0.278823 0.010738 0.395385 0.139551 0.003545 
28.1682 0.977151 0.793369 0.633528 0.278823 0.010749 0.395385 0.139551 0.003545 
28.2282 0.978151 0.794181 0.634177 0.279108 0.010749 0.39579 0.139694 0.003548 
28.2883 0.978151 0.794181 0.634177 0.279108 0.01076 0.39579 0.139694 0.003548 
28.3483 0.979151 0.794993 0.634825 0.279393 0.01076 0.396194 0.139836 0.003552 
28.4084 0.979151 0.794993 0.634825 0.279393 0.010771 0.396194 0.139836 0.003552 
28.4685 0.980151 0.795805 0.635473 0.279679 0.010771 0.396599 0.139979 0.003555 
28.5285 0.980151 0.795805 0.635473 0.279679 0.010782 0.396599 0.139979 0.003555 
28.5886 0.981151 0.796617 0.636122 0.279964 0.010782 0.397004 0.140122 0.003559 
28.6486 0.981151 0.796617 0.636122 0.279964 0.010793 0.397004 0.140122 0.003559 
28.7087 0.982151 0.797429 0.63677 0.280249 0.010793 0.397408 0.140265 0.003563 
28.7688 0.982151 0.797429 0.63677 0.280249 0.010804 0.397408 0.140265 0.003563 
28.8288 0.983151 0.798241 0.637418 0.280535 0.010804 0.397813 0.140408 0.003566 
28.8889 0.983151 0.798241 0.637418 0.280535 0.010815 0.397813 0.140408 0.003566 
28.9489 0.984151 0.799053 0.638067 0.28082 0.010815 0.398218 0.14055 0.00357 
29.009 0.984151 0.799053 0.638067 0.28082 0.010826 0.398218 0.14055 0.00357 
29.0691 0.985151 0.799865 0.638715 0.281105 0.010826 0.398622 0.140693 0.003574 
29.1291 0.985151 0.799865 0.638715 0.281105 0.010837 0.398622 0.140693 0.003574 
29.1892 0.986151 0.800677 0.639363 0.281391 0.010837 0.399027 0.140836 0.003577 
29.2492 0.986151 0.800677 0.639363 0.281391 0.010848 0.399027 0.140836 0.003577 
29.3093 0.987151 0.801489 0.640012 0.281676 0.010848 0.399432 0.140979 0.003581 
29.3694 0.987151 0.801489 0.640012 0.281676 0.010859 0.399432 0.140979 0.003581 
29.4294 0.988151 0.802301 0.64066 0.281961 0.010859 0.399836 0.141122 0.003584 
29.4895 0.988151 0.802301 0.64066 0.281961 0.01087 0.399836 0.141122 0.003584 
29.5495 0.989151 0.803112 0.641308 0.282247 0.01087 0.40024 0.141265 0.003588 
29.6096 0.989151 0.803112 0.641308 0.282247 0.010881 0.40024 0.141265 0.003588 
29.6697 0.990151 0.803924 0.641957 0.282532 0.010881 0.400645 0.141407 0.003592 
29.7297 0.990151 0.803924 0.641957 0.282532 0.010892 0.400645 0.141407 0.003592 
29.7898 0.991151 0.804736 0.642605 0.282817 0.010892 0.40105 0.14155 0.003595 
29.8498 0.991151 0.804736 0.642605 0.282817 0.010903 0.40105 0.14155 0.003595 
29.9099 0.992151 0.805548 0.643253 0.283103 0.010903 0.401454 0.141693 0.003599 
29.97 0.992151 0.805548 0.643253 0.283103 0.010914 0.401454 0.141693 0.003599 
30 0.993151 0.80636 0.643902 0.283388 0.01025 0.401859 0.141836 0.003603 
29.7297 0.990151 0.803924 0.641957 0.282532 0.010892 0.400645 0.141407 0.003592 
29.7898 0.991151 0.804736 0.642605 0.282817 0.010892 0.40105 0.14155 0.003595 
29.8498 0.991151 0.804736 0.642605 0.282817 0.010903 0.40105 0.14155 0.003595 
29.9099 0.992151 0.805548 0.643253 0.283103 0.010903 0.401454 0.141693 0.003599 
29.97 0.992151 0.805548 0.643253 0.283103 0.010914 0.401454 0.141693 0.003599 
30 0.993151 0.80636 0.643902 0.283388 0.01025 0.401859 0.141836 0.003603 
The parameters for the control simulation were based on the mean values from wild-type rats 
(Chapter 5; Table 5.1); where scenario 1 is a 3-fold increase in kperfusate; scenario 2 is a 5-fold 
increase in kperfusate; scenario 3 is a 10-fold increase in kperfusate; scenario 4 is a 100-fold increase 
in kperfusate; scenario 5 is a 3-fold increase in kperfusate and 0.5-fold decrease in CLup; scenario 6 is a 
10-fold increase in kperfusate and 0.5-fold decrease in CLup; scenario 7 is a 200-fold increase in 
kperfusate.  
